
<html lang="en"     class="pb-page"  data-request-id="0693bc78-e6a4-49a4-9b11-d9394c2ee5ec"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2016.59.issue-2;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.5b01857;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Structure-Based Design and Synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors" /></meta><meta name="dc.Creator" content="Takatoshi  Yogo" /></meta><meta name="dc.Creator" content="Hiroyuki  Nagamiya" /></meta><meta name="dc.Creator" content="Masaki  Seto" /></meta><meta name="dc.Creator" content="Satoshi  Sasaki" /></meta><meta name="dc.Creator" content="Huang  Shih-Chung" /></meta><meta name="dc.Creator" content="Yusuke  Ohba" /></meta><meta name="dc.Creator" content="Norihito  Tokunaga" /></meta><meta name="dc.Creator" content="Gil Nam  Lee" /></meta><meta name="dc.Creator" content="Chul Yun  Rhim" /></meta><meta name="dc.Creator" content="Cheol Hwan  Yoon" /></meta><meta name="dc.Creator" content="Suk Young  Cho" /></meta><meta name="dc.Creator" content="Robert  Skene" /></meta><meta name="dc.Creator" content="Syunsuke  Yamamoto" /></meta><meta name="dc.Creator" content="Yousuke  Satou" /></meta><meta name="dc.Creator" content="Masako  Kuno" /></meta><meta name="dc.Creator" content="Takahiro  Miyazaki" /></meta><meta name="dc.Creator" content="Hideyuki  Nakagawa" /></meta><meta name="dc.Creator" content="Atsutoshi  Okabe" /></meta><meta name="dc.Creator" content="Shogo  Marui" /></meta><meta name="dc.Creator" content="Kazuyoshi  Aso" /></meta><meta name="dc.Creator" content="Masato  Yoshida" /></meta><meta name="dc.Description" content="We report herein the discovery and optimization of 3-amino-1,5-dihydro-4H-pyrazolopyridin-4-one TYK2 inhibitors. High-throughput screening against TYK2 and JAK1–3 provided aminoindazole derivative ..." /></meta><meta name="Description" content="We report herein the discovery and optimization of 3-amino-1,5-dihydro-4H-pyrazolopyridin-4-one TYK2 inhibitors. High-throughput screening against TYK2 and JAK1–3 provided aminoindazole derivative ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 8, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01857" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01857" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01857" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01857" /></link>
        
    
    

<title>Structure-Based Design and Synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01857" /></meta><meta property="og:title" content="Structure-Based Design and Synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0015.jpeg" /></meta><meta property="og:description" content="We report herein the discovery and optimization of 3-amino-1,5-dihydro-4H-pyrazolopyridin-4-one TYK2 inhibitors. High-throughput screening against TYK2 and JAK1–3 provided aminoindazole derivative 1 as a hit compound. Scaffold hopping of the aminoindazole core led to the discovery of 3-amino-1,5-dihydro-4H-pyrazolopyridin-4-one derivative 3 as a novel chemotype of TYK2 inhibitors. Interestingly, initial SAR study suggested that this scaffold could have a vertically flipped binding mode, which prompted us to introduce a substituent at the 7-position as a moiety directed toward the solvent-exposed region. Introduction of a 1-methyl-3-pyrazolyl moiety at the 7-position resulted in a dramatic increase in TYK2 inhibitory activity, and further optimization led to the discovery of 20. Compound 20 inhibited IL-23-induced IL-22 production in a rat PD assay, as well as inhibited IL-23 signaling in human PBMC. Furthermore, 20 showed selectivity for IL-23 signaling inhibition against GM-CSF, demonstrating the unique cytokine selectivity of the novel TYK2 inhibitor." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="We report herein the discovery and optimization of 3-amino-1,5-dihydro-4H-pyrazolopyridin-4-one TYK2 inhibitors. High-throughput screening against TYK2 and JAK1–3 provided aminoindazole derivative 1 as a hit compound. Scaffold hopping of the aminoindazole core led to the discovery of 3-amino-1,5-dihydro-4H-pyrazolopyridin-4-one derivative 3 as a novel chemotype of TYK2 inhibitors. Interestingly, initial SAR study suggested that this scaffold could have a vertically flipped binding mode, which prompted us to introduce a substituent at the 7-position as a moiety directed toward the solvent-exposed region. Introduction of a 1-methyl-3-pyrazolyl moiety at the 7-position resulted in a dramatic increase in TYK2 inhibitory activity, and further optimization led to the discovery of 20. Compound 20 inhibited IL-23-induced IL-22 production in a rat PD assay, as well as inhibited IL-23 signaling in human PBMC. Furthermore, 20 showed selectivity for IL-23 signaling inhibition against GM-CSF, demonstrating the unique cytokine selectivity of the novel TYK2 inhibitor." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0015.jpeg" /></meta><meta name="twitter:title" content="Structure-Based Design and Synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01857"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01857">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01857&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01857&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01857&amp;href=/doi/10.1021/acs.jmedchem.5b01857" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 733-749</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01771" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01168" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structure-Based Design and Synthesis of 3-Amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Takatoshi++Yogo">Takatoshi Yogo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hiroyuki++Nagamiya">Hiroyuki Nagamiya</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Masaki++Seto">Masaki Seto</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Satoshi++Sasaki">Satoshi Sasaki</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Huang++Shih-Chung">Huang Shih-Chung</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yusuke++Ohba">Yusuke Ohba</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Norihito++Tokunaga">Norihito Tokunaga</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gil+Nam++Lee">Gil Nam Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chul+Yun++Rhim">Chul Yun Rhim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cheol+Hwan++Yoon">Cheol Hwan Yoon</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Suk+Young++Cho">Suk Young Cho</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert++Skene">Robert Skene</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Syunsuke++Yamamoto">Syunsuke Yamamoto</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yousuke++Satou">Yousuke Satou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Masako++Kuno">Masako Kuno</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Takahiro++Miyazaki">Takahiro Miyazaki</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hideyuki++Nakagawa">Hideyuki Nakagawa</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Atsutoshi++Okabe">Atsutoshi Okabe</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shogo++Marui">Shogo Marui</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kazuyoshi++Aso">Kazuyoshi Aso</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Masato++Yoshida">Masato Yoshida</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Chemizon, 3F Dongbang Rental Building, 333-1 Sangdaewon-Dong, Jungwon-Gu, Seongnam-Si, Kyunggi-Do 462-120, Korea</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Takeda California, 10410 Science Center Drive, San Diego, California 92121, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: (+81)-466-321-221. Fax: (+81)-466-29-4454. E-mail: <a href="/cdn-cgi/l/email-protection#0865697b697c672671677b60616c69487c69636d6c69266b6765"><span class="__cf_email__" data-cfemail="95f8f4e6f4e1fabbecfae6fdfcf1f4d5e1f4fef0f1f4bbf6faf8">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01857&amp;href=/doi/10.1021%2Facs.jmedchem.5b01857" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 733–749</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 24, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 December 2015</li><li><span class="item_label"><b>Published</b> online</span>8 January 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 January 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01857" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01857</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D733%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTakatoshi%2BYogo%252C%2BHiroyuki%2BNagamiya%252C%2BMasaki%2BSeto%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D2%26contentID%3Dacs.jmedchem.5b01857%26title%3DStructure-Based%2BDesign%2Band%2BSynthesis%2Bof%2B3-Amino-1%252C5-dihydro-4H-pyrazolopyridin-4-one%2BDerivatives%2Bas%2BTyrosine%2BKinase%2B2%2BInhibitors%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D749%26publicationDate%3DJanuary%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01857"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3406</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">11</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01857" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structure-Based Design and Synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Takatoshi&quot;,&quot;last_name&quot;:&quot;Yogo&quot;},{&quot;first_name&quot;:&quot;Hiroyuki&quot;,&quot;last_name&quot;:&quot;Nagamiya&quot;},{&quot;first_name&quot;:&quot;Masaki&quot;,&quot;last_name&quot;:&quot;Seto&quot;},{&quot;first_name&quot;:&quot;Satoshi&quot;,&quot;last_name&quot;:&quot;Sasaki&quot;},{&quot;first_name&quot;:&quot;Huang&quot;,&quot;last_name&quot;:&quot;Shih-Chung&quot;},{&quot;first_name&quot;:&quot;Yusuke&quot;,&quot;last_name&quot;:&quot;Ohba&quot;},{&quot;first_name&quot;:&quot;Norihito&quot;,&quot;last_name&quot;:&quot;Tokunaga&quot;},{&quot;first_name&quot;:&quot;Gil&quot;,&quot;last_name&quot;:&quot;Nam Lee&quot;},{&quot;first_name&quot;:&quot;Chul&quot;,&quot;last_name&quot;:&quot;Yun Rhim&quot;},{&quot;first_name&quot;:&quot;Cheol&quot;,&quot;last_name&quot;:&quot;Hwan Yoon&quot;},{&quot;first_name&quot;:&quot;Suk&quot;,&quot;last_name&quot;:&quot;Young Cho&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;Skene&quot;},{&quot;first_name&quot;:&quot;Syunsuke&quot;,&quot;last_name&quot;:&quot;Yamamoto&quot;},{&quot;first_name&quot;:&quot;Yousuke&quot;,&quot;last_name&quot;:&quot;Satou&quot;},{&quot;first_name&quot;:&quot;Masako&quot;,&quot;last_name&quot;:&quot;Kuno&quot;},{&quot;first_name&quot;:&quot;Takahiro&quot;,&quot;last_name&quot;:&quot;Miyazaki&quot;},{&quot;first_name&quot;:&quot;Hideyuki&quot;,&quot;last_name&quot;:&quot;Nakagawa&quot;},{&quot;first_name&quot;:&quot;Atsutoshi&quot;,&quot;last_name&quot;:&quot;Okabe&quot;},{&quot;first_name&quot;:&quot;Shogo&quot;,&quot;last_name&quot;:&quot;Marui&quot;},{&quot;first_name&quot;:&quot;Kazuyoshi&quot;,&quot;last_name&quot;:&quot;Aso&quot;},{&quot;first_name&quot;:&quot;Masato&quot;,&quot;last_name&quot;:&quot;Yoshida&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;733-749&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01857&quot;},&quot;abstract&quot;:&quot;We report herein the discovery and optimization of 3-amino-1,5-dihydro-4H-pyrazolopyridin-4-one TYK2 inhibitors. High-throughput screening against TYK2 and JAK1–3 provided aminoindazole derivative 1 as a hit compound. Scaffold hopping of the aminoindazole core led to the discovery of 3-amino-1,5-dihydro-4H-pyrazolopyridin-4-one derivative 3 as a novel chemotype of TYK2 inhibitors. Interestingly, initial SAR study suggested that this scaffold could have a vertically flipped binding mode, which prompted us to introduce a substituent at the 7-position as a moiety directed toward the solvent-exposed region. Introduction of a 1-methyl-3-pyrazolyl moiety at the 7-position resulted in a dramatic increase in TYK2 inhibitory activity, and further optimization led to the discovery of 20. Compound 20 inhibited IL-23-induced IL-22 production in a rat PD assay, as well as inhibited IL-23 signaling in human PBMC. Furthermore, 20 showed selectivity for IL-23 signaling inhibition against GM-CSF, demonstrating the unique cyto&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01857&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01857" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01857&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01857" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01857&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01857" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01857&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01857&amp;href=/doi/10.1021/acs.jmedchem.5b01857" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01857" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01857" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01857%26sid%3Dliteratum%253Aachs%26pmid%3D26701356%26genre%3Darticle%26aulast%3DYogo%26date%3D2016%26atitle%3DStructure-Based%2BDesign%2Band%2BSynthesis%2Bof%2B3-Amino-1%252C5-dihydro-4H-pyrazolopyridin-4-one%2BDerivatives%2Bas%2BTyrosine%2BKinase%2B2%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D2%26spage%3D733%26epage%3D749%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/2" title="Go to Volume 59, Issue 2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/jmcmar.2016.59.issue-2/20160128/jmcmar.2016.59.issue-2.largecover.jpg" alt="Go to Volume 59, Issue 2"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We report herein the discovery and optimization of 3-amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one TYK2 inhibitors. High-throughput screening against TYK2 and JAK1–3 provided aminoindazole derivative <b>1</b> as a hit compound. Scaffold hopping of the aminoindazole core led to the discovery of 3-amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one derivative <b>3</b> as a novel chemotype of TYK2 inhibitors. Interestingly, initial SAR study suggested that this scaffold could have a vertically flipped binding mode, which prompted us to introduce a substituent at the 7-position as a moiety directed toward the solvent-exposed region. Introduction of a 1-methyl-3-pyrazolyl moiety at the 7-position resulted in a dramatic increase in TYK2 inhibitory activity, and further optimization led to the discovery of <b>20</b>. Compound <b>20</b> inhibited IL-23-induced IL-22 production in a rat PD assay, as well as inhibited IL-23 signaling in human PBMC. Furthermore, <b>20</b> showed selectivity for IL-23 signaling inhibition against GM-CSF, demonstrating the unique cytokine selectivity of the novel TYK2 inhibitor.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10154" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10154" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The Janus kinases (JAKs), including JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), are an important family of cytoplasmic/nonreceptor tyrosine kinases as a consequence of their essential role in cytokine signal transduction.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Association of individual JAK proteins to activated cytokine receptors leads to autophosphorylation and subsequent phosphorylation of specific Signal Transducer and Activation of Transcription (STAT) proteins. JAK-STAT signaling, through genetic mutations or increased localized concentration of cytokines, has been identified in various inflammatory diseases and in a variety of cancers.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">Psoriasis is an autoimmune skin disease characterized by red scaly plaques, which are itchy and painful. It is estimated that 2–4% of general population is affected by this disease.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The selection of psoriasis treatment depends on the severity of the patients. For mild to moderate psoriasis patients, topical medications are the first line of treatment. However, moderate to severe psoriasis patients require phototherapy, oral therapies, and biologics.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In clinical practice for moderate to severe psoriasis, the anti-IL-12/23 p40 monoclonal antibody ustekinumab is widely used, and anti-IL-12/23 p40 antibody as well as the IL-17A antibody are significantly more efficacious than the anti-TNF-α therapy such as etanercept.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> Results of clinical practice suggest the IL-12/23 signaling pathway might be correlated very closely with psoriasis. The IL-12/23 signaling pathway is mediated by JAK2/TYK2 heterodimer via phosphorylation of STAT3/4. A genome-wide association study (GWAS) also reveals that TYK2 is associated with psoriasis<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> as well as other autoimmune diseases such as Crohn’s disease,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> multiple sclerosis,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and systemic lupus.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> JAK2 also regulates the erythropoietin signaling pathway, which controls erythropoiesis, and its inactivation leads to anemia in mouse models.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Additionally, hemoglobin reduction and/or anemia have been noted in human patients enrolled in clinical trials of tofacitinib, baricitinib, and ruxolitinib.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> On the basis of this background, we focused on the development of inhibitors of TYK2, with selectivity over JAK2, for treatment of psoriasis with fewer adverse effects on erythropoietin (EPO), thrombopoietin (TPO), and granulocyte macrophage colony-stimulating factor (GM-CSF) signaling. Despite the attractiveness of TYK2 as a therapeutic target for inflammatory diseases and the progress of small molecule JAK inhibitors such as tofacitinib in clinical trial for psoriasis,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> only a few classes of compounds that selectively inhibit TYK2 over JAK1–3 are reported (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">Herein, we report the design and synthesis of 3-amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one derivatives as potent TYK2 inhibitors. A series of modifications at the 5- and 7-positions of 3-amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one core utilizing structure-based drug design (SBDD) led to the discovery of (<i>S</i>)-3-amino-7-[5-(2-hydroxypropan-2-yl)-1-methyl-1<i>H</i>-pyrazol-3-yl]-5-(3-methylbutan-2-yl)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4(5<i>H</i>)-one (<b>20</b>) as a potent TYK2 inhibitor with excellent cell potency and pharmacokinetic (PK) profile in rats. The design hypothesis was later confirmed by solving the X-ray crystal structure of TYK2 in complex with compound <b>20</b>. Furthermore, in vivo pharmacodynamic (PD) efficacy of compound <b>20</b> and its cytokine selectivity profile in human peripheral blood mononuclear cell (PBMC) are described.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of reported JAKs<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and TYK2 inhibitors.<a onclick="showRef(event, 'cit13c'); return false;" href="javascript:void(0);" class="ref cit13c">(13c)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06208" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06208" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Hit Compound and Design Strategy</h3><div class="NLM_p">High-throughput screening of our compound library against TYK2 and JAK1–3 enzymes provided a hit compound, aminoindazole derivative <b>1</b>, with moderate inhibitory activity of TYK2 (IC<sub>50</sub> = 650 nM) and a 10-fold JAK2 selectivity (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). A model of compound <b>1</b> docked in the ATP binding site of TYK2 (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) suggested that the aminoindazole core of compound <b>1</b> binds to the hinge region while the thiazoleacetic acid moiety is directed toward the solvent-exposed region. To confirm the potential of the aminoindazole core as the TYK2 inhibitor scaffold, as well as to reduce molecular weight, the thiazoleacetic acid moiety was removed (compound <b>2</b>) without loss of potency. Although compound <b>2</b> showed improved TYK2 inhibitory activity with reduced molecular weight, cytotoxicity and phototoxicity were identified as issues for further development. We considered that the toxicities were induced by the basic amino group of the aminoindazole.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Therefore, a scaffold hopping of the aminoindazole was conducted. Toward this end, the benzene part of the aminoindazole was replaced with pyridone to mask its basicity by intramolecular hydrogen bonding to the carbonyl oxygen. This transformation (compound <b>3</b>) drastically reduced cytotoxicity and phototoxicity while maintaining equivalent inhibitory activity as compared to compound <b>2</b>. These results demonstrated that 3-amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one was a promising scaffold for further examination. The thiazoleacetic acid moiety, which worked as a solvent-exposed substituent in the case of the aminoindazoles, was introduced into this novel scaffold (compound <b>4</b>), resulting in a drastic decrease in TYK2 inhibitory activity. On the basis of this result, we considered that the binding mode of compound <b>4</b> was different from that of compound <b>1</b>. We proposed that the 3-amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one scaffold could have two binding modes with TYK2, in which Type B was a vertically flipped binding mode of Type A. To verify this hypothesis, we designed and synthesized 3-amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one derivatives with substitution at the 7-position as a solvent side substituent.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design concept of 3-amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one scaffold. (a) ATP content (% of control at 30 μM). (b) Caspase 3/7 activity (% of maximum staurosporine activity at 30 μM). (c) Δ<sub>max</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Initial Substitutions at the 7-Position of 3-Amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one</h3><div class="NLM_p">Substituent effects at the 7-position of 3-amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one derivatives are described in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. Introduction of a 1-methyl-3-pyrazolyl moiety (<b>5</b>) or a 2-pyridyl moiety (<b>6</b>) at the 7-position resulted in 37- and 58-fold increases in TYK2 inhibitory activity (IC<sub>50</sub> = 9.9 and 6.7 nM), respectively. On the other hand, a compound with an unsubstituted benzene moiety at the 7-position (<b>7</b>) was 26-fold less potent than pyrazole derivative <b>8</b>. These results suggested that nitrogen-containing heteroaryl groups such as 1-methyl-3-pyrazolyl or 2-pyridyl may construct the effective binding mode through an intramolecular hydrogen bond between their nitrogen atoms (hydrogen-bond acceptor) and pyrazol NH (hydrogen-bond donor) on the central core (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>C). Introduction of these heteroaryl groups had a dramatic impact on TYK2 potency. Regarding the 5-substituent, replacement of the <i>ortho</i>-chloro with a methyl group (<b>8</b>) was tolerated. In addition to potent TYK2 inhibitory activity, derivatives <b>5</b>, <b>6</b>, and <b>8</b> showed excellent selectivity over JAK2 (50–90-fold).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Effect of Introducing a Substituent into the 7-Position of the 3-Amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one Core</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0011.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0012.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">The enzyme inhibition assay using JAK1–3, or TYK2 enzymes. 95% confidence intervals (CI) conducted in duplicate (<i>n</i> = 2).</p></div></div><div></div></div><div class="NLM_p">These results were consistent with the X-ray crystal structure of TYK2 in complex with compound <b>8</b> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A,B), showing that the 1-methyl-3-pyrazolyl moiety at the 7-position was directed toward the solvent-exposed region of the ATP-binding site (i.e., Type B binding mode). As predicted, the pyrazole moiety was nearly coplanar with the 3-amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one core, presumably due to the intramolecular hydrogen bond. Other interesting features were also observed: (1) the phenyl group was located in the hydrophobic environment of the TYK2 binding cavity in the ribose pocket and the <i>ortho</i>-methyl in the lower rim of the binding cavity (we refer to this cavity as the JAK pocket), which is characteristic of the JAK family (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B);<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> (2) Leu903, Asp988, Arg992, and Arg901 in the solvent-exposed region could be targeted for further interactions with the 7-position substituent to improve potency. On the basis of these observations, optimization was continued by (1) exploration of chiral alkyl groups as replacements of the <i>ortho</i>-tolyl to efficiently occupy the JAK pocket as well as to improve physicochemical properties by increasing the sp<sup>3</sup> carbon ratio, and (2) optimization of the 7-position substituent to take advantage of hydrogen bonding to amino acid residues in the solvent-exposed region (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>C).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Top view (A) and side view (B) of X-ray structure of compound <b>8</b> with TYK2. (C) Structure-based design strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Optimization of the 5- and 7-Positions of 3-Amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one</h3><div class="NLM_p last">The structure–activity relationships (SAR) of 5- and 7-substituted 3-amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one derivatives are described in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. Our initial efforts focused on exploring an alkyl substituent at the 5-position, which could efficiently occupy the JAK pocket to improve TYK2 inhibitory activity. Replacement of the <i>ortho</i>-tolyl group at the 5-position with 3-methybutan-2-yl group (racemate <b>9</b>) afforded a 5-fold increase in TYK2 inhibitory activity as compared to <b>8</b>. Removal or introduction of methyl groups on the methylbutanyl group (<b>10</b>–<b>12</b>) resulted in a decrease in potency, suggesting that 3-methybutan-2-yl was the optimal size for occupying the hydrophobic binding cavity of JAK pocket. Furthermore, optimization of the 7-substituent of 5-(3-methybutan-2-yl) derivatives was examined. On the basis of the X-ray crystal structure of <b>8</b> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>), we considered that the 5′-substituent (e.g., morpholino group) of the 2-pyridyl group could offer an attractive vector to interact with Arg901 or Arg992. As a result, the compound with an added (morpholin-4-yl)pyridin-2-yl group (<b>13</b>) showed potent TYK2 inhibitory activity (IC<sub>50</sub> = 1.5 nM). Thus, the racemic mixtures were separated (<b>14</b>, <b>15</b>). TYK2 inhibitory activity of the (<i>S</i>)-form (<b>14</b>) with subnanomolar IC<sub>50</sub> values was 10-fold more potent than that of the (<i>R</i>)-form (<b>15</b>). Next, the effect of introducing substitution at the 5′-position of the 1-methyl-3-pyrazolyl moiety (e.g., <b>16</b>–<b>20</b>), which were expected to interact with Leu903 or Asp988, was investigated (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Introduction of morpholine onto the 5′-position of 1-methyl-3-pyrazole (<b>17</b>) afforded a 10-fold increase in TYK2 inhibitory activity as compared to the corresponding unsubstituted analogue (<b>16</b>) with 25-fold selectivity over JAK2. Compounds with either a tetrahydropyran (<b>18</b>) or a thiomorpholine-1,1-dioxide (<b>19</b>) showed the same trend of TYK2 inhibitory activity and JAK2 selectivity. TYK2 inhibitory activity and JAK2 selectivity of a compound bearing propan-2-ol (<b>20</b>) slightly decreased as compared to those of the morpholine derivative (<b>17</b>). The above results demonstrated that further improvement in TYK2 inhibitory activity was achieved by the optimization of the 5- and 7-positions of 3-amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one, (1) through occupying the JAK pocket efficiently with a chiral alkyl group and (2) by additional interaction with the amino acid residues in the solvent-exposed region. Further evaluation of compounds <b>9</b>–<b>20</b> was conducted in a cellular assay measuring the inhibitory activities against IL-23-induced luciferase gene expression using Jurkat cells. Compounds <b>9</b>–<b>20</b> experienced a shift in potency in the cellular context, but cellular activities were well correlated with TYK2 enzyme inhibitory activities (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> PK Profiles of Selected Candidates</h3><div class="NLM_p">Compounds (<b>14</b>, <b>17</b>, <b>18</b>, and <b>20</b>) with potent TYK2 inhibitory activity and good JAK2 selectivity as well as promising cellular potency were selected for further evaluation, and plasma concentration was determined after oral (po, 1 mg/kg) and intravenous (iv, 0.1 mg/kg) administration in rats (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Among them, compound <b>20</b> presented a highly desirable PK profile in rats, high maximum concentration (<i>C</i><sub>max</sub> = 215 ng/mL) and good plasma duration (MRT = 2.19 h), leading to a high plasma exposure (AUC = 609 ng·h/mL) after oral administration. On the other hand, compounds <b>14</b>, <b>17</b>, and <b>20</b> showed poor PK profiles.</div><div class="NLM_p">On the basis of the above results, compound <b>20</b> was selected for further evaluation in cellular and in vivo experiments.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of 5- and 7-Substituted 3-Amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0013.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0014.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">The enzyme inhibition assay using JAK1–3, or TYK2 enzymes.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Inhibitory activity of IL-23-induced luciferase gene expression in Jurkat cells.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Racemate. 95% confidence intervals (CI) conducted in duplicate (<i>n</i> = 2).</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Pharmacokinetic Parameters of Compounds <b>14</b>, <b>17</b>, <b>18</b>, and <b>20</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">PK parameters in rat</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no.</th><th class="colsep0 rowsep0" align="center" char=".">CL* (mL/h/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub>** (ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">MRT** (h)</th><th class="colsep0 rowsep0" align="center" char=".">AUC** (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="char" char=".">18 700</td><td class="colsep0 rowsep0" align="char" char=".">13.6</td><td class="colsep0 rowsep0" align="char" char=".">0.40</td><td class="colsep0 rowsep0" align="char" char=".">8.4</td><td class="colsep0 rowsep0" align="char" char=".">15.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="char" char=".">2490</td><td class="colsep0 rowsep0" align="char" char=".">29.9</td><td class="colsep0 rowsep0" align="char" char=".">0.92</td><td class="colsep0 rowsep0" align="char" char=".">38.7</td><td class="colsep0 rowsep0" align="char" char=".">9.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="char" char=".">3080</td><td class="colsep0 rowsep0" align="char" char=".">32.4</td><td class="colsep0 rowsep0" align="char" char=".">1.57</td><td class="colsep0 rowsep0" align="char" char=".">71.8</td><td class="colsep0 rowsep0" align="char" char=".">21.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="char" char=".">1100</td><td class="colsep0 rowsep0" align="char" char=".">215</td><td class="colsep0 rowsep0" align="char" char=".">2.19</td><td class="colsep0 rowsep0" align="char" char=".">609</td><td class="colsep0 rowsep0" align="char" char=".">67.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">The values are shown as means of three determinations (0.1 mg/kg, iv*, and 1.0 mg/kg, po**).</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> In Vivo PD Study and Cytokine Selectivity Profile in Human PBMC</h3><div class="NLM_p">To determine if a TYK2 inhibitor could inhibit the IL-23 signaling pathway, which is elevated in skin lesions of psoriasis patients, an in vivo rat skin PD model was developed. Evaluation of compound <b>20</b> in rat IL-23 skin PD assay is shown in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>. IL-22 production in the ear was measured 24 h after IL-23 injection (1 μg/site). IL-23-induced IL-22 production in the ear was dose-dependently suppressed after oral administration of compound <b>20</b> at 3, 10, and 30 mg/kg (ED<sub>50</sub> = 6.2 mg/kg), indicating that compound <b>20</b> inhibited IL-23 and its downstream JAK/STAT signaling.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Assessment of <b>20</b> in rat IL-23 skin PD assay. ***: <i>p</i> < 0.001 vs vehicle, by Dunnett’s test (PBS <i>n</i> = 4, IL-23 <i>n</i> = 6).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We then evaluated the cytokine selectivity of compound <b>20</b> in a cell signaling assay. A previously reported pan-JAK inhibitor and a JAK1/2 inhibitor showed more potent inhibition of JAK2 than TYK2, and potent inhibition of JAK2 might be associated with adverse effects such as anemia and hemoglobin reduction. To confirm whether the TYK2 selective profile of compound <b>20</b> over JAK2 would lead to a more preferential inhibition profile of the IL-12/23 signaling pathway over JAK2-related cytokine such as GM-CSF, cytokine selectivity profiles were assessed in human PBMC (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Inhibition of phosphorylation of downstream STAT proteins upon treatment with varying stimuli was measured in this assay. Stimulation with IL-23, IFNα, IL-6, IL-21, or GM-CSF is reported to induce TYK2/JAK2, TYK2/JAK1, JAK1/JAK2/TYK2, JAK1/JAK3, or JAK2/JAK2-mediated phosphorylation of STAT3/4, STAT1/3/5, STAT1/3/5, STAT1/3, or STAT5, respectively.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> As a result, compound <b>20</b> robustly inhibited IL-23 (IC<sub>50</sub> = 230 nM, 11-fold selectivity against GM-CSF), IFNα, IL-6, and IL-21 signaling, while inhibition of GM-CSF signaling was attenuated as expected. Baricitinib inhibited IL-23<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and GM-CSF signaling as well as IFNα, IL-6, and IL-21 in an equivalent concentration range, but showed less selectivity between IL-23 and GM-CSF when compared to compound <b>20</b>. The robust inhibition of IL-23 by compound <b>20</b> is consistent with the importance of TYK2 catalytic function in the signaling of IL-23.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> These results demonstrated that compound <b>20</b> was a novel chemical class of inhibitor of JAK family with a unique and desirable cytokine selectivity, especially considering the wide margin between IL-23 and GM-CSF, which could reduce adverse effects such as hemoglobin reduction and anemia caused by JAK2 inhibition.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Cytokine Selectivity of <b>20</b> in Human PBMC Assay</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">human enzyme IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">human PBMC pSTAT IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">JAK1 (95% CI)</th><th class="colsep0 rowsep0" align="center" char=".">JAK2 (95% CI)</th><th class="colsep0 rowsep0" align="center" char=".">JAK3 (95% CI)</th><th class="colsep0 rowsep0" align="center" char=".">TYK2 (95% CI)</th><th class="colsep0 rowsep0" align="center" char=".">IL-23</th><th class="colsep0 rowsep0" align="center" char=".">IFNα</th><th class="colsep0 rowsep0" align="center" char=".">IL-6</th><th class="colsep0 rowsep0" align="center" char=".">IL-21</th><th class="colsep0 rowsep0" align="center" char=".">GM-CSF</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="char" char=".">16 (14–19)</td><td class="colsep0 rowsep0" align="char" char=".">17 (13–22)</td><td class="colsep0 rowsep0" align="char" char=".">3.3 (3.0–3.6)</td><td class="colsep0 rowsep0" align="char" char=".">2.1 (1.5–3.0)</td><td class="colsep0 rowsep0" align="char" char=".">230</td><td class="colsep0 rowsep0" align="char" char=".">65</td><td class="colsep0 rowsep0" align="char" char=".">230</td><td class="colsep0 rowsep0" align="char" char=".">280</td><td class="colsep0 rowsep0" align="char" char=".">2600</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">baricitinib</td><td class="colsep0 rowsep0" align="char" char=".">0.99 (0.89–1.1)</td><td class="colsep0 rowsep0" align="char" char=".">0.8 (0.70–0.92)</td><td class="colsep0 rowsep0" align="char" char=".">25 (19–35)</td><td class="colsep0 rowsep0" align="char" char=".">8.7 (6.4–12)</td><td class="colsep0 rowsep0" align="char" char=".">200</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">67</td><td class="colsep0 rowsep0" align="char" char=".">290</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">The enzyme inhibition assay using JAK1–3, or TYK2 enzymes. 95% confidence intervals (CI) conducted in duplicate (<i>n</i> = 2).</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Phosphorylation of STAT4 (IL-23), STAT1 (IFNα), STAT1 (IL-6), STAT 3 (IL-21), and STAT5 (GM-CSF) was measured, respectively. IC<sub>50</sub> values represent the mean from two healthy volunteer PBMC.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Crystal Structure of Compound <b>20</b></h3><div class="NLM_p">An X-ray crystal structure of <b>20</b> bound to TYK2 revealed the expected mode of binding (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). The pyrazolopyridinone ring made two hydrogen bonds with the backbone carbonyl and NH of hinge residue Val981. The 3-amino group made an additional interaction with the backbone of Glu979, while the carbonyl substituent engaged in water-mediated interactions with the catalytic Lys930 and DFG-Asp1041. The methylbutane group occupied the JAK pocket, making several hydrophobic contacts. In the front pocket, the methylpyrazole packed between Gly984 and Leu903, with the propan-2-ol exposed to the solvent and its hydroxyl group hydrogen bound with the backbone carbonyl of Leu903.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Top view (A) and side view (B) of X-ray structure of <b>20</b> with TYK2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20763" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20763" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Synthesis of the 3-amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one derivatives possessing 2-chloro phenyl group, 2-methyl phenyl group, or 3-methybutan-2-yl group at the 5-position is described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Commercially available β-keto amides <b>22a</b>,<b>b</b> or <b>22c</b>,<b>d</b>, which were readily prepared from amine <b>21a</b>,<b>b</b>, were reacted with <i>N</i>,<i>N</i>-dimethylformamide dimethyl acetal (DMF/DMA) to afford enaminone <b>23a</b>–<b>d</b>. Formation of chlorinated pyridine-2(1<i>H</i>)-ones <b>24a</b>–<b>d</b> was achieved by the reaction of enaminone <b>23a</b>–<b>d</b> with Vilsmeier reagent POCl<sub>3</sub>/DMF.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The formyl group of <b>24a</b>–<b>d</b> was converted to a cyano group via aldoxime, followed by bromination using <i>N</i>-bromosuccinimide (NBS) to give key intermediates, 1-substituted 5-bromo-pyridin-2(1<i>H</i>)-ones <b>27a</b>–<b>d</b>. The targeted analogues (<b>5</b>–<b>9</b>, <b>13</b>, <b>16</b>–<b>20</b>) were synthesized from <b>27a</b>–<b>d</b> via two-step reactions: condensation with hydrazine to form the aminopyrazole part, and Suzuki–Miyaura coupling to introduce 7-substituent. Optically pure 3-methylbutan-2-yl analogues were prepared by chiral HPLC resolution of the racemic analogue <b>13</b>, or the key chiral intermediate <b>29d</b>.</div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2,2,6-trimethyl-4<i>H</i>-1,3-dioxin-4-one, NaOAc, THF, reflux, 74% for <b>22c</b>; (b) diketene, MeOH, 0 °C, 96% for <b>22d</b>; (c) K<sub>2</sub>CO<sub>3</sub>, DMF/DMA, DMF, rt, 69–84% for <b>23a</b>,<b>b</b>,<b>d</b>; (d) DMF/DMA, DMF, rt, 95% for <b>23c</b>; (e) POCl<sub>3</sub>, DMF, 0 °C → 100–125 °C, 59–64% for <b>24a</b>–<b>c</b>; (f) (chloromethylene)dimethylammonium chloride, DMF 100 °C, 57% for <b>24d</b>; (g) hydroxylamine hydrochloride, NaOAc, MeOH–H<sub>2</sub>O, 75 °C, 77–92% for <b>25a</b>,<b> 25c</b>; (h) hydroxylamine hydrochloride, conc. HCl, 2-propanol, 100 °C, 68–95% for <b>25b</b>,<b> 25d</b>; (i) POCl<sub>3</sub>, CH<sub>3</sub>CN, 90 °C, 53–100% for <b>26a</b>–<b>c</b>; (j) SOCl<sub>2</sub>, CH<sub>3</sub>CN, rt, 68% for <b>26d</b>; (k) NBS, DMF, 50–60 °C, 81–98%; (l) PhB(OH)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub> aq, DME, 90 °C, 64%; (m) hydrazine monohydrate, EtOH, 70 °C, 27%; (n) hydrazine monohydrate, EtOH, 70–90 °C, 82–94%; (o) chiral HPLC, CHIRALPAK AD, hexane/EtOH, 44%; (p) KOAc, PdCl<sub>2</sub>(dppf) (or Pd(PPh<sub>3</sub>)<sub>4</sub>), bis(pinacolato)diboron, DMF (or DMA), 110–120 °C, then R<sup>2</sup>–Br (or R<sup>2</sup>–I, or R<sup>2</sup>–OTf), Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub> aq, 120 °C, 8–41% for <b>5</b>, <b>6</b>, <b>13</b>,<b> 15</b>,<b> 17</b>, <b>19</b>, <b>20</b>, <b>30</b>; (q) 1-methyl-3-(4,4,5,5-tetramethy-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub> aq, DMF, 120 °C, 11–29% for <b>8</b>, <b>9</b>,<b> 16</b>; (r) chiral HPLC, CHIRALCEL OJ, hexane/EtOH/diethylamine, 56–76%; (s) PtO<sub>2</sub>, H<sub>2</sub>, rt, MeOH, 45%.</p></p></figure><div class="NLM_p">To acquire SAR of the 5-position efficiently, an alternative synthetic route was developed (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Pyridone <b>31</b> was reacted with alkyl halides, followed by the separation of <i>N</i>-alkylated pyridones from the mixture of <i>N</i>- and <i>O</i>-alkylated products by chromatography to give <b>32a</b>–<b>c</b>. Subsequent three-step reactions as described above afforded targeted products <b>10</b>–<b>12</b>.</div><figure id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) R<sup>1</sup>–Br, Cs<sub>2</sub>CO<sub>3</sub>, KI, DMF–DME, 60 °C, 6–48% for <b>32a</b>,<b>c</b>; (b) 1-bromo-2-methylpropane, Cs<sub>2</sub>CO<sub>3</sub>, DMSO, 50 °C, 63% for <b>32b</b>; (c) NBS, DMF, 60 °C, 47–72% for <b>33a</b>,<b>c</b>; (d) NBS, DMF, 70 °C, then POCl<sub>3</sub>, 120 °C, 15% for <b>33b</b>; (e) 1-methyl-3-(4,4,5,5-tetramethy-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub> aq, DME, 100 °C, 60–69% for <b>10</b>, <b>12</b>; (f) hydrazine monohydrate, EtOH, 90 °C, 40–59% for <b>10</b>, <b>12</b>; (g) hydrazine monohydrate, EtOH, reflux, 98% for <b>11</b>; (h) 1-methyl-3-(4,4,5,5-tetramethy-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub> aq, DMF, 150 °C, 17% for <b>11</b>.</p></p></figure><div class="NLM_p">Preparation of pyrazole derivatives possessing a substituent at the 5-position as a coupling partner with 3-amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one core is described in <a class="ref internalNav" href="#sch3" aria-label="Schemes 3">Schemes 3</a> and <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. 5-Morpholinopyrazole derivative <b>39</b> was initially synthesized by using pyrazole-5-carboxylic acid <b>34</b><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> as a starting material. Compound <b>34</b> was converted to 5-aminopyrazole <b>36</b> via Curtius rearrangement and successive removal of Boc group. Morpholine was then constructed by reacting <b>36</b> with 1-chloro-2-(2-chloroethoxy) ethane to give <b>37</b>. The benzyl group at 3-position was removed by hydrogenation using 10% Pd/C, followed by the conversion to triflate to provide <b>39</b>, which was used in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The morpholine analogue <b>17</b> showed promising TYK2 potency as shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. Therefore, an alternative synthetic route suitable for further optimization of the 5-position of 1-methyl pyrazole moiety was developed (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).</div><figure id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0009.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DPPA, Et<sub>3</sub>N, <i>t</i>-BuOH, reflux, 93%; (b) 4 M HCl/EtOAc, EtOAc/MeOH, rt, 97%; (c) 1-chloro-2-(2-chloroethoxy)ethane, Et<sub>3</sub>N, NaI, DMF, 150 °C, 13%; (d) Pd/C (10%), H<sub>2</sub>, EtOH, rt, 93%; (e) trifluoromethanesulfonic anhydride, Et<sub>3</sub>N, CH<sub>3</sub>CN, 0 °C, 58%.</p></p></figure><div class="NLM_p">A key intermediate, 3,5-dibromo-1-methyl-pyrazole derivative <b>42</b>, was prepared by bromination of commercially available ethyl 1<i>H</i>-pyrazole-4-carboxylate <b>40</b>, followed by the reaction with methyl iodide. The S<sub>N</sub>Ar reaction of <b>42</b> with morpholine proceeded with an excellent regio-selectivity in favor of 5-position to afford <b>43a</b>. Decarboxylation of <b>43a</b> provided the coupling partner <b>44a</b> in an excellent overall yield. The thiomorpholine-1,1-dioxide analogue <b>44b</b> was prepared in the same manner. We next examined the reactivity of 3,5-dibromo-1-methyl-1<i>H</i>-pyrazole <b>45</b>, prepared by decarboxylation of <b>42</b>. Suzuki–Miyaura coupling of 3,5-dibromo-pyrazole <b>45</b> with boronic acid pinacol ester underwent regioselectively at the 5-position to give 5-substituted pyrazole <b>46</b>. Lithiation of <b>45</b> using <i>n</i>-BuLi also proceeded regioselectively at the 5-position, and the successive treatment with acetone gave propan-2-ol derivative <b>47</b>. These reactions described in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> provide a convenient approach to 1,3,5-trisubstituted pyrazoles.</div><figure id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0010.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaOAc, Br<sub>2</sub>, H<sub>2</sub>O–EtOH, rt, 99%; (b) NaH, MeI, THF, 0 °C to rt, 99%; (c) 150 °C, 76% for <b>43a</b>; (d) NMP 200 °C, 43% for <b>43b</b>; (e) 2 M NaOH, EtOH, 60–70 °C, then conc. H<sub>2</sub>SO<sub>4</sub>, 60 °C, 81–99%; (f) 50% H<sub>2</sub>SO<sub>4</sub> aq, 160 °C, 86%; (g) 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2<i>H</i>-pyran, Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub> aq, DME, 80 °C, 64% ; (h) <i>n</i>-BuLi, THF, −78 °C, then acetone, −78 °C to rt, 70%.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73762" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73762" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">3-Amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one derivatives were discovered as selective TYK2 inhibitors through the hypothesis that this scaffold had a vertically flipped binding mode as compared to the aminoindazole lead compound <b>1</b>. The optimization of the 5- and 7-positions of 3-amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one core utilizing a SBDD approach led to the discovery of (<i>S</i>)-3-amino-7-[5-(2-hydroxypropan-2-yl)-1-methyl-1<i>H</i>-pyrazol-3-yl]-5-(3-methylbutan-2-yl)-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4(5<i>H</i>)-one (<b>20</b>), a potent and orally active TYK2 inhibitor with excellent cell potency and PK profiles. Compound <b>20</b> significantly inhibited IL-23-induced IL-22 production in the rat ear PD assay. Moreover, <b>20</b> was demonstrated to inhibit IL-23 signaling (IC<sub>50</sub> = 230 nM) with high selectivity (11-fold) against GM-CSF. Therefore, it is believed that JAK2-related adverse effects such as hemoglobin reduction and anemia may be mitigated.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10224" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10224" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Chemistry</h3><div class="NLM_p">Reagents and solvents were obtained from commercial sources and used without further purification. Reaction progress was determined by thin layer chromatography (TLC) analysis on Merck Kieselgel 60 F254 plates or Fuji Silysia NH plates. Silica gel column chromatography was performed on Purif-Pack (SI or NH, SHOKO SCIENTIFIC). Proton nuclear magnetic resonance (<sup>1</sup>H NMR) spectra were recorded on Bruker Ultra Shield-300 (300 MHz) instruments. Chemical shifts are given in parts per million (ppm) with tetramethylsilane as an internal standard. Abbreviations are used as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublets of doublet, br = broad. Coupling constants (<i>J</i> values) are given in hertz (Hz). LC–MS analysis was performed on a Shimadzu LC-20AD separations module or Agilent 1200 series, operating in ESI (+ or −) ionization mode. Analytes were eluted using a linear gradient of 0.05% TFA containing H<sub>2</sub>O/CH<sub>3</sub>CN or 0.01% TFA containing H<sub>2</sub>O/CH<sub>3</sub>CN or 5 mM ammonium acetate containing H<sub>2</sub>O/CH<sub>3</sub>CN or 10 mM NH<sub>4</sub>HCO<sub>3</sub> containing H<sub>2</sub>O/CH<sub>3</sub>CN or 0.01% heptafluorobutyric acid/1.0% isopropyl alcohol containing H<sub>2</sub>O/CH<sub>3</sub>CN mobile phase. Preparative HPLC was performed on a Waters 2525 separations module (L-column2 ODS (20 × 150 mm ID), CERI, Japan); MS spectra were recorded using a Waters ZQ2000 with electrospray ionization or on a GILSON system, equipped with a L-column2 ODS (20 × 150 mm ID, CERI, Japan) or on a Waters Deltaprep 300 system or on a Shimadzu 10A VP system. Samples were eluted using a linear gradient of 0.1% TFA in H<sub>2</sub>O/CH<sub>3</sub>CN or 10 mM NH<sub>4</sub>HCO<sub>3</sub> in H<sub>2</sub>O/CH<sub>3</sub>CN, or H<sub>2</sub>O/CH<sub>3</sub>CN. Purity data were collected by a HPLC with Corona CAD (Charged Aerosol Detector), Nano quantity analyte detector (NQAD), or photo diode array detector. The column was a Capcell Pak C18AQ (50 mm × 3.0 mm ID, Shiseido, Japan) or L-column 2 ODS (30 mm × 2.0 mm ID, CERI, Japan) with a temperature of 50 °C and a flow rate of 0.5 mL/min. Mobile phases A and B under a neutral condition were a mixture of 50 mM Aammonium acetate, H<sub>2</sub>O, and CH<sub>3</sub>CN (1:8:1, v/v/v) and a mixture of 50 mM ammonium acetate and CH<sub>3</sub>CN (1:9, v/v), respectively. The ratio of mobile phase B was increased linearly from 5% to 95% over 3 min, 95% over the next 1 min. Mobile phases A and B under an acidic condition were a mixture of 0.2% formic acid in 10 mM ammonium formate and 0.2% formic acid in CH<sub>3</sub>CN, respectively. The ratio of mobile phase B was increased linearly from 14% to 86% over 3 min, 86% over the next 1 min. The purity of all test compounds was assessed by analytical HPLC (>95%). Microwave reaction was conducted in a sealed vial with Biotage Initiator model or CEM Explorer S model.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> <i>N</i>-(3-Methylbutan-2-yl)-3-oxobutanamide (<b>22c</b>)</h4><div class="NLM_p">To a mixture of compound <b>21a</b> (1.00 g, 11.5 mmol) and 2,2,6-trimethyl-4<i>H</i>-1,3-dioxin-4-one (2.12 g, 14.9 mmol) in THF (3.0 mL) was added NaOAc (941 mg, 11.5 mmol) at room temperature. The mixture was heated overnight. After being cooled to room temperature, the mixture was poured into H<sub>2</sub>O and EtOAc. The separated organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexanes/EtOAc = 2:1) to give the <b>22c</b> (1.46 g, 74%) as a yellow oil.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.90 (6H, dd, <i>J</i> = 6.8, 4.0 Hz), 1.09 (3H, d, <i>J</i> = 6.8 Hz), 1.67–1.76 (1H, m), 2.27 (3H, s), 3.41 (2H, s), 3.83–3.92 (1H, m), 6.82 (1H, brs).</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> <i>N</i>-((2<i>S</i>)-3-Methylbutan-2-yl)-3-oxobutanamide (<b>22d</b>)</h4><div class="NLM_p last">Diketene (28.9 mL, 378.6 mmol) was added dropwise to a solution of (<i>S</i>)-3-methylbutan-2-amine (30 g, 344.2 mmol) in MeOH (180 mL) at 0 °C. After being stirred at room temperature for 20 h, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexane = 0:10 to 35:65) to give <b>22d</b> (56.6 g, 96%) as an orange oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.90 (6H, dd, <i>J</i> = 6.8, 4.2 Hz), 1.09 (3H, d, <i>J</i> = 6.8 Hz), 1.59–1.77 (1H, m), 2.27 (3H, s), 3.41 (2H, d, <i>J</i> = 1.5 Hz), 3.81–3.98 (1H, m), 6.82 (1H, brs). LC/MS <i>m</i>/<i>z</i> 171.8 (M + H).</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> <i>N</i>-(2-Chlorophenyl)-2-[(dimethylamino)methylene]-3-oxobutanamide (<b>23a</b>)</h4><div class="NLM_p last">To a mixture of <i>N</i>-(2-chlorophenyl)-3-oxobutanamide (2.63 g. 12.4 mmol), K<sub>2</sub>CO<sub>3</sub> (1.72 g, 12.4 mmol), and DMF (31 mL) was added dropwise 1,1-dimethoxy-<i>N</i>,<i>N</i>-dimethylmethanamine (3.3 mL, 24.9 mmol) over 30 min at room temperature, and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was slowly poured into H<sub>2</sub>O, and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The extract was washed with H<sub>2</sub>O, and dried over MgSO<sub>4</sub>, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexane = 5:5 to 10:0) to give <b>23a</b> (2.30 g, 69%) as a white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.32 (3H, s), 3.21 (6H, s), 6.95–7.00 (1H, m), 7.21–7.26 (1H, m), 7.37 (1H, dd, <i>J</i> = 8.0, 1.6 Hz), 7.73 (1H, s), 8.48 (1H, dd, <i>J</i> = 8.0, 1.6 Hz), 11.04 (1H, brs).</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 2-[(Dimethylamino)methylene]-<i>N</i>-(2-methylphenyl)-3-oxobutanamide (<b>23b</b>)</h4><div class="NLM_p last">Compound <b>23b</b> was prepared in a manner similar to that described for <b>23a</b> in 79% yield as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 2.32 (3H, s), 2.38 (3H, s), 3.22 (6H, brs), 6.99 (1H, dd, <i>J</i> = 7.6, 7.2 Hz), 7.17–7.21 (2H, m), 7.72 (1H, s), 8.13 (1H, d, <i>J</i> = 8.0 Hz), 10.60 (1H, brs).</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 2-[(Dimethylamino)methylene]-<i>N</i>-(3-methylbutan-2-yl)-3-oxobutanamide (<b>23c</b>)</h4><div class="NLM_p last">To a solution of compound <b>22c</b> (500 mg, 2.92 mmol) in DMF (6.0 mL) was added dropwise 1,1-dimethoxy-<i>N</i>,<i>N</i>-dimethylmethanamine (696 mg, 5.84 mmol) at room temperature over 5 min. The mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (EtOAc/MeOH = 95:5 to 9:1) to give <b>23c</b> (630 mg, 95%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.93 (6H, m), 1.11 (3H, d, <i>J</i> = 6.8 Hz), 1.71–1.79 (1H, m), 2.22 (3H, s), 3.11 (6H, m), 3.89–3.97 (1H, m), 7.50 (1H, brs), 7.61 (1H, brs).</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 2-[(Dimethylamino)methylene]-<i>N</i>-((2<i>S</i>)-3-methylbutan-2-yl)-3-oxobutanamide (<b>23d</b>)</h4><div class="NLM_p last">Compound <b>23d</b> was prepared in a manner similar to that described for <b>23a</b> in 84% yield as an orange oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.84–0.99 (6H, m), 1.11 (3H, dd, <i>J</i> = 6.6, 2.0 Hz), 1.68–1.79 (1H, m), 2.22 (3H, d, <i>J</i> = 2.0 Hz), 3.11 (6H, brs), 3.85–4.07 (1H, m), 7.51 (1H, brs), 7.62 (1H, brs).</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 4-Chloro-1-(2-chlorophenyl)-2-oxo-1,2-dihydropyridine-3-carbaldehyde (<b>24a</b>)</h4><div class="NLM_p last">POCl<sub>3</sub> (2.35 mL, 25.2 mL) was slowly added to DMF (12.6 mL) under ice-cooling, and the mixture was stirred for 15 min. To the reaction mixture was added a solution of <b>23a</b> (1.68 g, 6.29 mmol) in DMF (50.0 mL) under ice-cooling, and the reaction mixture was heated at 100 °C for 30 min. The reaction mixture was cooled to room temperature, and poured into ice H<sub>2</sub>O, and the mixture was neutralized with saturated aqueous NaHCO<sub>3</sub>, and extracted with EtOAc. The extract was washed with H<sub>2</sub>O, and dried over MgSO<sub>4</sub>, and the solvent was evaporated under reduced pressure. The residue was recrystallized from 2-propanol to give <b>24a</b> (995 mg, 59%) as a brown solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.43 (1H, d, <i>J</i> = 7.2 Hz), 7.36 (1H, d, <i>J</i> = 7.2 Hz), 7.37–7.39 (1H, m), 7.43–7.52 (2H, m), 7.59–7.62 (1H, m), 10.39 (1H, s).</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 4-Chloro-1-(2-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carbaldehyde (<b>24b</b>)</h4><div class="NLM_p last">Compound <b>24b</b> was prepared in a manner similar to that described for <b>24a</b> in 59% yield as a brown solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 2.20 (3H, s), 6.41 (1H, d, <i>J</i> = 7.6 Hz), 7.18 (1H, d, <i>J</i> = 8.0 Hz), 7.33–7.44 (4H, m), 10.40 (1H, s).</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 4-Chloro-1-(3-methylbutan-2-yl)-2-oxo-1,2-dihydropyridine-3-carbaldehyde (<b>24c</b>)</h4><div class="NLM_p last">Compound <b>24c</b> was prepared in a manner similar to that described for <b>20a</b> in 64% yield as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.85 (3H, d, <i>J</i> = 6.8 Hz), 1.04 (3H, d, <i>J</i> = 6.8 Hz), 1.36 (3H, d, <i>J</i> = 7.2 Hz), 1.88–1.97 (1H, m), 4.82–4.90 (1H, m), 6.34 (1H, d, <i>J</i> = 7.6 Hz), 7.38 (1H, d, <i>J</i> = 7.2 Hz), 10.40 (1H, s).</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 4-Chloro-1-((2<i>S</i>)-3-methylbutan-2-yl)-2-oxo-1,2-dihydropyridine-3-carbaldehyde (<b>24d</b>)</h4><div class="NLM_p last">(Chloromethylene)dimethylammonium chloride (75 g, 585.9 mmol) was added to a solution of <b>23d</b> (31 g, 136.98 mmol) in DMF (250 mL) at 0 °C. The mixture was stirred at 100 °C under a dry atmosphere (CaCl<sub>2</sub> tube) for 40 min. The mixture was poured into iced water at 0 °C and extracted with EtOAc. The organic layer was separated, washed with H<sub>2</sub>O and brine, dried over MgSO<sub>4</sub>, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexane = 0:10 to 2:8) to give <b>24d</b> (17.8 g, 57%) as an orange oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.85 (3H, d, <i>J</i> = 6.6 Hz), 1.04 (3H, d, <i>J</i> = 6.6 Hz), 1.36 (3H, d, <i>J</i> = 7.1 Hz), 1.92 (1H, m), 4.71–5.02 (1H, m), 6.34 (1H, d, <i>J</i> = 7.3 Hz), 7.38 (1H, d, <i>J</i> = 7.3 Hz), 10.40 (1H, d, <i>J</i> = 0.5 Hz). LC/MS <i>m</i>/<i>z</i> 228.2 (M + H).</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 4-Chloro-1-(2-chlorophenyl)-3-[(hydroxyimino)methyl]pyridin-2(1<i>H</i>)-one (<b>25a</b>)</h4><div class="NLM_p last">A mixture of <b>24a</b> (995 mg, 3.71 mmol), hydroxylamine hydrochloride (516 mg, 7.42 mmol), and sodium acetate (609 mg, 7.42 mmol) in MeOH/H<sub>2</sub>O (4:1, 12.4 mL) was heated at 75 °C for 2 h, cooled to room temperature, and poured into iced water. The resulting solid was collected by filtration, washed with H<sub>2</sub>O, and dried under reduced pressure to give <b>25a</b> (968 mg, 92%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.41 (1H, d, <i>J</i> = 7.2 Hz), 7.14 (1H, d, <i>J</i> = 7.2 Hz), 7.34–7.44 (3H, m), 7.54–7.56 (1H, m), 8.46 (1H, s).</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 4-Chloro-3-[(hydroxyimino)methyl]-1-(2-methylphenyl)pyridin-2(1<i>H</i>)-one (<b>25b</b>)</h4><div class="NLM_p last">Compound <b>25b</b> was prepared in a manner similar to that described for <b>25a</b> in 95% yield as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 2.15 (3H, s), 6.42 (1H, d, <i>J</i> = 7.2 Hz), 7.15 (1H, d, <i>J</i> = 8.0 Hz), 7.21 (1H, d, <i>J</i> = 7.2 Hz), 7.29–7.42 (3H, m), 8.50 (1H, s).</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 4-Chloro-3-[(hydroxyimino)methyl]-1-(3-methylbutan-2-yl)pyridin-2(1<i>H</i>)-one (<b>25c</b>)</h4><div class="NLM_p last">Compound <b>25c</b> was prepared in a manner similar to that described for <b>25a</b> in 77% yield as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.84 (3H, d, <i>J</i> = 6.8 Hz), 1.02 (3H, d, <i>J</i> = 6.4 Hz), 1.32 (3H, d, <i>J</i> = 6.8 Hz), 1.85–1.94 (1H, m), 4.95–4.99 (1H, m), 6.34 (1H, d, <i>J</i> = 7.6 Hz), 7.19 (1H, d, <i>J</i> = 7.2 Hz), 8.51 (1H, s), 10.89 (1H, brs).</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 4-Chloro-3-[(hydroxyimino)methyl]-1-((2<i>S</i>)-3-methylbutan-2-yl)pyridin-2(1<i>H</i>)-one (<b>25d</b>)</h4><div class="NLM_p last">Compound <b>25d</b> was prepared in a manner similar to that described for <b>21b</b> in 68% yield as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.82 (3H, d, <i>J</i> = 6.6 Hz), 1.05 (3H, d, <i>J</i> = 6.6 Hz), 1.41 (3H, d, <i>J</i> = 6.8 Hz), 1.85–2.08 (1H, m), 4.74–5.12 (1H, m), 6.66 (1H, d, <i>J</i> = 7.3 Hz), 7.56 (1H, d, <i>J</i> = 7.3 Hz), 8.85 (1H, s). LC/MS <i>m</i>/<i>z</i> 228.2 (M + H).</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 4-Chloro-1-(2-chlorophenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>26a</b>)</h4><div class="NLM_p last">To a solution of <b>25a</b> (968 mg, 3.42 mmol) in CH<sub>3</sub>CN (6.80 mL) was added POCl<sub>3</sub> (0.319 mL, 3.42 mmol) at room temperature. The reaction mixture was heated at 90 °C for 1 h, cooled to room temperature, and poured into iced water, and the mixture was neutralized with saturated aqueous NaHCO<sub>3</sub> under ice-cooling. The aqueous layer was extracted with EtOAc. The extract was washed with H<sub>2</sub>O, and dried over MgSO<sub>4</sub>, and the solvent was evaporated under reduced pressure to give <b>26a</b> (891 mg, 98%) as a light brown solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.47 (1H, d, <i>J</i> = 7.6 Hz), 7.35 (1H, dd, <i>J</i> = 7.6, 1.6 Hz), 7.39 (1H, d, <i>J</i> = 7.6 Hz), 7.42–7.50 (2H, m), 7.60 (1H, dd, <i>J</i> = 7.6, 1.6 Hz).</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 4-Chloro-1-(2-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>26b</b>)</h4><div class="NLM_p last">Compound <b>26b</b> was prepared in a manner similar to that described for <b>26a</b> in 53% yield as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 2.17 (3H, s), 6.45 (1H, d, <i>J</i> = 7.2 Hz), 7.13–7.15 (1H, m), 7.32–7.44 (4H, m).</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 4-Chloro-1-(3-methylbutan-2-yl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>26c</b>)</h4><div class="NLM_p last">Compound <b>26c</b> was prepared in a manner similar to that described for <b>26a</b> in 100% yield a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.83 (3H, d, <i>J</i> = 6.4 Hz), 1.03 (3H, d, <i>J</i> = 6.4 Hz), 1.36 (3H, d, <i>J</i> = 7.2 Hz), 1.87–1.96 (1H, m), 4.77–4.84 (1H, m), 6.39 (1H, d, <i>J</i> = 7.2 Hz), 7.42 (1H, d, <i>J</i> = 7.6 Hz).</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 4-Chloro-1-((2<i>S</i>)-3-methylbutan-2-yl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>26d</b>)</h4><div class="NLM_p last">SOCl<sub>2</sub> (13.89 mL, 191.18 mmol) was added to a solution of <b>25d</b> (23.2 g, 95.59 mmol) in CH<sub>3</sub>CN (300 mL) at room temperature. The mixture was stirred at room temperature for 1 h. After evaporation of CH<sub>3</sub>CN, the residue was triturated with IPE/EtOAc/hexane, and the solid was removed by filtration. The filtrate was evaporated. The residue was diluted with EtOAc, washed with saturated aqueous NaHCO<sub>3</sub> and brine, and dried over MgSO<sub>4</sub>. After removal of the solvent in vacuo, the residue was purified by silica gel column chromatography (EtOAc/hexane = 0:10 to 1:3) to give <b>26d</b> (14.6 g, 68%) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.83 (3H, d, <i>J</i> = 6.6 Hz), 1.03 (3H, d, <i>J</i> = 6.6 Hz), 1.36 (3H, d, <i>J</i> = 6.8 Hz), 1.79–2.05 (1H, m), 4.71–4.91 (1H, m), 6.38 (1H, d, <i>J</i> = 7.6 Hz), 7.40 (1H, d, <i>J</i> = 7.3 Hz). LC/MS <i>m</i>/<i>z</i> 224.8 (M + H).</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 5-Bromo-4-chloro-1-(2-chlorophenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>27a</b>)</h4><div class="NLM_p last">To a mixture of <b>26a</b> (16.4 g, 61.9 mmol) and DMF (124 mL) was added <i>N</i>-bromosuccinimide (16.5 g, 93.5 mmol), and the mixture was stirred at 60 °C for 40 h. The reaction mixture was cooled to room temperature, and poured into H<sub>2</sub>O. The resulting solid was collected by filtration, and washed with H<sub>2</sub>O to give <b>27a</b> (20.9 g, 98%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.36 (1H, dd, <i>J</i> = 7.6, 1.6 Hz), 7.43–7.52 (2H, m), 7.61 (1H, dd, <i>J</i> = 8.0, 1.6 Hz), 7.73 (1H, s).</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 5-Bromo-4-chloro-1-(2-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>27b</b>)</h4><div class="NLM_p last">Compound <b>27b</b> was prepared in a manner similar to that described for <b>27a</b> in 81% yield as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 2.19 (3H, s), 7.14–7.16 (1H, m), 7.32–7.75 (3H, m), 7.76 (1H, s).</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 5-Bromo-4-chloro-1-(3-methylbutan-2-yl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>27c</b>)</h4><div class="NLM_p last">Compound <b>27c</b> was prepared in a manner similar to that described for <b>27a</b> in 94% yield as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.85 (3H, d, <i>J</i> = 6.8 Hz), 1.03 (3H, d, <i>J</i> = 6.8 Hz), 1.38 (3H, d, <i>J</i> = 6.8 Hz), 1.87–1.96 (1H, m), 4.77–4.84 (1H, m), 7.66 (1H, s).</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 5-Bromo-4-chloro-1-((2<i>S</i>)-3-methylbutan-2-yl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>27d</b>)</h4><div class="NLM_p last">Compound <b>27d</b> was prepared in a manner similar to that described for <b>27a</b> in 97% yield as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.85 (3H, d, <i>J</i> = 6.6 Hz), 1.03 (3H, d, <i>J</i> = 6.8 Hz), 1.38 (3H, d, <i>J</i> = 7.1 Hz), 1.82–2.00 (1H, m), 4.69–4.90 (1H, m), 7.66 (1H, s). LC/MS <i>m</i>/<i>z</i> 303.2.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 4-Chloro-1-(2-methylphenyl)-2-oxo-5-phenyl-1,2-dihydropyridine-3-carbonitrile (<b>28</b>)</h4><div class="NLM_p last">A mixture of compound <b>27b</b> (400 mg, 1.24 mmol), phenylboronic acid (211 mg, 1.73 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (143 mg, 0.124 mmol), and 2 M aqueous Na<sub>2</sub>CO<sub>3</sub> (1.24 mL, 2.47 mmol) in DME (4.0 mL) was subjected to microwave irradiation at 90 °C for 1 h. The reaction mixture was cooled to room temperature and partitioned between EtOAc and H<sub>2</sub>O. The separated organic layer was washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexanes = 1:3) to give the crude compound <b>28</b> (255 mg, 64%) as a brown oil, which was used for the next step without further purification. LC/MS <i>m</i>/<i>z</i> 321.1 (M + H).</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 3-Amino-5-(2-methylphenyl)-7-phenyl-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>7</b>)</h4><div class="NLM_p last">To a solution of compound <b>28</b> (255 mg, 0.795 mmol) in EtOH (1.6 mL) was added hydrazine monohydrate (59.7 mg, 1.19 mmol) at room temperature. The reaction mixture was heated at 70 °C for 2 h. The mixture was cooled to room temperature and partitioned between EtOAc and H<sub>2</sub>O. The separated organic layer was dried over MgSO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 9:1) to give <b>7</b> (67.0 mg, 27%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 2.12 (3H, s), 5.36 (1H, brs), 6.14 (1H, brs), 7.24–7.45 (7H, m), 7.58 (1H, brs), 7.94 (1H, brs), 12.24 (1H, brs). LC/MS <i>m</i>/<i>z</i> 317.3 (M + H). HPLC purity 99.2%.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 3-Amino-7-bromo-5-(2-chlorophenyl)-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>29a</b>)</h4><div class="NLM_p last">To a solution of <b>27a</b> (20.9 g, 60.8 mmol) in EtOH (122 mL) was added hydrazine monohydrate (6.08 g, 122 mmol) at room temperature. The reaction mixture was heated at 70 °C for 2 h. The reaction mixture was cooled to room temperature, and poured into H<sub>2</sub>O. The resulting solid was collected by filtration, and washed with H<sub>2</sub>O to give <b>29a</b> (16.9 g, 82%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.35 (1H, brs), 7.44–7.52 (3H, m), 7.60–7.64 (1H, m). LC/MS <i>m</i>/<i>z</i> 339.2 (M + H).</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 3-Amino-7-bromo-5-(2-methylphenyl)-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>29b</b>)</h4><div class="NLM_p last">Compound <b>29b</b> was prepared in a manner similar to that described for <b>29a</b> in 94% yield as a yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 2.16 (3H, s), 7.24 (1H, d, <i>J</i> = 7.2 Hz), 7.31–7.39 (4H, m).</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 3-Amino-7-bromo-5-(3-methylbutan-2-yl)-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>29c</b>)</h4><div class="NLM_p last">Compound <b>29c</b> was prepared in a manner similar to that described for <b>29a</b> in 87% yield as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.81 (3H, d, <i>J</i> = 6.4 Hz), 1.05 (3H, d, <i>J</i> = 6.4 Hz), 1.34 (3H, d, <i>J</i> = 7.2 Hz), 1.81–1.90 (1H, m), 4.78–4.84 (1H, m), 4.89 (2H, brs), 7.11 (1H, s), 9.58 (1H, brs).</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 3-Amino-7-bromo-5-((2<i>S</i>)-3-methylbutan-2-yl)-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>29d</b>) (Method A)</h4><div class="NLM_p">Compound <b>29d</b> was prepared in a manner similar to that described for <b>29a</b> in 82% yield as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.81 (3H, d, <i>J</i> = 6.6 Hz), 1.05 (3H, d, <i>J</i> = 6.6 Hz), 1.34 (3H, d, <i>J</i> = 6.8 Hz), 1.78–1.92 (1H, m), 4.64–5.00 (3H, m), 7.12 (1H, s), 9.27 (1H, brs). LC/MS <i>m</i>/<i>z</i> 299.2 (M + H).</div><div class="NLM_p last">Liquid chromatography analysis was performed on a HITACHI system, equipped with a CHIRALPAK AD (4.6 mm ID × 250 mm L, 10 μm-particle size, Daicel, Japan), eluting with a flow rate of 0.5 mL/min hexane/EtOH = 600/400 (v/v) at 30 °C. Retention time: 10.00 min (99.4% ee).</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 3-Amino-7-bromo-5-((2<i>S</i>)-3-methylbutan-2-yl)-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>29d</b>) (Method B)</h4><div class="NLM_p last">Liquid chromatography separation of compound <b>29c</b> (7.89 g) was performed on a YMC K-Prep system, equipped with a CHIRALPAK AD (50 mm ID × 500 mm L, 20 μm-particle size, Daicel, Japan), eluting with a flow rate of 80 mL/min hexane/EtOH = 600/400/1 (v/v/v) at 30 °C. Elution in shorter retention time was collected to give <b>29d</b> (3.75 g, 48%) as a colorless solid. Liquid chromatography analysis was performed on a HITACHI system, equipped with a CHIRALPAK AD (4.6 mm ID × 250 mm L, 10 μm-particle size, Daicel, Japan), eluting with a flow rate of 0.5 mL/min hexane/EtOH = 600/400 (v/v) at 30 °C. Retention time: 9.88 min (>99.9% ee). LC/MS <i>m</i>/<i>z</i> 299.1 (M + H).</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 3-Amino-5-(2-chlorophenyl)-7-(1-methyl-1<i>H</i>-pyrazol-3-yl)-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>5</b>)</h4><div class="NLM_p last">The mixture of <b>29a</b> (300 mg, 0.883 mmol), KOAc (173 mg, 1.77 mmol), PdCl<sub>2</sub>(dppf) (36.1 mg, 0.044 mmol), and bis(pinacolato)diboron (337 mg, 1.33 mmol) in DMF (5.0 mL) was subjected to microwave irradiation at 120 °C for 5 h. After being cooled to room temperature, to the mixture were added compound 3-iodo-1-methyl-1<i>H</i>-pyrazole (551 mg, 2.65 mmol), 2 M aqueous Na<sub>2</sub>CO<sub>3</sub> (884 μL, 1.77 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (102 mg, 0.088 mmol) at room temperature. The reaction mixture was subjected to microwave irradiation at 120 °C for 4 h. After being cooled to room temperature, the mixture was partitioned between EtOAc and H<sub>2</sub>O. The separated organic layer was washed with H<sub>2</sub>O and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 20:1), followed by preparative HPLC to give compound <b>5</b> (24.0 mg, 8%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 3.96 (3H, s), 6.59 (1H, s), 7.49–7.54 (3H, m), 7.57–7.65 (3H, m). LC/MS <i>m</i>/<i>z</i> 341.2 (M + H). HPLC purity 100.0%.</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 3-Amino-5-(2-chlorophenyl)-7-(pyridin-2-yl)-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>6</b>)</h4><div class="NLM_p last">Compound <b>6</b> was prepared in a manner similar to that described for <b>5</b> in 36% yield as pale yellow crystals. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.77 (2H, s), 7.19–7.25 (1H, m), 7.43–7.51 (3H, m), 7.57–7.64 (3H, m), 7.68–7.75 (1H, m), 8.64–8.69 (1H, m), 11.37 (1H, brs). LC/MS <i>m</i>/<i>z</i> 338.0 (M + H). HPLC purity 99.5%.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 3-Amino-5-(2-methylphenyl)-7-(1-methyl-1<i>H</i>-pyrazol-3-yl)-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>8</b>)</h4><div class="NLM_p last">A mixture of compound <b>29b</b> (250 mg, 0.783 mmol), 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (440 mg, 1.55 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (91.0 mg, 0.0783 mmol), and 2 M aqueous Na<sub>2</sub>CO<sub>3</sub> (0.783 mL, 1.57 mmol) in DMF (4.0 mL) was subjected to microwave irradiation at 120 °C for 3 h. After being cooled to room temperature, the mixture was partitioned between EtOAc and H<sub>2</sub>O. The separated organic layer was washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 9:1) to give <b>8</b> (72.0 mg, 29%) as a brown solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 2.18 (3H, s), 3.97 (3H, s), 6.58 (1H, brs), 7.29–7.42 (4H, m), 7.58–7.60 (2H, m). LC/MS <i>m</i>/<i>z</i> 321.3 (M + H). HPLC purity 97.4%.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 3-Amino-5-(3-methylbutan-2-yl)-7-(1-methyl-1<i>H</i>-pyrazol-3-yl)-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>9</b>)</h4><div class="NLM_p last">A mixture of compound <b>29c</b> (332 mg, 1.11 mmol), 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (347 mg, 1.67 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (128 mg, 0.111 mmol), and 2 M aqueous Na<sub>2</sub>CO<sub>3</sub> (1.11 mL, 2.22 mmol) in DMF (6.0 mL) was subjected to microwave irradiation at 120 °C for 1 h. After being cooled to room temperature, the mixture was partitioned between EtOAc and H<sub>2</sub>O. The separated organic layer was washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/MeOH = 97:3 to 95:5), followed by preparative HPLC to give <b>9</b> (36 mg, 11%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.82 (3H, d, <i>J</i> = 6.8 Hz), 1.08 (3H, d, <i>J</i> = 6.8 Hz), 1.39 (3H, d, <i>J</i> = 6.8 Hz), 1.88–1.97 (1H, m), 3.96 (3H, s), 4.77 (2H, brs), 4.84–4.94 (1H, m), 6.42 (1H, d, <i>J</i> = 2.4 Hz), 7.31 (1H, s), 7.39 (1H, d, <i>J</i> = 2.4 Hz), 10.44 (1H, brs). LC/MS <i>m</i>/<i>z</i> 301.2 (M + H). HPLC purity 100.0%.</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 3-Amino-5-(3-methylbutan-2-yl)-7-[5-(morpholin-4-yl)pyridin-2-yl]-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>13</b>)</h4><div class="NLM_p last">Compound <b>13</b> was prepared in a manner using <b>29c</b> similar to that described for <b>5</b> in 26% yield as a colorless solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 0.84 (3H, d, <i>J</i> = 6.7 Hz), 1.09 (3H, d, <i>J</i> = 6.6 Hz), 1.41 (3H, d, <i>J</i> = 7.0 Hz), 1.87–2.01 (1H, m), 3.19–3.27 (4H, m), 3.86–3.94 (4H, m), 4.78 (2H, s), 4.85–4.99 (1H, m), 7.24–7.29 (1H, m), 7.47 (1H, s), 7.52 (1H, d, <i>J</i> = 8.9 Hz), 8.30 (1H, d, <i>J</i> = 2.8 Hz), 11.08 (1H, brs). LC/MS <i>m</i>/<i>z</i> 383.2 (M + H). HPLC purity 100.0%.</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 3-Amino-5-((2<i>S</i>)-3-methylbutan-2-yl)-7-[5-(morpholin-4-yl)pyridin-2-yl]-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>14</b>) (Method A)</h4><div class="NLM_p last">Liquid chromatography separation of compound <b>13</b> (90 mg) was performed on a YMC K-Prep system, equipped with a CHIRALCEL OJ (50 mm ID × 500 mm L, 20 μm-particle size, Daicel, Japan), eluting with a flow rate of 80 mL/min hexane/EtOH/DEA = 700/300/1 (v/v/v) at 35 °C. Elution in longer retention time was collected. The solvent was evaporated. The solid was triturated with Et<sub>2</sub>O to give <b>14</b> (34 mg, 76%) as a colorless solid. Liquid chromatography analysis was performed on a HITACHI system, equipped with a CHIRALCEL OJ (4.6 mm ID × 250 mm L, 10 μm-particle size, Daicel, Japan), eluting with a flow rate of 1 mL/min hexane/ethanol/DEA = 700/300/1 (v/v/v) at 35 °C. Retention time: 16.41 min (99.2% ee). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 0.84 (3H, d, <i>J</i> = 6.6 Hz), 1.09 (3H, d, <i>J</i> = 6.6 Hz), 1.41 (3H, d, <i>J</i> = 7.0 Hz), 1.86–2.04 (1H, m), 3.20–3.27 (4H, m), 3.87–3.96 (4H, m), 4.78 (2H, s), 4.87–4.97 (1H, m), 7.24–7.29 (1H, m), 7.47 (1H, s), 7.52 (1H, d, <i>J</i> = 8.9 Hz), 8.30 (1H, d, <i>J</i> = 2.8 Hz), 11.08 (1H, brs). LC/MS <i>m</i>/<i>z</i> 383.2 (M + H). HPLC purity 100.0%.</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 3-Amino-5-((2<i>R</i>)-3-methylbutan-2-yl)-7-[5-(morpholin-4-yl)pyridin-2-yl]-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>15</b>)</h4><div class="NLM_p last">Liquid chromatography separation of compound <b>13</b> (90 mg) was performed on a YMC K-Prep system, equipped with a CHIRALCEL OJ (50 mm ID × 500 mm L., 20 μm-particle size, Daicel, Japan), eluting with a flow rate of 80 mL/min hexane/ethanol/DEA = 700/300/1 (v/v/v) at 35 °C. Elution in shorter retention time was collected. The solvent was evaporated. The solid was triturated with EtOAc/Et<sub>2</sub>O to give <b>15</b> (25 mg, 56%) as a colorless solid. Liquid chromatography analysis was performed on a HITACHI system, equipped with a CHIRALCEL OJ (4.6 mm ID × 250 mm L, 10 μm-particle size, Daicel, Japan), eluting with a flow rate of 1 mL/min hexane/ethanol/DEA = 700/300/1 (v/v/v) at 35 °C. Retention time: 12.71 min (99.9% ee). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 0.84 (3H, d, <i>J</i> = 6.7 Hz), 1.09 (3H, d, <i>J</i> = 6.6 Hz), 1.41 (3H, d, <i>J</i> = 7.0 Hz), 1.87–2.01 (1H, m), 3.19–3.27 (4H, m), 3.86–3.94 (4H, m), 4.78 (2H, s), 4.85–4.99 (1H, m), 7.24–7.29 (1H, m), 7.47 (1H, s), 7.52 (1H, d, <i>J</i> = 8.9 Hz), 8.30 (1H, d, <i>J</i> = 2.8 Hz), 11.08 (1H, brs). LC/MS <i>m</i>/<i>z</i> 383.3 (M + H). HPLC purity 100.0%.</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 3-Amino-5-((2<i>S</i>)-3-methylbutan-2-yl)-7-[5-(morpholin-4-yl)pyridin-2-yl]-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>14</b>) (Method B)</h4><div class="NLM_p last">Compound <b>14</b> was prepared in a manner using <b>29d</b> similar to that described for <b>5</b> in 17% yield a colorless solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 0.84 (3H, d, <i>J</i> = 6.6 Hz), 1.09 (3H, d, <i>J</i> = 6.6 Hz), 1.41 (3H, d, <i>J</i> = 7.1 Hz), 1.85–2.00 (1H, m), 3.20–3.28 (4H, m), 3.88–3.94 (4H, m), 4.79 (2H, s), 4.87–4.98 (1H, m), 7.23–7.30 (1H, m), 7.47 (1H, s), 7.50–7.55 (1H, m), 8.30 (1H, d, <i>J</i> = 2.7 Hz), 11.09 (1H, brs). Liquid chromatography analysis was performed on a HITACHI system, equipped with a CHIRALCEL OJ3 (4.6 mm ID × 250 mm L, 10 μm-particle size, Daicel, Japan), eluting with a flow rate of 1 mL/min hexane/ethanol/DEA = 700/300/1 (v/v/v) at 35 °C. Retention time: 17.82 min (99.9% ee). LC/MS <i>m</i>/<i>z</i> 383.4 (M + H).</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 3-Amino-5-((2<i>S</i>)-3-methylbutan-2-yl)-7-(1-methyl-1<i>H</i>-pyrazol-3-yl)-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>16</b>)</h4><div class="NLM_p last">Compound <b>16</b> was prepared in a manner similar to that described for <b>9</b> in 29% yield as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.82 (3H, d, <i>J</i> = 6.8 Hz), 1.08 (3H, d, <i>J</i> = 6.6 Hz), 1.39 (3H, d, <i>J</i> = 7.1 Hz), 1.85–1.99 (1H, m), 3.96 (3H, s), 4.77 (2H, s), 4.85–4.97 (1H, m), 6.43 (1H, d, <i>J</i> = 2.2 Hz), 7.31 (1H, s), 7.39 (1H, d, <i>J</i> = 2.2 Hz), 10.45 (1H, brs). LC/MS <i>m</i>/<i>z</i> 301.3 (M + H). HPLC purity 100.0%.</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 3-Amino-5-((2<i>S</i>)-3-methylbutan-2-yl)-7-[1-methyl-5-(morpholin-4-yl)-1<i>H</i>-pyrazol-3-yl]-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>17</b>)</h4><div class="NLM_p last">Compound <b>17</b> was prepared in a manner similar to that described for <b>5</b> in 30% yield as a white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 0.82 (3H, d, <i>J</i> = 6.8 Hz), 1.08 (3H, d, <i>J</i> = 6.8 Hz), 1.39 (3H, d, <i>J</i> = 7.2 Hz), 1.94 (1H, m), 2.92–3.01 (4H, m), 3.77 (3H, s), 3.83–3.91 (4H, m), 4.77 (2H, s), 4.81–4.97 (1H, m), 6.00 (1H, s). LC/MS <i>m</i>/<i>z</i> 386.4 (M + H). HPLC purity 99.8%.</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 3-Amino-7-[5-(3,6-dihydro-2<i>H</i>-pyran-4-yl)-1-methyl-1<i>H</i>-pyrazol-3-yl]-5-((2<i>S</i>)-3-methylbutan-2-yl)-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>30</b>)</h4><div class="NLM_p last">Compound <b>30</b> was prepared in a manner similar to that described for <b>5</b> in 41% yield as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.82 (3H, d, <i>J</i> = 6.6 Hz), 1.07 (3H, d, <i>J</i> = 6.6 Hz), 1.39 (3H, d, <i>J</i> = 6.8 Hz), 1.86–1.97 (1H, m), 2.41–2.50 (2H, m), 3.92–3.97 (5H, m), 4.31–4.39 (2H, m), 4.78 (2H, s), 4.84–4.95 (1H, m), 5.98–6.02 (1H, m), 6.34 (1H, s), 7.29 (1H, s), 10.44 (1H, brs). LC/MS <i>m</i>/<i>z</i> 383.4 (M + H).</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 3-Amino-5-((2<i>S</i>)-3-methylbutan-2-yl)-7-[1-methyl-5-(tetrahydro-2H-pyran-4-yl)-1<i>H</i>-pyrazol-3-yl]-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>18</b>)</h4><div class="NLM_p last">A mixture of <b>30</b> (62 mg, 0.16 mmol) and PtO<sub>2</sub> (8 mg, 0.04 mmol) in MeOH (5 mL) was hydrogenated under balloon pressure at room temperature for 3 h. Insoluble material was removed by filtration through Celite. The filtrate was evaporated to give crude product (63 mg). The crude product was purified by preparative HPLC. Obtained solid was crystallized from EtOAc/hexane to give <b>18</b> (28 mg, 45%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.82 (3H, d, <i>J</i> = 6.6 Hz), 1.08 (3H, d, <i>J</i> = 6.6 Hz), 1.40 (3H, d, <i>J</i> = 7.1 Hz), 1.75–1.99 (5H, m), 2.82–2.91 (1H, m), 3.51–3.62 (2H, m), 3.88 (3H, s), 4.06–4.14 (2H, m), 4.76 (2H, s), 4.84–4.94 (1H, m), 6.23 (1H, s), 7.29 (1H, s), 10.44 (1H, brs). LC/MS <i>m</i>/<i>z</i> 385.4 (M + H). HPLC purity 100.0%.</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 3-Amino-7-[5-(1,1-dioxidothiomorpholin-4-yl)-1-methyl-1<i>H</i>-pyrazol-3-yl]-5-((2<i>S</i>)-3-methylbutan-2-yl)-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>19</b>)</h4><div class="NLM_p last">Compound <b>19</b> was prepared in a manner similar to that described for <b>5</b> in 32% yield as off-white crystals. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 0.82 (3H, d, <i>J</i> = 6.8 Hz), 1.08 (3H, d, <i>J</i> = 6.4 Hz), 1.39 (3H, d, <i>J</i> = 6.8 Hz), 1.83–2.03 (1H, m), 3.18–3.33 (4H, m), 3.46–3.60 (4H, m), 3.79 (3H, s), 4.77 (2H, s), 4.82–4.99 (1H, m), 6.13 (1H, s), 7.25 (1H, s), 10.40 (1H, brs). LC/MS <i>m</i>/<i>z</i> 434.1 (M + H). HPLC purity 99.6%.</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 3-Amino-7-[5-(2-hydroxypropan-2-yl)-1-methyl-1<i>H</i>-pyrazol-3-yl]-5-((2<i>S</i>)-3-methylbutan-2-yl)-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>20</b>)</h4><div class="NLM_p last">A mixture of <b>29d</b> (5.4 g, 18.05 mmol), bis(pinacolato)diboron (9.17 g, 36.10 mmol), Pd(Ph<sub>3</sub>P)<sub>4</sub> (3.13 g, 2.71 mmol), and potassium acetate (3.54 g, 36.10 mmol) in DMA (50 mL) was stirred at 110 °C under Ar for 4 h. It was cooled to room temperature. <b>47</b> (5.93 g, 27.08 mmol) in DMA (25 mL), Pd(Ph<sub>3</sub>P)<sub>4</sub> (2.086 g, 1.81 mmol), and 2 M aqueous Na<sub>2</sub>CO<sub>3</sub> (18.05 mL, 36.10 mmol) were added to the reaction mixture at room temperature, and the mixture was stirred at 120 °C under Ar for 2 h. It was cooled to room temperature, and H<sub>2</sub>O was added to the mixture. The mixture was extracted with EtOAc. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (NH silica gel, EtOAc/hexane = 0:10 to 10:0, followed by EtOAc/MeOH = 9:1) to give a pale yellow solid. The solid was purified by preparative HPLC. After addition of saturated aqueous NaHCO<sub>3</sub> solution, the purified fraction was evaporated. The mixture was extracted with EtOAc. The organic layer was dried over MgSO<sub>4</sub>, and the solvent was evaporated under reduced pressure to give the solid, which was triturated with EtOAc–hexane to give <b>20</b> (2.21 g, 34%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.74–0.85 (3H, m), 1.04–1.13 (3H, m), 1.23–1.31 (1H, m), 1.37–1.43 (3H, m), 1.70 (6H, s), 1.90–2.00 (1H, m), 4.11 (3H, s), 4.76 (2H, s), 4.84–4.94 (1H, m), 6.26 (1H, s), 7.26 (1H, s), 10.42 (1H, brs). LC/MS <i>m</i>/<i>z</i> 359.4 (M + H). HPLC purity 99.2%.</div></div><div id="sec5_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 1-<i>sec</i>-Butyl-4-methoxy-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>32a</b>)</h4><div class="NLM_p last">2-Bromobutane (776 mg, 5.66 mmol) was added to a mixture of <b>31</b> (500 mg, 3.33 mmol), Cs<sub>2</sub>CO<sub>3</sub> (2170 mg, 6.66 mmol), and KI (553 mg, 3.33 mmol) in DMF (10 mL)/DME (10 mL) at room temperature. The mixture was stirred at 60 °C overnight. The mixture was diluted with saturated aqueous NaHCO<sub>3</sub> at room temperature and extracted with EtOAc three times. The combined organic layer was washed with brine, dried over MgSO<sub>4</sub>, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexane = 1:9 to 10:0) to give <b>32a</b> (330 mg, 48%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 0.74 (3H, t, <i>J</i> = 7.4 Hz), 1.27 (3H, d, <i>J</i> = 6.8 Hz), 1.68 (2H, quin, <i>J</i> = 7.4 Hz), 3.99 (3H, s), 4.69–4.90 (1H, m), 6.44 (1H, d, <i>J</i> = 7.9 Hz), 8.09 (1H, d, <i>J</i> = 7.9 Hz). LC/MS <i>m</i>/<i>z</i> 206.8 (M + H).</div></div><div id="sec5_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 1-Isobutyl-4-methoxy-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>32b</b>)</h4><div class="NLM_p last">A mixture of <b>31</b> (15.0 g, 100 mmol), 1-bromo-2-methylpropane (21.4 g, 150.0 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (65.2 g, 200.0 mmol) in DMSO (150 mL) was stirred at 50 °C for 24 h. The mixture was cooled to room temperature, then poured into H<sub>2</sub>O, and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give a residue, which was washed with ether to give <b>32b</b> (13.0 g, 63%) as a yellow solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 0.93 (6H, d, <i>J</i> = 7.0 Hz), 2.12–2.18 (1H, m), 3.74 (2H, d, <i>J</i> = 7.0 Hz), 4.00 (3H, s), 6.11 (1H, d, <i>J</i> = 8.0 Hz), 7.51 (1H, d, <i>J</i> = 7.5 Hz). LC/MS <i>m</i>/<i>z</i> 207.2 (M + H).</div></div><div id="sec5_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 4-Methoxy-1-(2-methylpentan-3-yl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>32c</b>)</h4><div class="NLM_p last">3-Bromo-2-methylpentane (1099 mg, 6.66 mmol) was added to a mixture of <b>31</b> (500 mg, 3.33 mmol), KI (553 mg, 3.33 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (2170 mg, 6.66 mmol) in DMF (10 mL) at room temperature. The mixture was stirred at 60 °C overnight. The mixture was diluted with saturated aqueous NaHCO<sub>3</sub> at room temperature and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexane = 5:5 to 10:0) to give <b>32c</b> (43 mg, 6%) as a pale orange oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 0.71–0.84 (6H, m), 1.04 (3H, d, <i>J</i> = 6.4 Hz), 1.69–2.16 (3H, m), 4.01 (3H, s), 4.55–4.99 (1H, m), 6.16 (1H, d, <i>J</i> = 7.9 Hz), 7.41 (1H, d, <i>J</i> = 7.9 Hz). LC/MS <i>m</i>/<i>z</i> 234.9 (M + H).</div></div><div id="sec5_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 5-Bromo-1-<i>sec</i>-butyl-4-methoxy-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>33a</b>)</h4><div class="NLM_p last">Compound <b>33a</b> was prepared in a manner similar to that described for <b>27a</b> in 72% yield as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 0.75 (3H, t, <i>J</i> = 7.4 Hz), 1.29 (3H, d, <i>J</i> = 6.8 Hz), 1.60–1.80 (2H, m), 4.32 (3H, s), 4.65–4.82 (1H, m), 8.30 (1H, s). LC/MS <i>m</i>/<i>z</i> 284.8 (M + H).</div></div><div id="sec5_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 5-Bromo-4-chloro-1-isobutyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>33b</b>)</h4><div id="sec5_1_48_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> Step 1 of 2</h5><div class="NLM_p last">To a solution of <b>32b</b> (12.88 g, 62.5 mmol) in DMF (100 mL) at room temperature was added <i>N</i>-bromosuccinimide (22.26 g, 125.0 mmol) portionwise over 20 min. The reaction mixture was heated at 70 °C for 48 h. The reaction mixture was cooled to room temperature, poured into H<sub>2</sub>O, and extracted with EtOAc. The combined organic layers were washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give a residue, which was purified by silica gel column chromatography (EtOAc/petroleum ether = 1:3) to give 5-bromo-4-hydroxy-1-isobutyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (4.0 g, 24%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 0.82 (6H, d, <i>J</i> = 6.8 Hz), 1.95–3.05 (1H, m), 3.64 (2H, d, <i>J</i> = 7.6 Hz), 8.24 (1H, s), 11.82 (1H, brs). LC/MS <i>m</i>/<i>z</i> 271.1 (M + H).</div></div><div id="sec5_1_48_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> Step 2 of 2</h5><div class="NLM_p last">A mixture of 5-bromo-4-hydroxy-1-isobutyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (6.6 g, 24.35 mmol) in POCl<sub>3</sub> (50 mL) was heated at 120 °C for 24 h. The mixture was cooled, poured into H<sub>2</sub>O, neutralized with K<sub>2</sub>CO<sub>3</sub> to pH 10, and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give a residue, which was purified by silica gel column chromatography (EtOAc/petroleum ether = 15:85) to give <b>33b</b> (4.6 g, 65%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 0.97 (6H, d, <i>J</i> = 6.8 Hz), 2.11–2.21 (1H, m), 3.79 (2H, d, <i>J</i> = 7.6 Hz), 7.73 (1H, s). LC/MS <i>m</i>/<i>z</i> 289.0 (M + H).</div></div></div><div id="sec5_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 5-Bromo-4-methoxy-1-(2-methylpentan-3-yl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (<b>33c</b>)</h4><div class="NLM_p last">Compound <b>33c</b> was prepared in a manner similar to that described for <b>27a</b> in 47% yield as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.72–0.87 (6H, m), 1.04 (3H, d, <i>J</i> = 6.8 Hz), 1.39–2.02 (3H, m), 4.45 (3H, s), 4.54–4.92 (1H, br), 7.42 (1H, s). LC/MS <i>m</i>/<i>z</i> 312.9 (M + H).</div></div><div id="sec5_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 3-Amino-5-<i>sec</i>-butyl-7-(1-methyl-1<i>H</i>-pyrazol-3-yl)-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>10</b>)</h4><div id="sec5_1_50_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> Step 1 of 2</h5><div class="NLM_p last">Pd(Ph<sub>3</sub>P)<sub>4</sub> (52.7 mg, 0.05 mmol) was added to a mixture of 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (114 mg, 0.55 mmol), <b>33a</b> (130 mg, 0.46 mmol), and aqueous 2 M Na<sub>2</sub>CO<sub>3</sub> (1.37 mL, 2.74 mmol) in DME (2.5 mL) at room temperature. The mixture was heated at 100 °C for 1 h under microwave irradiation. After being cooled, the mixture was diluted with H<sub>2</sub>O at room temperature and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (NH silica gel, EtOAc/hexane = 5:5 to 10:0) to give 1-<i>sec</i>-butyl-4-methoxy-5-(1-methyl-1<i>H</i>-pyrazol-3-yl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (90 mg, 69%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 0.78 (3H, t, <i>J</i> = 7.4 Hz), 1.32 (3H, d, <i>J</i> = 6.8 Hz), 1.73 (2H, quin, <i>J</i> = 7.4 Hz), 3.87 (3H, s), 4.20 (3H, s), 4.80 (1H, q, <i>J</i> = 7.2 Hz), 6.45 (1H, d, <i>J</i> = 2.3 Hz), 7.74 (1H, d, <i>J</i> = 2.3 Hz), 8.06 (1H, s). LC/MS <i>m</i>/<i>z</i> 287.0 (M + H).</div></div><div id="sec5_1_50_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> Step 2 of 2</h5><div class="NLM_p last">Hydrazine monohydrate (122 mg, 2.44 mmol) was added to a solution of 1-<i>sec</i>-butyl-4-methoxy-5-(1-methyl-1<i>H</i>-pyrazol-3-yl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (140 mg, 0.49 mmol) in EtOH (5 mL) at room temperature. The mixture was stirred at 90 °C for 1 h. After the mixture was cooled, the solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (NH silica gel, MeOH/EtOAc = 0:10 to 1:9) to give a white solid (120 mg). The solid was crystallized from EtOAc-IPE to give <b>10</b> (82 mg, 59%) as a white powder. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 0.75 (3H, t, <i>J</i> = 7.4 Hz), 1.32 (3H, d, <i>J</i> = 6.8 Hz), 1.74 (2H, quin, <i>J</i> = 7.3 Hz), 3.90 (3H, s), 4.82–5.05 (1H, m), 5.35 (2H, brs), 6.80 (1H, d, <i>J</i> = 1.9 Hz), 7.64 (1H, brs), 7.73 (1H, d, <i>J</i> = 2.3 Hz), 11.60 (1H, brs). LC/MS <i>m</i>/<i>z</i> 287.0. HPLC purity 100.0%.</div></div></div><div id="sec5_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 3-Amino-5-isobutyl-7-(1-methyl-1<i>H</i>-pyrazol-3-yl)-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>11</b>)</h4><div id="sec5_1_51_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> Step 1 of 2</h5><div class="NLM_p last">A solution of <b>33b</b> (4.60 g, 16.0 mmol) and hydrazine monohydrate (2.99 g, 80%, 47.9 mol) in EtOH (90 mL) was heated at 80 °C for 2 h. The mixture was cooled, poured into H<sub>2</sub>O, and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give a residue, which was recrystallized from MeOH/ether to give 3-amino-7-bromo-5-isobutyl-1<i>H</i>-pyrazolo[4,3-<i>c</i>] pyridin-4(5<i>H</i>)-one (4.44 g, 98%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.95 (6H, d, <i>J</i> = 6.8 Hz), 2.05–2.15 (1H, m), 3.71 (2H, d, <i>J</i> = 7.2 Hz), 5.29 (2H, brs), 7.13 (1H, s). LC/MS <i>m</i>/<i>z</i> 284.7 (M + H).</div></div><div id="sec5_1_51_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> Step 2 of 2</h5><div class="NLM_p last">A mixture of 3-amino-7-bromo-5-isobutyl-1<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4(5<i>H</i>)-one (994.0 mg, 3.5 mmol), 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (1.0 g, 4.8 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (404 mg, 0.35 mmol), and 2 M aqueous Na<sub>2</sub>CO<sub>3</sub> (742 mg, 7.0 mmol) in DMF (20 mL) was irradiated by microwave at 150 °C for 3 h. The mixture was cooled, poured into H<sub>2</sub>O, and extracted with EtOAc. The combined organic layers were washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give a residue, which was purified by silica gel column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3</sub>H<sub>2</sub>O = 100:10:1) to give a residue that was purified again by preparative HPLC to give <b>11</b> (120 mg, 17%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.97 (6H, d, <i>J</i> = 6.8 Hz), 2.10–2.25 (1H, m), 3.79 (2H, d, <i>J</i> = 7.6 Hz), 3.95 (3H, s), 4.77 (2H, brs), 6.41 (1H, d, <i>J</i> = 2.0 Hz), 7.30 (1H, s), 7.39 (1H, d, <i>J</i> = 3.0 Hz). LC/MS <i>m</i>/<i>z</i> 287.2 (M + H). HPLC purity 97.1%.</div></div></div><div id="sec5_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 3-Amino-5-(2-methylpentan-3-yl)-7-(1-methyl-1<i>H</i>-pyrazol-3-yl)-1,5-dihydro-4<i>H</i>-pyrazolo[4,3-<i>c</i>]pyridin-4-one (<b>12</b>)</h4><div class="NLM_p last">Compound <b>12</b> was prepared in a manner similar to that described for <b>10</b> in 24% yield as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.73–0.85 (6H, m), 1.09 (3H, d, <i>J</i> = 6.4 Hz), 1.39–2.19 (3H, m), 3.96 (3H, s), 4.78 (2H, brs), 4.80–5.50 (1H, br), 6.42 (1H, d, <i>J</i> = 2.3 Hz), 7.24 (1H, s), 7.39 (1H, d, <i>J</i> = 1.9 Hz), 9.68–11.29 (1H, br). LC/MS <i>m</i>/<i>z</i> 315.0 (M + H). HPLC purity 98.9%.</div></div><div id="sec5_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> <i>tert</i>-Butyl [3-(Benzyloxy)-1-methyl-1<i>H</i>-pyrazol-5-yl]carbamate (<b>35</b>)</h4><div class="NLM_p last">To a solution of <b>34</b> (5.0 g, 21.53 mmol) and Et<sub>3</sub>N (9.00 mL, 64.59 mmol) in <i>tert</i>-BuOH (55 mL) was added DPPA (6.96 mL, 32.29 mmol) at 0 °C. The mixture was refluxed under N<sub>2</sub> for 3 h. The mixture was cooled to room temperature, H<sub>2</sub>O was added at room temperature, and extracted with EtOAc. The organic layer was separated, washed with brine, dried over MgSO<sub>4</sub>, and the solvent was evaporated under reduced pressure. To the mixture was added toluene, and the solid was filtered off. The filtrate was purified by silica gel column chromatography (EtOAc/hexane = 1:9 to 5:5) to <b>35</b> (6.10 g, 93%) as a colorless oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.50 (9H, s), 3.60 (3H, s), 5.15 (2H, s), 5.64 (1H, s), 6.13 (1H, brs), 7.28–7.47 (5H, m). LC/MS <i>m</i>/<i>z</i> 304.2 (M + H).</div></div><div id="sec5_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 3-(Benzyloxy)-1-methyl-1<i>H</i>-pyrazol-5-amine (<b>36</b>)</h4><div class="NLM_p last">To a solution of <b>35</b> (6.0 g, 19.78 mmol) in MeOH (20 mL) and EtOAc (80 mL) was added 4 N HCl/EtOAc (49.4 mL, 197.79 mmol) dropwise at 0 °C. The mixture was stirred at room temperature under N<sub>2</sub> overnight. The mixture was quenched with 2 M aqueous NaOH (99 mL, 197.79 mmol) at 0 °C and extracted with EtOAc. The organic layer was separated, washed with brine, dried over MgSO<sub>4</sub>, and the solvent was evaporated under reduced pressure to give <b>36</b> (3.90 g, 97%) as a colorless oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 3.54 (3H, s), 5.05 (1H, s), 5.14 (2H, s), 7.29–7.47 (5H, m). LC/MS <i>m</i>/<i>z</i> 204.2 (M + H).</div></div><div id="sec5_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 4-(3-(Benzyloxy)-1-methyl-1<i>H</i>-pyrazol-5-yl)morpholine (<b>37</b>)</h4><div class="NLM_p last">To a solution of <b>36</b> (4.50 g, 22.14 mmol), 1-chloro-2-(2-chloroethoxy)ethane (3.11 mL, 26.57 mmol), and triethylamine (7.41 mL, 53.14 mmol) in DMF (55 mL) was added NaI (0.332 g, 2.21 mmol) at room temperature. The mixture was stirred at 150 °C under Ar overnight. The mixture was added saturated aqueous NaHCO<sub>3</sub> and H<sub>2</sub>O (1:1) at room temperature and extracted with EtOAc. The organic layer was separated, washed with brine, dried over MgSO<sub>4</sub>, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (NH silica gel, EtOAc/hexane = 1:9 to 6:4) to give <b>37</b> (800 mg, 13%) as a colorless oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.84–2.94 (4H, m), 3.60 (3H, s), 3.76–3.86 (4H, m), 5.16 (2H, s), 5.29 (1H, s), 7.30–7.47 (5H, m). LC/MS <i>m</i>/<i>z</i> 274.2 (M + H).</div></div><div id="sec5_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 1-Methyl-5-(morpholin-4-yl)-1<i>H</i>-pyrazol-3-ol (<b>38</b>)</h4><div class="NLM_p last">A mixture of <b>37</b> (800 mg, 2.93 mmol) and 10% Pd/C (80 mg) in EtOH (10 mL) was hydrogenated under balloon pressure at room temperature for 4 h. The catalyst was removed by filtration, and the filtrate was evaporated under reduced pressure to give <b>38</b> (499 mg, 93%) as an off-white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.85–2.97 (4H, m), 3.51 (3H, s), 3.76–3.86 (4H, m), 5.17 (1H, s). LC/MS <i>m</i>/<i>z</i> 184.2 (M + H).</div></div><div id="sec5_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 1-Methyl-5-(morpholin-4-yl)-1<i>H</i>-pyrazol-3-yl Trifluoromethanesulfonate (<b>39</b>)</h4><div class="NLM_p last">To a solution of <b>38</b> (500 mg, 2.73 mmol) and TEA (0.571 mL, 4.09 mmol) in CH<sub>3</sub>CN (9 mL) was added trifluoromethanesulfonic anhydride (0.689 mL, 4.09 mmol) at 0 °C. The mixture was stirred at 0 °C under N<sub>2</sub> for 1 h. To the mixture was added saturated aqueous NaHCO<sub>3</sub> at 0 °C, and extraction was done with EtOAc. The organic layer was separated, washed with brine, dried over MgSO<sub>4</sub>, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexane = 0:10 to 3:7) to give <b>39</b> (501 mg, 58%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.89–2.96 (4H, m), 3.68 (3H, s), 3.79–3.86 (4H, m), 5.70 (1H, s). LC/MS <i>m</i>/<i>z</i> 316.2 (M + H).</div></div><div id="sec5_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> Ethyl 3,5-Dibromo-1<i>H</i>-pyrazole-4-carboxylate (<b>41</b>)</h4><div class="NLM_p last">To a solution of <b>40</b> (31 g, 221.2 mmol) and sodium acetate (118 g, 1437.9 mmol) in EtOH (200 mL) and H<sub>2</sub>O (300 mL) was added dibromine (141 g, 884.83 mmol) at room temperature. The mixture was stirred at room temperature for 10 h. After addition of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (175 g, 1106 mmol) and evaporation, the mixture was poured into H<sub>2</sub>O at room temperature and was extracted with EtOAc. The organic layer was separated, washed with brine, dried over MgSO<sub>4</sub>, and the solvent was evaporated under reduced pressure to give <b>41</b> (65.1 g, 99%) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.36–1.48 (3H, m), 4.30–4.47 (2H, m). LC/MS <i>m</i>/<i>z</i> 296.7 (M + H).</div></div><div id="sec5_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> Ethyl 3,5-Dibromo-1-methyl-1<i>H</i>-pyrazole-4-carboxylate (<b>42</b>)</h4><div class="NLM_p last">To a solution of <b>41</b> (30 g, 100.7 mmol) in THF (400 mL) was added NaH (4.23 g, 105.7 mmol) at 0 °C. After being stirred at 0 °C under N<sub>2</sub> for 1 h, iodomethane (41.4 g, 292.0 mmol) was added to the reaction mixture. The mixture was stirred at room temperature under N<sub>2</sub> for 10 h. After addition of H<sub>2</sub>O and evaporation, the mixture was extracted with EtOAc. The organic layer was separated, washed with brine, dried over MgSO<sub>4</sub>, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexane = 1:9) to give <b>42</b> (31.1 g, 100 mmol, 99%) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.31–1.45 (3H, m), 3.91 (3H, s), 4.28–4.44 (2H, m). LC/MS <i>m</i>/<i>z</i> 310.7 (M + H).</div></div><div id="sec5_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> Ethyl 3-Bromo-1-methyl-5-(morpholin-4-yl)-1<i>H</i>-pyrazole-4-carboxylate (<b>43a</b>)</h4><div class="NLM_p last">A mixture of <b>42</b> (10 g, 32.1 mmol) and morpholine (11.2 g, 128.2 mmol) was stirred at 150 °C for 10 h. After being cooled, to the mixture was added H<sub>2</sub>O (100 mL) slowly at room temperature with stirring. The obtained crystals were washed with H<sub>2</sub>O and hexane, and dried under reduced pressure to give <b>43a</b> (7.80 g, 24.52 mmol, 76%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.38–1.45 (3H, m), 3.11–3.16 (4H, m), 3.76 (3H, s), 3.78–3.83 (4H, m), 4.28–4.41 (2H, m). LC/MS <i>m</i>/<i>z</i> 319.8 (M + H).</div></div><div id="sec5_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> Ethyl 3-Bromo-5-(1,1-dioxidothiomorpholin-4-yl)-1-methyl-1<i>H</i>-pyrazole-4-carboxylate (<b>43b</b>)</h4><div class="NLM_p last">The mixture of <b>42</b> (2.0 g, 6.41 mmol), thiomorpholine 1,1-dioxide (3.47 g, 25.64 mmol), and NMP (8 mL) was heated at 200 °C for 5 h under microwave irradiation. After being cooled, the mixture was poured into H<sub>2</sub>O at room temperature and extracted with EtOAc three times. The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexane = 2:8 to 10:0) to give <b>43b</b> (1.02 g, 2.79 mmol, 43%) as a white solid. LC/MS <i>m</i>/<i>z</i> 365.8 (M + H).</div></div><div id="sec5_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 4-(3-Bromo-1-methyl-1<i>H</i>-pyrazol-5-yl)morpholine (<b>44a</b>)</h4><div class="NLM_p last">A mixture of <b>43a</b> (7.7 g, 24.2 mmol) and 2 M aqueous NaOH (48.4 mL, 96.80 mmol) in EtOH (80 mL) was stirred at 60 °C for 2.5 h. After being cooled, the mixture was acidified by H<sub>2</sub>SO<sub>4</sub> (12.90 mL, 242.01 mmol) at 0 °C and stirred at 60 °C for 30 min. The mixture was basicified by 8 N aqueous NaOH at 0 °C and extracted with EtOAc three times. The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, and the solvent was evaporated under reduced pressure to give <b>44a</b> (5.87 g, 99%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.55–7.67 (4H, m), 8.37 (3H, s), 8.44–8.51 (4H, m), 10.79 (1H, s). LC/MS <i>m</i>/<i>z</i> 245.7 (M + H).</div></div><div id="sec5_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 4-(3-Bromo-1-methyl-1<i>H</i>-pyrazol-5-yl)thiomorpholine 1,1-Dioxide (<b>44b</b>)</h4><div class="NLM_p last">Compound <b>44b</b> was prepared in a manner similar to that described for <b>44a</b> in 81% yield as a white powder. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 3.23–3.43 (8H, m), 3.65 (3H, s), 6.23 (1H, s). LC/MS <i>m</i>/<i>z</i> 294.8 (M + H).</div></div><div id="sec5_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 3,5-Dibromo-1-methyl-1<i>H</i>-pyrazole (<b>45</b>)</h4><div class="NLM_p last">A mixture of <b>44</b> (40 g, 128.2 mmol) in 50% aqueous H<sub>2</sub>SO<sub>4</sub> (150 mL) was stirred at 160 °C for 90 min. The mixture was diluted with H<sub>2</sub>O at 0 °C and extracted three times with EtOAc. Organic layer was washed with brine, dried over MgSO<sub>4</sub>, and evaporated under reduced pressure to give <b>45</b> (26.5 g, 86%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 3.85 (3H, s), 6.30 (1H, s). LC/MS <i>m</i>/<i>z</i> 238.6 (M + H).</div></div><div id="sec5_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 3-Bromo-5-(3,6-dihydro-2<i>H</i>-pyran-4-yl)-1-methyl-1<i>H</i>-pyrazole (<b>46</b>)</h4><div class="NLM_p last">Pd(Ph<sub>3</sub>P)<sub>4</sub> (385 mg, 0.33 mmol) was added to a solution of <b>45</b> (800 mg, 3.33 mmol), 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (841 mg, 4.00 mmol), and 1 N aqueous Na<sub>2</sub>CO<sub>3</sub> (3.3 mL, 6.7 mmol) in DME (30 mL) at room temperature under Ar. The mixture was stirred at 80 °C for 4 h under Ar. To this mixture was added Pd(Ph<sub>3</sub>P)<sub>4</sub> (190 mg, 0.16 mmol), and the mixture was stirred at 80 °C under Ar for 16 h. The mixture was quenched with H<sub>2</sub>O and extracted with EtOAc. The organic layer was separated, washed with brine, dried over MgSO<sub>4</sub>, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexane = 5:95 to 30:70) to give <b>46</b> (522 mg, 64%) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 2.32–2.40 (2H, m), 3.85 (3H, s), 3.90 (2H, t, <i>J</i> = 5.5 Hz), 4.28–4.35 (2H, m), 5.91–5.97 (1H, m), 6.15 (1H, s). LC/MS <i>m</i>/<i>z</i> 242.8 (M + H).</div></div><div id="sec5_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 2-(3-Bromo-1-methyl-1<i>H</i>-pyrazol-5-yl)propan-2-ol (<b>47</b>)</h4><div class="NLM_p last">To a solution of <b>45</b> (14.1 g, 58.78 mmol) in THF (200 mL) was added <i>n</i>-BuLi (40.4 mL, 64.65 mmol, 1.6 M in hexane) at −78 °C. After being stirred at −78 °C under Ar for 30 min, acetone (5.61 mL, 76.4 mmol) was added to the reaction mixture. The mixture was stirred at room temperature under Ar for 10 h. To the mixture was added H<sub>2</sub>O, and extraction was done twice with EtOAc. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexane = 0:10 to 4:6) to give <b>47</b> (9.1 g, 70%) as a pale yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.62 (6H, s), 1.73–1.74 (1H, m), 4.03 (3H, s), 6.09 (1H, s). LC/MS <i>m</i>/<i>z</i> 218.8 (M + H).</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Docking Study</h3><div class="NLM_p last">We used the X-ray cocrystal structure of TYK2 in the Protein Data Bank (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LXP">3LXP</a>). The protein structure for the docking study was prepared with Protein Preparation Workflow on Maestro version 9.3 (Schrödinger software, <a href="http://www.schrodinger.com" class="extLink">http://www.schrodinger.com</a>), as described below. (1) All crystallographic waters were removed and chain A was kept. (2) Hydrogens were added. (3) The orientation of hydroxyl groups, Asn, and Gln, and the protonation states of His were optimized. (4) Constrained energy minimization was performed with the OPLS_2005 force field, setting the max root-mean square deviation (RMSD) to 0.30 for the heavy atoms. Compound A whose carboxyl group was deprotonated was built on Maestro, and the most stable conformation of ligand, which was generated in the water model by Macromodel (version 9.9) tool, was used for docking. Molecular docking was performed by Glide SP (version 5.8) using the default setting. The docking box was centered on the ligand of the crystal structure. The best scoring pose of GlideScore was evaluated.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> Biology</h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> TYK2 and JAK1–3 Enzyme Assay</h4><div class="NLM_p last">Catalytically active human TYK2 used in the enzyme inhibition assay was obtained from Invitrogen, which was prepared by a baculovirus expression system. The inhibitory activity of test compounds was assessed by LANCE Ultra assay in which there was ATP-dependent phosphorylation of a ULight-JAK1 substrate peptide. Briefly, the enzyme reaction was run in reaction buffer, which consisted of 50 mM HEPES (pH7.5), 10 mM MgCl<sub>2</sub>, 0.01% BSA, 0.01% Tween 20, and 2 mM dithiothreitol. The assay was done by a 384-well plate (12 μL) assay format. The end concentration of the substrate, ATP, was 100 nM or 10 μM, respectively. The end concentration of TYK2 was 125 ng/mL. After 45 min incubation at room temperature, the reaction was terminated by adding 20 mM EDTA in detection buffer. Reagents for detection (4 nM antibody and FRET acceptor (europium-labeled anti-phosphotyrosine antibody (PT66))) were also added in detection buffer. For JAK1, JAK2, and JAK3 enzyme inhibition assays, the following conditions were used: the end concentration of enzyme, ULight-JAK1 substrate, ATP was 62.5 ng/mL, 100 nM, 50 μM for JAK1, 2 ng/mL, 100 nM, 15 μM for JAK2, 4 ng/mL, 100 nM, 5 μM for JAK3, respectively. The enzyme reaction was done for 45 min at room temperature. Time-resolved fluorescence was monitored with an EnVision (PerkinElmer Life Sciences, CA) by excitation at 320 nm and emission donor at 615 nm or emission acceptor at 665 nm, respectively. The files recorded by the EnVision were read with Excel and contained the acceptor and donor counts for each sample. The readout was calculated as (acceptor counts/donor counts)*1000. IC<sub>50</sub> values were derived by fitting a sigmoidal dose–response curve to a plot of assay readout over inhibitor concentration.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> IL-23 Reporter Gene Assay</h4><div class="NLM_p last">The human T cell lymphoblast-like cell line Jurkat was purchased from the American Type Culture Collection. Jurkat cells were cultured in RPMI medium (Life Technologies) supplemented with 10% fetal bovine serum (FBS, Ausgene), penicillin, and streptomycin at 37 °C in 5% CO<sub>2</sub>. The reporter assay using interferon-gamma-activated sequence (GAS) reporter vector and the expression vectors of IL-23 receptor, IL-12 receptor beta1, and STAT4 were constructed. Briefly, 3 repeated GAS was inserted into pGL4.26 reporter vector (Promega). IL-23 receptor sequence, IL-12 receptor beta1 sequence, and STAT4 sequence were inserted into pcDNA3.1 (Life Technologies), pIRESpuro (Clontech), and pcDNA3.1zeo (Life Technologies), respectively. Jurkat cells were cultured in 50 mL of culture medium until the cell density reached 8.0 × 10<sup>5</sup> cells/mL in a flask (Corning 430825). The cells were centrifuged and washed with PBS (Life Technologies) once. The washed cells were resuspended in 2 mL of R buffer (NEON transfection kit, Life Technologies). For electroporation, 20 μg of the pGL4.26/GAS reporter vector, 20 μg of IL-23 receptor expression vector, 20 μg of IL-12 receptor beta1 expression vector, and 20 μg of STAT4 expression vector were added into the suspended cells. The condition of electroporation was pulse voltage 1350 V, width 10 ms, and number 3 times using NEON. 100 μL scale electroporation was repeated 20 times, and the treated cells were suspended into 40 mL of culture medium. Next, 80 μL of the cells was plated to the 96 well plates at the density of 8 × 10<sup>4</sup> cells/well, and the 10 μL of test compounds diluted in the culture medium was added. Subsequently, 10 μL of 100 ng/mL IL-23 diluted in culture medium was added. The plates were incubated in a CO<sub>2</sub> incubator at 37 °C in 5% CO<sub>2</sub> for 24 h. 100 μL of Bright-Glo (Promega) was added, and after 5 min agitation the luciferase activity was measured by Envision (PerkinElmer).</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> In Vitro PBMC STAT Phosphorylation Assay</h4><div id="sec5_3_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> Antibodies and Reagents</h5><div class="NLM_p last">Lineage-specific antibodies were purchased from BD Biosciences. IL-23, GM-CSF, and IL-6 were purchased from R&D. IL-21 was purchased from Peprothech. IFNα was purchased from PBL.</div></div><div id="sec5_3_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> Isolation of PBMC</h5><div class="NLM_p last">Human PBMCs were isolated from heparinized normal human whole blood by leukapheresis followed by Ficoll-Hypaque centrifugation. Cells collected from interface were suspended in RPMI1640 medium supplemented with heat inactivated fetal bovine serum (10%), penicillin (100 U/mL), and streptomycin (100 μg/mL).</div></div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> In Vitro PBMC STAT Phosphorylation Assay</h4><div class="NLM_p last">Isolated human PBMC was stained with lineage-specific antibodies. Specifically, human-specific antibodies to CD3 conjugated FITC and CD56 conjugated PE were used to identify human NKT cell, anti-CD4 antibody conjugated FITC was used to label human CD4 T cell, and anti-CD14 antibody conjugated PE was used to label human monocytes. PBMC was preincubated with compound solution at 37 °C for 5 min. PBMC was stimulated with or without cytokine (IL-23 at 30 ng/mL, IFNα at 1000 U/mL, IL-6 at 100 ng/mL, IL-21 at 10 ng/mL, or GM-CSF at 0.1 ng/mL) at 37 °C for 15–60 min. Activation was stopped by the addition of Lyse/Fix Buffer (BD Biosciences) following the manufacturer’s protocol. Cells were washed, permeabilized in Perm Buffer 4 (BD Biosciences) for 30 min, and stained with Alexa647-conjugated phospho STAT-specific monoclonal antibodies. Flow cytometric analysis (FACS) was performed on a LSR Fortessa Cell Analyzer. One thousand target cellular events were collected per sample, and data were analyzed using FlowJo software. IC<sub>50</sub> values were determined using GrafPad Prism software.</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> PD Assay</h4><div class="NLM_p">Male LEWIS rats were purchased from Charles-River Japan and used at 7–8 weeks of age. Experimental protocols were conformed for the guidelines for animal experiments in Takeda Pharmaceutical Co. Ltd. All rats were housed in sterile cages in pasogen-free conditions and provided food and water ad libitum.</div><div class="NLM_p">Intradermal injection of 1 μg of recombinant mouse IL-23 (Takeda Pharmaceutical Company Limited, Biomolecular Research Laboratories) in 20 μL of phosphate buffered saline (PBS) was performed into the right ear of rats under isoflurane anesthetization. Control rats received the same volume of PBS injections. Twenty-four hours after IL-23 injection, rats were euthanized, and tissue was collected.</div><div class="NLM_p">Compound <b>20</b>, at doses of 3, 10, and 30 mg/kg in 0.5% methylcellulose (MC), was orally dosed 30 min prior to the intradermal cytokine injection. The vehicle was provided orally as 0.5% MC only.</div><div class="NLM_p last">Ear tissue of 6 mm in diameter was collected using a tissue biopsy punch (Kai medical) for protein extraction. Weighed tissues were collected in the tissue extraction reagent I (invitrogen) supplemented with a cocktail of protease inhibitors (Roche) and phosphatase inhibitors (Phostop, Roche). Tissues were homogenized by a ceramic bead, and, after centrifugation, supernatants were used for the protein quantification. IL-22 was quantified by Quantikine mouse/rat IL-22 ELISA kit (R&D systems) according to the manufacture’s instruction. ED<sub>50</sub> was calculated using Prism software (Graph Pad).</div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> Statistics</h4><div class="NLM_p">Statistical significance was calculated by one-way ANOVA using Prism software (Graph Pad). <i>P</i> values are indicated in the figure or expressed by asterisks as ***, <i>P</i> < 0.001.</div><div class="NLM_p last">Comparative analysis of experimental groups has been conducted against the vehicle controls.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i99"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01857">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44062" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44062" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01857" class="ext-link">10.1021/acs.jmedchem.5b01857</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental methods for cloning, expression, and purification of TYK2, as well as crystallization, data collection, and structure solution of TYK2 (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01857/suppl_file/jm5b01857_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES and IC<sub>50</sub> data (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01857/suppl_file/jm5b01857_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01857/suppl_file/jm5b01857_si_001.pdf">jm5b01857_si_001.pdf (176.14 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01857/suppl_file/jm5b01857_si_002.csv">jm5b01857_si_002.csv (1.16 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F20">5F20</a> for compound <b>8</b> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F1Z">5F1Z</a> for compound <b>20</b>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.5b01857" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50288" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50288" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Masato Yoshida</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0865697b697c672671677b60616c69487c69636d6c69266b6765"><span class="__cf_email__" data-cfemail="aac7cbd9cbdec584d3c5d9c2c3cecbeadecbc1cfcecb84c9c5c7">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takatoshi Yogo</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hiroyuki Nagamiya</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Masaki Seto</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Satoshi Sasaki</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huang Shih-Chung</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical
Company Limited, 40 Landsdowne
Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yusuke Ohba</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Norihito Tokunaga</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gil Nam Lee</span> - <span class="hlFld-Affiliation affiliation">Chemizon, 3F Dongbang
Rental Building, 333-1
Sangdaewon-Dong, Jungwon-Gu, Seongnam-Si, Kyunggi-Do 462-120, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chul Yun Rhim</span> - <span class="hlFld-Affiliation affiliation">Chemizon, 3F Dongbang
Rental Building, 333-1
Sangdaewon-Dong, Jungwon-Gu, Seongnam-Si, Kyunggi-Do 462-120, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheol Hwan Yoon</span> - <span class="hlFld-Affiliation affiliation">Chemizon, 3F Dongbang
Rental Building, 333-1
Sangdaewon-Dong, Jungwon-Gu, Seongnam-Si, Kyunggi-Do 462-120, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suk Young Cho</span> - <span class="hlFld-Affiliation affiliation">Chemizon, 3F Dongbang
Rental Building, 333-1
Sangdaewon-Dong, Jungwon-Gu, Seongnam-Si, Kyunggi-Do 462-120, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert Skene</span> - <span class="hlFld-Affiliation affiliation">Takeda
California, 10410 Science
Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Syunsuke Yamamoto</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yousuke Satou</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Masako Kuno</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takahiro Miyazaki</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hideyuki Nakagawa</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Atsutoshi Okabe</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shogo Marui</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kazuyoshi Aso</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Division, Takeda Pharmaceutical
Company Limited, 26-1
Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ACK-d240e5291-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i104">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56355" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56355" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Tsuneo Oda, Yuji Ishichi, Hideo Suzuki, Tomokazu Kusumoto, Toshihiro Imaeda, Toshiro Yamashita, Hitoaki Nishikawa, Akira Kaieda, Tetsuji Kawamoto, Tetsuya Tsukamoto, Satoshi Yamamoto, Hyun Bin Kang, Kwang Ok Kim, and Hye Sun Jeon for discussion on chemistry. We thank Mitsuyoshi Nishitani for structural analysis of synthesized compound. We thank Mitsuki Shimada and Yan Zhu for the support of external collaboration.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i105" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i105"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i106" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i106"> Abbreviations Used</h2><tr><td class="NLM_term">TYK2</td><td class="NLM_def"><p class="first last">tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinases</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cell</p></td></tr><tr><td class="NLM_term">EPO</td><td class="NLM_def"><p class="first last">erythropoietin</p></td></tr><tr><td class="NLM_term">TPO</td><td class="NLM_def"><p class="first last">thrombopoietin</p></td></tr><tr><td class="NLM_term">GM-CSF</td><td class="NLM_def"><p class="first last">granulocyte macrophage colony-stimulating factor</p></td></tr><tr><td class="NLM_term">SBDD</td><td class="NLM_def"><p class="first last">structure-based drug design</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">total clearance</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum plasma concentration</p></td></tr><tr><td class="NLM_term">MRT</td><td class="NLM_def"><p class="first last">mean residence time</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the plasma concentration–time curve</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">bioavailability</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i107">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21264" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21264" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 20 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shuai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span> </span><span class="NLM_article-title">Regulation of JAK-STAT Signalling in the Immune System</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">900</span><span class="NLM_x">–</span> <span class="NLM_lpage">911</span><span class="refDoi"> DOI: 10.1038/nri1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-911&author=K.+Shuaiauthor=B.+Liu&title=Regulation+of+JAK-STAT+Signalling+in+the+Immune+System&doi=10.1038%2Fnri1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0lh99Q1_Xw5L3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK-STAT%2520Signalling%2520in%2520the%2520Immune%2520System%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D911%26doi%3D10.1038%2Fnri1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">Janus Kinases in Immune Cell Signalling</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">287</span><span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1111%2Fj.1600-065X.2008.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=19290934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=273-287&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Janus+Kinases+in+Immune+Cell+Signalling&doi=10.1111%2Fj.1600-065X.2008.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases in immune cell signaling</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non-receptor protein tyrosine kinases.  They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.  Data from exptl. mice and clin. observations have unraveled multiple signaling events mediated by Jaks in innate and adaptive immunity.  Deficiency of Jak3 or Tyk2 results in defined clin. disorders, which are also evident in mouse models.  A striking phenotype assocd. with inactivating Jak3 mutations is severe combined immunodeficiency syndrome, whereas mutation of Tyk2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.  By contrast, complete deletion of Jak1 or Jak2 in the mouse are not compatible with life and, unsurprisingly, do not have counterparts in human disease.  However, activating mutations of each of the Jaks are found in assocn. with malignant transformation, the most common being gain-of-function mutations of Jak2 in polycythemia vera and other myeloproliferative disorders.  Our existing knowledge on Jak signaling pathways and fundamental work on their biochem. structure and intracellular interactions allow us to develop new strategies for controlling autoimmune diseases or malignancies by developing selective Jak inhibitors, which are now coming into clin. use.  Despite the fact that Jaks were discovered only a little more than a decade ago, at the time of writing there are 20 clin. trials underway testing the safely and efficacy of Jak inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23ncK0nYqpbVg90H21EOLACvtfcHk0lh99Q1_Xw5L3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ&md5=adc282a9ad381ee18abe57a82c921f65</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520Kinases%2520in%2520Immune%2520Cell%2520Signalling%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D273%26epage%3D287%26doi%3D10.1111%2Fj.1600-065X.2008.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Aringer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudarshan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">Janus kinases and their role in growth and disease</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">2173</span><span class="NLM_x">–</span> <span class="NLM_lpage">2186</span><span class="refDoi"> DOI: 10.1016/S0024-3205(98)00538-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2FS0024-3205%2898%2900538-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=2173-2186&author=M.+Aringerauthor=A.+Chengauthor=J.+W.+Nelsonauthor=M.+Chenauthor=C.+Sudarshanauthor=Y.+J.+Zhouauthor=J.+J.+O%E2%80%99Shea&title=Janus+kinases+and+their+role+in+growth+and+disease&doi=10.1016%2FS0024-3205%2898%2900538-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2FS0024-3205%2898%2900538-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0024-3205%252898%252900538-4%26sid%3Dliteratum%253Aachs%26aulast%3DAringer%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DA.%26aulast%3DNelson%26aufirst%3DJ.%2BW.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DSudarshan%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520kinases%2520and%2520their%2520role%2520in%2520growth%2520and%2520disease%26jtitle%3DLife%2520Sci.%26date%3D1999%26volume%3D64%26spage%3D2173%26epage%3D2186%26doi%3D10.1016%2FS0024-3205%2898%2900538-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schindler, C. W.</span><span> </span><span class="NLM_article-title">Series introduction. JAK-STAT signaling in human disease</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">1133</span><span class="NLM_x">–</span> <span class="NLM_lpage">1137</span><span class="refDoi"> DOI: 10.1172/JCI0215644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1172%2FJCI0215644" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=1133-1137&author=C.+W.+Schindler&title=Series+introduction.+JAK-STAT+signaling+in+human+disease&doi=10.1172%2FJCI0215644"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1172%2FJCI0215644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI0215644%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DC.%2BW.%26atitle%3DSeries%2520introduction.%2520JAK-STAT%2520signaling%2520in%2520human%2520disease%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D109%26spage%3D1133%26epage%3D1137%26doi%3D10.1172%2FJCI0215644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, C. E.</span><span> </span><span class="NLM_article-title">Novel systemic therapies for the treatment of psoriasis</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1517/14656566.2016.1109636</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1517%2F14656566.2016.1109636" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=1-14&author=K.+W.+Tanauthor=C.+E.+Griffiths&title=Novel+systemic+therapies+for+the+treatment+of+psoriasis&doi=10.1517%2F14656566.2016.1109636"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1517%2F14656566.2016.1109636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2016.1109636%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DK.%2BW.%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%26atitle%3DNovel%2520systemic%2520therapies%2520for%2520the%2520treatment%2520of%2520psoriasis%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2015%26spage%3D1%26epage%3D14%26doi%3D10.1517%2F14656566.2016.1109636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mahmood, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaghi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menter, A.</span><span> </span><span class="NLM_article-title">Emerging oral drugs for psoriasis</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span><span class="refDoi"> DOI: 10.1517/14728214.2015.1010509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1517%2F14728214.2015.1010509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=25643592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFahur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=209-20&author=T.+Mahmoodauthor=D.+Zaghiauthor=A.+Menter&title=Emerging+oral+drugs+for+psoriasis&doi=10.1517%2F14728214.2015.1010509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging oral drugs for psoriasis</span></div><div class="casAuthors">Mahmood, Tahmina; Zaghi, Daniel; Menter, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-220</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Psoriasis is a chronic, immune-mediated inflammatory disease that classically presents with well-demarcated, scaly, erythematous plaques on the extensor surfaces of the extremities, scalp, and trunk.  Nails and joints are frequently affected as well.  Whereas a significant no. of patients maintain adequate control with topical therapy, up to 25% of patients will require phototherapy, oral systemic medication, or biol. therapy.  Areas covered: The majority of recent advances in therapeutic options for moderate-to-severe psoriasis have been in biol. therapies whereas development of new oral agents has lagged behind.  Currently, oral agents are largely confined to methotrexate, acitretin, cyclosporine and most recently apremilast.  This article reviews emerging oral treatments for moderate-to-severe psoriasis.  Expert opinion: Despite the recent FDA approval of apremilast, the development of new oral treatments for moderate-to-severe psoriasis has not kept pace with biol. therapies.  There continues to be a need for safe and effective long-term oral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZl9zzOE0nyrVg90H21EOLACvtfcHk0lh-NUTE-3ii0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFahur0%253D&md5=c860c2f6f0b51a21c436dfdffc6fb70e</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1517%2F14728214.2015.1010509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728214.2015.1010509%26sid%3Dliteratum%253Aachs%26aulast%3DMahmood%26aufirst%3DT.%26aulast%3DZaghi%26aufirst%3DD.%26aulast%3DMenter%26aufirst%3DA.%26atitle%3DEmerging%2520oral%2520drugs%2520for%2520psoriasis%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2015%26volume%3D20%26spage%3D209%26epage%3D20%26doi%3D10.1517%2F14728214.2015.1010509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Weger, W.</span><span> </span><span class="NLM_article-title">Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">810</span><span class="NLM_x">–</span> <span class="NLM_lpage">820</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00702.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1111%2Fj.1476-5381.2010.00702.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=20590580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVKnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=810-820&author=W.+Weger&title=Current+status+and+new+developments+in+the+treatment+of+psoriasis+and+psoriatic+arthritis+with+biological+agents&doi=10.1111%2Fj.1476-5381.2010.00702.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents</span></div><div class="casAuthors">Weger, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">810-820</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Psoriasis is a chronic inflammatory disease affecting 1-3% of the general population.  Among psoriatic patients, 5-40% are affected by psoriatic arthritis.  Due to the chronic nature of the disease, patients suffer from substantial psychol. and financial burdens, thus adding to a significantly impaired quality of life.  Traditional systemic therapies for psoriasis, such as methotrexate, cyclosporin A, retinoids or PUVA therapy, have a potential for long-term toxicity and may not always provide sufficient improvement of the disease.  The development of novel therapies targeting key steps in the pathogenesis of psoriasis and psoriatic arthritis now provide new and efficient treatment options.  Biol. therapies for the treatment of psoriasis and/or psoriatic arthritis are defined by their mode of action and can be classified into three categories: the T-cell modulating agents (alefacept and efalizumab), the inhibitors of tumor necrosis factor-α (TNFα blockers, e.g. adalimumab, certolizumab, etanercept, golimumab and infliximab) and the inhibitors of interleukin (IL) 12 and IL-23 (e.g. ustekinumab and briakinumab).  This article provides a brief overview of the currently approved biol. agents in the European Union and of some newer agents, such as briakinumab, certolizumab and golimumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3bFpMNNoCM7Vg90H21EOLACvtfcHk0lh-NUTE-3ii0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVKnsbk%253D&md5=b317a08a8dcaec53033e5216dbe8e6f8</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00702.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00702.x%26sid%3Dliteratum%253Aachs%26aulast%3DWeger%26aufirst%3DW.%26atitle%3DCurrent%2520status%2520and%2520new%2520developments%2520in%2520the%2520treatment%2520of%2520psoriasis%2520and%2520psoriatic%2520arthritis%2520with%2520biological%2520agents%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D810%26epage%3D820%26doi%3D10.1111%2Fj.1476-5381.2010.00702.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schafer, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjesbo, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gleason, P. P.</span><span> </span><span class="NLM_article-title">Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis</span> <span class="citation_source-journal">J. Manag. Care Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">402</span><span class="NLM_x">–</span> <span class="NLM_lpage">416</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=20635831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A280%3ADC%252BC3cnos12ltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=402-416&author=J.+A.+Schaferauthor=N.+K.+Kjesboauthor=P.+P.+Gleason&title=Formulary+review+of+2+new+biologic+agents%3A+tocilizumab+for+rheumatoid+arthritis+and+ustekinumab+for+plaque+psoriasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis</span></div><div class="casAuthors">Schafer Jeremy A; Kjesbo Nicole K; Gleason Patrick P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of managed care pharmacy : JMCP</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">402-16</span>
        ISSN:<span class="NLM_cas:issn">1083-4087</span>.
    </div><div class="casAbstract">BACKGROUND:  Two autoimmune biologics were recently approved by the FDA: ustekinumab in September 2009 for the treatment of moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy and tocilizumab in January 2010 for adult patients with moderate to severe rheumatoid arthritis (RA) who have not responded adequately to 1 or more tumor necrosis factor (TNF) antagonist therapies.  Both agents use new mechanisms of action and add to the growing group of autoimmune biologics.  OBJECTIVE:  To critically review the phase 3 trials for ustekinumab and tocilizumab and provide managed care considerations in the context of the 9 other biologic agents on the market in the United States that are used to treat moderate to severe RA or psoriasis.  METHODS:  A MEDLINE review was performed for articles published and available through January 2010 using keywords "ustekinumab" and "tocilizumab" with an emphasis on phase 3 trials.  The literature search was limited to articles in English, clinical trials, randomized controlled trials, and research conducted in humans.  Search results for ustekinumab included 8 articles of which 4 were excluded for not being psoriasis or psoriatic arthritis trials.  Search results for tocilizumab included 16 articles of which 8 were excluded for not being RA trials or using biomarkers as primary endpoints.  Additional information was obtained from the FDA website.  RESULTS:  Three phase 3 trials are available for ustekinumab.  Ustekinumab demonstrated superior efficacy to placebo in 2 trials for the treatment of psoriasis.  In a 12-week trial, ustekinumab 45 milligrams (mg) and 90 mg demonstrated significantly higher rates of 75% improvement in the psoriasis area and severity index (PASI 75) (67.5% and 73.8%, respectively) compared with etanercept (56.8%) in the first phase 3 comparative psoriasis trial between autoimmune biologics (P < 0.05 for both comparisons).  In a phase 3 trial of RA patients who had failed prior TNF antagonist therapy, a 20% improvement in signs or symptoms according to the American College of Rheumatology criteria (ACR 20) at week 24 was achieved by significantly more study participants in the tocilizumab 8 mg per kilogram (kg) (50.0%) and 4 mg per kg (30.4%) groups than the placebo group (10.1%, P < 0.001 for both tocilizumab groups compared with placebo).  Safety data for ustekinumab are limited to use for less than 2 years, and the prescribing information contains warnings regarding infection and malignancy.  Tocilizumab is associated with neutropenia, thrombocytopenia, and elevations in lipids and liver function tests.  Tocilizumab has unique adverse events when compared with other autoimmune biologics and requires laboratory testing and careful monitoring.  CONCLUSIONS:  Ustekinumab and tocilizumab are new additions to the treatment of autoinflammatory disease.  The majority of safety data for both agents are from trials lasting 3 to 6 months.  Published long-term safety data for tocilizumab are limited to less than 143 patients treated longer than 5 years, and safety data for ustekinumab are scant beyond 2 years of use; therefore, clinicians should exercise caution prior to widespread adoption.  The comparative efficacy and safety trial of etanercept and ustekinumab brings important clinical information to decision makers.  Tocilizumab is indicated after failure or intolerance to a TNF antagonist and has unique safety concerns.  Managed care plans will consider the experience and long-term data of these agents along with efficacy data and cost when establishing management programs such as prior authorization or step therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQIB67pB_0BtZp6t8nS6Nc3fW6udTcc2ebm6qdSDGKz1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnos12ltA%253D%253D&md5=df490517f0eb903cc351add796f04d79</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchafer%26aufirst%3DJ.%2BA.%26aulast%3DKjesbo%26aufirst%3DN.%2BK.%26aulast%3DGleason%26aufirst%3DP.%2BP.%26atitle%3DFormulary%2520review%2520of%25202%2520new%2520biologic%2520agents%253A%2520tocilizumab%2520for%2520rheumatoid%2520arthritis%2520and%2520ustekinumab%2520for%2520plaque%2520psoriasis%26jtitle%3DJ.%2520Manag.%2520Care%2520Pharm.%26date%3D2010%26volume%3D16%26spage%3D402%26epage%3D416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Laws, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, H. S.</span><span> </span><span class="NLM_article-title">Update of the management of chronic psoriasis: new approaches and emerging treatment options</span> <span class="citation_source-journal">Clin., Cosmet. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span><span class="refDoi"> DOI: 10.2147/CCID.S6497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.2147%2FCCID.S6497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=21437057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXls1Gqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=25-37&author=P.+M.+Lawsauthor=H.+S.+Young&title=Update+of+the+management+of+chronic+psoriasis%3A+new+approaches+and+emerging+treatment+options&doi=10.2147%2FCCID.S6497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">Update of the management of chronic psoriasis: new approaches and emerging treatment options</span></div><div class="casAuthors">Laws, Philip M.; Young, Helen S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical, Cosmetic and Investigational Dermatology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25-37</span>CODEN:
                <span class="NLM_cas:coden">CCIDCL</span>;
        ISSN:<span class="NLM_cas:issn">1178-7015</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Psoriasis is a common, chronic inflammatory skin disease which is assocd. with a no. of significant co-morbidities including: impairment of quality of life; cardiovascular disease; and a seroneg. arthritis known as psoriatic arthritis.  Our understanding of the pathogenesis of psoriasis has developed at a remarkable rate in recent years.  These new insights have significantly changed our perception of the condition and have led to the development of several new treatment strategies.  Biol. agents have proved a major step forward in therapeutic options for psoriasis.  The ability to clear, or almost clear, cutaneous disease has changed the outcomes and expectations of many patients with this disease.  The impact on both phys. and psychol. health may be great.  This review covers the clin. features and management of psoriasis with specific ref. to new therapeutic options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzPMMW51CCVbVg90H21EOLACvtfcHk0lgYM9-phtEv6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXls1Gqurg%253D&md5=3824542e4ba93ac6d7dbedf4c99ef8a4</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.2147%2FCCID.S6497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCCID.S6497%26sid%3Dliteratum%253Aachs%26aulast%3DLaws%26aufirst%3DP.%2BM.%26aulast%3DYoung%26aufirst%3DH.%2BS.%26atitle%3DUpdate%2520of%2520the%2520management%2520of%2520chronic%2520psoriasis%253A%2520new%2520approaches%2520and%2520emerging%2520treatment%2520options%26jtitle%3DClin.%252C%2520Cosmet.%2520Invest.%2520Dermatol.%26date%3D2010%26volume%3D3%26spage%3D25%26epage%3D37%26doi%3D10.2147%2FCCID.S6497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Johnsson, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInnes, I. B.</span><span> </span><span class="NLM_article-title">Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis</span> <span class="citation_source-journal">Clin. Exp. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">S115</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=S115-8&author=H.+J.+Johnssonauthor=I.+B.+McInnes&title=Interleukin-12+and+interleukin-23+inhibition+in+psoriatic+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnsson%26aufirst%3DH.%2BJ.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26atitle%3DInterleukin-12%2520and%2520interleukin-23%2520inhibition%2520in%2520psoriatic%2520arthritis%26jtitle%3DClin.%2520Exp.%2520Rheumatol.%26date%3D2015%26volume%3D33%26spage%3DS115%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Scanlon, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Exter, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvis, C. I.</span><span> </span><span class="NLM_article-title">Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis</span> <span class="citation_source-journal">Ann. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1456</span><span class="NLM_x">–</span> <span class="NLM_lpage">1465</span><span class="refDoi"> DOI: 10.1345/aph.1M151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1345%2Faph.1M151" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2009&pages=1456-1465&author=J.+V.+Scanlonauthor=B.+P.+Exterauthor=M.+Steinbergauthor=C.+I.+Jarvis&title=Ustekinumab%3A+treatment+of+adult+moderate-to-severe+chronic+plaque+psoriasis&doi=10.1345%2Faph.1M151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1345%2Faph.1M151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1345%252Faph.1M151%26sid%3Dliteratum%253Aachs%26aulast%3DScanlon%26aufirst%3DJ.%2BV.%26aulast%3DExter%26aufirst%3DB.%2BP.%26aulast%3DSteinberg%26aufirst%3DM.%26aulast%3DJarvis%26aufirst%3DC.%2BI.%26atitle%3DUstekinumab%253A%2520treatment%2520of%2520adult%2520moderate-to-severe%2520chronic%2520plaque%2520psoriasis%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2009%26volume%3D43%26spage%3D1456%26epage%3D1465%26doi%3D10.1345%2Faph.1M151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Elliott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blank, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodmerkel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharples, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szapary, P.</span><span> </span><span class="NLM_article-title">Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases</span> <span class="citation_source-journal">Ann. N. Y. Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1182</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span><span class="refDoi"> DOI: 10.1111/j.1749-6632.2009.05070.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1111%2Fj.1749-6632.2009.05070.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1182&publication_year=2009&pages=97-110&author=M.+Elliottauthor=J.+Bensonauthor=M.+Blankauthor=C.+Brodmerkelauthor=D.+Bakerauthor=K.+R.+Sharplesauthor=P.+Szapary&title=Ustekinumab%3A+lessons+learned+from+targeting+interleukin-12%2F23p40+in+immune-mediated+diseases&doi=10.1111%2Fj.1749-6632.2009.05070.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2009.05070.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2009.05070.x%26sid%3Dliteratum%253Aachs%26aulast%3DElliott%26aufirst%3DM.%26aulast%3DBenson%26aufirst%3DJ.%26aulast%3DBlank%26aufirst%3DM.%26aulast%3DBrodmerkel%26aufirst%3DC.%26aulast%3DBaker%26aufirst%3DD.%26aulast%3DSharples%26aufirst%3DK.%2BR.%26aulast%3DSzapary%26aufirst%3DP.%26atitle%3DUstekinumab%253A%2520lessons%2520learned%2520from%2520targeting%2520interleukin-12%252F23p40%2520in%2520immune-mediated%2520diseases%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2009%26volume%3D1182%26spage%3D97%26epage%3D110%26doi%3D10.1111%2Fj.1749-6632.2009.05070.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Leonardi, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimball, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papp, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeilding, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dooley, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, K. B.</span><span> </span><span class="NLM_article-title">Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">1665</span><span class="NLM_x">–</span> <span class="NLM_lpage">1674</span><span class="refDoi"> DOI: 10.1016/S0140-6736(08)60725-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2FS0140-6736%2808%2960725-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2008&pages=1665-1674&author=C.+L.+Leonardiauthor=A.+B.+Kimballauthor=K.+A.+Pappauthor=N.+Yeildingauthor=C.+Guzzoauthor=Y.+Wangauthor=L.+T.+Dooleyauthor=K.+B.+Gordon&title=Efficacy+and+safety+of+ustekinumab%2C+a+human+interleukin-12%2F23+monoclonal+antibody%2C+in+patients+with+psoriasis%3A+76-week+results+from+a+randomised%2C+double-blind%2C+placebo-controlled+trial+%28PHOENIX+1%29&doi=10.1016%2FS0140-6736%2808%2960725-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2960725-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252960725-4%26sid%3Dliteratum%253Aachs%26aulast%3DLeonardi%26aufirst%3DC.%2BL.%26aulast%3DKimball%26aufirst%3DA.%2BB.%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DYeilding%26aufirst%3DN.%26aulast%3DGuzzo%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDooley%26aufirst%3DL.%2BT.%26aulast%3DGordon%26aufirst%3DK.%2BB.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520ustekinumab%252C%2520a%2520human%2520interleukin-12%252F23%2520monoclonal%2520antibody%252C%2520in%2520patients%2520with%2520psoriasis%253A%252076-week%2520results%2520from%2520a%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520%2528PHOENIX%25201%2529%26jtitle%3DLancet%26date%3D2008%26volume%3D371%26spage%3D1665%26epage%3D1674%26doi%3D10.1016%2FS0140-6736%2808%2960725-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Papp, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szapary, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeilding, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, M. – C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dooley, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, K.</span><span> </span><span class="NLM_article-title">Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">1675</span><span class="NLM_x">–</span> <span class="NLM_lpage">1684</span><span class="refDoi"> DOI: 10.1016/S0140-6736(08)60726-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2FS0140-6736%2808%2960726-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2008&pages=1675-1684&author=K.+A.+Pappauthor=R.+G.+Langleyauthor=M.+Lebwohlauthor=G.+G.+Kruegerauthor=P.+Szaparyauthor=N.+Yeildingauthor=C.+Guzzoauthor=M.+%E2%80%93+C.+Hsuauthor=Y.+Wangauthor=S.+Liauthor=L.+T.+Dooleyauthor=K.+Reich&title=Efficacy+and+safety+of+ustekinumab%2C+a+human+interleukin-12%2F23+monoclonal+antibody%2C+in+patients+with+psoriasis%3A+52-week+results+from+a+randomised%2C+double-blind%2C+placebo-controlled+trial+%28PHOENIX+2%29&doi=10.1016%2FS0140-6736%2808%2960726-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2960726-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252960726-6%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DLangley%26aufirst%3DR.%2BG.%26aulast%3DLebwohl%26aufirst%3DM.%26aulast%3DKrueger%26aufirst%3DG.%2BG.%26aulast%3DSzapary%26aufirst%3DP.%26aulast%3DYeilding%26aufirst%3DN.%26aulast%3DGuzzo%26aufirst%3DC.%26aulast%3DHsu%26aufirst%3DM.%2B%25E2%2580%2593%2BC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DDooley%26aufirst%3DL.%2BT.%26aulast%3DReich%26aufirst%3DK.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520ustekinumab%252C%2520a%2520human%2520interleukin-12%252F23%2520monoclonal%2520antibody%252C%2520in%2520patients%2520with%2520psoriasis%253A%252052-week%2520results%2520from%2520a%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520%2528PHOENIX%25202%2529%26jtitle%3DLancet%26date%3D2008%26volume%3D371%26spage%3D1675%26epage%3D1684%26doi%3D10.1016%2FS0140-6736%2808%2960726-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Griffiths, C. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strober, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerkhof, P. V. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidelus, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeilding, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dooley, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menter, A.</span><span> </span><span class="NLM_article-title">Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">362</span><span class="NLM_x">, </span> <span class="NLM_fpage">118</span><span class="NLM_x">–</span> <span class="NLM_lpage">128</span><span class="refDoi"> DOI: 10.1056/NEJMoa0810652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1056%2FNEJMoa0810652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=20071701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFGjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2010&pages=118-128&author=C.+E.+M.+Griffithsauthor=B.+E.+Stroberauthor=P.+V.+D.+Kerkhofauthor=V.+Hoauthor=G.+R.+Fidelusauthor=N.+Yeildingauthor=C.+Guzzoauthor=Y.+Xiaauthor=B.+Zhouauthor=S.+Liauthor=L.+T.+Dooleyauthor=N.+H.+Goldsteinauthor=A.+Menter&title=Comparison+of+ustekinumab+and+etanercept+for+moderate-to-severe+psoriasis&doi=10.1056%2FNEJMoa0810652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5eR"><div class="casContent"><span class="casTitleNuber">5e</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis</span></div><div class="casAuthors">Griffiths, Christopher E. M.; Strober, Bruce E.; van de Kerkhof, Peter; Ho, Vincent; Fidelus-Gort, Roseanne; Yeilding, Newman; Guzzo, Cynthia; Xia, Yichuan; Zhou, Bei; Li, Shu; Dooley, Lisa T.; Goldstein, Neil H.; Menter, Alan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">118-128</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Biol. agents offer a range of new therapeutic options for patients with psoriasis; however, the relative benefit-risk profiles of such therapies are not well known.  We compared two biol. agents, ustekinumab (an interleukin-12 and interleukin-23 blocker) and etanercept (an inhibitor of tumor necrosis factor α), for the treatment of psoriasis.  We randomly assigned 903 patients with moderate-to-severe psoriasis to receive s.c. injections of either 45 or 90 mg of ustekinumab (at weeks 0 and 4) or high-dose etanercept (50 mg twice weekly for 12 wk).  The primary end point was the proportion of patients with at least 75% improvement in the psoriasis area-and-severity index (PASI) at week 12; a secondary end point was the proportion with cleared or minimal disease on the basis of the physician's global assessment.  Assessors were unaware of the treatment assignments.  The efficacy and safety of a crossover from etanercept to ustekinumab were evaluated after week 12.  There was at least 75% improvement in the PASI at week 12 in 67.5% of patients who received 45 mg of ustekinumab and 73.8% of patients who received 90 mg, as compared with 56.8% of those who received etanercept (P = 0.01 and P < 0.001, resp.).  Similarly, 65.1% of patients who received 45 mg of ustekinumab and 70.6% of patients who received 90 mg of ustekinumab had cleared or minimal disease according to the physician's global assessment, as compared with 49.0% of those who received etanercept (P < 0.001 for both comparisons).  Among patients who did not have a response to etanercept, 48.9% had at least 75% improvement in the PASI within 12 wk after crossover to ustekinumab.  One or more adverse events occurred through week 12 in 66.0% of patients who received 45 mg of ustekinumab and 69.2% of patients who received 90 mg of ustekinumab and in 70.0% who received etanercept; 1.9%, 1.2%, and 1.2%, resp., had serious adverse events.  Safety patterns were similar before and after crossover from etanercept to ustekinumab.  The efficacy of ustekinumab at a dose of 45 or 90 mg was superior to that of high-dose etanercept over a 12-wk period in patients with psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMoaei3TsvwLVg90H21EOLACvtfcHk0lgBs8DRLKjFHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFGjtA%253D%253D&md5=46527d6bbad0113d88a7b45b18512897</span></div><a href="/servlet/linkout?suffix=cit5e&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0810652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0810652%26sid%3Dliteratum%253Aachs%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%2BM.%26aulast%3DStrober%26aufirst%3DB.%2BE.%26aulast%3DKerkhof%26aufirst%3DP.%2BV.%2BD.%26aulast%3DHo%26aufirst%3DV.%26aulast%3DFidelus%26aufirst%3DG.%2BR.%26aulast%3DYeilding%26aufirst%3DN.%26aulast%3DGuzzo%26aufirst%3DC.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DDooley%26aufirst%3DL.%2BT.%26aulast%3DGoldstein%26aufirst%3DN.%2BH.%26aulast%3DMenter%26aufirst%3DA.%26atitle%3DComparison%2520of%2520ustekinumab%2520and%2520etanercept%2520for%2520moderate-to-severe%2520psoriasis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D362%26spage%3D118%26epage%3D128%26doi%3D10.1056%2FNEJMoa0810652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Krueger, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonardi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeilding, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dooley, L. T.</span><span> </span><span class="NLM_article-title">A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">580</span><span class="NLM_x">–</span> <span class="NLM_lpage">592</span><span class="refDoi"> DOI: 10.1056/NEJMoa062382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1056%2FNEJMoa062382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=17287478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsFOksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=580-592&author=G.+G.+Kruegerauthor=R.+G.+Langleyauthor=C.+Leonardiauthor=N.+Yeildingauthor=C.+Guzzoauthor=Y.+Wangauthor=L.+T.+Dooley&title=A+human+interleukin-12%2F23+monoclonal+antibody+for+the+treatment+of+psoriasis&doi=10.1056%2FNEJMoa062382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5fR"><div class="casContent"><span class="casTitleNuber">5f</span><div class="casTitle"><span class="NLM_cas:atitle">A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis</span></div><div class="casAuthors">Krueger, Gerald G.; Langley, Richard G.; Leonardi, Craig; Yeilding, Newman; Guzzo, Cynthia; Wang, Yuhua; Dooley, Lisa T.; Lebwohl, Mark; Altmeyer, P.; Bissonnette, R.; Blum, R.; Bourcier, M.; Carey, W.; Chambers, M.; Florentino, D.; Fretzin, S.; Gratton, D.; Guenther, L.; Hamlin, R.; Harvey, D.; Hudson, C.; Kaufmann, R.; Kircik, L.; Kirsner, R.; Korman, N.; Krueger, G.; Krusinski, P.; Zavod, M.; Lambert, J.; Langley, R.; Loenardi, C.; Ling, M.; Lubin, B.; Luger, T.; Marot, L.; Matheson, R.; Menter, A.; Nayak, A.; Nieves, D.; Nigra, T.; Packman, B.; Papp, K.; Poulin, Y.; Reich, K.; Rich, P.; Rosoph, L.; Sobell, J.; Swinehart, J.; Tomi, Z.; Toth, D.; Truett, A., III; Tschen, E.; Wasel, N.; Zanolli, M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">580-592</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiol. of psoriasis.  We evaluated the safety and efficacy of a human interleukin-12/23 monoclonal antibody in treating psoriasis.  In this double-blind, placebo-controlled trial, 320 patients with moderate-to-severe plaque psoriasis underwent randomization to treatment with the interleukin-12/23 monoclonal antibody (one 45-mg dose, one 90-mg dose, four weekly 45-mg doses, or four weekly 90-mg doses) or placebo; 64 patients were randomly assigned to each group.  Patients assigned to the interleukin-12/23 monoclonal antibody received one addnl. dose at week 16 if needed.  Patients assigned to placebo crossed over to receive one 90-mg dose of interleukin-12/23 monoclonal antibody at week 20.  There was at least 75% improvement in the psoriasis area-and-severity index at week 12 (the primary end point) in 52% of patients who received 45 mg of the interleukin-12/23 monoclonal antibody, in 59% of those who received 90 mg, in 67% of those who received four weekly 45-mg doses, and in 81% of those who received four weekly 90-mg doses, as compared with 2% of those who received placebo, and there was at least 90% improvement in 23%, 30%, 44%, and 52%, resp., of patients who received the monoclonal antibody as compared with 2% of patients who received placebo.  Adverse events occurred in 79% of patients treated with the interleukin-12/23 monoclonal antibody as compared with 72% of patients in the placebo group.  Serious adverse events occurred in 40% of patients who received the monoclonal antibody and in 10% of those who received placebo.  This study demonstrates the therapeutic efficacy of an interleukin-12/23 monoclonal antibody in psoriasis and provides further evidence of a role of the interleukin-12/23 p40 cytokines in the pathophysiol. of psoriasis.  Larger studies are needed to det. whether serious adverse events might limit the clin. usefulness of this new therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuwr1TZp_wfrVg90H21EOLACvtfcHk0liSnFRS-u_q2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsFOksbo%253D&md5=4be21c1e7370c170b6fcf0c6fd5e790f</span></div><a href="/servlet/linkout?suffix=cit5f&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa062382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa062382%26sid%3Dliteratum%253Aachs%26aulast%3DKrueger%26aufirst%3DG.%2BG.%26aulast%3DLangley%26aufirst%3DR.%2BG.%26aulast%3DLeonardi%26aufirst%3DC.%26aulast%3DYeilding%26aufirst%3DN.%26aulast%3DGuzzo%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDooley%26aufirst%3DL.%2BT.%26atitle%3DA%2520human%2520interleukin-12%252F23%2520monoclonal%2520antibody%2520for%2520the%2520treatment%2520of%2520psoriasis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D580%26epage%3D592%26doi%3D10.1056%2FNEJMoa062382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Lopez-Ferrer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilarrasa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puig, L.</span><span> </span><span class="NLM_article-title">Secukinumab (AIN457) for the treatment of psoriasis</span> <span class="citation_source-journal">Expert Rev. Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1177</span><span class="NLM_x">–</span> <span class="NLM_lpage">88</span><span class="refDoi"> DOI: 10.1586/1744666X.2015.1095092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1586%2F1744666X.2015.1095092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=26428036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKksbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=1177-88&author=A.+Lopez-Ferrerauthor=E.+Vilarrasaauthor=L.+Puig&title=Secukinumab+%28AIN457%29+for+the+treatment+of+psoriasis&doi=10.1586%2F1744666X.2015.1095092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5gR"><div class="casContent"><span class="casTitleNuber">5g</span><div class="casTitle"><span class="NLM_cas:atitle">Secukinumab (AIN457) for the treatment of psoriasis</span></div><div class="casAuthors">Lopez-Ferrer, Anna; Vilarrasa, Eva; Puig, Lluis</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1177-1188</span>CODEN:
                <span class="NLM_cas:coden">ERCIBU</span>;
        ISSN:<span class="NLM_cas:issn">1744-666X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Psoriasis is a chronic inflammatory disease with a multifactorial origin that appears in patients with genetic predisposition and is induced by environmental factors, and characterized by alterations in the innate and adaptive immunity.  IL-17A is one of the specific cytokines involved in the pathogenesis of psoriasis and its inhibition is highly effective in the treatment of patients with moderate and severe psoriasis.  Secukinumab is a monoclonal antibody that specifically binds to IL-17A and inhibits the interaction to its receptor, and it has demonstrated its efficacy and safety in the treatment of psoriasis.  Phase II and III clin. trials indicate that > 80% of the patients receiving secukinumab achieve Psoriasis Area Severity Index (PASI) 75 at week 12.  In the Phase III efficacy of response and safety of two fixed secukinumab regimens in psoriasis trial, PASI 75 rates were 81.6% with 300 mg secukinumab, 71.6% with 150 mg secukinumab and 4.5% with placebo, and responses were maintained up to 52 wk in the majority of patients.  In the Phase III Full Year Investigative Examn. Of Secukinumab vs. Etanercept Using Two Dosing Regimens To Det. Efficacy in Psoriasis study, the efficacy of secukinumab was compared to etanercept.  The results indicate that both doses of secukinumab (150 and 300 mg) showed superior efficacy compared with etanercept throughout the study; PASI 75 rates at week 12 were 77.1% with 300 mg secukinumab, 67% with 150 mg of secukinumab, 44% with etanercept and 4.9% with placebo.  PASI 90 and PASI 100 were 54 and 24% with secukinumab 300 mg and 21 and 4% with etanercept at week 12.  At week 52, PASI 90 continued to be higher in the secukinumab group (65%) compared with the etanercept group (33%).  Regarding safety, the most common side effects were nasopharyngitis and headache.  The rate of infections was higher with secukinumab than placebo.  This was esp. the case for Candida infections, which were more common in the secukinumab group (4.7% with secukinumab 300 mg and 2.3% with secukinumab 150 mg), but all cases were resolved with conventional treatment.  Secukinumab is a well-tolerated treatment that has demonstrated efficacy in treating moderate-to-severe plaque psoriasis.  Nevertheless, long-term studies are necessary to confirm Phase II and Phase III data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6G3TVfUViuLVg90H21EOLACvtfcHk0liSnFRS-u_q2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKksbvK&md5=eed7f467cad7919c682853413438d08e</span></div><a href="/servlet/linkout?suffix=cit5g&amp;dbid=16384&amp;doi=10.1586%2F1744666X.2015.1095092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F1744666X.2015.1095092%26sid%3Dliteratum%253Aachs%26aulast%3DLopez-Ferrer%26aufirst%3DA.%26aulast%3DVilarrasa%26aufirst%3DE.%26aulast%3DPuig%26aufirst%3DL.%26atitle%3DSecukinumab%2520%2528AIN457%2529%2520for%2520the%2520treatment%2520of%2520psoriasis%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Immunol.%26date%3D2015%26volume%3D11%26spage%3D1177%26epage%3D88%26doi%3D10.1586%2F1744666X.2015.1095092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Griffiths, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Kerkhof, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Secrest, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osuntokun, O. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffernan, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickoloff, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papp, K.</span><span> </span><span class="NLM_article-title">Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">386</span><span class="NLM_x">, </span> <span class="NLM_fpage">541</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1016/S0140-6736(15)60125-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2FS0140-6736%2815%2960125-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=541-51&author=C.+E.+Griffithsauthor=K.+Reichauthor=M.+Lebwohlauthor=P.+van+de+Kerkhofauthor=C.+Paulauthor=A.+Menterauthor=G.+S.+Cameronauthor=J.+Ericksonauthor=L.+Zhangauthor=R.+J.+Secrestauthor=S.+Ballauthor=D.+K.+Braunauthor=O.+O.+Osuntokunauthor=M.+P.+Heffernanauthor=B.+J.+Nickoloffauthor=K.+Papp&title=Comparison+of+ixekizumab+with+etanercept+or+placebo+in+moderate-to-severe+psoriasis+%28UNCOVER-2+and+UNCOVER-3%29%3A+results+from+two+phase+3+randomised+trials&doi=10.1016%2FS0140-6736%2815%2960125-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5h&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2960125-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252960125-8%26sid%3Dliteratum%253Aachs%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%26aulast%3DReich%26aufirst%3DK.%26aulast%3DLebwohl%26aufirst%3DM.%26aulast%3Dvan%2Bde%2BKerkhof%26aufirst%3DP.%26aulast%3DPaul%26aufirst%3DC.%26aulast%3DMenter%26aufirst%3DA.%26aulast%3DCameron%26aufirst%3DG.%2BS.%26aulast%3DErickson%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSecrest%26aufirst%3DR.%2BJ.%26aulast%3DBall%26aufirst%3DS.%26aulast%3DBraun%26aufirst%3DD.%2BK.%26aulast%3DOsuntokun%26aufirst%3DO.%2BO.%26aulast%3DHeffernan%26aufirst%3DM.%2BP.%26aulast%3DNickoloff%26aufirst%3DB.%2BJ.%26aulast%3DPapp%26aufirst%3DK.%26atitle%3DComparison%2520of%2520ixekizumab%2520with%2520etanercept%2520or%2520placebo%2520in%2520moderate-to-severe%2520psoriasis%2520%2528UNCOVER-2%2520and%2520UNCOVER-3%2529%253A%2520results%2520from%2520two%2520phase%25203%2520randomised%2520trials%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26spage%3D541%26epage%3D51%26doi%3D10.1016%2FS0140-6736%2815%2960125-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Strange, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weale, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Band, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellenguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergboer, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwell, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bramon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bumpstead, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casas, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cork, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deloukas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dilthey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncanson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estivill, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzgerald, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giardina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hüffmeier, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irvine, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jankowski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirby, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langford, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lascorz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leslie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallbris, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markus, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathew, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLean, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McManus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mössner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moutsianas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naluai, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nestle, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onoufriadis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perricone, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plomin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pujol, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rautanen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riveira-Munoz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmhofer, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawcer, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schalkwijk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ståhle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tazi-Ahnini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traupe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viswanathan, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worthington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeeuwen, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayday, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burden, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kere, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McVean, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltonen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trembath, R. C.</span><span> </span><span class="NLM_article-title">A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">985</span><span class="NLM_x">–</span> <span class="NLM_lpage">990</span><span class="refDoi"> DOI: 10.1038/ng.694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1038%2Fng.694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=20953190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlSgtbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=985-990&author=A.+Strangeauthor=F.+Caponauthor=C.+C.+Spencerauthor=J.+Knightauthor=M.+E.+Wealeauthor=M.+H.+Allenauthor=A.+Bartonauthor=G.+Bandauthor=C.+Bellenguezauthor=J.+G.+Bergboerauthor=J.+M.+Blackwellauthor=E.+Bramonauthor=S.+J.+Bumpsteadauthor=J.+P.+Casasauthor=M.+J.+Corkauthor=A.+Corvinauthor=P.+Deloukasauthor=A.+Diltheyauthor=A.+Duncansonauthor=S.+Edkinsauthor=X.+Estivillauthor=O.+Fitzgeraldauthor=C.+Freemanauthor=E.+Giardinaauthor=E.+Grayauthor=A.+Hoferauthor=U.+H%C3%BCffmeierauthor=S.+E.+Huntauthor=A.+D.+Irvineauthor=J.+Jankowskiauthor=B.+Kirbyauthor=C.+Langfordauthor=J.+Lascorzauthor=J.+Lemanauthor=S.+Leslieauthor=L.+Mallbrisauthor=H.+S.+Markusauthor=C.+G.+Mathewauthor=W.+H.+McLeanauthor=R.+McManusauthor=R.+M%C3%B6ssnerauthor=L.+Moutsianasauthor=A.+T.+Naluaiauthor=F.+O.+Nestleauthor=G.+Novelliauthor=A.+Onoufriadisauthor=C.+N.+Palmerauthor=C.+Perriconeauthor=M.+Pirinenauthor=R.+Plominauthor=S.+C.+Potterauthor=R.+M.+Pujolauthor=A.+Rautanenauthor=E.+Riveira-Munozauthor=A.+W.+Ryanauthor=W.+Salmhoferauthor=L.+Samuelssonauthor=S.+J.+Sawcerauthor=J.+Schalkwijkauthor=C.+H.+Smithauthor=M.+St%C3%A5hleauthor=Z.+Suauthor=R.+Tazi-Ahniniauthor=H.+Traupeauthor=A.+C.+Viswanathanauthor=R.+B.+Warrenauthor=W.+Wegerauthor=K.+Wolkauthor=N.+Woodauthor=J.+Worthingtonauthor=H.+S.+Youngauthor=P.+L.+Zeeuwenauthor=A.+Haydayauthor=A.+D.+Burdenauthor=C.+E.+Griffithsauthor=J.+Kereauthor=A.+Reisauthor=G.+McVeanauthor=D.+M.+Evansauthor=M.+A.+Brownauthor=J.+N.+Barkerauthor=L.+Peltonenauthor=P.+Donnellyauthor=R.+C.+Trembath&title=A+genome-wide+association+study+identifies+new+psoriasis+susceptibility+loci+and+an+interaction+between+HLA-C+and+ERAP1&doi=10.1038%2Fng.694"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1</span></div><div class="casAuthors">Strange, Amy; Capon, Francesca; Spencer, Chris C. A.; Knight, Jo; Weale, Michael E.; Allen, Michael H.; Barton, Anne; Band, Gavin; Bellenguez, Celine; Bergboer, Judith G. M.; Blackwell, Jenefer M.; Bramon, Elvira; Bumpstead, Suzannah J.; Casas, Juan P.; Cork, Michael J.; Corvin, Aiden; Deloukas, Panos; Dilthey, Alexander; Duncanson, Audrey; Edkins, Sarah; Estivill, Xavier; Fitzgerald, Oliver; Freeman, Colin; Giardina, Emiliano; Gray, Emma; Hofer, Angelika; Hueffmeier, Ulrike; Hunt, Sarah E.; Irvine, Alan D.; Jankowski, Janusz; Kirby, Brian; Langford, Cordelia; Lascorz, Jesus; Leman, Joyce; Leslie, Stephen; Mallbris, Lotus; Markus, Hugh S.; Mathew, Christopher G.; McLean, W. H. Irwin; McManus, Ross; Moessner, Rotraut; Moutsianas, Loukas; Naluai, Asa T.; Nestle, Frank O.; Novelli, Giuseppe; Onoufriadis, Alexandros; Palmer, Colin N. A.; Perricone, Carlo; Pirinen, Matti; Plomin, Robert; Potter, Simon C.; Pujol, Ramon M.; Rautanen, Anna; Riveira-Munoz, Eva; Ryan, Anthony W.; Salmhofer, Wolfgang; Samuelsson, Lena; Sawcer, Stephen J.; Schalkwijk, Joost; Smith, Catherine H.; Stahle, Mona; Su, Zhan; Tazi-Ahnini, Rachid; Traupe, Heiko; Viswanathan, Ananth C.; Warren, Richard B.; Weger, Wolfgang; Wolk, Katarina; Wood, Nicholas; Worthington, Jane; Young, Helen S.; Zeeuwen, Patrick L. J. M.; Hayday, Adrian; Burden, A. David; Griffiths, Christopher E. M.; Kere, Juha; Reis, Andre; McVean, Gilean; Evans, David M.; Brown, Matthew A.; Barker, Jonathan N.; Peltonen, Leena; Donnelly, Peter; Trembath, Richard C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">985-990</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To identify new susceptibility loci for psoriasis, we undertook a genome-wide assocn. study of 594,224 SNPs in 2622 individuals with psoriasis and 5667 controls.  We identified assocns. at 8 previously unreported genomic loci.  7 Loci harbored genes with recognized immune functions (IL28RA, REL, IFIH1, ERAP1, TRAF3IP2, NFKBIA, and TYK2).  These assocns. were replicated in 9079 European samples (six loci with a combined P < 5 × 10-8 and two loci with a combined P < 5 × 10-7).  We also report compelling evidence for an interaction between the HLA-C and ERAP1 loci (combined P = 6.95 × 10-6).  ERAP1 plays an important role in MHC class I peptide processing.  ERAP1 variants only influenced psoriasis susceptibility in individuals carrying the HLA-C risk allele.  Our findings implicate pathways that integrate epidermal barrier dysfunction with innate and adaptive immune dysregulation in psoriasis pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr-vCehUruE7Vg90H21EOLACvtfcHk0lgurhL6EsFlwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlSgtbjF&md5=4a680242e04e2087a1d186e2c3d71a2b</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1038%2Fng.694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.694%26sid%3Dliteratum%253Aachs%26aulast%3DStrange%26aufirst%3DA.%26aulast%3DCapon%26aufirst%3DF.%26aulast%3DSpencer%26aufirst%3DC.%2BC.%26aulast%3DKnight%26aufirst%3DJ.%26aulast%3DWeale%26aufirst%3DM.%2BE.%26aulast%3DAllen%26aufirst%3DM.%2BH.%26aulast%3DBarton%26aufirst%3DA.%26aulast%3DBand%26aufirst%3DG.%26aulast%3DBellenguez%26aufirst%3DC.%26aulast%3DBergboer%26aufirst%3DJ.%2BG.%26aulast%3DBlackwell%26aufirst%3DJ.%2BM.%26aulast%3DBramon%26aufirst%3DE.%26aulast%3DBumpstead%26aufirst%3DS.%2BJ.%26aulast%3DCasas%26aufirst%3DJ.%2BP.%26aulast%3DCork%26aufirst%3DM.%2BJ.%26aulast%3DCorvin%26aufirst%3DA.%26aulast%3DDeloukas%26aufirst%3DP.%26aulast%3DDilthey%26aufirst%3DA.%26aulast%3DDuncanson%26aufirst%3DA.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DEstivill%26aufirst%3DX.%26aulast%3DFitzgerald%26aufirst%3DO.%26aulast%3DFreeman%26aufirst%3DC.%26aulast%3DGiardina%26aufirst%3DE.%26aulast%3DGray%26aufirst%3DE.%26aulast%3DHofer%26aufirst%3DA.%26aulast%3DH%25C3%25BCffmeier%26aufirst%3DU.%26aulast%3DHunt%26aufirst%3DS.%2BE.%26aulast%3DIrvine%26aufirst%3DA.%2BD.%26aulast%3DJankowski%26aufirst%3DJ.%26aulast%3DKirby%26aufirst%3DB.%26aulast%3DLangford%26aufirst%3DC.%26aulast%3DLascorz%26aufirst%3DJ.%26aulast%3DLeman%26aufirst%3DJ.%26aulast%3DLeslie%26aufirst%3DS.%26aulast%3DMallbris%26aufirst%3DL.%26aulast%3DMarkus%26aufirst%3DH.%2BS.%26aulast%3DMathew%26aufirst%3DC.%2BG.%26aulast%3DMcLean%26aufirst%3DW.%2BH.%26aulast%3DMcManus%26aufirst%3DR.%26aulast%3DM%25C3%25B6ssner%26aufirst%3DR.%26aulast%3DMoutsianas%26aufirst%3DL.%26aulast%3DNaluai%26aufirst%3DA.%2BT.%26aulast%3DNestle%26aufirst%3DF.%2BO.%26aulast%3DNovelli%26aufirst%3DG.%26aulast%3DOnoufriadis%26aufirst%3DA.%26aulast%3DPalmer%26aufirst%3DC.%2BN.%26aulast%3DPerricone%26aufirst%3DC.%26aulast%3DPirinen%26aufirst%3DM.%26aulast%3DPlomin%26aufirst%3DR.%26aulast%3DPotter%26aufirst%3DS.%2BC.%26aulast%3DPujol%26aufirst%3DR.%2BM.%26aulast%3DRautanen%26aufirst%3DA.%26aulast%3DRiveira-Munoz%26aufirst%3DE.%26aulast%3DRyan%26aufirst%3DA.%2BW.%26aulast%3DSalmhofer%26aufirst%3DW.%26aulast%3DSamuelsson%26aufirst%3DL.%26aulast%3DSawcer%26aufirst%3DS.%2BJ.%26aulast%3DSchalkwijk%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DC.%2BH.%26aulast%3DSt%25C3%25A5hle%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DTazi-Ahnini%26aufirst%3DR.%26aulast%3DTraupe%26aufirst%3DH.%26aulast%3DViswanathan%26aufirst%3DA.%2BC.%26aulast%3DWarren%26aufirst%3DR.%2BB.%26aulast%3DWeger%26aufirst%3DW.%26aulast%3DWolk%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DN.%26aulast%3DWorthington%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DH.%2BS.%26aulast%3DZeeuwen%26aufirst%3DP.%2BL.%26aulast%3DHayday%26aufirst%3DA.%26aulast%3DBurden%26aufirst%3DA.%2BD.%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%26aulast%3DKere%26aufirst%3DJ.%26aulast%3DReis%26aufirst%3DA.%26aulast%3DMcVean%26aufirst%3DG.%26aulast%3DEvans%26aufirst%3DD.%2BM.%26aulast%3DBrown%26aufirst%3DM.%2BA.%26aulast%3DBarker%26aufirst%3DJ.%2BN.%26aulast%3DPeltonen%26aufirst%3DL.%26aulast%3DDonnelly%26aufirst%3DP.%26aulast%3DTrembath%26aufirst%3DR.%2BC.%26atitle%3DA%2520genome-wide%2520association%2520study%2520identifies%2520new%2520psoriasis%2520susceptibility%2520loci%2520and%2520an%2520interaction%2520between%2520HLA-C%2520and%2520ERAP1%26jtitle%3DNat.%2520Genet.%26date%3D2010%26volume%3D42%26spage%3D985%26epage%3D990%26doi%3D10.1038%2Fng.694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tsoi, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spain, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellinghaus, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tejasvi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudjonsson, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McManus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schalkwijk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ståhle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burden, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cork, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estivill, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowcock, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worthington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tazi-Ahnini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nestle, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayday, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkelmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijmenga, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langford, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackburn, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strange, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Band, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vukcevic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deloukas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mrowietz, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weidinger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koks, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kingo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esko, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metspalu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voorhees, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weichenthal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wichmann, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandran, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gladman, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kere, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collaborative Association Study of Psoriasis (CASP); Genetic Analysis of Psoriasis Consortium; Psoriasis Association Genetics Extension; Wellcome Trust Case Control Consortium 2.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abecasis, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elder, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trembath, R. C.</span><span> </span><span class="NLM_article-title">Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1341</span><span class="NLM_x">–</span> <span class="NLM_lpage">1348</span><span class="refDoi"> DOI: 10.1038/ng.2467</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1038%2Fng.2467" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=23143594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Ckt77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2012&pages=1341-1348&author=L.+C.+Tsoiauthor=S.+L.+Spainauthor=J.+Knightauthor=E.+Ellinghausauthor=P.+E.+Stuartauthor=F.+Caponauthor=J.+Dingauthor=Y.+Liauthor=T.+Tejasviauthor=J.+E.+Gudjonssonauthor=H.+M.+Kangauthor=M.+H.+Allenauthor=R.+McManusauthor=G.+Novelliauthor=L.+Samuelssonauthor=J.+Schalkwijkauthor=M.+St%C3%A5hleauthor=A.+D.+Burdenauthor=C.+H.+Smithauthor=M.+J.+Corkauthor=X.+Estivillauthor=A.+M.+Bowcockauthor=G.+G.+Kruegerauthor=W.+Wegerauthor=J.+Worthingtonauthor=R.+Tazi-Ahniniauthor=F.+O.+Nestleauthor=A.+Haydayauthor=P.+Hoffmannauthor=J.+Winkelmannauthor=C.+Wijmengaauthor=C.+Langfordauthor=S.+Edkinsauthor=R.+Andrewsauthor=H.+Blackburnauthor=A.+Strangeauthor=G.+Bandauthor=R.+D.+Pearsonauthor=D.+Vukcevicauthor=C.+C.+Spencerauthor=P.+Deloukasauthor=U.+Mrowietzauthor=S.+Schreiberauthor=S.+Weidingerauthor=S.+Koksauthor=K.+Kingoauthor=T.+Eskoauthor=A.+Metspaluauthor=H.+W.+Limauthor=J.+J.+Voorheesauthor=M.+Weichenthalauthor=H.+E.+Wichmannauthor=V.+Chandranauthor=C.+F.+Rosenauthor=P.+Rahmanauthor=D.+D.+Gladmanauthor=C.+E.+Griffithsauthor=A.+Reisauthor=J.+Kereauthor=Collaborative+Association+Study+of+Psoriasis+%28CASP%29%3B+Genetic+Analysis+of+Psoriasis+Consortium%3B+Psoriasis+Association+Genetics+Extension%3B+Wellcome+Trust+Case+Control+Consortium+2.author=R.+P.+Nairauthor=A.+Frankeauthor=J.+N.+Barkerauthor=G.+R.+Abecasisauthor=J.+T.+Elderauthor=R.+C.+Trembath&title=Identification+of+15+new+psoriasis+susceptibility+loci+highlights+the+role+of+innate+immunity&doi=10.1038%2Fng.2467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity</span></div><div class="casAuthors">Tsoi, Lam C.; Spain, Sarah L.; Knight, Jo; Ellinghaus, Eva; Stuart, Philip E.; Capon, Francesca; Ding, Jun; Li, Yanming; Tejasvi, Trilokraj; Gudjonsson, Johann E.; Kang, Hyun M.; Allen, Michael H.; McManus, Ross; Novelli, Giuseppe; Samuelsson, Lena; Schalkwijk, Joost; Staahle, Mona; Burden, A. David; Smith, Catherine H.; Cork, Michael J.; Estivill, Xavier; Bowcock, Anne M.; Krueger, Gerald G.; Weger, Wolfgang; Worthington, Jane; Tazi-Ahnini, Rachid; Nestle, Frank O.; Hayday, Adrian; Hoffmann, Per; Winkelmann, Juliane; Wijmenga, Cisca; Langford, Cordelia; Edkins, Sarah; Andrews, Robert; Blackburn, Hannah; Strange, Amy; Band, Gavin; Pearson, Richard D.; Vukcevic, Damjan; Spencer, Chris C. A.; Deloukas, Panos; Mrowietz, Ulrich; Schreiber, Stefan; Weidinger, Stephan; Koks, Sulev; Kingo, Kulli; Esko, Tonu; Metspalu, Andres; Lim, Henry W.; Voorhees, John J.; Weichenthal, Michael; Wichmann, H. Erich; Chandran, Vinod; Rosen, Cheryl F.; Rahman, Proton; Gladman, Dafna D.; Griffiths, Christopher E. M.; Reis, Andre; Kere, Juha; Duffin, Kristina Callis; Helms, Cindy; Goldgar, David; Li, Yun; Paschall, Justin; Malloy, Mary J.; Pullinger, Clive R.; Kane, John P.; Gardner, Jennifer; Perlmutter, Amy; Miner, Andrew; Feng, Bing Jian; Hiremagalore, Ravi; Ike, Robert W.; Christophers, Enno; Henseler, Tilo; Ruether, Andreas; Schrodi, Steven J.; Prahalad, Sampath; Guthery, Stephen L.; Fischer, Judith; Liao, Wilson; Kwok, Pui; Menter, Alan; Lathrop, G. Mark; Wise, C.; Begovich, Ann B.; Onoufriadis, Alexandros; Weale, Michael E.; Hofer, Angelika; Salmhofer, Wolfgang; Wolf, Peter; Kainu, Kati; Saarialho-Kere, Ulpu; Suomela, Sari; Badorf, Petra; Hueffmeier, Ulrike; Kurrat, Werner; Kuester, Wolfgang; Lascorz, Jesus; Moessner, Rotraut; Schuermeier-Horst, Funda; Staender, Markward; Traupe, Heiko; Bergboer, Judith G. M.; den Heijer, Martin; van de Kerkhof, Peter C.; Zeeuwen, Patrick L. J. M.; Barnes, Louise; Campbell, Linda E.; Cusack, Caitriona; Coleman, Ciara; Conroy, Judith; Ennis, Sean; Fitzgerald, Oliver; Gallagher, Phil; Irvine, Alan D.; Kirby, Brian; Markham, Trevor; McLean, W. H. Irwin; McPartlin, Joe; Rogers, Sarah F.; Ryan, Anthony W.; Zawirska, Agnieszka; Giardina, Emiliano; Lepre, Tiziana; Perricone, Carlo; Martin-Ezquerra, Gemma; Pujol, Ramon M.; Riveira-Munoz, Eva; Inerot, Annica; Naluai, Aasa T.; Mallbris, Lotus; Wolk, Katarina; Leman, Joyce; Barton, Anne; Warren, Richard B.; Young, Helen S.; Ricano-Ponce, Isis; Trynka, Gosia; Pellett, Fawnda J.; Henschel, Andrew; Aurand, Marin; Bebo, Bruce; Gieger, Christian; Illig, Thomas; Moebus, Susanne; Joeckel, Karl-Heinz; Erbel, Raimund; Donnelly, Peter; Peltonen, Leena; Blackwell, Jenefer M.; Bramon, Elvira; Brown, Matthew A.; Casas, Juan P.; Corvin, Aiden; Craddock, Nicholas; Duncanson, Audrey; Jankowski, Janusz; Markus, Hugh S.; Mathew, Christopher G.; McCarthy, Mark I.; Palmer, Colin N. A.; Plomin, Robert; Rautanen, Anna; Sawcer, Stephen J.; Samani, Nilesh; Viswanathan, Ananth C.; Wood, Nicholas W.; Bellenguez, Celine; Freeman, Colin; Hellenthal, Garrett; Giannoulatou, Eleni; Pirinen, Matti; Su, Zhan; Hunt, Sarah E.; Gwilliam, Rhian; Bumpstead, Suzannah J.; Dronov, Serge; Gillman, Matthew; Gray, Emma; Hammond, Naomi; Jayakumar, Alagurevathi; McCann, Owen T.; Liddle, Jennifer; Perez, Marc L.; Potter, Simon C.; Ravindrarajah, Radhi; Ricketts, Michelle; Waller, Matthew; Weston, Paul; Widaa, Sara; Whittaker, Pamela; Nair, Rajan P.; Franke, Andre; Barker, Jonathan N. W. N.; Abecasis, Goncalo R.; Elder, James T.; Trembath, Richard C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1341-1348</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To gain further insight into the genetic architecture of psoriasis, we conducted a meta-anal. of 3 genome-wide assocn. studies (GWAS) and 2 independent data sets genotyped on the Immunochip, including 10,588 cases and 22,806 controls.  We identified 15 new susceptibility loci, increasing to 36 the no. assocd. with psoriasis in European individuals.  We also identified, using conditional analyses, five independent signals within previously known loci.  The newly identified loci shared with other autoimmune diseases include candidate genes with roles in regulating T-cell function (such as RUNX3, TAGAP and STAT3).  Notably, they included candidate genes whose products are involved in innate host defense, including interferon-mediated antiviral responses (DDX58), macrophage activation (ZC3H12C) and nuclear factor (NF)-κB signaling (CARD14 and CARM1).  These results portend a better understanding of shared and distinctive genetic determinants of immune-mediated inflammatory disorders and emphasize the importance of the skin in innate and acquired host defense.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUdQISitEvYLVg90H21EOLACvtfcHk0limLOrhYzAmoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Ckt77F&md5=0887b0024bb2fa2d01173b716b507284</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1038%2Fng.2467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2467%26sid%3Dliteratum%253Aachs%26aulast%3DTsoi%26aufirst%3DL.%2BC.%26aulast%3DSpain%26aufirst%3DS.%2BL.%26aulast%3DKnight%26aufirst%3DJ.%26aulast%3DEllinghaus%26aufirst%3DE.%26aulast%3DStuart%26aufirst%3DP.%2BE.%26aulast%3DCapon%26aufirst%3DF.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTejasvi%26aufirst%3DT.%26aulast%3DGudjonsson%26aufirst%3DJ.%2BE.%26aulast%3DKang%26aufirst%3DH.%2BM.%26aulast%3DAllen%26aufirst%3DM.%2BH.%26aulast%3DMcManus%26aufirst%3DR.%26aulast%3DNovelli%26aufirst%3DG.%26aulast%3DSamuelsson%26aufirst%3DL.%26aulast%3DSchalkwijk%26aufirst%3DJ.%26aulast%3DSt%25C3%25A5hle%26aufirst%3DM.%26aulast%3DBurden%26aufirst%3DA.%2BD.%26aulast%3DSmith%26aufirst%3DC.%2BH.%26aulast%3DCork%26aufirst%3DM.%2BJ.%26aulast%3DEstivill%26aufirst%3DX.%26aulast%3DBowcock%26aufirst%3DA.%2BM.%26aulast%3DKrueger%26aufirst%3DG.%2BG.%26aulast%3DWeger%26aufirst%3DW.%26aulast%3DWorthington%26aufirst%3DJ.%26aulast%3DTazi-Ahnini%26aufirst%3DR.%26aulast%3DNestle%26aufirst%3DF.%2BO.%26aulast%3DHayday%26aufirst%3DA.%26aulast%3DHoffmann%26aufirst%3DP.%26aulast%3DWinkelmann%26aufirst%3DJ.%26aulast%3DWijmenga%26aufirst%3DC.%26aulast%3DLangford%26aufirst%3DC.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DAndrews%26aufirst%3DR.%26aulast%3DBlackburn%26aufirst%3DH.%26aulast%3DStrange%26aufirst%3DA.%26aulast%3DBand%26aufirst%3DG.%26aulast%3DPearson%26aufirst%3DR.%2BD.%26aulast%3DVukcevic%26aufirst%3DD.%26aulast%3DSpencer%26aufirst%3DC.%2BC.%26aulast%3DDeloukas%26aufirst%3DP.%26aulast%3DMrowietz%26aufirst%3DU.%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DWeidinger%26aufirst%3DS.%26aulast%3DKoks%26aufirst%3DS.%26aulast%3DKingo%26aufirst%3DK.%26aulast%3DEsko%26aufirst%3DT.%26aulast%3DMetspalu%26aufirst%3DA.%26aulast%3DLim%26aufirst%3DH.%2BW.%26aulast%3DVoorhees%26aufirst%3DJ.%2BJ.%26aulast%3DWeichenthal%26aufirst%3DM.%26aulast%3DWichmann%26aufirst%3DH.%2BE.%26aulast%3DChandran%26aufirst%3DV.%26aulast%3DRosen%26aufirst%3DC.%2BF.%26aulast%3DRahman%26aufirst%3DP.%26aulast%3DGladman%26aufirst%3DD.%2BD.%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%26aulast%3DReis%26aufirst%3DA.%26aulast%3DKere%26aufirst%3DJ.%26aulast%3D%26aulast%3DNair%26aufirst%3DR.%2BP.%26aulast%3DFranke%26aufirst%3DA.%26aulast%3DBarker%26aufirst%3DJ.%2BN.%26aulast%3DAbecasis%26aufirst%3DG.%2BR.%26aulast%3DElder%26aufirst%3DJ.%2BT.%26aulast%3DTrembath%26aufirst%3DR.%2BC.%26atitle%3DIdentification%2520of%252015%2520new%2520psoriasis%2520susceptibility%2520loci%2520highlights%2520the%2520role%2520of%2520innate%2520immunity%26jtitle%3DNat.%2520Genet.%26date%3D2012%26volume%3D44%26spage%3D1341%26epage%3D1348%26doi%3D10.1038%2Fng.2467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Franke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGovern, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radford-Smith, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmad, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lees, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balschun, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bis, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bumpstead, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellinghaus, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Festen, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georges, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haritunians, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jostins, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latiano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathew, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prescott, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raychaudhuri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotter, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schumm, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simms, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijmenga, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldassano, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barclay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayless, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brand, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Büning, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombel, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stronati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Inca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubinsky, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Florin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franchimont, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gearry, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Gossum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guthery, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halfvarson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verspaget, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hugot, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karban, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laukens, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrance, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Libioulle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mowat, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panés, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proctor, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regueiro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutgeerts, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sans, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seibold, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinhart, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokkers, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torkvist, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kullak-Ublick, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Targan, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brant, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rioux, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Amato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weersma, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugathasan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansfield, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeire, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duerr, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverberg, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satsangi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annese, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakonarson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, M.</span><span> </span><span class="NLM_article-title">Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1118</span><span class="NLM_x">–</span> <span class="NLM_lpage">1125</span><span class="refDoi"> DOI: 10.1038/ng.717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1038%2Fng.717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=21102463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGhsrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=1118-1125&author=A.+Frankeauthor=D.+P.+McGovernauthor=J.+C.+Barrettauthor=K.+Wangauthor=G.+L.+Radford-Smithauthor=T.+Ahmadauthor=C.+W.+Leesauthor=T.+Balschunauthor=J.+Leeauthor=R.+Robertsauthor=C.+A.+Andersonauthor=J.+C.+Bisauthor=S.+Bumpsteadauthor=D.+Ellinghausauthor=E.+M.+Festenauthor=M.+Georgesauthor=T.+Greenauthor=T.+Harituniansauthor=L.+Jostinsauthor=A.+Latianoauthor=C.+G.+Mathewauthor=G.+W.+Montgomeryauthor=N.+J.+Prescottauthor=S.+Raychaudhuriauthor=J.+I.+Rotterauthor=P.+Schummauthor=Y.+Sharmaauthor=L.+A.+Simmsauthor=K.+D.+Taylorauthor=D.+Whitemanauthor=C.+Wijmengaauthor=R.+N.+Baldassanoauthor=M.+Barclayauthor=T.+M.+Baylessauthor=S.+Brandauthor=C.+B%C3%BCningauthor=A.+Cohenauthor=J.+F.+Colombelauthor=M.+Cottoneauthor=L.+Stronatiauthor=T.+Densonauthor=M.+De+Vosauthor=R.+D%E2%80%99Incaauthor=M.+Dubinskyauthor=C.+Edwardsauthor=T.+Florinauthor=D.+Franchimontauthor=R.+Gearryauthor=J.+Glasauthor=A.+Van+Gossumauthor=S.+L.+Gutheryauthor=J.+Halfvarsonauthor=H.+W.+Verspagetauthor=J.+P.+Hugotauthor=A.+Karbanauthor=D.+Laukensauthor=I.+Lawranceauthor=M.+Lemannauthor=A.+Levineauthor=C.+Libioulleauthor=E.+Louisauthor=C.+Mowatauthor=W.+Newmanauthor=J.+Pan%C3%A9sauthor=A.+Phillipsauthor=D.+D.+Proctorauthor=M.+Regueiroauthor=R.+Russellauthor=P.+Rutgeertsauthor=J.+Sandersonauthor=M.+Sansauthor=F.+Seiboldauthor=A.+H.+Steinhartauthor=P.+C.+Stokkersauthor=L.+Torkvistauthor=G.+Kullak-Ublickauthor=D.+Wilsonauthor=T.+Waltersauthor=S.+R.+Targanauthor=S.+R.+Brantauthor=J.+D.+Riouxauthor=M.+D%E2%80%99Amatoauthor=R.+K.+Weersmaauthor=S.+Kugathasanauthor=A.+M.+Griffithsauthor=J.+C.+Mansfieldauthor=S.+Vermeireauthor=R.+H.+Duerrauthor=M.+S.+Silverbergauthor=J.+Satsangiauthor=S.+Schreiberauthor=J.+H.+Choauthor=V.+Anneseauthor=H.+Hakonarsonauthor=M.+J.+Dalyauthor=M.+Parkes&title=Genome-wide+meta-analysis+increases+to+71+the+number+of+confirmed+Crohn%E2%80%99s+disease+susceptibility+loci&doi=10.1038%2Fng.717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci</span></div><div class="casAuthors">Franke, Andre; McGovern, Dermot P. B.; Barrett, Jeffrey C.; Wang, Kai; Radford-Smith, Graham L.; Ahmad, Tariq; Lees, Charlie W.; Balschun, Tobias; Lee, James; Roberts, Rebecca; Anderson, Carl A.; Bis, Joshua C.; Bumpstead, Suzanne; Ellinghaus, David; Festen, Eleonora M.; Georges, Michel; Green, Todd; Haritunians, Talin; Jostins, Luke; Latiano, Anna; Mathew, Christopher G.; Montgomery, Grant W.; Prescott, Natalie J.; Raychaudhuri, Soumya; Rotter, Jerome I.; Schumm, Philip; Sharma, Yashoda; Simms, Lisa A.; Taylor, Kent D.; Whiteman, David; Wijmenga, Cisca; Baldassano, Robert N.; Barclay, Murray; Bayless, Theodore M.; Brand, Stephan; Buening, Carsten; Cohen, Albert; Colombel, Jean-Frederick; Cottone, Mario; Stronati, Laura; Denson, Ted; De Vos, Martine; D'Inca, Renata; Dubinsky, Marla; Edwards, Cathryn; Florin, Tim; Franchimont, Denis; Gearry, Richard; Glas, Juergen; Van Gossum, Andre; Guthery, Stephen L.; Halfvarson, Jonas; Verspaget, Hein W.; Hugot, Jean-Pierre; Karban, Amir; Laukens, Debby; Lawrance, Ian; Lemann, Marc; Levine, Arie; Libioulle, Cecile; Louis, Edouard; Mowat, Craig; Newman, William; Panes, Julian; Phillips, Anne; Proctor, Deborah D.; Regueiro, Miguel; Russell, Richard; Rutgeerts, Paul; Sanderson, Jeremy; Sans, Miquel; Seibold, Frank; Steinhart, A. Hillary; Stokkers, Pieter C. F.; Torkvist, Leif; Kullak-Ublick, Gerd; Wilson, David; Walters, Thomas; Targan, Stephan R.; Brant, Steven R.; Rioux, John D.; D'Amato, Mauro; Weersma, Rinse K.; Kugathasan, Subra; Griffiths, Anne M.; Mansfield, John C.; Vermeire, Severine; Duerr, Richard H.; Silverberg, Mark S.; Satsangi, Jack; Schreiber, Stefan; Cho, Judy H.; Annese, Vito; Hakonarson, Hakon; Daly, Mark J.; Parkes, Miles</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1118-1125</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We undertook a meta-anal. of six Crohn's disease genome-wide assocn. studies (GWAS) comprising 6,333 affected individuals (cases) and 15,056 controls and followed up the top assocn. signals in 15,694 cases, 14,026 controls and 414 parent-offspring trios.  We identified 30 new susceptibility loci meeting genome-wide significance (P < 5 × 10-8).  A series of in silico analyses highlighted particular genes within these loci and, together with manual curation, implicated functionally interesting candidate genes including SMAD3, ERAP2, IL10, IL2RA, TYK2, FUT2, DNMT3A, DENND1B, BACH2 and TAGAP.  Combined with previously confirmed loci, these results identify 71 distinct loci with genome-wide significant evidence for assocn. with Crohn's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1uFTYE1cn1bVg90H21EOLACvtfcHk0lgFjfm4Yt8bOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGhsrzO&md5=902e2b2f3ffbeef3a3a75f3a757d4350</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fng.717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.717%26sid%3Dliteratum%253Aachs%26aulast%3DFranke%26aufirst%3DA.%26aulast%3DMcGovern%26aufirst%3DD.%2BP.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DRadford-Smith%26aufirst%3DG.%2BL.%26aulast%3DAhmad%26aufirst%3DT.%26aulast%3DLees%26aufirst%3DC.%2BW.%26aulast%3DBalschun%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DR.%26aulast%3DAnderson%26aufirst%3DC.%2BA.%26aulast%3DBis%26aufirst%3DJ.%2BC.%26aulast%3DBumpstead%26aufirst%3DS.%26aulast%3DEllinghaus%26aufirst%3DD.%26aulast%3DFesten%26aufirst%3DE.%2BM.%26aulast%3DGeorges%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DT.%26aulast%3DHaritunians%26aufirst%3DT.%26aulast%3DJostins%26aufirst%3DL.%26aulast%3DLatiano%26aufirst%3DA.%26aulast%3DMathew%26aufirst%3DC.%2BG.%26aulast%3DMontgomery%26aufirst%3DG.%2BW.%26aulast%3DPrescott%26aufirst%3DN.%2BJ.%26aulast%3DRaychaudhuri%26aufirst%3DS.%26aulast%3DRotter%26aufirst%3DJ.%2BI.%26aulast%3DSchumm%26aufirst%3DP.%26aulast%3DSharma%26aufirst%3DY.%26aulast%3DSimms%26aufirst%3DL.%2BA.%26aulast%3DTaylor%26aufirst%3DK.%2BD.%26aulast%3DWhiteman%26aufirst%3DD.%26aulast%3DWijmenga%26aufirst%3DC.%26aulast%3DBaldassano%26aufirst%3DR.%2BN.%26aulast%3DBarclay%26aufirst%3DM.%26aulast%3DBayless%26aufirst%3DT.%2BM.%26aulast%3DBrand%26aufirst%3DS.%26aulast%3DB%25C3%25BCning%26aufirst%3DC.%26aulast%3DCohen%26aufirst%3DA.%26aulast%3DColombel%26aufirst%3DJ.%2BF.%26aulast%3DCottone%26aufirst%3DM.%26aulast%3DStronati%26aufirst%3DL.%26aulast%3DDenson%26aufirst%3DT.%26aulast%3DDe%2BVos%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Inca%26aufirst%3DR.%26aulast%3DDubinsky%26aufirst%3DM.%26aulast%3DEdwards%26aufirst%3DC.%26aulast%3DFlorin%26aufirst%3DT.%26aulast%3DFranchimont%26aufirst%3DD.%26aulast%3DGearry%26aufirst%3DR.%26aulast%3DGlas%26aufirst%3DJ.%26aulast%3DVan%2BGossum%26aufirst%3DA.%26aulast%3DGuthery%26aufirst%3DS.%2BL.%26aulast%3DHalfvarson%26aufirst%3DJ.%26aulast%3DVerspaget%26aufirst%3DH.%2BW.%26aulast%3DHugot%26aufirst%3DJ.%2BP.%26aulast%3DKarban%26aufirst%3DA.%26aulast%3DLaukens%26aufirst%3DD.%26aulast%3DLawrance%26aufirst%3DI.%26aulast%3DLemann%26aufirst%3DM.%26aulast%3DLevine%26aufirst%3DA.%26aulast%3DLibioulle%26aufirst%3DC.%26aulast%3DLouis%26aufirst%3DE.%26aulast%3DMowat%26aufirst%3DC.%26aulast%3DNewman%26aufirst%3DW.%26aulast%3DPan%25C3%25A9s%26aufirst%3DJ.%26aulast%3DPhillips%26aufirst%3DA.%26aulast%3DProctor%26aufirst%3DD.%2BD.%26aulast%3DRegueiro%26aufirst%3DM.%26aulast%3DRussell%26aufirst%3DR.%26aulast%3DRutgeerts%26aufirst%3DP.%26aulast%3DSanderson%26aufirst%3DJ.%26aulast%3DSans%26aufirst%3DM.%26aulast%3DSeibold%26aufirst%3DF.%26aulast%3DSteinhart%26aufirst%3DA.%2BH.%26aulast%3DStokkers%26aufirst%3DP.%2BC.%26aulast%3DTorkvist%26aufirst%3DL.%26aulast%3DKullak-Ublick%26aufirst%3DG.%26aulast%3DWilson%26aufirst%3DD.%26aulast%3DWalters%26aufirst%3DT.%26aulast%3DTargan%26aufirst%3DS.%2BR.%26aulast%3DBrant%26aufirst%3DS.%2BR.%26aulast%3DRioux%26aufirst%3DJ.%2BD.%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DM.%26aulast%3DWeersma%26aufirst%3DR.%2BK.%26aulast%3DKugathasan%26aufirst%3DS.%26aulast%3DGriffiths%26aufirst%3DA.%2BM.%26aulast%3DMansfield%26aufirst%3DJ.%2BC.%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DDuerr%26aufirst%3DR.%2BH.%26aulast%3DSilverberg%26aufirst%3DM.%2BS.%26aulast%3DSatsangi%26aufirst%3DJ.%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DJ.%2BH.%26aulast%3DAnnese%26aufirst%3DV.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DDaly%26aufirst%3DM.%2BJ.%26aulast%3DParkes%26aufirst%3DM.%26atitle%3DGenome-wide%2520meta-analysis%2520increases%2520to%252071%2520the%2520number%2520of%2520confirmed%2520Crohn%25E2%2580%2599s%2520disease%2520susceptibility%2520loci%26jtitle%3DNat.%2520Genet.%26date%3D2010%26volume%3D42%26spage%3D1118%26epage%3D1125%26doi%3D10.1038%2Fng.717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_contrib-group">Bahlo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broadley, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foote, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilpatrick, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lechner-Scott, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moscato, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perreau, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubio, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stankovich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, B. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csurhes, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danoy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drysdale, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Field, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foote, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guru, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMorran, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCallum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merriman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merriman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pryce, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tajouri, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkins, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubio, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahlo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browning, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browning, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubio, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stankovich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broadley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butzkueven, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kermode, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marriott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heard, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pender, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tubridy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lechner-Scott, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, B. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willoughby, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilpatrick, T. J.</span><span> </span><span class="NLM_article-title">Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">824</span><span class="NLM_x">–</span> <span class="NLM_lpage">828</span><span class="refDoi"> DOI: 10.1038/ng.396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1038%2Fng.396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=19525955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1ShsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2009&pages=824-828&author=M.+Bahloauthor=D.+R.+Boothauthor=S.+A.+Broadleyauthor=M.+A.+Brownauthor=S.+J.+Footeauthor=L.+R.+Griffithsauthor=T.+J.+Kilpatrickauthor=J.+Lechner-Scottauthor=P.+Moscatoauthor=V.+M.+Perreauauthor=J.+P.+Rubioauthor=R.+J.+Scottauthor=J.+Stankovichauthor=G.+J.+Stewartauthor=B.+V.+Taylorauthor=J.+Wileyauthor=M.+A.+Brownauthor=D.+R.+Boothauthor=G.+Clarkeauthor=M.+B.+Coxauthor=P.+A.+Csurhesauthor=P.+Danoyauthor=K.+Drysdaleauthor=J.+Fieldauthor=S.+J.+Footeauthor=J.+M.+Greerauthor=L.+R.+Griffithsauthor=P.+Guruauthor=J.+Hadlerauthor=B.+J.+McMorranauthor=C.+J.+Jensenauthor=L.+J.+Johnsonauthor=R.+McCallumauthor=M.+Merrimanauthor=T.+Merrimanauthor=K.+Pryceauthor=R.+J.+Scottauthor=G.+J.+Stewartauthor=L.+Tajouriauthor=E.+J.+Wilkinsauthor=J.+P.+Rubioauthor=M.+Bahloauthor=M.+A.+Brownauthor=B.+L.+Browningauthor=S.+R.+Browningauthor=D.+Pereraauthor=J.+P.+Rubioauthor=J.+Stankovichauthor=S.+Broadleyauthor=H.+Butzkuevenauthor=W.+M.+Carrollauthor=C.+Chapmanauthor=A.+G.+Kermodeauthor=M.+Marriottauthor=D.+Masonauthor=R.+N.+Heardauthor=M.+P.+Penderauthor=M.+Sleeauthor=N.+Tubridyauthor=J.+Lechner-Scottauthor=B.+V.+Taylorauthor=E.+Willoughbyauthor=T.+J.+Kilpatrick&title=Genome-wide+association+study+identifies+new+multiple+sclerosis+susceptibility+loci+on+chromosomes+12+and+20&doi=10.1038%2Fng.396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20</span></div><div class="casAuthors">Bahlo, Melanie; Booth, David R.; Broadley, Simon A.; Brown, Matthew A.; Foote, Simon J.; Griffiths, Lyn R.; Kilpatrick, Trevor J.; Lechner-Scott, Jeanette; Moscato, Pablo; Perreau, Victoria M.; Rubio, Justin P.; Scott, Rodney J.; Stankovich, Jim; Stewart, Graeme J.; Taylor, Bruce V.; Wiley, James; Brown, Matthew A.; Booth, David R.; Clarke, Glynnis; Cox, Mathew B.; Csurhes, Peter A.; Danoy, Patrick; Drysdale, Karen; Field, Judith; Foote, Simon J.; Greer, Judith M.; Griffiths, Lyn R.; Guru, Preethi; Hadler, Johanna; McMorran, Brendan J.; Jensen, Cathy J.; Johnson, Laura J.; McCallum, Ruth; Merriman, Marilyn; Merriman, Tony; Pryce, Karen; Scott, Rodney J.; Stewart, Graeme J.; Tajouri, Lotfi; Wilkins, Ella J.; Rubio, Justin P.; Bahlo, Melanie; Brown, Matthew A.; Browning, Brian L.; Browning, Sharon R.; Perera, Devindri; Rubio, Justin P.; Stankovich, Jim; Broadley, Simon; Butzkueven, Helmut; Carroll, William M.; Chapman, Caron; Kermode, Allan G.; Marriott, Mark; Mason, Deborah; Heard, Robert N.; Pender, Michael P.; Slee, Mark; Tubridy, Niall; Lechner-Scott, Jeanette; Taylor, Bruce V.; Willoughby, Ernest; Kilpatrick, Trevor J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">824-828</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To identify multiple sclerosis (MS) susceptibility loci, we conducted a genome-wide assocn. study (GWAS) in 1618 cases and used shared data for 3413 controls.  We performed replication in an independent set of 2256 cases and 2310 controls, for a total of 3874 cases and 5723 controls.  We identified risk-assocd. SNPs on chromosome 12q13-14 (rs703842, P = 5.4 × 10-11; rs10876994, P = 2.7 × 10-10; rs12368653, P = 1.0 × 10-7) and upstream of CD40 on chromosome 20q13 (rs6074022, P = 1.3 × 10-7; rs1569723, P = 2.9 × 10-7).  Both loci are also assocd. with other autoimmune diseases.  We also replicated several known MS assocns. (HLA-DR15, P = 7.0 × 10-184; CD58, P = 9.6 × 10-8; EVI5-RPL5, P = 2.5 × 10-6; IL2RA, P = 7.4 × 10-6; CLEC16A, P = 1.1 × 10-4; IL7R, P = 1.3 × 10-3; TYK2, P = 3.5 × 10-3) and obsd. a statistical interaction between SNPs in EVI5-RPL5 and HLA-DR15 (P = 0.001).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZy7n4G_foY7Vg90H21EOLACvtfcHk0lh71qRFuYSz6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1ShsL8%253D&md5=532ff8b3e608398c2e1be19bcc03577f</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1038%2Fng.396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.396%26sid%3Dliteratum%253Aachs%26aulast%3DBahlo%26aufirst%3DM.%26aulast%3DBooth%26aufirst%3DD.%2BR.%26aulast%3DBroadley%26aufirst%3DS.%2BA.%26aulast%3DBrown%26aufirst%3DM.%2BA.%26aulast%3DFoote%26aufirst%3DS.%2BJ.%26aulast%3DGriffiths%26aufirst%3DL.%2BR.%26aulast%3DKilpatrick%26aufirst%3DT.%2BJ.%26aulast%3DLechner-Scott%26aufirst%3DJ.%26aulast%3DMoscato%26aufirst%3DP.%26aulast%3DPerreau%26aufirst%3DV.%2BM.%26aulast%3DRubio%26aufirst%3DJ.%2BP.%26aulast%3DScott%26aufirst%3DR.%2BJ.%26aulast%3DStankovich%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DG.%2BJ.%26aulast%3DTaylor%26aufirst%3DB.%2BV.%26aulast%3DWiley%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DM.%2BA.%26aulast%3DBooth%26aufirst%3DD.%2BR.%26aulast%3DClarke%26aufirst%3DG.%26aulast%3DCox%26aufirst%3DM.%2BB.%26aulast%3DCsurhes%26aufirst%3DP.%2BA.%26aulast%3DDanoy%26aufirst%3DP.%26aulast%3DDrysdale%26aufirst%3DK.%26aulast%3DField%26aufirst%3DJ.%26aulast%3DFoote%26aufirst%3DS.%2BJ.%26aulast%3DGreer%26aufirst%3DJ.%2BM.%26aulast%3DGriffiths%26aufirst%3DL.%2BR.%26aulast%3DGuru%26aufirst%3DP.%26aulast%3DHadler%26aufirst%3DJ.%26aulast%3DMcMorran%26aufirst%3DB.%2BJ.%26aulast%3DJensen%26aufirst%3DC.%2BJ.%26aulast%3DJohnson%26aufirst%3DL.%2BJ.%26aulast%3DMcCallum%26aufirst%3DR.%26aulast%3DMerriman%26aufirst%3DM.%26aulast%3DMerriman%26aufirst%3DT.%26aulast%3DPryce%26aufirst%3DK.%26aulast%3DScott%26aufirst%3DR.%2BJ.%26aulast%3DStewart%26aufirst%3DG.%2BJ.%26aulast%3DTajouri%26aufirst%3DL.%26aulast%3DWilkins%26aufirst%3DE.%2BJ.%26aulast%3DRubio%26aufirst%3DJ.%2BP.%26aulast%3DBahlo%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%2BA.%26aulast%3DBrowning%26aufirst%3DB.%2BL.%26aulast%3DBrowning%26aufirst%3DS.%2BR.%26aulast%3DPerera%26aufirst%3DD.%26aulast%3DRubio%26aufirst%3DJ.%2BP.%26aulast%3DStankovich%26aufirst%3DJ.%26aulast%3DBroadley%26aufirst%3DS.%26aulast%3DButzkueven%26aufirst%3DH.%26aulast%3DCarroll%26aufirst%3DW.%2BM.%26aulast%3DChapman%26aufirst%3DC.%26aulast%3DKermode%26aufirst%3DA.%2BG.%26aulast%3DMarriott%26aufirst%3DM.%26aulast%3DMason%26aufirst%3DD.%26aulast%3DHeard%26aufirst%3DR.%2BN.%26aulast%3DPender%26aufirst%3DM.%2BP.%26aulast%3DSlee%26aufirst%3DM.%26aulast%3DTubridy%26aufirst%3DN.%26aulast%3DLechner-Scott%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DB.%2BV.%26aulast%3DWilloughby%26aufirst%3DE.%26aulast%3DKilpatrick%26aufirst%3DT.%2BJ.%26atitle%3DGenome-wide%2520association%2520study%2520identifies%2520new%2520multiple%2520sclerosis%2520susceptibility%2520loci%2520on%2520chromosomes%252012%2520and%252020%26jtitle%3DNat.%2520Genet.%26date%3D2009%26volume%3D41%26spage%3D824%26epage%3D828%26doi%3D10.1038%2Fng.396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ban, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorentzen, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihalova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingram, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heard, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogaert, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubois, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbo, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celius, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spurkland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strange, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudbridge, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wason, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Jager, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hafler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rioux, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivinson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pericak-Vance, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oksenberg, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauser, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawcer, S.</span><span> </span><span class="NLM_article-title">Wellcome Trust Case-Control Consortium (WTCCC).; Compston A. Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor</span> <span class="citation_source-journal">Eur. J. Hum. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1309</span><span class="NLM_x">–</span> <span class="NLM_lpage">1313</span><span class="refDoi"> DOI: 10.1038/ejhg.2009.41</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1038%2Fejhg.2009.41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=19293837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFKnsLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=1309-1313&author=M.+Banauthor=A.+Gorisauthor=A.+R.+Lorentzenauthor=A.+Bakerauthor=T.+Mihalovaauthor=G.+Ingramauthor=D.+R.+Boothauthor=R.+N.+Heardauthor=G.+J.+Stewartauthor=E.+Bogaertauthor=B.+Duboisauthor=H.+F.+Harboauthor=E.+G.+Celiusauthor=A.+Spurklandauthor=R.+Strangeauthor=C.+Hawkinsauthor=N.+P.+Robertsonauthor=F.+Dudbridgeauthor=J.+Wasonauthor=P.+L.+De+Jagerauthor=D.+Haflerauthor=J.+D.+Riouxauthor=A.+J.+Ivinsonauthor=J.+L.+McCauleyauthor=M.+Pericak-Vanceauthor=J.+R.+Oksenbergauthor=S.+L.+Hauserauthor=D.+Sextonauthor=J.+Hainesauthor=S.+Sawcer&title=Wellcome+Trust+Case-Control+Consortium+%28WTCCC%29.%3B+Compston+A.+Replication+analysis+identifies+TYK2+as+a+multiple+sclerosis+susceptibility+factor&doi=10.1038%2Fejhg.2009.41"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor</span></div><div class="casAuthors">Ban, Maria; Goris, An; Lorentzen, Aslaug R.; Baker, Amie; Mihalova, Tania; Ingram, Gillian; Booth, David R.; Heard, Robert N.; Stewart, Graeme J.; Bogaert, Elke; Dubois, Benedicte; Harbo, Hanne F.; Celius, Elisabeth G.; Spurkland, Anne; Strange, Richard; Hawkins, Clive; Robertson, Neil P.; Dudbridge, Frank; Wason, James; De Jager, Philip L.; Hafler, David; Rioux, John D.; Ivinson, Adrian J.; McCauley, Jacob L.; Pericak-Vance, Margaret; Oksenberg, Jorge R.; Hauser, Stephen L.; Sexton, David; Haines, Jonathan; Sawcer, Stephen; Compston, Alastair</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1309-1313</span>CODEN:
                <span class="NLM_cas:coden">EJHGEU</span>;
        ISSN:<span class="NLM_cas:issn">1018-4813</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In a recent genome-wide assocn. study (GWAS) based on 12 374 non-synonymous single nucleotide polymorphisms we identified a no. of candidate multiple sclerosis susceptibility genes.  Here, we describe the extended anal. of 17 of these loci undertaken using an addnl. 4234 patients, 2983 controls and 2053 trio families.  In the final anal. combining all available data, we found that evidence for assocn. was substantially increased for one of the 17 loci, rs34536443 from the tyrosine kinase 2 (TYK2) gene (P = 2.7 × 10-6, odds ratio=1.32 (1.17-1.47)).  This single nucleotide polymorphism results in an amino acid substitution (proline to alanine) in the kinase domain of TYK2, which is predicted to influence the levels of phosphorylation and therefore activity of the protein and so is likely to have a functional role in multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy4Sk3LPBK-LVg90H21EOLACvtfcHk0lihqabWJjO7wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFKnsLbP&md5=b4950e39098927ecdb09dee395c7bc52</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1038%2Fejhg.2009.41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fejhg.2009.41%26sid%3Dliteratum%253Aachs%26aulast%3DBan%26aufirst%3DM.%26aulast%3DGoris%26aufirst%3DA.%26aulast%3DLorentzen%26aufirst%3DA.%2BR.%26aulast%3DBaker%26aufirst%3DA.%26aulast%3DMihalova%26aufirst%3DT.%26aulast%3DIngram%26aufirst%3DG.%26aulast%3DBooth%26aufirst%3DD.%2BR.%26aulast%3DHeard%26aufirst%3DR.%2BN.%26aulast%3DStewart%26aufirst%3DG.%2BJ.%26aulast%3DBogaert%26aufirst%3DE.%26aulast%3DDubois%26aufirst%3DB.%26aulast%3DHarbo%26aufirst%3DH.%2BF.%26aulast%3DCelius%26aufirst%3DE.%2BG.%26aulast%3DSpurkland%26aufirst%3DA.%26aulast%3DStrange%26aufirst%3DR.%26aulast%3DHawkins%26aufirst%3DC.%26aulast%3DRobertson%26aufirst%3DN.%2BP.%26aulast%3DDudbridge%26aufirst%3DF.%26aulast%3DWason%26aufirst%3DJ.%26aulast%3DDe%2BJager%26aufirst%3DP.%2BL.%26aulast%3DHafler%26aufirst%3DD.%26aulast%3DRioux%26aufirst%3DJ.%2BD.%26aulast%3DIvinson%26aufirst%3DA.%2BJ.%26aulast%3DMcCauley%26aufirst%3DJ.%2BL.%26aulast%3DPericak-Vance%26aufirst%3DM.%26aulast%3DOksenberg%26aufirst%3DJ.%2BR.%26aulast%3DHauser%26aufirst%3DS.%2BL.%26aulast%3DSexton%26aufirst%3DD.%26aulast%3DHaines%26aufirst%3DJ.%26aulast%3DSawcer%26aufirst%3DS.%26atitle%3DWellcome%2520Trust%2520Case-Control%2520Consortium%2520%2528WTCCC%2529.%253B%2520Compston%2520A.%2520Replication%2520analysis%2520identifies%2520TYK2%2520as%2520a%2520multiple%2520sclerosis%2520susceptibility%2520factor%26jtitle%3DEur.%2520J.%2520Hum.%2520Genet.%26date%3D2009%26volume%3D17%26spage%3D1309%26epage%3D1313%26doi%3D10.1038%2Fejhg.2009.41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Suarez-Gestal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calaza, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endreffy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pullmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ordi-Ros, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebastiani, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruzickova, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jose Santos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papasteriades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skopouli, F. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suarez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanco, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Alfonso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bijl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreira, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliaresi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Reino, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, A.</span><span> </span><span class="NLM_article-title">European Consortium of SLE DNA Collections. Replication of recently identified systemic lupus erythematosus genetic associations: a case-control study</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">R69</span><span class="refDoi"> DOI: 10.1186/ar2698</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1186%2Far2698" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=R69&author=M.+Suarez-Gestalauthor=M.+Calazaauthor=E.+Endreffyauthor=R.+Pullmannauthor=J.+Ordi-Rosauthor=G.+D.+Sebastianiauthor=S.+Ruzickovaauthor=M.+Jose+Santosauthor=C.+Papasteriadesauthor=M.+Marchiniauthor=F.+N.+Skopouliauthor=A.+Suarezauthor=F.+J.+Blancoauthor=S.+D%E2%80%99Alfonsoauthor=M.+Bijlauthor=P.+Carreiraauthor=T.+Witteauthor=S.+Migliaresiauthor=J.+J.+Gomez-Reinoauthor=A.+Gonzalez&title=European+Consortium+of+SLE+DNA+Collections.+Replication+of+recently+identified+systemic+lupus+erythematosus+genetic+associations%3A+a+case-control+study&doi=10.1186%2Far2698"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1186%2Far2698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Far2698%26sid%3Dliteratum%253Aachs%26aulast%3DSuarez-Gestal%26aufirst%3DM.%26aulast%3DCalaza%26aufirst%3DM.%26aulast%3DEndreffy%26aufirst%3DE.%26aulast%3DPullmann%26aufirst%3DR.%26aulast%3DOrdi-Ros%26aufirst%3DJ.%26aulast%3DSebastiani%26aufirst%3DG.%2BD.%26aulast%3DRuzickova%26aufirst%3DS.%26aulast%3DJose%2BSantos%26aufirst%3DM.%26aulast%3DPapasteriades%26aufirst%3DC.%26aulast%3DMarchini%26aufirst%3DM.%26aulast%3DSkopouli%26aufirst%3DF.%2BN.%26aulast%3DSuarez%26aufirst%3DA.%26aulast%3DBlanco%26aufirst%3DF.%2BJ.%26aulast%3DD%25E2%2580%2599Alfonso%26aufirst%3DS.%26aulast%3DBijl%26aufirst%3DM.%26aulast%3DCarreira%26aufirst%3DP.%26aulast%3DWitte%26aufirst%3DT.%26aulast%3DMigliaresi%26aufirst%3DS.%26aulast%3DGomez-Reino%26aufirst%3DJ.%2BJ.%26aulast%3DGonzalez%26aufirst%3DA.%26atitle%3DEuropean%2520Consortium%2520of%2520SLE%2520DNA%2520Collections.%2520Replication%2520of%2520recently%2520identified%2520systemic%2520lupus%2520erythematosus%2520genetic%2520associations%253A%2520a%2520case-control%2520study%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2009%26volume%3D11%26spage%3DR69%26doi%3D10.1186%2Far2698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cunninghame Graham, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhangale, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Criswell, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Syvänen, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rönnblom, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behrens, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyse, T. J.</span><span> </span><span class="NLM_article-title">Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus</span> <span class="citation_source-journal">PLoS Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1002341</span><span class="refDoi"> DOI: 10.1371/journal.pgen.1002341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1371%2Fjournal.pgen.1002341" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=e1002341&author=D.+S.+Cunninghame+Grahamauthor=D.+L.+Morrisauthor=T.+R.+Bhangaleauthor=L.+A.+Criswellauthor=A.+C.+Syv%C3%A4nenauthor=L.+R%C3%B6nnblomauthor=T.+W.+Behrensauthor=R.+R.+Grahamauthor=T.+J.+Vyse&title=Association+of+NCF2%2C+IKZF1%2C+IRF8%2C+IFIH1%2C+and+TYK2+with+systemic+lupus+erythematosus&doi=10.1371%2Fjournal.pgen.1002341"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1002341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1002341%26sid%3Dliteratum%253Aachs%26aulast%3DCunninghame%2BGraham%26aufirst%3DD.%2BS.%26aulast%3DMorris%26aufirst%3DD.%2BL.%26aulast%3DBhangale%26aufirst%3DT.%2BR.%26aulast%3DCriswell%26aufirst%3DL.%2BA.%26aulast%3DSyv%25C3%25A4nen%26aufirst%3DA.%2BC.%26aulast%3DR%25C3%25B6nnblom%26aufirst%3DL.%26aulast%3DBehrens%26aufirst%3DT.%2BW.%26aulast%3DGraham%26aufirst%3DR.%2BR.%26aulast%3DVyse%26aufirst%3DT.%2BJ.%26atitle%3DAssociation%2520of%2520NCF2%252C%2520IKZF1%252C%2520IRF8%252C%2520IFIH1%252C%2520and%2520TYK2%2520with%2520systemic%2520lupus%2520erythematosus%26jtitle%3DPLoS%2520Genet.%26date%3D2011%26volume%3D7%26spage%3De1002341%26doi%3D10.1371%2Fjournal.pgen.1002341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Parganas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stravopodis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marine, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teglund, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanin, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colamonici, O. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">vanDeursen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosveld, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, J. N.</span><span> </span><span class="NLM_article-title">Jak2 is essential for signaling through a variety of cytokine receptors</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">395</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)81167-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2FS0092-8674%2800%2981167-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=385-395&author=E.+Parganasauthor=D.+Wangauthor=D.+Stravopodisauthor=D.+J.+Tophamauthor=J.+C.+Marineauthor=S.+Teglundauthor=E.+F.+Vaninauthor=S.+Bodnerauthor=O.+R.+Colamoniciauthor=J.+M.+vanDeursenauthor=G.+Grosveldauthor=J.+N.+Ihle&title=Jak2+is+essential+for+signaling+through+a+variety+of+cytokine+receptors&doi=10.1016%2FS0092-8674%2800%2981167-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981167-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981167-8%26sid%3Dliteratum%253Aachs%26aulast%3DParganas%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DStravopodis%26aufirst%3DD.%26aulast%3DTopham%26aufirst%3DD.%2BJ.%26aulast%3DMarine%26aufirst%3DJ.%2BC.%26aulast%3DTeglund%26aufirst%3DS.%26aulast%3DVanin%26aufirst%3DE.%2BF.%26aulast%3DBodner%26aufirst%3DS.%26aulast%3DColamonici%26aufirst%3DO.%2BR.%26aulast%3DvanDeursen%26aufirst%3DJ.%2BM.%26aulast%3DGrosveld%26aufirst%3DG.%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26atitle%3DJak2%2520is%2520essential%2520for%2520signaling%2520through%2520a%2520variety%2520of%2520cytokine%2520receptors%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D385%26epage%3D395%26doi%3D10.1016%2FS0092-8674%2800%2981167-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Frenzel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDoom, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capecchi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sayeski, P. P.</span><span> </span><span class="NLM_article-title">A functional Jak2 tyrosine kinase domain is essential for mouse development</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x">, </span> <span class="NLM_fpage">2735</span><span class="NLM_x">–</span> <span class="NLM_lpage">2744</span><span class="refDoi"> DOI: 10.1016/j.yexcr.2006.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2Fj.yexcr.2006.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=16887119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BD28XovVWqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2006&pages=2735-2744&author=K.+Frenzelauthor=T.+A.+Wallaceauthor=I.+McDoomauthor=H.+D.+Xiaoauthor=M.+R.+Capecchiauthor=K.+E.+Bernsteinauthor=P.+P.+Sayeski&title=A+functional+Jak2+tyrosine+kinase+domain+is+essential+for+mouse+development&doi=10.1016%2Fj.yexcr.2006.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">A functional Jak2 tyrosine kinase domain is essential for mouse development</span></div><div class="casAuthors">Frenzel, Kristen; Wallace, Tiffany A.; McDoom, Issam; Xiao, Hong D.; Capecchi, Mario R.; Bernstein, Kenneth E.; Sayeski, Peter P.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2735-2744</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Jak2 is a member of the Janus family of tyrosine kinases and is involved in cytokine signaling.  As a part of a study to det. biol. functions of Jak2, we used mol. modeling to identify W1038 as a residue that is crit. for tyrosine kinase function.  Mutation of W1038, in tandem with E1046, generates a dominant-neg. form of the Jak2 protein.  Mice that were engineered to express two copies of this dominant-neg. Jak2 protein died in utero.  Addnl., heterozygous mice expressing Jak2 with kinase activity that is moderately reduced when compared to wild-type activity appear phenotypically normal.  Collectively, these data suggest that Jak2 kinase activity is essential for normal mammalian development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_eBTfkGGF3rVg90H21EOLACvtfcHk0ljRGl-Kd8HVFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovVWqtbg%253D&md5=347e54bb72e8fdb6cce0563020c5656e</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2006.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2006.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DFrenzel%26aufirst%3DK.%26aulast%3DWallace%26aufirst%3DT.%2BA.%26aulast%3DMcDoom%26aufirst%3DI.%26aulast%3DXiao%26aufirst%3DH.%2BD.%26aulast%3DCapecchi%26aufirst%3DM.%2BR.%26aulast%3DBernstein%26aufirst%3DK.%2BE.%26aulast%3DSayeski%26aufirst%3DP.%2BP.%26atitle%3DA%2520functional%2520Jak2%2520tyrosine%2520kinase%2520domain%2520is%2520essential%2520for%2520mouse%2520development%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2006%26volume%3D312%26spage%3D2735%26epage%3D2744%26doi%3D10.1016%2Fj.yexcr.2006.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Neubauer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huffstadt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfeffer, K.</span><span> </span><span class="NLM_article-title">Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">397</span><span class="NLM_x">–</span> <span class="NLM_lpage">409</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)81168-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2FS0092-8674%2800%2981168-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=9590174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADyaK1cXjtFCjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=397-409&author=H.+Neubauerauthor=A.+Cumanoauthor=M.+Mullerauthor=H.+Wuauthor=U.+Huffstadtauthor=K.+Pfeffer&title=Jak2+deficiency+defines+an+essential+developmental+checkpoint+in+definitive+hematopoiesis&doi=10.1016%2FS0092-8674%2800%2981168-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis</span></div><div class="casAuthors">Neubauer, Hans; Cumano, Ana; Muller, Mathias; Wu, Hong; Huffstadt, Ulrike; Pfeffer, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">397-409</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Janus kinases (Jaks) play an important role in signal transduction via cytokine and growth factor receptors.  A targeted inactivation of Jak2 was performed.  Jak2-/- embryos are anemic and die around day 12.5 postcoitum.  Primitive erythrocytes are found, but definitive erythropoiesis is absent.  Compared to erythropoietin receptor-deficient mice, the phenotype of Jak2 deficiency is more severe.  Fetal liver BFU-E and CFU-E colonies are completely absent.  However, multilineage hematopoietic stem cells (CD34low, c-kitpos) can be found, and B lymphopoiesis appears intact.  In contrast to IFNα stimulation, Jak2-/- cells do not respond to IFNγ.  Jak2-/- embryonic stem cells are competent for LIF signaling.  The data provided demonstrate that Jak2 has pivotal functions for signal transduction of a set of cytokine receptors required in definitive erythropoiesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8oeTh0n3FcbVg90H21EOLACvtfcHk0lg8NNmoaw8FkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtFCjtLk%253D&md5=74275b73c807331170c096145e69af94</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981168-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981168-X%26sid%3Dliteratum%253Aachs%26aulast%3DNeubauer%26aufirst%3DH.%26aulast%3DCumano%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DHuffstadt%26aufirst%3DU.%26aulast%3DPfeffer%26aufirst%3DK.%26atitle%3DJak2%2520deficiency%2520defines%2520an%2520essential%2520developmental%2520checkpoint%2520in%2520definitive%2520hematopoiesis%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D397%26epage%3D409%26doi%3D10.1016%2FS0092-8674%2800%2981168-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">Phase 2B doseranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to DMARDs</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">629</span><span class="refDoi"> DOI: 10.1002/art.33383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1002%2Fart.33383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=21952978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVGjurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=617-629&author=R.+Fleischmannauthor=M.+Cutoloauthor=M.+C.+Genoveseauthor=E.+B.+Leeauthor=K.+S.+Kanikauthor=S.+Sadisauthor=C.+A.+Connellauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=G.+Wallensteinauthor=B.+E.+Wilkinsonauthor=S.+H.+Zwillich&title=Phase+2B+doseranging+study+of+the+oral+JAK+inhibitor+tofacitinib+%28CP-690%2C550%29+or+adalimumab+monotherapy+versus+placebo+in+patients+with+active+rheumatoid+arthritis+with+an+inadequate+response+to+DMARDs&doi=10.1002%2Fart.33383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs</span></div><div class="casAuthors">Fleischmann, Roy; Cutolo, Maurizio; Genovese, Mark C.; Lee, Eun Bong; Kanik, Keith S.; Sadis, Seth; Connell, Carol A.; Gruben, David; Krishnaswami, Sriram; Wallenstein, Gene; Wilkinson, Bethanie E.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">617-629</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP-690,550) or adalimumab monotherapy with placebo for the treatment of active rheumatoid arthritis (RA) in patients with an inadequate response to disease-modifying antirheumatic drugs.  Methods : In this 24-wk, double-blind, phase IIb study, patients with RA (n = 384) were randomized to receive placebo, tofacitinib at 1, 3, 5, 10, or 15 mg administered orally twice a day, or adalimumab at 40 mg injected s.c. every 2 wk (total of 6 injections) followed by oral tofacitinib at 5 mg twice a day for 12 wk.  The primary end point was the responder rate according to the American College of Rheumatol. 20% improvement criteria (ACR20) at week 12.  Results : Treatment with tofacitinib at a dose of ≥3 mg twice a day resulted in a rapid response with significant efficacy when compared to placebo, as indicated by the primary end point (ACR20 response at week 12), achieved in 39.2% (3 mg; P ≤ 0.05), 59.2% (5 mg; P < 0.0001), 70.5% (10 mg; P < 0.0001), and 71.9% (15 mg; P < 0.0001) in the tofacitinib group and 35.9% of patients in the adalimumab group (P = 0.105), compared with 22.0% of patients receiving placebo.  Improvements were sustained at week 24, according to the ACR20, ACR50, and ACR70 response rates as well as classifications of remission according to the 3-variable Disease Activity Score in 28 joints (DAS28) using C-reactive protein and the 4-variable DAS28 using the erythrocyte sedimentation rate.  The most common treatment-emergent adverse events (AEs) in patients across all tofacitinib treatment arms (n = 272) were urinary tract infection (7.7%), diarrhea (4.8%), headache (4.8%), and bronchitis (4.8%).  Conclusion : Tofacitinib monotherapy at ≥3 mg twice a day was efficacious in the treatment of patients with active RA over 24 wk and demonstrated a manageable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuu7Uf_SwBXbVg90H21EOLACvtfcHk0lg8NNmoaw8FkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVGjurs%253D&md5=99d7be4fd115ffa87410dcbd6c6ea860</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1002%2Fart.33383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.33383%26sid%3Dliteratum%253Aachs%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DCutolo%26aufirst%3DM.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26aulast%3DSadis%26aufirst%3DS.%26aulast%3DConnell%26aufirst%3DC.%2BA.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DWilkinson%26aufirst%3DB.%2BE.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DPhase%25202B%2520doseranging%2520study%2520of%2520the%2520oral%2520JAK%2520inhibitor%2520tofacitinib%2520%2528CP-690%252C550%2529%2520or%2520adalimumab%2520monotherapy%2520versus%2520placebo%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520with%2520an%2520inadequate%2520response%2520to%2520DMARDs%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3D617%26epage%3D629%26doi%3D10.1002%2Fart.33383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kremer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">French, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Reino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascual-Ramos, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">A phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">970</span><span class="NLM_x">–</span> <span class="NLM_lpage">981</span><span class="refDoi"> DOI: 10.1002/art.33419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1002%2Fart.33419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=22006202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvVygt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=970-981&author=J.+M.+Kremerauthor=S.+Cohenauthor=B.+E.+Wilkinsonauthor=C.+A.+Connellauthor=J.+L.+Frenchauthor=J.+Gomez-Reinoauthor=D.+Grubenauthor=K.+S.+Kanikauthor=S.+Krishnaswamiauthor=V.+Pascual-Ramosauthor=G.+Wallensteinauthor=S.+H.+Zwillich&title=A+phase+2B+dose-ranging+study+of+the+oral+JAK+inhibitor+tofacitinib+%28CP-690%2C550%29+versus+placebo+in+combination+with+background+methotrexate+in+patients+with+active+rheumatoid+arthritis+and+inadequate+response+to+methotrexate+alone&doi=10.1002%2Fart.33419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone</span></div><div class="casAuthors">Kremer, Joel M.; Cohen, Stanley; Wilkinson, Bethanie E.; Connell, Carol A.; French, Jonathan L.; Gomez-Reino, Juan; Gruben, David; Kanik, Keith S.; Krishnaswami, Sriram; Pascual-Ramos, Virginia; Wallenstein, Gene; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">970-981</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective. To compare the efficacy, safety, and tolerability of 6 dosages of oral tofacitinib (CP-690,550) with placebo for the treatment of active rheumatoid arthritis (RA) in patients receiving a stable background regimen of methotrexate (MTX) who have an inadequate response to MTX monotherapy.  Methods. In this 24-wk, double-blind, phase IIb study, patients with active RA (n = 507) were randomized to receive placebo or tofacitinib (20 mg/day, 1 mg twice daily, 3 mg twice daily, 5 mg twice daily, 10 mg twice daily, or 15 mg twice daily).  All patients continued to receive a stable dosage of MTX.  The primary end point was the American College of Rheumatol. 20% improvement criteria (ACR20) response rate at week 12.  Results. At week 12, ACR20 response rates for patients receiving all tofacitinib dosages ≥3 mg twice daily (52.9% for 3 mg twice daily, 50.7% for 5 mg twice daily, 58.1% for 10 mg twice daily, 56.0% for 15 mg twice daily, and 53.8% for 20 mg/day) were significantly (P ≤ 0.05) greater than those for placebo (33.3%).  Improvements were sustained at week 24 for the ACR20, ACR50, and ACR70 responses, scores for the Health Assessment Questionnaire disability index, the 3-variable Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP), and a 3-variable DAS28-CRP of <2.6.  The most common treatment-emergent adverse events occurring in >10% of patients in any tofacitinib group were diarrhea, upper respiratory tract infection, and headache; 21 patients (4.1%) experienced serious adverse events.  Sporadic increases in transaminase levels, increases in cholesterol and serum creatinine levels, and decreases in neutrophil and Hb levels were obsd.  Conclusion. In patients with active RA in whom the response to MTX has been inadequate, the addn. of tofacitinib at a dosage ≥3 mg twice daily showed sustained efficacy and a manageable safety profile over 24 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGQK92I8twr7Vg90H21EOLACvtfcHk0ljq6l_ZD1JYSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvVygt78%253D&md5=69d74dbdde12d7d1b45fa3d3a413645a</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1002%2Fart.33419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.33419%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DWilkinson%26aufirst%3DB.%2BE.%26aulast%3DConnell%26aufirst%3DC.%2BA.%26aulast%3DFrench%26aufirst%3DJ.%2BL.%26aulast%3DGomez-Reino%26aufirst%3DJ.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DPascual-Ramos%26aufirst%3DV.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DA%2520phase%25202B%2520dose-ranging%2520study%2520of%2520the%2520oral%2520JAK%2520inhibitor%2520tofacitinib%2520%2528CP-690%252C550%2529%2520versus%2520placebo%2520in%2520combination%2520with%2520background%2520methotrexate%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520and%2520inadequate%2520response%2520to%2520methotrexate%2520alone%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3D970%26epage%3D981%26doi%3D10.1002%2Fart.33419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardanani, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes-Franco, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson-Viitanen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1117</span><span class="NLM_x">–</span> <span class="NLM_lpage">1127</span><span class="refDoi"> DOI: 10.1056/NEJMoa1002028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1056%2FNEJMoa1002028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=20843246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1117-1127&author=S.+Verstovsekauthor=H.+Kantarjianauthor=R.+A.+Mesaauthor=A.+D.+Pardananiauthor=J.+Cortes-Francoauthor=D.+A.+Thomasauthor=Z.+Estrovauthor=J.+S.+Fridmanauthor=E.+C.+Bradleyauthor=S.+Erickson-Viitanenauthor=K.+Vaddiauthor=R.+Levyauthor=A.+Tefferi&title=Safety+and+efficacy+of+INCB018424%2C+a+JAK1+and+JAK2+inhibitor%2C+in+myelofibrosis&doi=10.1056%2FNEJMoa1002028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11c</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span></div><div class="casAuthors">Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cortes-Franco, Jorge; Thomas, Deborah A.; Estrov, Zeev; Fridman, Jordan S.; Bradley, Edward C.; Erickson-Viitanen, Susan; Vaddi, Kris; Levy, Richard; Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1117-1127</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Myelofibrosis is a Philadelphia chromosome-neg. myeloproliferative neoplasm assocd. with cytopenias, splenomegaly, poor quality of life, and shortened survival.  About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiol. of the disease.  INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.  Methods: We conducted a phase 1-2 trial of INCB018424 in patients with JAK2 V617F-pos. or JAK2 V617F-neg. primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis.  Results: A total of 153 patients received INCB018424 for a median duration of more than 14.7 mo.  The initial dose-escalation phase established 25 mg twice daily or 100 mg once daily as max. tolerated doses, on the basis of reversible thrombocytopenia.  A dose-dependent suppression of phosphorylated signal transducer and activator of transcription 3 (STAT3), a marker of JAK signaling, was demonstrated in patients with wild-type JAK2 and in patients with the JAK2 V617F mutation.  We studied addnl. doses and established that a 15-mg twice-daily starting dose, followed by individualized dose titrn., was the most effective and safest dosing regimen.  At this dose, 17 of 33 patients (52%) had a rapid objective response (>50% redn. of splenomegaly) lasting for 12 mo or more, and this therapy was assocd. with grade 3 or grade 4 adverse events (mainly myelosuppression) in less than 10% of patients.  Patients with debilitating symptoms, including wt. loss, fatigue, night sweats, and pruritus, had rapid improvement.  Clin. benefits were assocd. with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myelofibrosis.  Conclusions: INCB018424 was assocd. with marked and durable clin. benefits in patients with myelofibrosis for whom no approved therapies existed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUi05ApP1FLrVg90H21EOLACvtfcHk0ljq6l_ZD1JYSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ&md5=ba6fe766323a10a1508c686fdb3720b1</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002028%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DPardanani%26aufirst%3DA.%2BD.%26aulast%3DCortes-Franco%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DBradley%26aufirst%3DE.%2BC.%26aulast%3DErickson-Viitanen%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520INCB018424%252C%2520a%2520JAK1%2520and%2520JAK2%2520inhibitor%252C%2520in%2520myelofibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1117%26epage%3D1127%26doi%3D10.1056%2FNEJMoa1002028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Keystone, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drescher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlichting, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beattie, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berclaz, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidelus-Gort, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luchi, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macias, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span> </span><span class="NLM_article-title">Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span><span class="refDoi"> DOI: 10.1136/annrheumdis-2014-206478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1136%2Fannrheumdis-2014-206478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=25431052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVSltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2015&pages=333-40&author=E.+C.+Keystoneauthor=P.+C.+Taylorauthor=E.+Drescherauthor=D.+E.+Schlichtingauthor=S.+D.+Beattieauthor=P.+Y.+Berclazauthor=C.+H.+Leeauthor=R.+K.+Fidelus-Gortauthor=M.+E.+Luchiauthor=T.+P.+Rooneyauthor=W.+L.+Maciasauthor=M.+C.+Genovese&title=Safety+and+efficacy+of+baricitinib+at+24+weeks+in+patients+with+rheumatoid+arthritis+who+have+had+an+inadequate+response+to+methotrexate&doi=10.1136%2Fannrheumdis-2014-206478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11dR"><div class="casContent"><span class="casTitleNuber">11d</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate</span></div><div class="casAuthors">Keystone, Edward C.; Taylor, Peter C.; Drescher, Edit; Schlichting, Douglas E.; Beattie, Scott D.; Berclaz, Pierre-Yves; Lee, Chin H.; Fidelus-Gort, Rosanne K.; Luchi, Monica E.; Rooney, Terence P.; Macias, William L.; Genovese, Mark C.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">333-340</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite treatment with methotrexate.  Methods In this phase IIb study, 301 patients were randomized 2:1:1:1:1 to receive once daily doses of placebo or 1, 2, 4 or 8 mg baricitinib for 12 wk.  Patients assigned to 2, 4 and 8 mg baricitinib continued blinded treatment for an addnl. 12 wk.  Patients assigned to placebo or 1 mg baricitinib were reassigned to 2 mg twice daily or 4 mg once daily baricitinib between weeks 12-24.  The primary endpoint was the proportion of patients in the combined 4 and 8 mg groups achieving an American College of Rheumatol. 20% (ACR20) response vs. placebo at week 12.  Results Significantly more patients in the combined baricitinib 4 and 8 mg groups compared with placebo achieved an ACR20 response at week 12 (76% vs 41%, p<0.001).  At week 12, significant differences vs. placebo were also obsd. in patients achieving ACR50, ACR70 and remission as measured by Disease Activity Score for 28-joint counts, Clin. Disease Activity Index and Simplified Disease Activity Index.  Patients receiving 2, 4, or 8 mg baricitinib maintained or improved in all measures through 24 wk.  Similar proportions of patients experienced at least one adverse event in the placebo and baricitinib groups.  Serious infections developed in three patients receiving baricitinib.  No cases of tuberculosis, herpes zoster, opportunistic infections or deaths were reported.  Dose-dependent decreases in Hb were obsd. with baricitinib.  Conclusions Baricitinib improved the signs and symptoms of RA in methotrexate inadequate responders with active disease.  Baricitinib was well tolerated with no unexpected safety findings through week 24.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz3lYB7HU_KbVg90H21EOLACvtfcHk0liUVcrwxc2hZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVSltbc%253D&md5=2f13c96c1c1dc5f68e69cd3e6da457b7</span></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2014-206478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2014-206478%26sid%3Dliteratum%253Aachs%26aulast%3DKeystone%26aufirst%3DE.%2BC.%26aulast%3DTaylor%26aufirst%3DP.%2BC.%26aulast%3DDrescher%26aufirst%3DE.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DBeattie%26aufirst%3DS.%2BD.%26aulast%3DBerclaz%26aufirst%3DP.%2BY.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DFidelus-Gort%26aufirst%3DR.%2BK.%26aulast%3DLuchi%26aufirst%3DM.%2BE.%26aulast%3DRooney%26aufirst%3DT.%2BP.%26aulast%3DMacias%26aufirst%3DW.%2BL.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520baricitinib%2520at%252024%2520weeks%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%2520who%2520have%2520had%2520an%2520inadequate%2520response%2520to%2520methotrexate%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2015%26volume%3D74%26spage%3D333%26epage%3D40%26doi%3D10.1136%2Fannrheumdis-2014-206478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bachelez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Kerkhof, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strohal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubanov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenzuela, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakusevich, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chimenti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papacharalambous, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proulx, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tawadrous, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, R.</span><span> </span><span class="NLM_article-title">Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">386</span><span class="NLM_x">, </span> <span class="NLM_fpage">552</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1016/S0140-6736(14)62113-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2FS0140-6736%2814%2962113-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=26051365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSgt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=552-61&author=H.+Bachelezauthor=P.+C.+van+de+Kerkhofauthor=R.+Strohalauthor=A.+Kubanovauthor=F.+Valenzuelaauthor=J.+H.+Leeauthor=V.+Yakusevichauthor=S.+Chimentiauthor=J.+Papacharalambousauthor=J.+Proulxauthor=P.+Guptaauthor=H.+Tanauthor=M.+Tawadrousauthor=H.+Valdezauthor=R.+Wolk&title=Tofacitinib+versus+etanercept+or+placebo+in+moderate-to-severe+chronic+plaque+psoriasis%3A+a+phase+3+randomised+non-inferiority+trial&doi=10.1016%2FS0140-6736%2814%2962113-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial</span></div><div class="casAuthors">Bachelez, Herve; van de Kerkhof, Peter C. M.; Strohal, Robert; Kubanov, Alexey; Valenzuela, Fernando; Lee, Joo-Heung; Yakusevich, Vladimir; Chimenti, Sergio; Papacharalambous, Jocelyne; Proulx, James; Gupta, Pankaj; Tan, Huaming; Tawadrous, Margaret; Valdez, Hernan; Wolk, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">386</span>
        (<span class="NLM_cas:issue">9993</span>),
    <span class="NLM_cas:pages">552-561</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">New therapeutic options are needed for patients with psoriasis.  Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe chronic plaque psoriasis.  In this study, we aimed to compare two tofacitinib doses with high-dose etanercept or placebo in this patient population.  In this phase 3, randomised, multicentre, double-dummy, placebo-controlled, 12-wk, non-inferiority trial, adult patients with chronic stable plaque psoriasis (for ≥12 mo) who were candidates for systemic or phototherapy and had a Psoriasis Area and Severity Index (PASI) score of 12 or higher and a Physician's Global Assessment (PGA) of moderate or severe, and had failed to respond to, had a contraindication to, or were intolerant to at least one conventional systemic therapy, were enrolled from 122 investigational dermatol. centers worldwide.  Eligible patients were randomly assigned in a 3:3:3:1 ratio to receive tofacitinib 5 mg or 10 mg twice daily at about 12 h intervals, etanercept 50 mg s.c. twice weekly at about 3-4 day intervals, or placebo.  Randomisation was done by a computer-generated randomisation schedule, and all patients and study personnel were masked to treatment assignment.  The co-primary endpoints were the proportion of patients at week 12 with at least a 75% redn. in the PASI score from baseline (PASI75 response) and the proportion of patients achieving a PGA score of "clear" or "almost clear" (PGA response), analyzed in the full anal. set (all patients who were randomised and received at least one dose of study drug).  This study is registered with ClinicalTrials.gov, no. NCT01241591.  Between Nov 29, 2010, and Sept 13, 2012, we enrolled 1106 eligible adult patients with chronic plaque psoriasis and randomly assigned them to the four treatment groups (330 to tofacitinib 5 mg twice daily, 332 to tofacitinib 10 mg twice daily, 336 to etanercept 50 mg twice weekly, and 108 to placebo).  Of these patients, 1101 actually received their assigned study medication (329 in the tofactinib 5 mg group, 330 in the tofacitinib 10 mg group, 335 in the etanercept group, and 107 in the placebo group).  At week 12, PASI75 responses were recorded in 130 (39·5%) of 329 patients in the tofacitinib 5 mg group, 210 (63·6%) of 330 in the tofacitinib 10 mg group, 197 (58·8%) of 335 in the etanercept group, and six (5·6%) of 107 in the placebo group.  A PGA response was achieved by 155 (47·1%) of 329 patients in the tofacitinib 5 mg group, 225 (68·2%) of 330 in the tofacitinib 10 mg group, 222 (66·3%) of 335 in the etanercept group, and 16 (15·0%) of 107 in the placebo group.  The rate of adverse events was similar across the four groups, with serious adverse events occurring in seven (2%) of 329 patients in the tofacitinib 5 mg group, five (2%) of 330 in the tofacitinib 10 mg group, seven (2%) of 335 in the etanercept group, and two (2%) of 107 in the placebo group.  Three (1%) of 329 patients in the tofacitinib 5 mg group, ten (3%) of 330 in the tofacitinib 10 mg group, 11 (3%) of 335 in the etanercept group, and four (4%) of 107 patients in the placebo group discontinued their assigned treatment because of adverse events.  In patients with moderate-to-severe plaque psoriasis, the 10 mg twice daily dose of tofacitinib was non-inferior to etanercept 50 mg twice weekly and was superior to placebo, but the 5 mg twice daily dose did not show non-inferiority to etanercept 50 mg twice weekly.  The adverse event rates over 12 wk were similar for tofacitinib and etanercept.  This study indicates that in the future tofacitinib could provide a convenient and well-tolerated therapeutic option for patients with moderate-to-severe plaque psoriasis.Pfizer Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKYcpF-XDavrVg90H21EOLACvtfcHk0liUVcrwxc2hZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSgt77J&md5=797adf1a67423e82ce47d96aa87daa6b</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2962113-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252962113-9%26sid%3Dliteratum%253Aachs%26aulast%3DBachelez%26aufirst%3DH.%26aulast%3Dvan%2Bde%2BKerkhof%26aufirst%3DP.%2BC.%26aulast%3DStrohal%26aufirst%3DR.%26aulast%3DKubanov%26aufirst%3DA.%26aulast%3DValenzuela%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DYakusevich%26aufirst%3DV.%26aulast%3DChimenti%26aufirst%3DS.%26aulast%3DPapacharalambous%26aufirst%3DJ.%26aulast%3DProulx%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DTawadrous%26aufirst%3DM.%26aulast%3DValdez%26aufirst%3DH.%26aulast%3DWolk%26aufirst%3DR.%26atitle%3DTofacitinib%2520versus%2520etanercept%2520or%2520placebo%2520in%2520moderate-to-severe%2520chronic%2520plaque%2520psoriasis%253A%2520a%2520phase%25203%2520randomised%2520non-inferiority%2520trial%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26spage%3D552%26epage%3D61%26doi%3D10.1016%2FS0140-6736%2814%2962113-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Papp, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menter, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elewski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottlieb, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thaci, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buonanno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proulx, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, R.</span><span> </span><span class="NLM_article-title">Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">173</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1111/bjd.14018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1111%2Fbjd.14018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=26149717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyns73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2015&pages=949-61&author=K.+A.+Pappauthor=M.+A.+Menterauthor=M.+Abeauthor=B.+Elewskiauthor=S.+R.+Feldmanauthor=A.+B.+Gottliebauthor=R.+Langleyauthor=T.+Lugerauthor=D.+Thaciauthor=M.+Buonannoauthor=P.+Guptaauthor=J.+Proulxauthor=S.+Lanauthor=R.+Wolk&title=Tofacitinib%2C+an+oral+Janus+kinase+inhibitor%2C+for+the+treatment+of+chronic+plaque+psoriasis%3A+results+from+two+randomized%2C+placebo-controlled%2C+phase+III+trials&doi=10.1111%2Fbjd.14018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials</span></div><div class="casAuthors">Papp, K. A.; Menter, M. A.; Abe, M.; Elewski, B.; Feldman, S. R.; Gottlieb, A. B.; Langley, R.; Luger, T.; Thaci, D.; Buonanno, M.; Gupta, P.; Proulx, J.; Lan, S.; Wolk, R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">949-961</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis.  Objectives : To det. the 16-wk efficacy and safety of two oral tofacitinib doses vs. placebo in patients with moderate-to-severe chronic plaque psoriasis.  Methods : Patients in two similarly designed phase III studies (OPT Pivotal 1, NCT01276639, n = 901; OPT Pivotal 2, NCT01309737, n = 960) were initially randomized 2 : 2 : 1 to tofacitinib 10 or 5 mg or placebo, twice daily.  Coprimary efficacy end points (week 16) included the proportion of patients achieving Physician's Global Assessment (PGA) of 'clear' or 'almost clear' (PGA response) and the proportion achieving ≥ 75% redn. in Psoriasis Area and Severity Index (PASI 75).  Results : Across OPT Pivotal 1 and OPT Pivotal 2, 745 patients received tofacitinib 5 mg, 741 received tofacitinib 10 mg and 373 received placebo.  At week 16, a greater proportion of patients achieved PGA responses with tofacitinib 5 and 10 mg twice daily vs. placebo (OPT Pivotal 1, 41·9% and 59·2% vs. 9·0%; OPT Pivotal 2, 46·0% and 59·1% vs. 10·9%; all P < 0·001).  Higher PASI 75 rates were obsd. with tofacitinib vs. placebo (OPT Pivotal 1, 39·9%, 59·2% and 6·2%, resp., for tofacitinib 5 and 10 mg twice daily and placebo; OPT Pivotal 2, 46·0%, 59·6% and 11·4%; all P < 0·001 vs. placebo).  Adverse event (AE) rates appeared generally similar across groups; rates of serious AEs, infections, malignancies and discontinuations due to AEs were low.  Twelve patients reported herpes zoster across the tofacitinib treatment groups in both studies vs. none in the resp. placebo groups.  The most common AE across groups was nasopharyngitis.  Conclusions : Oral tofacitinib demonstrated significant efficacy vs. placebo during the initial 16 wk of treatment in patients with moderate-to-severe psoriasis.  Safety findings were consistent with prior studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTWaBXP7bJbLVg90H21EOLACvtfcHk0lg-xjj6imFugg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyns73E&md5=2029ed12ccdeaeb36ab87425a8c534c1</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14018%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DMenter%26aufirst%3DM.%2BA.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DElewski%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26aulast%3DGottlieb%26aufirst%3DA.%2BB.%26aulast%3DLangley%26aufirst%3DR.%26aulast%3DLuger%26aufirst%3DT.%26aulast%3DThaci%26aufirst%3DD.%26aulast%3DBuonanno%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DProulx%26aufirst%3DJ.%26aulast%3DLan%26aufirst%3DS.%26aulast%3DWolk%26aufirst%3DR.%26atitle%3DTofacitinib%252C%2520an%2520oral%2520Janus%2520kinase%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520chronic%2520plaque%2520psoriasis%253A%2520results%2520from%2520two%2520randomized%252C%2520placebo-controlled%252C%2520phase%2520III%2520trials%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2015%26volume%3D173%26spage%3D949%26epage%3D61%26doi%3D10.1111%2Fbjd.14018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hsu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, A. W.</span><span> </span><span class="NLM_article-title">JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis</span> <span class="citation_source-journal">J. Immunol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">2014</span><span class="NLM_x">, </span> <span class="NLM_fpage">283617</span><span class="refDoi"> DOI: 10.1155/2014/283617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1155%2F2014%2F283617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=24883332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A280%3ADC%252BC2cfot1ehtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=283617&author=L.+Hsuauthor=A.+W.+Armstrong&title=JAK+inhibitors%3A+treatment+efficacy+and+safety+profile+in+patients+with+psoriasis&doi=10.1155%2F2014%2F283617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis</span></div><div class="casAuthors">Hsu Leeyen; Armstrong April W</div><div class="citationInfo"><span class="NLM_cas:title">Journal of immunology research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2014</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">283617</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Janus kinase (JAK) pathways are key mediators in the immunopathogenesis of psoriasis.  Psoriasis treatment has evolved with the advent of targeted therapies, which inhibit specific components of the psoriasis proinflammatory cascade.  JAK inhibitors have been studied in early phase trials for psoriasis patients, and the data are promising for these agents as potential treatment options.  Tofacitinib, an oral or topically administered JAK1 and JAK3 inhibitor, and ruxolitinib, a topical JAK1 and JAK2 inhibitor, have been most extensively studied in psoriasis, and both improved clinical symptoms of psoriasis.  Additional JAK1 or JAK3 inhibitors are being studied in clinical trials.  In phase III trials for rheumatoid arthritis, tofacitinib was efficacious in patients with inadequate responses to tumor necrosis factor inhibitors, methotrexate monotherapy, or disease-modifying antirheumatic drugs.  The results of phase III trials are pending for these therapies in psoriasis, and these agents may represent important alternatives for patients with inadequate responses to currently available agents.  Further investigations with long-term clinical trials are necessary to verify their utility in psoriasis treatment and assess their safety in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8NFwIZodl1tTiMd2aNQVUfW6udTcc2eb_4CUXSsq3ybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfot1ehtw%253D%253D&md5=241b16e23f36ea06d03b49fa4c53104f</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1155%2F2014%2F283617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F283617%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DL.%26aulast%3DArmstrong%26aufirst%3DA.%2BW.%26atitle%3DJAK%2520inhibitors%253A%2520treatment%2520efficacy%2520and%2520safety%2520profile%2520in%2520patients%2520with%2520psoriasis%26jtitle%3DJ.%2520Immunol.%2520Res.%26date%3D2014%26volume%3D2014%26spage%3D283617%26doi%3D10.1155%2F2014%2F283617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Kwatra, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dabade, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustafson, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, S. R.</span><span> </span><span class="NLM_article-title">JAK inhibitors in psoriasis: a promising new treatment modality</span> <span class="citation_source-journal">J. Drugs Dermatol.: JDD</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">913</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=22859235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlOgtb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=913-8&author=S.+G.+Kwatraauthor=T.+S.+Dabadeauthor=C.+J.+Gustafsonauthor=S.+R.+Feldman&title=JAK+inhibitors+in+psoriasis%3A+a+promising+new+treatment+modality"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12dR"><div class="casContent"><span class="casTitleNuber">12d</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibitors in psoriasis: a promising new treatment modality</span></div><div class="casAuthors">Kwatra, Shawn G.; Dabade, Tushar S.; Gustafson, Cheryl J.; Feldman, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drugs in Dermatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">913-918</span>CODEN:
                <span class="NLM_cas:coden">JDDOBA</span>;
        ISSN:<span class="NLM_cas:issn">1545-9616</span>.
    
            (<span class="NLM_cas:orgname">Journal of Drugs in Dermatology</span>)
        </div><div class="casAbstract">A review.  Background: Inflammatory cytokines play a crucial role in the pathophysiol. of psoriasis.  New therapies are targeting Janus kinases (JAKs), enzymes involved with transduction of cytokine receptor signaling.  Objective: Review the utility of JAK inhibitors in the treatment of psoriasis.  Methods: A review was performed using PubMed and Google to identify research relevant to the treatment of psoriasis using JAK inhibitors.  Results: In a CD18 mutant PL/J mouse model with T-cell dependent psoriasiform skin disease, the JAK inhibitor R348 reduced skin inflammation, with redns. in CD4+, CD8+, and CD25+T-cell infiltration and systemic decreases of IL-17, IL-19, IL-22, IL-23 and TNF-α.  Two JAK inhibitors, CP-690,550 (tasocitinib) and INCB018424 (ruxolitinib), were effective in psoriasis clin. trials.  In a phase 1, randomized, double-blind, dose escalation trial for plaque psoriasis, CP-690,050 led to improvements in Psoriatic Lesion Severity Sum score at doses greater than 5 mg.  A phase 2 trial showed CP-690,050 administered at 2, 5, and 15 mg twice daily resulted in a 75% redn. in Psoriasis Area and Severity Index (PASI) in 25%, 40.8%, and 66.7% of patients, resp., for moderate to severe psoriasis.  A phase 3 study of CP-690,550 for plaque psoriasis was begun in Sept. 2010 (NCT01163253).  INCB018424, another JAK inhibitor, was used topically at 3 doses (0.5%, 1%, 1.5%) in a phase 2B, double-blind, placebo-controlled trial, resulting in improved total lesion score, global assessment, and PASI for all doses.  Conclusion: Janus Kinase inhibitors are promising potential therapeutic options for psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsaZPQ6k6CN7Vg90H21EOLACvtfcHk0licyfpgVPmo5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlOgtb%252FK&md5=2640c1c8aca3b20982b06f06e9eeb81f</span></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwatra%26aufirst%3DS.%2BG.%26aulast%3DDabade%26aufirst%3DT.%2BS.%26aulast%3DGustafson%26aufirst%3DC.%2BJ.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26atitle%3DJAK%2520inhibitors%2520in%2520psoriasis%253A%2520a%2520promising%2520new%2520treatment%2520modality%26jtitle%3DJ.%2520Drugs%2520Dermatol.%253A%2520JDD%26date%3D2012%26volume%3D11%26spage%3D913%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Norman, P.</span><span> </span><span class="NLM_article-title">Selective JAK1 inhibitor and selective Tyk2 inhibitor patents</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1233</span><span class="NLM_x">–</span> <span class="NLM_lpage">1249</span><span class="refDoi"> DOI: 10.1517/13543776.2012.723693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1517%2F13543776.2012.723693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=22971156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlynsrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1233-1249&author=P.+Norman&title=Selective+JAK1+inhibitor+and+selective+Tyk2+inhibitor+patents&doi=10.1517%2F13543776.2012.723693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Selective JAK1 inhibitor and selective Tyk2 inhibitor patents</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1233-1249</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The JAK family comprises of the four non-receptor tyrosine kinases JAK1, JAK2, JAK3 and Tyk2, which play key, but differing, roles in cytokine receptor signal transduction.  A non-selective JAK inhibitor, ruxolitinib, has recently been approved to treat myelofibrosis whereas tofacitinib is poised for approval to treat rheumatoid arthritis.  Selective inhibition of JAK3, JAK1 or Tyk2 provides the opportunity to achieve clin. efficacy in the treatment of inflammatory diseases while reducing the risk of dose-limiting effects attributable to JAK2 inhibition.Areas covered: This review considers the small no. of published patent filings that claim either selective JAK1 or selective Tyk2 inhibitors.  These are considered in the context of the considerably larger no. of disclosures and patent filings claiming selective JAK2 or JAK3 inhibitors.Expert opinion: The recent disclosure of the clin. efficacy of a selective JAK1 inhibitor (GLPG-0634) in rheumatoid arthritis and detailed disclosure of the some potent and highly selective JAK1 inhibitors provide a clear stimulus for further activity in this area.  The availability of a selective Tyk2 inhibitor will provide the opportunity for better understanding of the physiol. role of this kinase.  Recent patent applications indicate that Tyk2 selectivity is achievable and Tyk2 inhibitors have potential in the treatment of multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjnYf5xYDtobVg90H21EOLACvtfcHk0licyfpgVPmo5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlynsrvE&md5=288bfaedead4c49351791b517992d8ee</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1517%2F13543776.2012.723693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2012.723693%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DSelective%2520JAK1%2520inhibitor%2520and%2520selective%2520Tyk2%2520inhibitor%2520patents%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2012%26volume%3D22%26spage%3D1233%26epage%3D1249%26doi%3D10.1517%2F13543776.2012.723693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Liang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berezhkovskiy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohli, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantik, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menghrajani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sambrone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S.</span><span> </span><span class="NLM_article-title">Lead identification of novel and selective TYK2 inhibitors</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2013.03.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2Fj.ejmech.2013.03.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=23867602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVejtL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2013&pages=175-87&author=J.+Liangauthor=V.+Tsuiauthor=A.+Van+Abbemaauthor=L.+Baoauthor=K.+Barrettauthor=M.+Beresiniauthor=L.+Berezhkovskiyauthor=W.+S.+Blairauthor=C.+Changauthor=J.+Driscollauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=J.+Halladayauthor=A.+Johnsonauthor=P.+B.+Kohliauthor=Y.+Laiauthor=M.+Liimattaauthor=P.+Mantikauthor=K.+Menghrajaniauthor=J.+Murrayauthor=A.+Sambroneauthor=Y.+Xiaoauthor=S.+Shiaauthor=Y.+Shinauthor=J.+Smithauthor=S.+Sohnauthor=M.+Stanleyauthor=M.+Ultschauthor=B.+Zhangauthor=L.+C.+Wuauthor=S.+Magnuson&title=Lead+identification+of+novel+and+selective+TYK2+inhibitors&doi=10.1016%2Fj.ejmech.2013.03.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Lead identification of novel and selective TYK2 inhibitors</span></div><div class="casAuthors">Liang, Jun; Tsui, Vickie; Van Abbema, Anne; Bao, Liang; Barrett, Kathy; Beresini, Maureen; Berezhkovskiy, Leo; Blair, Wade S.; Chang, Christine; Driscoll, James; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Halladay, Jason; Johnson, Adam; Kohli, Pawan Bir; Lai, Yingjie; Liimatta, Marya; Mantik, Priscilla; Menghrajani, Kapil; Murray, Jeremy; Sambrone, Amy; Xiao, Yisong; Shia, Steven; Shin, Young; Smith, Jan; Sohn, Sue; Stanley, Mark; Ultsch, Mark; Zhang, Birong; Wu, Lawren C.; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">175-187</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as psoriasis and inflammatory bowel diseases (IBD), by selective targeting of TYK2.  Hit triage, following a high-throughput screen for TYK2 inhibitors, revealed pyridine (I) as a promising starting point for lead identification.  Initial expansion of 3 sep. regions of the mol. led to eventual identification of cyclopropyl amide (II), a potent lead analog with good kinase selectivity, physicochem. properties, and pharmacokinetic profile.  Anal. of the binding modes of the series in TYK2 and JAK2 crystal structures revealed key interactions leading to good TYK2 potency and design options for future optimization of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXEWbuB0597rVg90H21EOLACvtfcHk0lj1hMfAXJt5eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVejtL%252FL&md5=4271738e73a0b680a4441b9231762ef0</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.03.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.03.070%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBeresini%26aufirst%3DM.%26aulast%3DBerezhkovskiy%26aufirst%3DL.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDriscoll%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DMantik%26aufirst%3DP.%26aulast%3DMenghrajani%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DSambrone%26aufirst%3DA.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DS.%26aulast%3DStanley%26aufirst%3DM.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DLead%2520identification%2520of%2520novel%2520and%2520selective%2520TYK2%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D67%26spage%3D175%26epage%3D87%26doi%3D10.1016%2Fj.ejmech.2013.03.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Liang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berezhkovsky, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delarosa, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVoss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohli, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssikatos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantik, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menghrajani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sambrone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S.</span><span> </span><span class="NLM_article-title">Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4521</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span><span class="refDoi"> DOI: 10.1021/jm400266t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400266t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFakuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4521-36&author=J.+Liangauthor=A.+van+Abbemaauthor=M.+Balazsauthor=K.+Barrettauthor=L.+Berezhkovskyauthor=W.+Blairauthor=C.+Changauthor=D.+Delarosaauthor=J.+DeVossauthor=J.+Driscollauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=J.+Halladayauthor=A.+Johnsonauthor=P.+B.+Kohliauthor=Y.+Laiauthor=Y.+Liuauthor=J.+Lyssikatosauthor=P.+Mantikauthor=K.+Menghrajaniauthor=J.+Murrayauthor=I.+Pengauthor=A.+Sambroneauthor=S.+Shiaauthor=Y.+Shinauthor=J.+Smithauthor=S.+Sohnauthor=V.+Tsuiauthor=M.+Ultschauthor=L.+C.+Wuauthor=Y.+Xiaoauthor=W.+Yangauthor=J.+Youngauthor=B.+Zhangauthor=B.+Y.+Zhuauthor=S.+Magnuson&title=Lead+optimization+of+a+4-aminopyridine+benzamide+scaffold+to+identify+potent%2C+selective%2C+and+orally+bioavailable+TYK2+inhibitors&doi=10.1021%2Fjm400266t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of a 4-Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors</span></div><div class="casAuthors">Liang, Jun; van Abbema, Anne; Balazs, Mercedesz; Barrett, Kathy; Berezhkovsky, Leo; Blair, Wade; Chang, Christine; Delarosa, Donnie; DeVoss, Jason; Driscoll, Jim; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Halladay, Jason; Johnson, Adam; Kohli, Pawan Bir; Lai, Yingjie; Liu, Yanzhou; Lyssikatos, Joseph; Mantik, Priscilla; Menghrajani, Kapil; Murray, Jeremy; Peng, Ivan; Sambrone, Amy; Shia, Steven; Shin, Young; Smith, Jan; Sohn, Sue; Tsui, Vickie; Ultsch, Mark; Wu, Lawren C.; Xiao, Yisong; Yang, Wenqian; Young, Judy; Zhang, Birong; Zhu, Bing-yan; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4521-4536</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the authors report the authors' lead optimization effort to identify potent, selective, and orally bioavailable TYK2 inhibitors, starting with lead mol. 2,6-dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide.  The authors used structure-based design to discover 2,6-dichloro-4-cyanophenyl and (1R,2R)-2-fluorocyclopropylamide modifications, each of which exhibited improved TYK2 potency and JAK1 and JAK2 selectivity relative to 2,6-dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide.  Further optimization eventually led to 2-Chloro-4-cyano-6-fluoro-N-(2-((1R,2R)-2-fluorocyclopropanecarboxamido)pyridin-4-yl)benzamide that showed good TYK2 enzyme and interleukin-12 (IL-12) cell potency, as well as acceptable cellular JAK1 and JAK2 selectivity and excellent oral exposure in mice.  When tested in a mouse IL-12 PK/PD model, 2-Chloro-4-cyano-6-fluoro-N-(2-((1R,2R)-2-ffluorocyclopropanecarboxamido)pyridin-4-yl)benzamide showed statistically significant knockdown of cytokine interferon-γ (IFNγ), suggesting that selective inhibition of TYK2 kinase activity might be sufficient to block the IL-12 pathway in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCinZ75WrtObVg90H21EOLACvtfcHk0lgxT-OEOEnQJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFakuro%253D&md5=290ee5f1e3e093136ac5fbb418323421</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1021%2Fjm400266t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400266t%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBerezhkovsky%26aufirst%3DL.%26aulast%3DBlair%26aufirst%3DW.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDelarosa%26aufirst%3DD.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDriscoll%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLyssikatos%26aufirst%3DJ.%26aulast%3DMantik%26aufirst%3DP.%26aulast%3DMenghrajani%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DI.%26aulast%3DSambrone%26aufirst%3DA.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DB.%2BY.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DLead%2520optimization%2520of%2520a%25204-aminopyridine%2520benzamide%2520scaffold%2520to%2520identify%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520TYK2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4521%26epage%3D36%26doi%3D10.1021%2Fjm400266t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Jang, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Son, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koo, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, N. S.</span><span> </span><span class="NLM_article-title">Discovery of Tyk2 inhibitors via the virtual site-directed fragment-based drug design</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3947</span><span class="NLM_x">–</span> <span class="NLM_lpage">52</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2Fj.bmcl.2015.07.037" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3947-52&author=W.+D.+Jangauthor=J.+T.+Kimauthor=H.+Y.+Sonauthor=S.+Y.+Parkauthor=Y.+S.+Choauthor=T.+S.+Kooauthor=H.+Leeauthor=N.+S.+Kang&title=Discovery+of+Tyk2+inhibitors+via+the+virtual+site-directed+fragment-based+drug+design&doi=10.1016%2Fj.bmcl.2015.07.037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.037%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DW.%2BD.%26aulast%3DKim%26aufirst%3DJ.%2BT.%26aulast%3DSon%26aufirst%3DH.%2BY.%26aulast%3DPark%26aufirst%3DS.%2BY.%26aulast%3DCho%26aufirst%3DY.%2BS.%26aulast%3DKoo%26aufirst%3DT.%2BS.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DKang%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520Tyk2%2520inhibitors%2520via%2520the%2520virtual%2520site-directed%2520fragment-based%2520drug%2520design%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3947%26epage%3D52%26doi%3D10.1016%2Fj.bmcl.2015.07.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Smith, G. F.</span><span> </span><span class="NLM_article-title">Designing drugs to avoid toxicity</span> <span class="citation_source-journal">Prog. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span><span class="refDoi"> DOI: 10.1016/B978-0-12-381290-2.00001-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2FB978-0-12-381290-2.00001-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=21315927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3MXoslekurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=1-47&author=G.+F.+Smith&title=Designing+drugs+to+avoid+toxicity&doi=10.1016%2FB978-0-12-381290-2.00001-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Designing drugs to avoid toxicity</span></div><div class="casAuthors">Smith, Graham F.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-47</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review on designing of drugs to avoid toxicity, including various common safety risks and their structure-toxicity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraIClQQ_p_2rVg90H21EOLACvtfcHk0lgxT-OEOEnQJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXoslekurs%253D&md5=23d0ca0ab1d53a7c90dbed0a89a9eeb2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-381290-2.00001-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-381290-2.00001-X%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DG.%2BF.%26atitle%3DDesigning%2520drugs%2520to%2520avoid%2520toxicity%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D50%26spage%3D1%26epage%3D47%26doi%3D10.1016%2FB978-0-12-381290-2.00001-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Chrencik, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patny, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korniski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmons, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gormley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommers, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenbrink, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomasselli, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, T. E.</span><span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">400</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">433</span><span class="refDoi"> DOI: 10.1016/j.jmb.2010.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+Patnyauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.+C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6&doi=10.1016%2Fj.jmb.2010.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0li3Z5qSc7mjnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.%2BC.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433%26doi%3D10.1016%2Fj.jmb.2010.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">O’Sullivan, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liongue, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephenson, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, A. C.</span><span> </span><span class="NLM_article-title">Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease</span> <span class="citation_source-journal">Mol. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">2497</span><span class="NLM_x">–</span> <span class="NLM_lpage">2506</span><span class="refDoi"> DOI: 10.1016/j.molimm.2006.11.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2Fj.molimm.2006.11.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=17208301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVSmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2007&pages=2497-2506&author=L.+A.+O%E2%80%99Sullivanauthor=C.+Liongueauthor=R.+S.+Lewisauthor=S.+E.+Stephensonauthor=A.+C.+Ward&title=Cytokine+receptor+signaling+through+the+Jak-Stat-Socs+pathway+in+disease&doi=10.1016%2Fj.molimm.2006.11.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease</span></div><div class="casAuthors">O'Sullivan, Lynda A.; Liongue, Clifford; Lewis, Rowena S.; Stephenson, Sarah E. M.; Ward, Alister C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2497-2506</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The complexity of multicellular organisms is dependent on systems enabling cells to respond to specific stimuli.  Cytokines and their receptors are one such system, whose perturbation can lead to a variety of disease states.  This review represents an overview of our current understanding of the cytokine receptors, Janus kinases (Jaks), Signal transducers and activators of transcription (Stats) and Suppressors of cytokine signaling (Socs), focusing on their contribution to diseases of an immune or hematol. nature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRJCsJ5di3XbVg90H21EOLACvtfcHk0li3Z5qSc7mjnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVSmur8%253D&md5=0011026cc2b9be7e0d7cdb854aab300a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.molimm.2006.11.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molimm.2006.11.025%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DL.%2BA.%26aulast%3DLiongue%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DR.%2BS.%26aulast%3DStephenson%26aufirst%3DS.%2BE.%26aulast%3DWard%26aufirst%3DA.%2BC.%26atitle%3DCytokine%2520receptor%2520signaling%2520through%2520the%2520Jak-Stat-Socs%2520pathway%2520in%2520disease%26jtitle%3DMol.%2520Immunol.%26date%3D2007%26volume%3D44%26spage%3D2497%26epage%3D2506%26doi%3D10.1016%2Fj.molimm.2006.11.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favata, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodgers, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span> </span><span class="NLM_article-title">Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">5298</span><span class="NLM_x">–</span> <span class="NLM_lpage">307</span><span class="refDoi"> DOI: 10.4049/jimmunol.0902819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.4049%2Fjimmunol.0902819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=20363976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=5298-307&author=J.+S.+Fridmanauthor=P.+A.+Scherleauthor=R.+Collinsauthor=T.+C.+Burnauthor=Y.+Liauthor=J.+Liauthor=M.+B.+Covingtonauthor=B.+Thomasauthor=P.+Collierauthor=M.+F.+Favataauthor=X.+Wenauthor=J.+Shiauthor=R.+McGeeauthor=P.+J.+Haleyauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=S.+Yeleswaramauthor=G.+Hollisauthor=R.+C.+Newtonauthor=B.+Metcalfauthor=S.+M.+Friedmanauthor=K.+Vaddi&title=Selective+inhibition+of+JAK1+and+JAK2+is+efficacious+in+rodent+models+of+arthritis%3A+preclinical+characterization+of+INCB028050&doi=10.4049%2Fjimmunol.0902819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050</span></div><div class="casAuthors">Fridman, Jordan S.; Scherle, Peggy A.; Collins, Robert; Burn, Timothy C.; Li, Yanlong; Li, Jun; Covington, Maryanne B.; Thomas, Beth; Collier, Paul; Favata, Margaret F.; Wen, Xiaoming; Shi, Jack; McGee, Ryan; Haley, Patrick J.; Shepard, Stacey; Rodgers, James D.; Yeleswaram, Swamy; Hollis, Greg; Newton, Robert C.; Metcalf, Brian; Friedman, Steven M.; Vaddi, Kris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5298-5307</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases such as rheumatoid arthritis.  Kinase inhibitors have shown promising oral disease-modifying antirheumatic drug potential with efficacy similar to anti-TNF biologics.  Direct and indirect inhibition of the JAKs, with small mol. inhibitors like CP-690,550 and INCB018424 or neutralizing Abs, such as the anti-IL6 receptor Ab tocilizumab, have demonstrated rapid and sustained improvement in clin. measures of disease, consistent with their resp. preclin. expts.  Therefore, it is of interest to identify optimized JAK inhibitors with unique profiles to maximize therapeutic opportunities.  INCB028050 is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).  INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concns. <50 nM.  Significant efficacy, as assessed by improvements in clin., histol. and radiog. signs of disease, was achieved in the rat adjuvant arthritis model with doses of INCB028050 providing partial and/or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3.  Diminution of inflammatory Th1 and Th17 assocd. cytokine mRNA levels was obsd. in the draining lymph nodes of treated rats.  INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematol. effects.  These data suggest that fractional inhibition of JAK1 and JAK2 is sufficient for significant activity in autoimmune disease models.  Clin. evaluation of INCB028050 in RA is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4QiklQbX72bVg90H21EOLACvtfcHk0li3Z5qSc7mjnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D&md5=30b22f275eb2ba2dbca7fb7bec768bb9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902819%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%2BB.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DFavata%26aufirst%3DM.%2BF.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DR.%26aulast%3DHaley%26aufirst%3DP.%2BJ.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DFriedman%26aufirst%3DS.%2BM.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DSelective%2520inhibition%2520of%2520JAK1%2520and%2520JAK2%2520is%2520efficacious%2520in%2520rodent%2520models%2520of%2520arthritis%253A%2520preclinical%2520characterization%2520of%2520INCB028050%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D5298%26epage%3D307%26doi%3D10.4049%2Fjimmunol.0902819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Sohn, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohli, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macleod, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewin-Koh, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dengler, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L. C.</span><span> </span><span class="NLM_article-title">A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">2205</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span><span class="refDoi"> DOI: 10.4049/jimmunol.1202859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.4049%2Fjimmunol.1202859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=23894201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=2205-16&author=S.+J.+Sohnauthor=K.+Barrettauthor=A.+Van+Abbemaauthor=C.+Changauthor=P.+B.+Kohliauthor=H.+Kandaauthor=J.+Smithauthor=Y.+Laiauthor=A.+Zhouauthor=B.+Zhangauthor=W.+Yangauthor=K.+Williamsauthor=C.+Macleodauthor=C.+A.+Hurleyauthor=J.+J.+Kulagowskiauthor=N.+Lewin-Kohauthor=H.+S.+Denglerauthor=A.+R.+Johnsonauthor=N.+Ghilardiauthor=M.+Zakauthor=J.+Liangauthor=W.+S.+Blairauthor=S.+Magnusonauthor=L.+C.+Wu&title=A+restricted+role+for+TYK2+catalytic+activity+in+human+cytokine+responses+revealed+by+novel+TYK2-selective+inhibitors&doi=10.4049%2Fjimmunol.1202859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors</span></div><div class="casAuthors">Sohn, Sue J.; Barrett, Kathy; Van Abbema, Anne; Chang, Christine; Kohli, Pawan Bir; Kanda, Hidenobu; Smith, Janice; Lai, Yingjie; Zhou, Aihe; Zhang, Birong; Yang, Wenqian; Williams, Karen; MacLeod, Calum; Hurley, Christopher A.; Kulagowski, Janusz J.; Lewin-Koh, Nicholas; Dengler, Hart S.; Johnson, Adam R.; Ghilardi, Nico; Zak, Mark; Liang, Jun; Blair, Wade S.; Magnuson, Steven; Wu, Lawren C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2205-2216</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">TYK2 is a JAK family protein tyrosine kinase activated in response to multiple cytokines, including type I IFNs, IL-6, IL-10, IL-12, and IL-23.  Extensive studies of mice that lack TYK2 expression indicate that the IFN-α, IL-12, and IL-23 pathways, but not the IL-6 or IL-10 pathways, are compromised.  In contrast, there have been few studies of the role of TYK2 in primary human cells.  A genetic mutation at the tyk2 locus that results in a lack of TYK2 protein in a single human patient has been linked to defects in the IFN-α, IL-6, IL-10, IL-12, and IL-23 pathways, suggesting a broad role for TYK2 protein in human cytokine responses.  In this article, we have used a panel of novel potent TYK2 small-mol. inhibitors with varying degrees of selectivity against other JAK kinases to address the requirement for TYK2 catalytic activity in cytokine pathways in primary human cells.  Our results indicate that the biol. processes that require TYK2 catalytic function in humans are restricted to the IL-12 and IL-23 pathways, and suggest that inhibition of TYK2 catalytic activity may be an efficacious approach for the treatment of select autoimmune diseases without broad immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgACYZYW8b07Vg90H21EOLACvtfcHk0ljSm9Y0uF0-lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtL%252FP&md5=527289e055e91fe2dfb15d3de7faa894</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1202859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1202859%26sid%3Dliteratum%253Aachs%26aulast%3DSohn%26aufirst%3DS.%2BJ.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DKanda%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DMacleod%26aufirst%3DC.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DLewin-Koh%26aufirst%3DN.%26aulast%3DDengler%26aufirst%3DH.%2BS.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DMagnuson%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DL.%2BC.%26atitle%3DA%2520restricted%2520role%2520for%2520TYK2%2520catalytic%2520activity%2520in%2520human%2520cytokine%2520responses%2520revealed%2520by%2520novel%2520TYK2-selective%2520inhibitors%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D2205%26epage%3D16%26doi%3D10.4049%2Fjimmunol.1202859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, D.</span><span> </span><span class="NLM_article-title">Vilsmeier reaction of enaminones: efficient synthesis of halogenated pyridin-2(1H)-ones</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">9504</span><span class="NLM_x">–</span> <span class="NLM_lpage">9507</span><span class="refDoi"> DOI: 10.1021/jo801959j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo801959j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOrsrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=9504-9507&author=R.+Zhangauthor=D.+Zhangauthor=Y.+Guoauthor=G.+Zhouauthor=Z.+Jiangauthor=D.+Dong&title=Vilsmeier+reaction+of+enaminones%3A+efficient+synthesis+of+halogenated+pyridin-2%281H%29-ones&doi=10.1021%2Fjo801959j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Vilsmeier Reaction of Enaminones: Efficient Synthesis of Halogenated Pyridin-2(1H)-ones</span></div><div class="casAuthors">Zhang, Rui; Zhang, Dingyuan; Guo, Yongli; Zhou, Guangyuan; Jiang, Zijiang; Dong, Dewen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9504-9507</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A facile and efficient one-pot synthesis of halogenated pyridin-2(1H)-ones, e.g., I, from a series of readily available enaminones under Vilsmeier conditions is described, and a mechanism involving sequential halogenation, formylation, and intramol. nucleophilic cyclization is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG9FeHPtloJLVg90H21EOLACvtfcHk0ljSm9Y0uF0-lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOrsrbM&md5=2e0fcd3b0419c693be4ae511cdc3abd1</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjo801959j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo801959j%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DD.%26atitle%3DVilsmeier%2520reaction%2520of%2520enaminones%253A%2520efficient%2520synthesis%2520of%2520halogenated%2520pyridin-2%25281H%2529-ones%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D9504%26epage%3D9507%26doi%3D10.1021%2Fjo801959j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Baraldi, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baraldi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saponaro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romagnoli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piccagli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recanatini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorman, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaid, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borea, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabrizi, M. A.</span><span> </span><span class="NLM_article-title">Novel 1,3-dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl)xanthines as potent and selective A<sub>2B</sub> adenosine receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">–</span> <span class="NLM_lpage">811</span><span class="refDoi"> DOI: 10.1021/jm201292w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201292w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=797-811&author=P.+G.+Baraldiauthor=S.+Baraldiauthor=G.+Saponaroauthor=D.+Pretiauthor=R.+Romagnoliauthor=L.+Piccagliauthor=A.+Cavalliauthor=M.+Recanatiniauthor=A.+R.+Moormanauthor=A.+N.+Zaidauthor=K.+Varaniauthor=P.+A.+Boreaauthor=M.+A.+Tabrizi&title=Novel+1%2C3-dipropyl-8-%283-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl%29xanthines+as+potent+and+selective+A2B+adenosine+receptor+antagonists&doi=10.1021%2Fjm201292w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm201292w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201292w%26sid%3Dliteratum%253Aachs%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DBaraldi%26aufirst%3DS.%26aulast%3DSaponaro%26aufirst%3DG.%26aulast%3DPreti%26aufirst%3DD.%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DPiccagli%26aufirst%3DL.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMoorman%26aufirst%3DA.%2BR.%26aulast%3DZaid%26aufirst%3DA.%2BN.%26aulast%3DVarani%26aufirst%3DK.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26aulast%3DTabrizi%26aufirst%3DM.%2BA.%26atitle%3DNovel%25201%252C3-dipropyl-8-%25283-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl%2529xanthines%2520as%2520potent%2520and%2520selective%2520A2B%2520adenosine%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D797%26epage%3D811%26doi%3D10.1021%2Fjm201292w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2a','cit2b'],'ref3':['cit3a','cit3b'],'ref4':['cit4a','cit4b','cit4c','cit4d'],'ref5':['cit5a','cit5b','cit5c','cit5d','cit5e','cit5f','cit5g','cit5h'],'ref6':['cit6a','cit6b'],'ref7':['cit7'],'ref8':['cit8a','cit8b'],'ref9':['cit9a','cit9b'],'ref10':['cit10a','cit10b','cit10c'],'ref11':['cit11a','cit11b','cit11c','cit11d'],'ref12':['cit12a','cit12b','cit12c','cit12d'],'ref13':['cit13a','cit13b','cit13c','cit13d'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 11 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Chunjian Liu, James Lin, Charles Langevine, Daniel Smith, Jianqing Li, John S. Tokarski, Javed Khan, Max Ruzanov, Joann Strnad, Adriana Zupa-Fernandez, Lihong Cheng, Kathleen M. Gillooly, David Shuster, Yifan Zhang, Anil Thankappan, Kim W. McIntyre, Charu Chaudhry, Paul A. Elzinga, Manoj Chiney, Anjaneya Chimalakonda, Louis J. Lombardo, John E. Macor, Percy H. Carter, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">David S. Weinstein</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 677-694. <a href="https://doi.org/10.1021/acs.jmedchem.0c01698" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01698</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01698%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBMS-986202%25253A%252BA%252BClinical%252BTyk2%252BInhibitor%252Bthat%252BBinds%252Bto%252BTyk2%252BJH2%26aulast%3DLiu%26aufirst%3DChunjian%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D28092020%26date%3D28122020%26volume%3D64%26issue%3D1%26spage%3D677%26epage%3D694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chunjian Liu, James Lin, Ryan Moslin, John S. Tokarski, Jodi Muckelbauer, ChiehYing Chang, Jeffrey Tredup, Dianlin Xie, Hyunsoo Park, Peng Li, Dauh-Rurng Wu, Joann Strnad, Adriana Zupa-Fernandez, Lihong Cheng, Charu Chaudhry, Jing Chen, Cliff Chen, Huadong Sun, Paul Elzinga, Celia D’arienzo, Kathleen Gillooly, Tracy L. Taylor, Kim W. McIntyre, Luisa Salter-Cid, Louis J. Lombardo, Percy H. Carter, Nelly Aranibar, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">David S. Weinstein</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (3)
                                     , 383-388. <a href="https://doi.org/10.1021/acsmedchemlett.9b00035" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00035%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIdentification%252Bof%252BImidazo%25255B1%25252C2-b%25255Dpyridazine%252BDerivatives%252Bas%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BActive%252BTyk2%252BJH2%252BInhibitors%26aulast%3DLiu%26aufirst%3DChunjian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D28012019%26date%3D21022019%26date%3D25022019%26date%3D21022019%26volume%3D10%26issue%3D3%26spage%3D383%26epage%3D388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kajal  Sharma</span>, <span class="hlFld-ContribAuthor ">Shalki  Choudhary</span>, <span class="hlFld-ContribAuthor ">Om  Silakari</span>. </span><span class="cited-content_cbyCitation_article-title">Portraying molecular modulation and therapeutic aspects of psoriasis: Retrospection and current status. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1243 </em>, 130770. <a href="https://doi.org/10.1016/j.molstruc.2021.130770" title="DOI URL">https://doi.org/10.1016/j.molstruc.2021.130770</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2021.130770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2021.130770%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DPortraying%252Bmolecular%252Bmodulation%252Band%252Btherapeutic%252Baspects%252Bof%252Bpsoriasis%25253A%252BRetrospection%252Band%252Bcurrent%252Bstatus%26aulast%3DSharma%26aufirst%3DKajal%26date%3D2021%26volume%3D1243%26spage%3D130770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Radek  Jorda</span>, <span class="hlFld-ContribAuthor ">Soňa  Krajčovičová</span>, <span class="hlFld-ContribAuthor ">Petra  Králová</span>, <span class="hlFld-ContribAuthor ">Miroslav  Soural</span>, <span class="hlFld-ContribAuthor ">Vladimír  Kryštof</span>. </span><span class="cited-content_cbyCitation_article-title">Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>204 </em>, 112636. <a href="https://doi.org/10.1016/j.ejmech.2020.112636" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112636</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112636%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DScaffold%252Bhopping%252Bof%252Bthe%252BSYK%252Binhibitor%252Bentospletinib%252Bleads%252Bto%252Bbroader%252Btargeting%252Bof%252Bthe%252BBCR%252Bsignalosome%26aulast%3DJorda%26aufirst%3DRadek%26date%3D2020%26volume%3D204%26spage%3D112636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingbin  Kong</span>, <span class="hlFld-ContribAuthor ">Rong  Huang</span>, <span class="hlFld-ContribAuthor ">Haodan  He</span>, <span class="hlFld-ContribAuthor ">Yunxiang  Fan</span>, <span class="hlFld-ContribAuthor ">Jun  Lin</span>, <span class="hlFld-ContribAuthor ">Shengjiao  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-component solvent-free cascade reaction of 2-cyanoacetamides: regioselective synthesis of pyridin-2-ones bearing quaternary centers. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2020,</strong> <em>22 </em>
                                    (1)
                                     , 256-264. <a href="https://doi.org/10.1039/C9GC03692J" title="DOI URL">https://doi.org/10.1039/C9GC03692J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9GC03692J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9GC03692J%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DMulti-component%252Bsolvent-free%252Bcascade%252Breaction%252Bof%252B2-cyanoacetamides%25253A%252Bregioselective%252Bsynthesis%252Bof%252Bpyridin-2-ones%252Bbearing%252Bquaternary%252Bcenters%26aulast%3DKong%26aufirst%3DLingbin%26date%3D2020%26date%3D2020%26volume%3D22%26issue%3D1%26spage%3D256%26epage%3D264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solvent‐exposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elham Y.  Al-Barghouthy</span>, <span class="hlFld-ContribAuthor ">Areej  Abuhammad</span>, <span class="hlFld-ContribAuthor ">Mutasem O.  Taha</span>. </span><span class="cited-content_cbyCitation_article-title">QSAR-guided pharmacophore modeling and subsequent virtual screening identify novel TYK2 inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2019,</strong> <em>28 </em>
                                    (9)
                                     , 1368-1387. <a href="https://doi.org/10.1007/s00044-019-02377-7" title="DOI URL">https://doi.org/10.1007/s00044-019-02377-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-019-02377-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-019-02377-7%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DQSAR-guided%252Bpharmacophore%252Bmodeling%252Band%252Bsubsequent%252Bvirtual%252Bscreening%252Bidentify%252Bnovel%252BTYK2%252Binhibitor%26aulast%3DAl-Barghouthy%26aufirst%3DElham%2BY.%26date%3D2019%26date%3D2019%26volume%3D28%26issue%3D9%26spage%3D1368%26epage%3D1387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kenneth F  Baker</span>, <span class="hlFld-ContribAuthor ">John D  Isaacs</span>. </span><span class="cited-content_cbyCitation_article-title">Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?. </span><span class="cited-content_cbyCitation_journal-name">Annals of the Rheumatic Diseases</span><span> <strong>2018,</strong> <em>77 </em>
                                    (2)
                                     , 175-187. <a href="https://doi.org/10.1136/annrheumdis-2017-211555" title="DOI URL">https://doi.org/10.1136/annrheumdis-2017-211555</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1136/annrheumdis-2017-211555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1136%2Fannrheumdis-2017-211555%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520the%2520Rheumatic%2520Diseases%26atitle%3DNovel%252Btherapies%252Bfor%252Bimmune-mediated%252Binflammatory%252Bdiseases%25253A%252BWhat%252Bcan%252Bwe%252Blearn%252Bfrom%252Btheir%252Buse%252Bin%252Brheumatoid%252Barthritis%25252C%252Bspondyloarthritis%25252C%252Bsystemic%252Blupus%252Berythematosus%25252C%252Bpsoriasis%25252C%252BCrohn%2525E2%252580%252599s%252Bdisease%252Band%252Bulcerative%252Bcolitis%25253F%26aulast%3DBaker%26aufirst%3DKenneth%2BF%26date%3D2018%26date%3D2017%26volume%3D77%26issue%3D2%26spage%3D175%26epage%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anastasiya I.  Govdi</span>, <span class="hlFld-ContribAuthor ">Alexandra E.  Kulyashova</span>, <span class="hlFld-ContribAuthor ">Sergey F.  Vasilevsky</span>, <span class="hlFld-ContribAuthor ">Irina A.  Balova</span>. </span><span class="cited-content_cbyCitation_article-title">Functionalized buta-1,3-diynyl- N -methylpyrazoles by sequential “diacetylene zipper” and Sonogashira coupling reactions. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2017,</strong> <em>58 </em>
                                    (8)
                                     , 762-765. <a href="https://doi.org/10.1016/j.tetlet.2017.01.032" title="DOI URL">https://doi.org/10.1016/j.tetlet.2017.01.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2017.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2017.01.032%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DFunctionalized%252Bbuta-1%25252C3-diynyl-%252BN%252B-methylpyrazoles%252Bby%252Bsequential%252B%2525E2%252580%25259Cdiacetylene%252Bzipper%2525E2%252580%25259D%252Band%252BSonogashira%252Bcoupling%252Breactions%26aulast%3DGovdi%26aufirst%3DAnastasiya%2BI.%26date%3D2017%26volume%3D58%26issue%3D8%26spage%3D762%26epage%3D765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M.  Herbrink</span>, <span class="hlFld-ContribAuthor ">J.H.M.  Schellens</span>, <span class="hlFld-ContribAuthor ">J.H.  Beijnen</span>, <span class="hlFld-ContribAuthor ">B.  Nuijen</span>. </span><span class="cited-content_cbyCitation_article-title">Inherent formulation issues of kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Controlled Release</span><span> <strong>2016,</strong> <em>239 </em>, 118-127. <a href="https://doi.org/10.1016/j.jconrel.2016.08.036" title="DOI URL">https://doi.org/10.1016/j.jconrel.2016.08.036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jconrel.2016.08.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jconrel.2016.08.036%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Controlled%2520Release%26atitle%3DInherent%252Bformulation%252Bissues%252Bof%252Bkinase%252Binhibitors%26aulast%3DHerbrink%26aufirst%3DM.%26date%3D2016%26volume%3D239%26spage%3D118%26epage%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">René  Galien</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinases in inflammatory bowel disease: Four kinases for multiple purposes. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reports</span><span> <strong>2016,</strong> <em>68 </em>
                                    (4)
                                     , 789-796. <a href="https://doi.org/10.1016/j.pharep.2016.04.001" title="DOI URL">https://doi.org/10.1016/j.pharep.2016.04.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharep.2016.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharep.2016.04.001%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reports%26atitle%3DJanus%252Bkinases%252Bin%252Binflammatory%252Bbowel%252Bdisease%25253A%252BFour%252Bkinases%252Bfor%252Bmultiple%252Bpurposes%26aulast%3DGalien%26aufirst%3DRen%25C3%25A9%26date%3D2016%26volume%3D68%26issue%3D4%26spage%3D789%26epage%3D796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of reported JAKs<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and TYK2 inhibitors.<a onclick="showRef(event, 'cit13c'); return false;" href="javascript:void(0);" class="ref cit13c">(13c)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design concept of 3-amino-1,5-dihydro-4<i>H</i>-pyrazolopyridin-4-one scaffold. (a) ATP content (% of control at 30 μM). (b) Caspase 3/7 activity (% of maximum staurosporine activity at 30 μM). (c) Δ<sub>max</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Top view (A) and side view (B) of X-ray structure of compound <b>8</b> with TYK2. (C) Structure-based design strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Assessment of <b>20</b> in rat IL-23 skin PD assay. ***: <i>p</i> < 0.001 vs vehicle, by Dunnett’s test (PBS <i>n</i> = 4, IL-23 <i>n</i> = 6).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Top view (A) and side view (B) of X-ray structure of <b>20</b> with TYK2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2,2,6-trimethyl-4<i>H</i>-1,3-dioxin-4-one, NaOAc, THF, reflux, 74% for <b>22c</b>; (b) diketene, MeOH, 0 °C, 96% for <b>22d</b>; (c) K<sub>2</sub>CO<sub>3</sub>, DMF/DMA, DMF, rt, 69–84% for <b>23a</b>,<b>b</b>,<b>d</b>; (d) DMF/DMA, DMF, rt, 95% for <b>23c</b>; (e) POCl<sub>3</sub>, DMF, 0 °C → 100–125 °C, 59–64% for <b>24a</b>–<b>c</b>; (f) (chloromethylene)dimethylammonium chloride, DMF 100 °C, 57% for <b>24d</b>; (g) hydroxylamine hydrochloride, NaOAc, MeOH–H<sub>2</sub>O, 75 °C, 77–92% for <b>25a</b>,<b> 25c</b>; (h) hydroxylamine hydrochloride, conc. HCl, 2-propanol, 100 °C, 68–95% for <b>25b</b>,<b> 25d</b>; (i) POCl<sub>3</sub>, CH<sub>3</sub>CN, 90 °C, 53–100% for <b>26a</b>–<b>c</b>; (j) SOCl<sub>2</sub>, CH<sub>3</sub>CN, rt, 68% for <b>26d</b>; (k) NBS, DMF, 50–60 °C, 81–98%; (l) PhB(OH)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub> aq, DME, 90 °C, 64%; (m) hydrazine monohydrate, EtOH, 70 °C, 27%; (n) hydrazine monohydrate, EtOH, 70–90 °C, 82–94%; (o) chiral HPLC, CHIRALPAK AD, hexane/EtOH, 44%; (p) KOAc, PdCl<sub>2</sub>(dppf) (or Pd(PPh<sub>3</sub>)<sub>4</sub>), bis(pinacolato)diboron, DMF (or DMA), 110–120 °C, then R<sup>2</sup>–Br (or R<sup>2</sup>–I, or R<sup>2</sup>–OTf), Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub> aq, 120 °C, 8–41% for <b>5</b>, <b>6</b>, <b>13</b>,<b> 15</b>,<b> 17</b>, <b>19</b>, <b>20</b>, <b>30</b>; (q) 1-methyl-3-(4,4,5,5-tetramethy-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub> aq, DMF, 120 °C, 11–29% for <b>8</b>, <b>9</b>,<b> 16</b>; (r) chiral HPLC, CHIRALCEL OJ, hexane/EtOH/diethylamine, 56–76%; (s) PtO<sub>2</sub>, H<sub>2</sub>, rt, MeOH, 45%.</p></p></figure><figure data-id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) R<sup>1</sup>–Br, Cs<sub>2</sub>CO<sub>3</sub>, KI, DMF–DME, 60 °C, 6–48% for <b>32a</b>,<b>c</b>; (b) 1-bromo-2-methylpropane, Cs<sub>2</sub>CO<sub>3</sub>, DMSO, 50 °C, 63% for <b>32b</b>; (c) NBS, DMF, 60 °C, 47–72% for <b>33a</b>,<b>c</b>; (d) NBS, DMF, 70 °C, then POCl<sub>3</sub>, 120 °C, 15% for <b>33b</b>; (e) 1-methyl-3-(4,4,5,5-tetramethy-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub> aq, DME, 100 °C, 60–69% for <b>10</b>, <b>12</b>; (f) hydrazine monohydrate, EtOH, 90 °C, 40–59% for <b>10</b>, <b>12</b>; (g) hydrazine monohydrate, EtOH, reflux, 98% for <b>11</b>; (h) 1-methyl-3-(4,4,5,5-tetramethy-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole, Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub> aq, DMF, 150 °C, 17% for <b>11</b>.</p></p></figure><figure data-id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0009.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DPPA, Et<sub>3</sub>N, <i>t</i>-BuOH, reflux, 93%; (b) 4 M HCl/EtOAc, EtOAc/MeOH, rt, 97%; (c) 1-chloro-2-(2-chloroethoxy)ethane, Et<sub>3</sub>N, NaI, DMF, 150 °C, 13%; (d) Pd/C (10%), H<sub>2</sub>, EtOH, rt, 93%; (e) trifluoromethanesulfonic anhydride, Et<sub>3</sub>N, CH<sub>3</sub>CN, 0 °C, 58%.</p></p></figure><figure data-id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/medium/jm-2015-018573_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0010.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01857/20160122/images/large/jm-2015-018573_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01857&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaOAc, Br<sub>2</sub>, H<sub>2</sub>O–EtOH, rt, 99%; (b) NaH, MeI, THF, 0 °C to rt, 99%; (c) 150 °C, 76% for <b>43a</b>; (d) NMP 200 °C, 43% for <b>43b</b>; (e) 2 M NaOH, EtOH, 60–70 °C, then conc. H<sub>2</sub>SO<sub>4</sub>, 60 °C, 81–99%; (f) 50% H<sub>2</sub>SO<sub>4</sub> aq, 160 °C, 86%; (g) 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2<i>H</i>-pyran, Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub> aq, DME, 80 °C, 64% ; (h) <i>n</i>-BuLi, THF, −78 °C, then acetone, −78 °C to rt, 70%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i107">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24638" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24638" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 20 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shuai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span> </span><span class="NLM_article-title">Regulation of JAK-STAT Signalling in the Immune System</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">900</span><span class="NLM_x">–</span> <span class="NLM_lpage">911</span><span class="refDoi"> DOI: 10.1038/nri1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-911&author=K.+Shuaiauthor=B.+Liu&title=Regulation+of+JAK-STAT+Signalling+in+the+Immune+System&doi=10.1038%2Fnri1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0lhHZ0eV19CB7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK-STAT%2520Signalling%2520in%2520the%2520Immune%2520System%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D911%26doi%3D10.1038%2Fnri1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">Janus Kinases in Immune Cell Signalling</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">287</span><span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1111%2Fj.1600-065X.2008.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=19290934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=273-287&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%E2%80%99Shea&title=Janus+Kinases+in+Immune+Cell+Signalling&doi=10.1111%2Fj.1600-065X.2008.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases in immune cell signaling</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non-receptor protein tyrosine kinases.  They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.  Data from exptl. mice and clin. observations have unraveled multiple signaling events mediated by Jaks in innate and adaptive immunity.  Deficiency of Jak3 or Tyk2 results in defined clin. disorders, which are also evident in mouse models.  A striking phenotype assocd. with inactivating Jak3 mutations is severe combined immunodeficiency syndrome, whereas mutation of Tyk2 results in another primary immunodeficiency termed autosomal recessive hyperimmunoglobulin E syndrome.  By contrast, complete deletion of Jak1 or Jak2 in the mouse are not compatible with life and, unsurprisingly, do not have counterparts in human disease.  However, activating mutations of each of the Jaks are found in assocn. with malignant transformation, the most common being gain-of-function mutations of Jak2 in polycythemia vera and other myeloproliferative disorders.  Our existing knowledge on Jak signaling pathways and fundamental work on their biochem. structure and intracellular interactions allow us to develop new strategies for controlling autoimmune diseases or malignancies by developing selective Jak inhibitors, which are now coming into clin. use.  Despite the fact that Jaks were discovered only a little more than a decade ago, at the time of writing there are 20 clin. trials underway testing the safely and efficacy of Jak inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23ncK0nYqpbVg90H21EOLACvtfcHk0lhHZ0eV19CB7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7vJ&md5=adc282a9ad381ee18abe57a82c921f65</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520Kinases%2520in%2520Immune%2520Cell%2520Signalling%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D273%26epage%3D287%26doi%3D10.1111%2Fj.1600-065X.2008.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Aringer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudarshan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">Janus kinases and their role in growth and disease</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">2173</span><span class="NLM_x">–</span> <span class="NLM_lpage">2186</span><span class="refDoi"> DOI: 10.1016/S0024-3205(98)00538-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2FS0024-3205%2898%2900538-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=2173-2186&author=M.+Aringerauthor=A.+Chengauthor=J.+W.+Nelsonauthor=M.+Chenauthor=C.+Sudarshanauthor=Y.+J.+Zhouauthor=J.+J.+O%E2%80%99Shea&title=Janus+kinases+and+their+role+in+growth+and+disease&doi=10.1016%2FS0024-3205%2898%2900538-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2FS0024-3205%2898%2900538-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0024-3205%252898%252900538-4%26sid%3Dliteratum%253Aachs%26aulast%3DAringer%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DA.%26aulast%3DNelson%26aufirst%3DJ.%2BW.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DSudarshan%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJanus%2520kinases%2520and%2520their%2520role%2520in%2520growth%2520and%2520disease%26jtitle%3DLife%2520Sci.%26date%3D1999%26volume%3D64%26spage%3D2173%26epage%3D2186%26doi%3D10.1016%2FS0024-3205%2898%2900538-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schindler, C. W.</span><span> </span><span class="NLM_article-title">Series introduction. JAK-STAT signaling in human disease</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">1133</span><span class="NLM_x">–</span> <span class="NLM_lpage">1137</span><span class="refDoi"> DOI: 10.1172/JCI0215644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1172%2FJCI0215644" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=1133-1137&author=C.+W.+Schindler&title=Series+introduction.+JAK-STAT+signaling+in+human+disease&doi=10.1172%2FJCI0215644"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1172%2FJCI0215644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI0215644%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DC.%2BW.%26atitle%3DSeries%2520introduction.%2520JAK-STAT%2520signaling%2520in%2520human%2520disease%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D109%26spage%3D1133%26epage%3D1137%26doi%3D10.1172%2FJCI0215644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, C. E.</span><span> </span><span class="NLM_article-title">Novel systemic therapies for the treatment of psoriasis</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1517/14656566.2016.1109636</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1517%2F14656566.2016.1109636" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=1-14&author=K.+W.+Tanauthor=C.+E.+Griffiths&title=Novel+systemic+therapies+for+the+treatment+of+psoriasis&doi=10.1517%2F14656566.2016.1109636"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1517%2F14656566.2016.1109636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2016.1109636%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DK.%2BW.%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%26atitle%3DNovel%2520systemic%2520therapies%2520for%2520the%2520treatment%2520of%2520psoriasis%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2015%26spage%3D1%26epage%3D14%26doi%3D10.1517%2F14656566.2016.1109636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mahmood, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaghi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menter, A.</span><span> </span><span class="NLM_article-title">Emerging oral drugs for psoriasis</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span><span class="refDoi"> DOI: 10.1517/14728214.2015.1010509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1517%2F14728214.2015.1010509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=25643592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFahur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=209-20&author=T.+Mahmoodauthor=D.+Zaghiauthor=A.+Menter&title=Emerging+oral+drugs+for+psoriasis&doi=10.1517%2F14728214.2015.1010509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging oral drugs for psoriasis</span></div><div class="casAuthors">Mahmood, Tahmina; Zaghi, Daniel; Menter, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-220</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Psoriasis is a chronic, immune-mediated inflammatory disease that classically presents with well-demarcated, scaly, erythematous plaques on the extensor surfaces of the extremities, scalp, and trunk.  Nails and joints are frequently affected as well.  Whereas a significant no. of patients maintain adequate control with topical therapy, up to 25% of patients will require phototherapy, oral systemic medication, or biol. therapy.  Areas covered: The majority of recent advances in therapeutic options for moderate-to-severe psoriasis have been in biol. therapies whereas development of new oral agents has lagged behind.  Currently, oral agents are largely confined to methotrexate, acitretin, cyclosporine and most recently apremilast.  This article reviews emerging oral treatments for moderate-to-severe psoriasis.  Expert opinion: Despite the recent FDA approval of apremilast, the development of new oral treatments for moderate-to-severe psoriasis has not kept pace with biol. therapies.  There continues to be a need for safe and effective long-term oral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZl9zzOE0nyrVg90H21EOLACvtfcHk0lhHtMoxkGMNgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFahur0%253D&md5=c860c2f6f0b51a21c436dfdffc6fb70e</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1517%2F14728214.2015.1010509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728214.2015.1010509%26sid%3Dliteratum%253Aachs%26aulast%3DMahmood%26aufirst%3DT.%26aulast%3DZaghi%26aufirst%3DD.%26aulast%3DMenter%26aufirst%3DA.%26atitle%3DEmerging%2520oral%2520drugs%2520for%2520psoriasis%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2015%26volume%3D20%26spage%3D209%26epage%3D20%26doi%3D10.1517%2F14728214.2015.1010509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Weger, W.</span><span> </span><span class="NLM_article-title">Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">810</span><span class="NLM_x">–</span> <span class="NLM_lpage">820</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00702.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1111%2Fj.1476-5381.2010.00702.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=20590580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVKnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=810-820&author=W.+Weger&title=Current+status+and+new+developments+in+the+treatment+of+psoriasis+and+psoriatic+arthritis+with+biological+agents&doi=10.1111%2Fj.1476-5381.2010.00702.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents</span></div><div class="casAuthors">Weger, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">810-820</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Psoriasis is a chronic inflammatory disease affecting 1-3% of the general population.  Among psoriatic patients, 5-40% are affected by psoriatic arthritis.  Due to the chronic nature of the disease, patients suffer from substantial psychol. and financial burdens, thus adding to a significantly impaired quality of life.  Traditional systemic therapies for psoriasis, such as methotrexate, cyclosporin A, retinoids or PUVA therapy, have a potential for long-term toxicity and may not always provide sufficient improvement of the disease.  The development of novel therapies targeting key steps in the pathogenesis of psoriasis and psoriatic arthritis now provide new and efficient treatment options.  Biol. therapies for the treatment of psoriasis and/or psoriatic arthritis are defined by their mode of action and can be classified into three categories: the T-cell modulating agents (alefacept and efalizumab), the inhibitors of tumor necrosis factor-α (TNFα blockers, e.g. adalimumab, certolizumab, etanercept, golimumab and infliximab) and the inhibitors of interleukin (IL) 12 and IL-23 (e.g. ustekinumab and briakinumab).  This article provides a brief overview of the currently approved biol. agents in the European Union and of some newer agents, such as briakinumab, certolizumab and golimumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3bFpMNNoCM7Vg90H21EOLACvtfcHk0lhHtMoxkGMNgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVKnsbk%253D&md5=b317a08a8dcaec53033e5216dbe8e6f8</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00702.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00702.x%26sid%3Dliteratum%253Aachs%26aulast%3DWeger%26aufirst%3DW.%26atitle%3DCurrent%2520status%2520and%2520new%2520developments%2520in%2520the%2520treatment%2520of%2520psoriasis%2520and%2520psoriatic%2520arthritis%2520with%2520biological%2520agents%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D810%26epage%3D820%26doi%3D10.1111%2Fj.1476-5381.2010.00702.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schafer, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjesbo, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gleason, P. P.</span><span> </span><span class="NLM_article-title">Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis</span> <span class="citation_source-journal">J. Manag. Care Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">402</span><span class="NLM_x">–</span> <span class="NLM_lpage">416</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=20635831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A280%3ADC%252BC3cnos12ltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=402-416&author=J.+A.+Schaferauthor=N.+K.+Kjesboauthor=P.+P.+Gleason&title=Formulary+review+of+2+new+biologic+agents%3A+tocilizumab+for+rheumatoid+arthritis+and+ustekinumab+for+plaque+psoriasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis</span></div><div class="casAuthors">Schafer Jeremy A; Kjesbo Nicole K; Gleason Patrick P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of managed care pharmacy : JMCP</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">402-16</span>
        ISSN:<span class="NLM_cas:issn">1083-4087</span>.
    </div><div class="casAbstract">BACKGROUND:  Two autoimmune biologics were recently approved by the FDA: ustekinumab in September 2009 for the treatment of moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy and tocilizumab in January 2010 for adult patients with moderate to severe rheumatoid arthritis (RA) who have not responded adequately to 1 or more tumor necrosis factor (TNF) antagonist therapies.  Both agents use new mechanisms of action and add to the growing group of autoimmune biologics.  OBJECTIVE:  To critically review the phase 3 trials for ustekinumab and tocilizumab and provide managed care considerations in the context of the 9 other biologic agents on the market in the United States that are used to treat moderate to severe RA or psoriasis.  METHODS:  A MEDLINE review was performed for articles published and available through January 2010 using keywords "ustekinumab" and "tocilizumab" with an emphasis on phase 3 trials.  The literature search was limited to articles in English, clinical trials, randomized controlled trials, and research conducted in humans.  Search results for ustekinumab included 8 articles of which 4 were excluded for not being psoriasis or psoriatic arthritis trials.  Search results for tocilizumab included 16 articles of which 8 were excluded for not being RA trials or using biomarkers as primary endpoints.  Additional information was obtained from the FDA website.  RESULTS:  Three phase 3 trials are available for ustekinumab.  Ustekinumab demonstrated superior efficacy to placebo in 2 trials for the treatment of psoriasis.  In a 12-week trial, ustekinumab 45 milligrams (mg) and 90 mg demonstrated significantly higher rates of 75% improvement in the psoriasis area and severity index (PASI 75) (67.5% and 73.8%, respectively) compared with etanercept (56.8%) in the first phase 3 comparative psoriasis trial between autoimmune biologics (P < 0.05 for both comparisons).  In a phase 3 trial of RA patients who had failed prior TNF antagonist therapy, a 20% improvement in signs or symptoms according to the American College of Rheumatology criteria (ACR 20) at week 24 was achieved by significantly more study participants in the tocilizumab 8 mg per kilogram (kg) (50.0%) and 4 mg per kg (30.4%) groups than the placebo group (10.1%, P < 0.001 for both tocilizumab groups compared with placebo).  Safety data for ustekinumab are limited to use for less than 2 years, and the prescribing information contains warnings regarding infection and malignancy.  Tocilizumab is associated with neutropenia, thrombocytopenia, and elevations in lipids and liver function tests.  Tocilizumab has unique adverse events when compared with other autoimmune biologics and requires laboratory testing and careful monitoring.  CONCLUSIONS:  Ustekinumab and tocilizumab are new additions to the treatment of autoinflammatory disease.  The majority of safety data for both agents are from trials lasting 3 to 6 months.  Published long-term safety data for tocilizumab are limited to less than 143 patients treated longer than 5 years, and safety data for ustekinumab are scant beyond 2 years of use; therefore, clinicians should exercise caution prior to widespread adoption.  The comparative efficacy and safety trial of etanercept and ustekinumab brings important clinical information to decision makers.  Tocilizumab is indicated after failure or intolerance to a TNF antagonist and has unique safety concerns.  Managed care plans will consider the experience and long-term data of these agents along with efficacy data and cost when establishing management programs such as prior authorization or step therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQIB67pB_0BtZp6t8nS6Nc3fW6udTcc2eY8KBYeRoEMvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnos12ltA%253D%253D&md5=df490517f0eb903cc351add796f04d79</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchafer%26aufirst%3DJ.%2BA.%26aulast%3DKjesbo%26aufirst%3DN.%2BK.%26aulast%3DGleason%26aufirst%3DP.%2BP.%26atitle%3DFormulary%2520review%2520of%25202%2520new%2520biologic%2520agents%253A%2520tocilizumab%2520for%2520rheumatoid%2520arthritis%2520and%2520ustekinumab%2520for%2520plaque%2520psoriasis%26jtitle%3DJ.%2520Manag.%2520Care%2520Pharm.%26date%3D2010%26volume%3D16%26spage%3D402%26epage%3D416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Laws, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, H. S.</span><span> </span><span class="NLM_article-title">Update of the management of chronic psoriasis: new approaches and emerging treatment options</span> <span class="citation_source-journal">Clin., Cosmet. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span><span class="refDoi"> DOI: 10.2147/CCID.S6497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.2147%2FCCID.S6497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=21437057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXls1Gqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=25-37&author=P.+M.+Lawsauthor=H.+S.+Young&title=Update+of+the+management+of+chronic+psoriasis%3A+new+approaches+and+emerging+treatment+options&doi=10.2147%2FCCID.S6497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">Update of the management of chronic psoriasis: new approaches and emerging treatment options</span></div><div class="casAuthors">Laws, Philip M.; Young, Helen S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical, Cosmetic and Investigational Dermatology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25-37</span>CODEN:
                <span class="NLM_cas:coden">CCIDCL</span>;
        ISSN:<span class="NLM_cas:issn">1178-7015</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Psoriasis is a common, chronic inflammatory skin disease which is assocd. with a no. of significant co-morbidities including: impairment of quality of life; cardiovascular disease; and a seroneg. arthritis known as psoriatic arthritis.  Our understanding of the pathogenesis of psoriasis has developed at a remarkable rate in recent years.  These new insights have significantly changed our perception of the condition and have led to the development of several new treatment strategies.  Biol. agents have proved a major step forward in therapeutic options for psoriasis.  The ability to clear, or almost clear, cutaneous disease has changed the outcomes and expectations of many patients with this disease.  The impact on both phys. and psychol. health may be great.  This review covers the clin. features and management of psoriasis with specific ref. to new therapeutic options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzPMMW51CCVbVg90H21EOLACvtfcHk0lh-NAbShVJYyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXls1Gqurg%253D&md5=3824542e4ba93ac6d7dbedf4c99ef8a4</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.2147%2FCCID.S6497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCCID.S6497%26sid%3Dliteratum%253Aachs%26aulast%3DLaws%26aufirst%3DP.%2BM.%26aulast%3DYoung%26aufirst%3DH.%2BS.%26atitle%3DUpdate%2520of%2520the%2520management%2520of%2520chronic%2520psoriasis%253A%2520new%2520approaches%2520and%2520emerging%2520treatment%2520options%26jtitle%3DClin.%252C%2520Cosmet.%2520Invest.%2520Dermatol.%26date%3D2010%26volume%3D3%26spage%3D25%26epage%3D37%26doi%3D10.2147%2FCCID.S6497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Johnsson, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInnes, I. B.</span><span> </span><span class="NLM_article-title">Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis</span> <span class="citation_source-journal">Clin. Exp. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">S115</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=S115-8&author=H.+J.+Johnssonauthor=I.+B.+McInnes&title=Interleukin-12+and+interleukin-23+inhibition+in+psoriatic+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnsson%26aufirst%3DH.%2BJ.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26atitle%3DInterleukin-12%2520and%2520interleukin-23%2520inhibition%2520in%2520psoriatic%2520arthritis%26jtitle%3DClin.%2520Exp.%2520Rheumatol.%26date%3D2015%26volume%3D33%26spage%3DS115%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Scanlon, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Exter, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvis, C. I.</span><span> </span><span class="NLM_article-title">Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis</span> <span class="citation_source-journal">Ann. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1456</span><span class="NLM_x">–</span> <span class="NLM_lpage">1465</span><span class="refDoi"> DOI: 10.1345/aph.1M151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1345%2Faph.1M151" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2009&pages=1456-1465&author=J.+V.+Scanlonauthor=B.+P.+Exterauthor=M.+Steinbergauthor=C.+I.+Jarvis&title=Ustekinumab%3A+treatment+of+adult+moderate-to-severe+chronic+plaque+psoriasis&doi=10.1345%2Faph.1M151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1345%2Faph.1M151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1345%252Faph.1M151%26sid%3Dliteratum%253Aachs%26aulast%3DScanlon%26aufirst%3DJ.%2BV.%26aulast%3DExter%26aufirst%3DB.%2BP.%26aulast%3DSteinberg%26aufirst%3DM.%26aulast%3DJarvis%26aufirst%3DC.%2BI.%26atitle%3DUstekinumab%253A%2520treatment%2520of%2520adult%2520moderate-to-severe%2520chronic%2520plaque%2520psoriasis%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2009%26volume%3D43%26spage%3D1456%26epage%3D1465%26doi%3D10.1345%2Faph.1M151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Elliott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blank, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodmerkel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharples, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szapary, P.</span><span> </span><span class="NLM_article-title">Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases</span> <span class="citation_source-journal">Ann. N. Y. Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1182</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span><span class="refDoi"> DOI: 10.1111/j.1749-6632.2009.05070.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1111%2Fj.1749-6632.2009.05070.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1182&publication_year=2009&pages=97-110&author=M.+Elliottauthor=J.+Bensonauthor=M.+Blankauthor=C.+Brodmerkelauthor=D.+Bakerauthor=K.+R.+Sharplesauthor=P.+Szapary&title=Ustekinumab%3A+lessons+learned+from+targeting+interleukin-12%2F23p40+in+immune-mediated+diseases&doi=10.1111%2Fj.1749-6632.2009.05070.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2009.05070.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2009.05070.x%26sid%3Dliteratum%253Aachs%26aulast%3DElliott%26aufirst%3DM.%26aulast%3DBenson%26aufirst%3DJ.%26aulast%3DBlank%26aufirst%3DM.%26aulast%3DBrodmerkel%26aufirst%3DC.%26aulast%3DBaker%26aufirst%3DD.%26aulast%3DSharples%26aufirst%3DK.%2BR.%26aulast%3DSzapary%26aufirst%3DP.%26atitle%3DUstekinumab%253A%2520lessons%2520learned%2520from%2520targeting%2520interleukin-12%252F23p40%2520in%2520immune-mediated%2520diseases%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2009%26volume%3D1182%26spage%3D97%26epage%3D110%26doi%3D10.1111%2Fj.1749-6632.2009.05070.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Leonardi, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimball, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papp, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeilding, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dooley, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, K. B.</span><span> </span><span class="NLM_article-title">Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">1665</span><span class="NLM_x">–</span> <span class="NLM_lpage">1674</span><span class="refDoi"> DOI: 10.1016/S0140-6736(08)60725-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2FS0140-6736%2808%2960725-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2008&pages=1665-1674&author=C.+L.+Leonardiauthor=A.+B.+Kimballauthor=K.+A.+Pappauthor=N.+Yeildingauthor=C.+Guzzoauthor=Y.+Wangauthor=L.+T.+Dooleyauthor=K.+B.+Gordon&title=Efficacy+and+safety+of+ustekinumab%2C+a+human+interleukin-12%2F23+monoclonal+antibody%2C+in+patients+with+psoriasis%3A+76-week+results+from+a+randomised%2C+double-blind%2C+placebo-controlled+trial+%28PHOENIX+1%29&doi=10.1016%2FS0140-6736%2808%2960725-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2960725-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252960725-4%26sid%3Dliteratum%253Aachs%26aulast%3DLeonardi%26aufirst%3DC.%2BL.%26aulast%3DKimball%26aufirst%3DA.%2BB.%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DYeilding%26aufirst%3DN.%26aulast%3DGuzzo%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDooley%26aufirst%3DL.%2BT.%26aulast%3DGordon%26aufirst%3DK.%2BB.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520ustekinumab%252C%2520a%2520human%2520interleukin-12%252F23%2520monoclonal%2520antibody%252C%2520in%2520patients%2520with%2520psoriasis%253A%252076-week%2520results%2520from%2520a%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520%2528PHOENIX%25201%2529%26jtitle%3DLancet%26date%3D2008%26volume%3D371%26spage%3D1665%26epage%3D1674%26doi%3D10.1016%2FS0140-6736%2808%2960725-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Papp, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szapary, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeilding, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, M. – C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dooley, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, K.</span><span> </span><span class="NLM_article-title">Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">1675</span><span class="NLM_x">–</span> <span class="NLM_lpage">1684</span><span class="refDoi"> DOI: 10.1016/S0140-6736(08)60726-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2FS0140-6736%2808%2960726-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2008&pages=1675-1684&author=K.+A.+Pappauthor=R.+G.+Langleyauthor=M.+Lebwohlauthor=G.+G.+Kruegerauthor=P.+Szaparyauthor=N.+Yeildingauthor=C.+Guzzoauthor=M.+%E2%80%93+C.+Hsuauthor=Y.+Wangauthor=S.+Liauthor=L.+T.+Dooleyauthor=K.+Reich&title=Efficacy+and+safety+of+ustekinumab%2C+a+human+interleukin-12%2F23+monoclonal+antibody%2C+in+patients+with+psoriasis%3A+52-week+results+from+a+randomised%2C+double-blind%2C+placebo-controlled+trial+%28PHOENIX+2%29&doi=10.1016%2FS0140-6736%2808%2960726-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2960726-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252960726-6%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DLangley%26aufirst%3DR.%2BG.%26aulast%3DLebwohl%26aufirst%3DM.%26aulast%3DKrueger%26aufirst%3DG.%2BG.%26aulast%3DSzapary%26aufirst%3DP.%26aulast%3DYeilding%26aufirst%3DN.%26aulast%3DGuzzo%26aufirst%3DC.%26aulast%3DHsu%26aufirst%3DM.%2B%25E2%2580%2593%2BC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DDooley%26aufirst%3DL.%2BT.%26aulast%3DReich%26aufirst%3DK.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520ustekinumab%252C%2520a%2520human%2520interleukin-12%252F23%2520monoclonal%2520antibody%252C%2520in%2520patients%2520with%2520psoriasis%253A%252052-week%2520results%2520from%2520a%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520%2528PHOENIX%25202%2529%26jtitle%3DLancet%26date%3D2008%26volume%3D371%26spage%3D1675%26epage%3D1684%26doi%3D10.1016%2FS0140-6736%2808%2960726-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Griffiths, C. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strober, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerkhof, P. V. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidelus, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeilding, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dooley, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menter, A.</span><span> </span><span class="NLM_article-title">Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">362</span><span class="NLM_x">, </span> <span class="NLM_fpage">118</span><span class="NLM_x">–</span> <span class="NLM_lpage">128</span><span class="refDoi"> DOI: 10.1056/NEJMoa0810652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1056%2FNEJMoa0810652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=20071701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFGjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2010&pages=118-128&author=C.+E.+M.+Griffithsauthor=B.+E.+Stroberauthor=P.+V.+D.+Kerkhofauthor=V.+Hoauthor=G.+R.+Fidelusauthor=N.+Yeildingauthor=C.+Guzzoauthor=Y.+Xiaauthor=B.+Zhouauthor=S.+Liauthor=L.+T.+Dooleyauthor=N.+H.+Goldsteinauthor=A.+Menter&title=Comparison+of+ustekinumab+and+etanercept+for+moderate-to-severe+psoriasis&doi=10.1056%2FNEJMoa0810652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5eR"><div class="casContent"><span class="casTitleNuber">5e</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis</span></div><div class="casAuthors">Griffiths, Christopher E. M.; Strober, Bruce E.; van de Kerkhof, Peter; Ho, Vincent; Fidelus-Gort, Roseanne; Yeilding, Newman; Guzzo, Cynthia; Xia, Yichuan; Zhou, Bei; Li, Shu; Dooley, Lisa T.; Goldstein, Neil H.; Menter, Alan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">118-128</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Biol. agents offer a range of new therapeutic options for patients with psoriasis; however, the relative benefit-risk profiles of such therapies are not well known.  We compared two biol. agents, ustekinumab (an interleukin-12 and interleukin-23 blocker) and etanercept (an inhibitor of tumor necrosis factor α), for the treatment of psoriasis.  We randomly assigned 903 patients with moderate-to-severe psoriasis to receive s.c. injections of either 45 or 90 mg of ustekinumab (at weeks 0 and 4) or high-dose etanercept (50 mg twice weekly for 12 wk).  The primary end point was the proportion of patients with at least 75% improvement in the psoriasis area-and-severity index (PASI) at week 12; a secondary end point was the proportion with cleared or minimal disease on the basis of the physician's global assessment.  Assessors were unaware of the treatment assignments.  The efficacy and safety of a crossover from etanercept to ustekinumab were evaluated after week 12.  There was at least 75% improvement in the PASI at week 12 in 67.5% of patients who received 45 mg of ustekinumab and 73.8% of patients who received 90 mg, as compared with 56.8% of those who received etanercept (P = 0.01 and P < 0.001, resp.).  Similarly, 65.1% of patients who received 45 mg of ustekinumab and 70.6% of patients who received 90 mg of ustekinumab had cleared or minimal disease according to the physician's global assessment, as compared with 49.0% of those who received etanercept (P < 0.001 for both comparisons).  Among patients who did not have a response to etanercept, 48.9% had at least 75% improvement in the PASI within 12 wk after crossover to ustekinumab.  One or more adverse events occurred through week 12 in 66.0% of patients who received 45 mg of ustekinumab and 69.2% of patients who received 90 mg of ustekinumab and in 70.0% who received etanercept; 1.9%, 1.2%, and 1.2%, resp., had serious adverse events.  Safety patterns were similar before and after crossover from etanercept to ustekinumab.  The efficacy of ustekinumab at a dose of 45 or 90 mg was superior to that of high-dose etanercept over a 12-wk period in patients with psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMoaei3TsvwLVg90H21EOLACvtfcHk0ljLQSp8IWPhjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFGjtA%253D%253D&md5=46527d6bbad0113d88a7b45b18512897</span></div><a href="/servlet/linkout?suffix=cit5e&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0810652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0810652%26sid%3Dliteratum%253Aachs%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%2BM.%26aulast%3DStrober%26aufirst%3DB.%2BE.%26aulast%3DKerkhof%26aufirst%3DP.%2BV.%2BD.%26aulast%3DHo%26aufirst%3DV.%26aulast%3DFidelus%26aufirst%3DG.%2BR.%26aulast%3DYeilding%26aufirst%3DN.%26aulast%3DGuzzo%26aufirst%3DC.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DDooley%26aufirst%3DL.%2BT.%26aulast%3DGoldstein%26aufirst%3DN.%2BH.%26aulast%3DMenter%26aufirst%3DA.%26atitle%3DComparison%2520of%2520ustekinumab%2520and%2520etanercept%2520for%2520moderate-to-severe%2520psoriasis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D362%26spage%3D118%26epage%3D128%26doi%3D10.1056%2FNEJMoa0810652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Krueger, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonardi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeilding, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dooley, L. T.</span><span> </span><span class="NLM_article-title">A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">580</span><span class="NLM_x">–</span> <span class="NLM_lpage">592</span><span class="refDoi"> DOI: 10.1056/NEJMoa062382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1056%2FNEJMoa062382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=17287478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsFOksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=580-592&author=G.+G.+Kruegerauthor=R.+G.+Langleyauthor=C.+Leonardiauthor=N.+Yeildingauthor=C.+Guzzoauthor=Y.+Wangauthor=L.+T.+Dooley&title=A+human+interleukin-12%2F23+monoclonal+antibody+for+the+treatment+of+psoriasis&doi=10.1056%2FNEJMoa062382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5fR"><div class="casContent"><span class="casTitleNuber">5f</span><div class="casTitle"><span class="NLM_cas:atitle">A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis</span></div><div class="casAuthors">Krueger, Gerald G.; Langley, Richard G.; Leonardi, Craig; Yeilding, Newman; Guzzo, Cynthia; Wang, Yuhua; Dooley, Lisa T.; Lebwohl, Mark; Altmeyer, P.; Bissonnette, R.; Blum, R.; Bourcier, M.; Carey, W.; Chambers, M.; Florentino, D.; Fretzin, S.; Gratton, D.; Guenther, L.; Hamlin, R.; Harvey, D.; Hudson, C.; Kaufmann, R.; Kircik, L.; Kirsner, R.; Korman, N.; Krueger, G.; Krusinski, P.; Zavod, M.; Lambert, J.; Langley, R.; Loenardi, C.; Ling, M.; Lubin, B.; Luger, T.; Marot, L.; Matheson, R.; Menter, A.; Nayak, A.; Nieves, D.; Nigra, T.; Packman, B.; Papp, K.; Poulin, Y.; Reich, K.; Rich, P.; Rosoph, L.; Sobell, J.; Swinehart, J.; Tomi, Z.; Toth, D.; Truett, A., III; Tschen, E.; Wasel, N.; Zanolli, M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">580-592</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiol. of psoriasis.  We evaluated the safety and efficacy of a human interleukin-12/23 monoclonal antibody in treating psoriasis.  In this double-blind, placebo-controlled trial, 320 patients with moderate-to-severe plaque psoriasis underwent randomization to treatment with the interleukin-12/23 monoclonal antibody (one 45-mg dose, one 90-mg dose, four weekly 45-mg doses, or four weekly 90-mg doses) or placebo; 64 patients were randomly assigned to each group.  Patients assigned to the interleukin-12/23 monoclonal antibody received one addnl. dose at week 16 if needed.  Patients assigned to placebo crossed over to receive one 90-mg dose of interleukin-12/23 monoclonal antibody at week 20.  There was at least 75% improvement in the psoriasis area-and-severity index at week 12 (the primary end point) in 52% of patients who received 45 mg of the interleukin-12/23 monoclonal antibody, in 59% of those who received 90 mg, in 67% of those who received four weekly 45-mg doses, and in 81% of those who received four weekly 90-mg doses, as compared with 2% of those who received placebo, and there was at least 90% improvement in 23%, 30%, 44%, and 52%, resp., of patients who received the monoclonal antibody as compared with 2% of patients who received placebo.  Adverse events occurred in 79% of patients treated with the interleukin-12/23 monoclonal antibody as compared with 72% of patients in the placebo group.  Serious adverse events occurred in 40% of patients who received the monoclonal antibody and in 10% of those who received placebo.  This study demonstrates the therapeutic efficacy of an interleukin-12/23 monoclonal antibody in psoriasis and provides further evidence of a role of the interleukin-12/23 p40 cytokines in the pathophysiol. of psoriasis.  Larger studies are needed to det. whether serious adverse events might limit the clin. usefulness of this new therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuwr1TZp_wfrVg90H21EOLACvtfcHk0ljLQSp8IWPhjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsFOksbo%253D&md5=4be21c1e7370c170b6fcf0c6fd5e790f</span></div><a href="/servlet/linkout?suffix=cit5f&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa062382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa062382%26sid%3Dliteratum%253Aachs%26aulast%3DKrueger%26aufirst%3DG.%2BG.%26aulast%3DLangley%26aufirst%3DR.%2BG.%26aulast%3DLeonardi%26aufirst%3DC.%26aulast%3DYeilding%26aufirst%3DN.%26aulast%3DGuzzo%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDooley%26aufirst%3DL.%2BT.%26atitle%3DA%2520human%2520interleukin-12%252F23%2520monoclonal%2520antibody%2520for%2520the%2520treatment%2520of%2520psoriasis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D580%26epage%3D592%26doi%3D10.1056%2FNEJMoa062382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Lopez-Ferrer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilarrasa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puig, L.</span><span> </span><span class="NLM_article-title">Secukinumab (AIN457) for the treatment of psoriasis</span> <span class="citation_source-journal">Expert Rev. Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1177</span><span class="NLM_x">–</span> <span class="NLM_lpage">88</span><span class="refDoi"> DOI: 10.1586/1744666X.2015.1095092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1586%2F1744666X.2015.1095092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=26428036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKksbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=1177-88&author=A.+Lopez-Ferrerauthor=E.+Vilarrasaauthor=L.+Puig&title=Secukinumab+%28AIN457%29+for+the+treatment+of+psoriasis&doi=10.1586%2F1744666X.2015.1095092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5gR"><div class="casContent"><span class="casTitleNuber">5g</span><div class="casTitle"><span class="NLM_cas:atitle">Secukinumab (AIN457) for the treatment of psoriasis</span></div><div class="casAuthors">Lopez-Ferrer, Anna; Vilarrasa, Eva; Puig, Lluis</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1177-1188</span>CODEN:
                <span class="NLM_cas:coden">ERCIBU</span>;
        ISSN:<span class="NLM_cas:issn">1744-666X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Psoriasis is a chronic inflammatory disease with a multifactorial origin that appears in patients with genetic predisposition and is induced by environmental factors, and characterized by alterations in the innate and adaptive immunity.  IL-17A is one of the specific cytokines involved in the pathogenesis of psoriasis and its inhibition is highly effective in the treatment of patients with moderate and severe psoriasis.  Secukinumab is a monoclonal antibody that specifically binds to IL-17A and inhibits the interaction to its receptor, and it has demonstrated its efficacy and safety in the treatment of psoriasis.  Phase II and III clin. trials indicate that > 80% of the patients receiving secukinumab achieve Psoriasis Area Severity Index (PASI) 75 at week 12.  In the Phase III efficacy of response and safety of two fixed secukinumab regimens in psoriasis trial, PASI 75 rates were 81.6% with 300 mg secukinumab, 71.6% with 150 mg secukinumab and 4.5% with placebo, and responses were maintained up to 52 wk in the majority of patients.  In the Phase III Full Year Investigative Examn. Of Secukinumab vs. Etanercept Using Two Dosing Regimens To Det. Efficacy in Psoriasis study, the efficacy of secukinumab was compared to etanercept.  The results indicate that both doses of secukinumab (150 and 300 mg) showed superior efficacy compared with etanercept throughout the study; PASI 75 rates at week 12 were 77.1% with 300 mg secukinumab, 67% with 150 mg of secukinumab, 44% with etanercept and 4.9% with placebo.  PASI 90 and PASI 100 were 54 and 24% with secukinumab 300 mg and 21 and 4% with etanercept at week 12.  At week 52, PASI 90 continued to be higher in the secukinumab group (65%) compared with the etanercept group (33%).  Regarding safety, the most common side effects were nasopharyngitis and headache.  The rate of infections was higher with secukinumab than placebo.  This was esp. the case for Candida infections, which were more common in the secukinumab group (4.7% with secukinumab 300 mg and 2.3% with secukinumab 150 mg), but all cases were resolved with conventional treatment.  Secukinumab is a well-tolerated treatment that has demonstrated efficacy in treating moderate-to-severe plaque psoriasis.  Nevertheless, long-term studies are necessary to confirm Phase II and Phase III data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6G3TVfUViuLVg90H21EOLACvtfcHk0lhiOczXsuaKfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKksbvK&md5=eed7f467cad7919c682853413438d08e</span></div><a href="/servlet/linkout?suffix=cit5g&amp;dbid=16384&amp;doi=10.1586%2F1744666X.2015.1095092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F1744666X.2015.1095092%26sid%3Dliteratum%253Aachs%26aulast%3DLopez-Ferrer%26aufirst%3DA.%26aulast%3DVilarrasa%26aufirst%3DE.%26aulast%3DPuig%26aufirst%3DL.%26atitle%3DSecukinumab%2520%2528AIN457%2529%2520for%2520the%2520treatment%2520of%2520psoriasis%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Immunol.%26date%3D2015%26volume%3D11%26spage%3D1177%26epage%3D88%26doi%3D10.1586%2F1744666X.2015.1095092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Griffiths, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Kerkhof, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Secrest, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osuntokun, O. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffernan, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickoloff, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papp, K.</span><span> </span><span class="NLM_article-title">Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">386</span><span class="NLM_x">, </span> <span class="NLM_fpage">541</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1016/S0140-6736(15)60125-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2FS0140-6736%2815%2960125-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=541-51&author=C.+E.+Griffithsauthor=K.+Reichauthor=M.+Lebwohlauthor=P.+van+de+Kerkhofauthor=C.+Paulauthor=A.+Menterauthor=G.+S.+Cameronauthor=J.+Ericksonauthor=L.+Zhangauthor=R.+J.+Secrestauthor=S.+Ballauthor=D.+K.+Braunauthor=O.+O.+Osuntokunauthor=M.+P.+Heffernanauthor=B.+J.+Nickoloffauthor=K.+Papp&title=Comparison+of+ixekizumab+with+etanercept+or+placebo+in+moderate-to-severe+psoriasis+%28UNCOVER-2+and+UNCOVER-3%29%3A+results+from+two+phase+3+randomised+trials&doi=10.1016%2FS0140-6736%2815%2960125-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5h&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2960125-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252960125-8%26sid%3Dliteratum%253Aachs%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%26aulast%3DReich%26aufirst%3DK.%26aulast%3DLebwohl%26aufirst%3DM.%26aulast%3Dvan%2Bde%2BKerkhof%26aufirst%3DP.%26aulast%3DPaul%26aufirst%3DC.%26aulast%3DMenter%26aufirst%3DA.%26aulast%3DCameron%26aufirst%3DG.%2BS.%26aulast%3DErickson%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSecrest%26aufirst%3DR.%2BJ.%26aulast%3DBall%26aufirst%3DS.%26aulast%3DBraun%26aufirst%3DD.%2BK.%26aulast%3DOsuntokun%26aufirst%3DO.%2BO.%26aulast%3DHeffernan%26aufirst%3DM.%2BP.%26aulast%3DNickoloff%26aufirst%3DB.%2BJ.%26aulast%3DPapp%26aufirst%3DK.%26atitle%3DComparison%2520of%2520ixekizumab%2520with%2520etanercept%2520or%2520placebo%2520in%2520moderate-to-severe%2520psoriasis%2520%2528UNCOVER-2%2520and%2520UNCOVER-3%2529%253A%2520results%2520from%2520two%2520phase%25203%2520randomised%2520trials%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26spage%3D541%26epage%3D51%26doi%3D10.1016%2FS0140-6736%2815%2960125-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Strange, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weale, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Band, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellenguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergboer, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwell, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bramon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bumpstead, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casas, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cork, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deloukas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dilthey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncanson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estivill, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzgerald, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giardina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hüffmeier, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irvine, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jankowski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirby, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langford, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lascorz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leslie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallbris, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markus, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathew, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLean, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McManus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mössner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moutsianas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naluai, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nestle, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onoufriadis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perricone, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plomin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pujol, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rautanen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riveira-Munoz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmhofer, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawcer, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schalkwijk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ståhle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tazi-Ahnini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traupe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viswanathan, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worthington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeeuwen, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayday, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burden, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kere, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McVean, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltonen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trembath, R. C.</span><span> </span><span class="NLM_article-title">A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">985</span><span class="NLM_x">–</span> <span class="NLM_lpage">990</span><span class="refDoi"> DOI: 10.1038/ng.694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1038%2Fng.694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=20953190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlSgtbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=985-990&author=A.+Strangeauthor=F.+Caponauthor=C.+C.+Spencerauthor=J.+Knightauthor=M.+E.+Wealeauthor=M.+H.+Allenauthor=A.+Bartonauthor=G.+Bandauthor=C.+Bellenguezauthor=J.+G.+Bergboerauthor=J.+M.+Blackwellauthor=E.+Bramonauthor=S.+J.+Bumpsteadauthor=J.+P.+Casasauthor=M.+J.+Corkauthor=A.+Corvinauthor=P.+Deloukasauthor=A.+Diltheyauthor=A.+Duncansonauthor=S.+Edkinsauthor=X.+Estivillauthor=O.+Fitzgeraldauthor=C.+Freemanauthor=E.+Giardinaauthor=E.+Grayauthor=A.+Hoferauthor=U.+H%C3%BCffmeierauthor=S.+E.+Huntauthor=A.+D.+Irvineauthor=J.+Jankowskiauthor=B.+Kirbyauthor=C.+Langfordauthor=J.+Lascorzauthor=J.+Lemanauthor=S.+Leslieauthor=L.+Mallbrisauthor=H.+S.+Markusauthor=C.+G.+Mathewauthor=W.+H.+McLeanauthor=R.+McManusauthor=R.+M%C3%B6ssnerauthor=L.+Moutsianasauthor=A.+T.+Naluaiauthor=F.+O.+Nestleauthor=G.+Novelliauthor=A.+Onoufriadisauthor=C.+N.+Palmerauthor=C.+Perriconeauthor=M.+Pirinenauthor=R.+Plominauthor=S.+C.+Potterauthor=R.+M.+Pujolauthor=A.+Rautanenauthor=E.+Riveira-Munozauthor=A.+W.+Ryanauthor=W.+Salmhoferauthor=L.+Samuelssonauthor=S.+J.+Sawcerauthor=J.+Schalkwijkauthor=C.+H.+Smithauthor=M.+St%C3%A5hleauthor=Z.+Suauthor=R.+Tazi-Ahniniauthor=H.+Traupeauthor=A.+C.+Viswanathanauthor=R.+B.+Warrenauthor=W.+Wegerauthor=K.+Wolkauthor=N.+Woodauthor=J.+Worthingtonauthor=H.+S.+Youngauthor=P.+L.+Zeeuwenauthor=A.+Haydayauthor=A.+D.+Burdenauthor=C.+E.+Griffithsauthor=J.+Kereauthor=A.+Reisauthor=G.+McVeanauthor=D.+M.+Evansauthor=M.+A.+Brownauthor=J.+N.+Barkerauthor=L.+Peltonenauthor=P.+Donnellyauthor=R.+C.+Trembath&title=A+genome-wide+association+study+identifies+new+psoriasis+susceptibility+loci+and+an+interaction+between+HLA-C+and+ERAP1&doi=10.1038%2Fng.694"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1</span></div><div class="casAuthors">Strange, Amy; Capon, Francesca; Spencer, Chris C. A.; Knight, Jo; Weale, Michael E.; Allen, Michael H.; Barton, Anne; Band, Gavin; Bellenguez, Celine; Bergboer, Judith G. M.; Blackwell, Jenefer M.; Bramon, Elvira; Bumpstead, Suzannah J.; Casas, Juan P.; Cork, Michael J.; Corvin, Aiden; Deloukas, Panos; Dilthey, Alexander; Duncanson, Audrey; Edkins, Sarah; Estivill, Xavier; Fitzgerald, Oliver; Freeman, Colin; Giardina, Emiliano; Gray, Emma; Hofer, Angelika; Hueffmeier, Ulrike; Hunt, Sarah E.; Irvine, Alan D.; Jankowski, Janusz; Kirby, Brian; Langford, Cordelia; Lascorz, Jesus; Leman, Joyce; Leslie, Stephen; Mallbris, Lotus; Markus, Hugh S.; Mathew, Christopher G.; McLean, W. H. Irwin; McManus, Ross; Moessner, Rotraut; Moutsianas, Loukas; Naluai, Asa T.; Nestle, Frank O.; Novelli, Giuseppe; Onoufriadis, Alexandros; Palmer, Colin N. A.; Perricone, Carlo; Pirinen, Matti; Plomin, Robert; Potter, Simon C.; Pujol, Ramon M.; Rautanen, Anna; Riveira-Munoz, Eva; Ryan, Anthony W.; Salmhofer, Wolfgang; Samuelsson, Lena; Sawcer, Stephen J.; Schalkwijk, Joost; Smith, Catherine H.; Stahle, Mona; Su, Zhan; Tazi-Ahnini, Rachid; Traupe, Heiko; Viswanathan, Ananth C.; Warren, Richard B.; Weger, Wolfgang; Wolk, Katarina; Wood, Nicholas; Worthington, Jane; Young, Helen S.; Zeeuwen, Patrick L. J. M.; Hayday, Adrian; Burden, A. David; Griffiths, Christopher E. M.; Kere, Juha; Reis, Andre; McVean, Gilean; Evans, David M.; Brown, Matthew A.; Barker, Jonathan N.; Peltonen, Leena; Donnelly, Peter; Trembath, Richard C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">985-990</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To identify new susceptibility loci for psoriasis, we undertook a genome-wide assocn. study of 594,224 SNPs in 2622 individuals with psoriasis and 5667 controls.  We identified assocns. at 8 previously unreported genomic loci.  7 Loci harbored genes with recognized immune functions (IL28RA, REL, IFIH1, ERAP1, TRAF3IP2, NFKBIA, and TYK2).  These assocns. were replicated in 9079 European samples (six loci with a combined P < 5 × 10-8 and two loci with a combined P < 5 × 10-7).  We also report compelling evidence for an interaction between the HLA-C and ERAP1 loci (combined P = 6.95 × 10-6).  ERAP1 plays an important role in MHC class I peptide processing.  ERAP1 variants only influenced psoriasis susceptibility in individuals carrying the HLA-C risk allele.  Our findings implicate pathways that integrate epidermal barrier dysfunction with innate and adaptive immune dysregulation in psoriasis pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr-vCehUruE7Vg90H21EOLACvtfcHk0lgAiXqqmj1wPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlSgtbjF&md5=4a680242e04e2087a1d186e2c3d71a2b</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1038%2Fng.694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.694%26sid%3Dliteratum%253Aachs%26aulast%3DStrange%26aufirst%3DA.%26aulast%3DCapon%26aufirst%3DF.%26aulast%3DSpencer%26aufirst%3DC.%2BC.%26aulast%3DKnight%26aufirst%3DJ.%26aulast%3DWeale%26aufirst%3DM.%2BE.%26aulast%3DAllen%26aufirst%3DM.%2BH.%26aulast%3DBarton%26aufirst%3DA.%26aulast%3DBand%26aufirst%3DG.%26aulast%3DBellenguez%26aufirst%3DC.%26aulast%3DBergboer%26aufirst%3DJ.%2BG.%26aulast%3DBlackwell%26aufirst%3DJ.%2BM.%26aulast%3DBramon%26aufirst%3DE.%26aulast%3DBumpstead%26aufirst%3DS.%2BJ.%26aulast%3DCasas%26aufirst%3DJ.%2BP.%26aulast%3DCork%26aufirst%3DM.%2BJ.%26aulast%3DCorvin%26aufirst%3DA.%26aulast%3DDeloukas%26aufirst%3DP.%26aulast%3DDilthey%26aufirst%3DA.%26aulast%3DDuncanson%26aufirst%3DA.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DEstivill%26aufirst%3DX.%26aulast%3DFitzgerald%26aufirst%3DO.%26aulast%3DFreeman%26aufirst%3DC.%26aulast%3DGiardina%26aufirst%3DE.%26aulast%3DGray%26aufirst%3DE.%26aulast%3DHofer%26aufirst%3DA.%26aulast%3DH%25C3%25BCffmeier%26aufirst%3DU.%26aulast%3DHunt%26aufirst%3DS.%2BE.%26aulast%3DIrvine%26aufirst%3DA.%2BD.%26aulast%3DJankowski%26aufirst%3DJ.%26aulast%3DKirby%26aufirst%3DB.%26aulast%3DLangford%26aufirst%3DC.%26aulast%3DLascorz%26aufirst%3DJ.%26aulast%3DLeman%26aufirst%3DJ.%26aulast%3DLeslie%26aufirst%3DS.%26aulast%3DMallbris%26aufirst%3DL.%26aulast%3DMarkus%26aufirst%3DH.%2BS.%26aulast%3DMathew%26aufirst%3DC.%2BG.%26aulast%3DMcLean%26aufirst%3DW.%2BH.%26aulast%3DMcManus%26aufirst%3DR.%26aulast%3DM%25C3%25B6ssner%26aufirst%3DR.%26aulast%3DMoutsianas%26aufirst%3DL.%26aulast%3DNaluai%26aufirst%3DA.%2BT.%26aulast%3DNestle%26aufirst%3DF.%2BO.%26aulast%3DNovelli%26aufirst%3DG.%26aulast%3DOnoufriadis%26aufirst%3DA.%26aulast%3DPalmer%26aufirst%3DC.%2BN.%26aulast%3DPerricone%26aufirst%3DC.%26aulast%3DPirinen%26aufirst%3DM.%26aulast%3DPlomin%26aufirst%3DR.%26aulast%3DPotter%26aufirst%3DS.%2BC.%26aulast%3DPujol%26aufirst%3DR.%2BM.%26aulast%3DRautanen%26aufirst%3DA.%26aulast%3DRiveira-Munoz%26aufirst%3DE.%26aulast%3DRyan%26aufirst%3DA.%2BW.%26aulast%3DSalmhofer%26aufirst%3DW.%26aulast%3DSamuelsson%26aufirst%3DL.%26aulast%3DSawcer%26aufirst%3DS.%2BJ.%26aulast%3DSchalkwijk%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DC.%2BH.%26aulast%3DSt%25C3%25A5hle%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DTazi-Ahnini%26aufirst%3DR.%26aulast%3DTraupe%26aufirst%3DH.%26aulast%3DViswanathan%26aufirst%3DA.%2BC.%26aulast%3DWarren%26aufirst%3DR.%2BB.%26aulast%3DWeger%26aufirst%3DW.%26aulast%3DWolk%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DN.%26aulast%3DWorthington%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DH.%2BS.%26aulast%3DZeeuwen%26aufirst%3DP.%2BL.%26aulast%3DHayday%26aufirst%3DA.%26aulast%3DBurden%26aufirst%3DA.%2BD.%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%26aulast%3DKere%26aufirst%3DJ.%26aulast%3DReis%26aufirst%3DA.%26aulast%3DMcVean%26aufirst%3DG.%26aulast%3DEvans%26aufirst%3DD.%2BM.%26aulast%3DBrown%26aufirst%3DM.%2BA.%26aulast%3DBarker%26aufirst%3DJ.%2BN.%26aulast%3DPeltonen%26aufirst%3DL.%26aulast%3DDonnelly%26aufirst%3DP.%26aulast%3DTrembath%26aufirst%3DR.%2BC.%26atitle%3DA%2520genome-wide%2520association%2520study%2520identifies%2520new%2520psoriasis%2520susceptibility%2520loci%2520and%2520an%2520interaction%2520between%2520HLA-C%2520and%2520ERAP1%26jtitle%3DNat.%2520Genet.%26date%3D2010%26volume%3D42%26spage%3D985%26epage%3D990%26doi%3D10.1038%2Fng.694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tsoi, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spain, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellinghaus, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tejasvi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudjonsson, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McManus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schalkwijk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ståhle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burden, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cork, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estivill, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowcock, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worthington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tazi-Ahnini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nestle, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayday, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkelmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijmenga, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langford, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackburn, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strange, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Band, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vukcevic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deloukas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mrowietz, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weidinger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koks, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kingo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esko, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metspalu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voorhees, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weichenthal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wichmann, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandran, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gladman, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kere, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collaborative Association Study of Psoriasis (CASP); Genetic Analysis of Psoriasis Consortium; Psoriasis Association Genetics Extension; Wellcome Trust Case Control Consortium 2.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nair, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abecasis, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elder, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trembath, R. C.</span><span> </span><span class="NLM_article-title">Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1341</span><span class="NLM_x">–</span> <span class="NLM_lpage">1348</span><span class="refDoi"> DOI: 10.1038/ng.2467</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1038%2Fng.2467" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=23143594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Ckt77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2012&pages=1341-1348&author=L.+C.+Tsoiauthor=S.+L.+Spainauthor=J.+Knightauthor=E.+Ellinghausauthor=P.+E.+Stuartauthor=F.+Caponauthor=J.+Dingauthor=Y.+Liauthor=T.+Tejasviauthor=J.+E.+Gudjonssonauthor=H.+M.+Kangauthor=M.+H.+Allenauthor=R.+McManusauthor=G.+Novelliauthor=L.+Samuelssonauthor=J.+Schalkwijkauthor=M.+St%C3%A5hleauthor=A.+D.+Burdenauthor=C.+H.+Smithauthor=M.+J.+Corkauthor=X.+Estivillauthor=A.+M.+Bowcockauthor=G.+G.+Kruegerauthor=W.+Wegerauthor=J.+Worthingtonauthor=R.+Tazi-Ahniniauthor=F.+O.+Nestleauthor=A.+Haydayauthor=P.+Hoffmannauthor=J.+Winkelmannauthor=C.+Wijmengaauthor=C.+Langfordauthor=S.+Edkinsauthor=R.+Andrewsauthor=H.+Blackburnauthor=A.+Strangeauthor=G.+Bandauthor=R.+D.+Pearsonauthor=D.+Vukcevicauthor=C.+C.+Spencerauthor=P.+Deloukasauthor=U.+Mrowietzauthor=S.+Schreiberauthor=S.+Weidingerauthor=S.+Koksauthor=K.+Kingoauthor=T.+Eskoauthor=A.+Metspaluauthor=H.+W.+Limauthor=J.+J.+Voorheesauthor=M.+Weichenthalauthor=H.+E.+Wichmannauthor=V.+Chandranauthor=C.+F.+Rosenauthor=P.+Rahmanauthor=D.+D.+Gladmanauthor=C.+E.+Griffithsauthor=A.+Reisauthor=J.+Kereauthor=Collaborative+Association+Study+of+Psoriasis+%28CASP%29%3B+Genetic+Analysis+of+Psoriasis+Consortium%3B+Psoriasis+Association+Genetics+Extension%3B+Wellcome+Trust+Case+Control+Consortium+2.author=R.+P.+Nairauthor=A.+Frankeauthor=J.+N.+Barkerauthor=G.+R.+Abecasisauthor=J.+T.+Elderauthor=R.+C.+Trembath&title=Identification+of+15+new+psoriasis+susceptibility+loci+highlights+the+role+of+innate+immunity&doi=10.1038%2Fng.2467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity</span></div><div class="casAuthors">Tsoi, Lam C.; Spain, Sarah L.; Knight, Jo; Ellinghaus, Eva; Stuart, Philip E.; Capon, Francesca; Ding, Jun; Li, Yanming; Tejasvi, Trilokraj; Gudjonsson, Johann E.; Kang, Hyun M.; Allen, Michael H.; McManus, Ross; Novelli, Giuseppe; Samuelsson, Lena; Schalkwijk, Joost; Staahle, Mona; Burden, A. David; Smith, Catherine H.; Cork, Michael J.; Estivill, Xavier; Bowcock, Anne M.; Krueger, Gerald G.; Weger, Wolfgang; Worthington, Jane; Tazi-Ahnini, Rachid; Nestle, Frank O.; Hayday, Adrian; Hoffmann, Per; Winkelmann, Juliane; Wijmenga, Cisca; Langford, Cordelia; Edkins, Sarah; Andrews, Robert; Blackburn, Hannah; Strange, Amy; Band, Gavin; Pearson, Richard D.; Vukcevic, Damjan; Spencer, Chris C. A.; Deloukas, Panos; Mrowietz, Ulrich; Schreiber, Stefan; Weidinger, Stephan; Koks, Sulev; Kingo, Kulli; Esko, Tonu; Metspalu, Andres; Lim, Henry W.; Voorhees, John J.; Weichenthal, Michael; Wichmann, H. Erich; Chandran, Vinod; Rosen, Cheryl F.; Rahman, Proton; Gladman, Dafna D.; Griffiths, Christopher E. M.; Reis, Andre; Kere, Juha; Duffin, Kristina Callis; Helms, Cindy; Goldgar, David; Li, Yun; Paschall, Justin; Malloy, Mary J.; Pullinger, Clive R.; Kane, John P.; Gardner, Jennifer; Perlmutter, Amy; Miner, Andrew; Feng, Bing Jian; Hiremagalore, Ravi; Ike, Robert W.; Christophers, Enno; Henseler, Tilo; Ruether, Andreas; Schrodi, Steven J.; Prahalad, Sampath; Guthery, Stephen L.; Fischer, Judith; Liao, Wilson; Kwok, Pui; Menter, Alan; Lathrop, G. Mark; Wise, C.; Begovich, Ann B.; Onoufriadis, Alexandros; Weale, Michael E.; Hofer, Angelika; Salmhofer, Wolfgang; Wolf, Peter; Kainu, Kati; Saarialho-Kere, Ulpu; Suomela, Sari; Badorf, Petra; Hueffmeier, Ulrike; Kurrat, Werner; Kuester, Wolfgang; Lascorz, Jesus; Moessner, Rotraut; Schuermeier-Horst, Funda; Staender, Markward; Traupe, Heiko; Bergboer, Judith G. M.; den Heijer, Martin; van de Kerkhof, Peter C.; Zeeuwen, Patrick L. J. M.; Barnes, Louise; Campbell, Linda E.; Cusack, Caitriona; Coleman, Ciara; Conroy, Judith; Ennis, Sean; Fitzgerald, Oliver; Gallagher, Phil; Irvine, Alan D.; Kirby, Brian; Markham, Trevor; McLean, W. H. Irwin; McPartlin, Joe; Rogers, Sarah F.; Ryan, Anthony W.; Zawirska, Agnieszka; Giardina, Emiliano; Lepre, Tiziana; Perricone, Carlo; Martin-Ezquerra, Gemma; Pujol, Ramon M.; Riveira-Munoz, Eva; Inerot, Annica; Naluai, Aasa T.; Mallbris, Lotus; Wolk, Katarina; Leman, Joyce; Barton, Anne; Warren, Richard B.; Young, Helen S.; Ricano-Ponce, Isis; Trynka, Gosia; Pellett, Fawnda J.; Henschel, Andrew; Aurand, Marin; Bebo, Bruce; Gieger, Christian; Illig, Thomas; Moebus, Susanne; Joeckel, Karl-Heinz; Erbel, Raimund; Donnelly, Peter; Peltonen, Leena; Blackwell, Jenefer M.; Bramon, Elvira; Brown, Matthew A.; Casas, Juan P.; Corvin, Aiden; Craddock, Nicholas; Duncanson, Audrey; Jankowski, Janusz; Markus, Hugh S.; Mathew, Christopher G.; McCarthy, Mark I.; Palmer, Colin N. A.; Plomin, Robert; Rautanen, Anna; Sawcer, Stephen J.; Samani, Nilesh; Viswanathan, Ananth C.; Wood, Nicholas W.; Bellenguez, Celine; Freeman, Colin; Hellenthal, Garrett; Giannoulatou, Eleni; Pirinen, Matti; Su, Zhan; Hunt, Sarah E.; Gwilliam, Rhian; Bumpstead, Suzannah J.; Dronov, Serge; Gillman, Matthew; Gray, Emma; Hammond, Naomi; Jayakumar, Alagurevathi; McCann, Owen T.; Liddle, Jennifer; Perez, Marc L.; Potter, Simon C.; Ravindrarajah, Radhi; Ricketts, Michelle; Waller, Matthew; Weston, Paul; Widaa, Sara; Whittaker, Pamela; Nair, Rajan P.; Franke, Andre; Barker, Jonathan N. W. N.; Abecasis, Goncalo R.; Elder, James T.; Trembath, Richard C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1341-1348</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To gain further insight into the genetic architecture of psoriasis, we conducted a meta-anal. of 3 genome-wide assocn. studies (GWAS) and 2 independent data sets genotyped on the Immunochip, including 10,588 cases and 22,806 controls.  We identified 15 new susceptibility loci, increasing to 36 the no. assocd. with psoriasis in European individuals.  We also identified, using conditional analyses, five independent signals within previously known loci.  The newly identified loci shared with other autoimmune diseases include candidate genes with roles in regulating T-cell function (such as RUNX3, TAGAP and STAT3).  Notably, they included candidate genes whose products are involved in innate host defense, including interferon-mediated antiviral responses (DDX58), macrophage activation (ZC3H12C) and nuclear factor (NF)-κB signaling (CARD14 and CARM1).  These results portend a better understanding of shared and distinctive genetic determinants of immune-mediated inflammatory disorders and emphasize the importance of the skin in innate and acquired host defense.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUdQISitEvYLVg90H21EOLACvtfcHk0liF-t6tkGXHeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Ckt77F&md5=0887b0024bb2fa2d01173b716b507284</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1038%2Fng.2467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2467%26sid%3Dliteratum%253Aachs%26aulast%3DTsoi%26aufirst%3DL.%2BC.%26aulast%3DSpain%26aufirst%3DS.%2BL.%26aulast%3DKnight%26aufirst%3DJ.%26aulast%3DEllinghaus%26aufirst%3DE.%26aulast%3DStuart%26aufirst%3DP.%2BE.%26aulast%3DCapon%26aufirst%3DF.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTejasvi%26aufirst%3DT.%26aulast%3DGudjonsson%26aufirst%3DJ.%2BE.%26aulast%3DKang%26aufirst%3DH.%2BM.%26aulast%3DAllen%26aufirst%3DM.%2BH.%26aulast%3DMcManus%26aufirst%3DR.%26aulast%3DNovelli%26aufirst%3DG.%26aulast%3DSamuelsson%26aufirst%3DL.%26aulast%3DSchalkwijk%26aufirst%3DJ.%26aulast%3DSt%25C3%25A5hle%26aufirst%3DM.%26aulast%3DBurden%26aufirst%3DA.%2BD.%26aulast%3DSmith%26aufirst%3DC.%2BH.%26aulast%3DCork%26aufirst%3DM.%2BJ.%26aulast%3DEstivill%26aufirst%3DX.%26aulast%3DBowcock%26aufirst%3DA.%2BM.%26aulast%3DKrueger%26aufirst%3DG.%2BG.%26aulast%3DWeger%26aufirst%3DW.%26aulast%3DWorthington%26aufirst%3DJ.%26aulast%3DTazi-Ahnini%26aufirst%3DR.%26aulast%3DNestle%26aufirst%3DF.%2BO.%26aulast%3DHayday%26aufirst%3DA.%26aulast%3DHoffmann%26aufirst%3DP.%26aulast%3DWinkelmann%26aufirst%3DJ.%26aulast%3DWijmenga%26aufirst%3DC.%26aulast%3DLangford%26aufirst%3DC.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DAndrews%26aufirst%3DR.%26aulast%3DBlackburn%26aufirst%3DH.%26aulast%3DStrange%26aufirst%3DA.%26aulast%3DBand%26aufirst%3DG.%26aulast%3DPearson%26aufirst%3DR.%2BD.%26aulast%3DVukcevic%26aufirst%3DD.%26aulast%3DSpencer%26aufirst%3DC.%2BC.%26aulast%3DDeloukas%26aufirst%3DP.%26aulast%3DMrowietz%26aufirst%3DU.%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DWeidinger%26aufirst%3DS.%26aulast%3DKoks%26aufirst%3DS.%26aulast%3DKingo%26aufirst%3DK.%26aulast%3DEsko%26aufirst%3DT.%26aulast%3DMetspalu%26aufirst%3DA.%26aulast%3DLim%26aufirst%3DH.%2BW.%26aulast%3DVoorhees%26aufirst%3DJ.%2BJ.%26aulast%3DWeichenthal%26aufirst%3DM.%26aulast%3DWichmann%26aufirst%3DH.%2BE.%26aulast%3DChandran%26aufirst%3DV.%26aulast%3DRosen%26aufirst%3DC.%2BF.%26aulast%3DRahman%26aufirst%3DP.%26aulast%3DGladman%26aufirst%3DD.%2BD.%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%26aulast%3DReis%26aufirst%3DA.%26aulast%3DKere%26aufirst%3DJ.%26aulast%3D%26aulast%3DNair%26aufirst%3DR.%2BP.%26aulast%3DFranke%26aufirst%3DA.%26aulast%3DBarker%26aufirst%3DJ.%2BN.%26aulast%3DAbecasis%26aufirst%3DG.%2BR.%26aulast%3DElder%26aufirst%3DJ.%2BT.%26aulast%3DTrembath%26aufirst%3DR.%2BC.%26atitle%3DIdentification%2520of%252015%2520new%2520psoriasis%2520susceptibility%2520loci%2520highlights%2520the%2520role%2520of%2520innate%2520immunity%26jtitle%3DNat.%2520Genet.%26date%3D2012%26volume%3D44%26spage%3D1341%26epage%3D1348%26doi%3D10.1038%2Fng.2467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Franke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGovern, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radford-Smith, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmad, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lees, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balschun, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bis, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bumpstead, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellinghaus, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Festen, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georges, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haritunians, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jostins, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latiano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathew, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prescott, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raychaudhuri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotter, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schumm, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simms, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijmenga, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldassano, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barclay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayless, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brand, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Büning, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombel, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stronati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Vos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Inca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubinsky, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Florin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franchimont, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gearry, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Gossum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guthery, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halfvarson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verspaget, H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hugot, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karban, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laukens, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrance, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Libioulle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mowat, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panés, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proctor, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regueiro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutgeerts, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sans, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seibold, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinhart, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokkers, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torkvist, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kullak-Ublick, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Targan, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brant, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rioux, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Amato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weersma, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugathasan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansfield, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeire, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duerr, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverberg, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satsangi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annese, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakonarson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, M.</span><span> </span><span class="NLM_article-title">Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1118</span><span class="NLM_x">–</span> <span class="NLM_lpage">1125</span><span class="refDoi"> DOI: 10.1038/ng.717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1038%2Fng.717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=21102463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGhsrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=1118-1125&author=A.+Frankeauthor=D.+P.+McGovernauthor=J.+C.+Barrettauthor=K.+Wangauthor=G.+L.+Radford-Smithauthor=T.+Ahmadauthor=C.+W.+Leesauthor=T.+Balschunauthor=J.+Leeauthor=R.+Robertsauthor=C.+A.+Andersonauthor=J.+C.+Bisauthor=S.+Bumpsteadauthor=D.+Ellinghausauthor=E.+M.+Festenauthor=M.+Georgesauthor=T.+Greenauthor=T.+Harituniansauthor=L.+Jostinsauthor=A.+Latianoauthor=C.+G.+Mathewauthor=G.+W.+Montgomeryauthor=N.+J.+Prescottauthor=S.+Raychaudhuriauthor=J.+I.+Rotterauthor=P.+Schummauthor=Y.+Sharmaauthor=L.+A.+Simmsauthor=K.+D.+Taylorauthor=D.+Whitemanauthor=C.+Wijmengaauthor=R.+N.+Baldassanoauthor=M.+Barclayauthor=T.+M.+Baylessauthor=S.+Brandauthor=C.+B%C3%BCningauthor=A.+Cohenauthor=J.+F.+Colombelauthor=M.+Cottoneauthor=L.+Stronatiauthor=T.+Densonauthor=M.+De+Vosauthor=R.+D%E2%80%99Incaauthor=M.+Dubinskyauthor=C.+Edwardsauthor=T.+Florinauthor=D.+Franchimontauthor=R.+Gearryauthor=J.+Glasauthor=A.+Van+Gossumauthor=S.+L.+Gutheryauthor=J.+Halfvarsonauthor=H.+W.+Verspagetauthor=J.+P.+Hugotauthor=A.+Karbanauthor=D.+Laukensauthor=I.+Lawranceauthor=M.+Lemannauthor=A.+Levineauthor=C.+Libioulleauthor=E.+Louisauthor=C.+Mowatauthor=W.+Newmanauthor=J.+Pan%C3%A9sauthor=A.+Phillipsauthor=D.+D.+Proctorauthor=M.+Regueiroauthor=R.+Russellauthor=P.+Rutgeertsauthor=J.+Sandersonauthor=M.+Sansauthor=F.+Seiboldauthor=A.+H.+Steinhartauthor=P.+C.+Stokkersauthor=L.+Torkvistauthor=G.+Kullak-Ublickauthor=D.+Wilsonauthor=T.+Waltersauthor=S.+R.+Targanauthor=S.+R.+Brantauthor=J.+D.+Riouxauthor=M.+D%E2%80%99Amatoauthor=R.+K.+Weersmaauthor=S.+Kugathasanauthor=A.+M.+Griffithsauthor=J.+C.+Mansfieldauthor=S.+Vermeireauthor=R.+H.+Duerrauthor=M.+S.+Silverbergauthor=J.+Satsangiauthor=S.+Schreiberauthor=J.+H.+Choauthor=V.+Anneseauthor=H.+Hakonarsonauthor=M.+J.+Dalyauthor=M.+Parkes&title=Genome-wide+meta-analysis+increases+to+71+the+number+of+confirmed+Crohn%E2%80%99s+disease+susceptibility+loci&doi=10.1038%2Fng.717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci</span></div><div class="casAuthors">Franke, Andre; McGovern, Dermot P. B.; Barrett, Jeffrey C.; Wang, Kai; Radford-Smith, Graham L.; Ahmad, Tariq; Lees, Charlie W.; Balschun, Tobias; Lee, James; Roberts, Rebecca; Anderson, Carl A.; Bis, Joshua C.; Bumpstead, Suzanne; Ellinghaus, David; Festen, Eleonora M.; Georges, Michel; Green, Todd; Haritunians, Talin; Jostins, Luke; Latiano, Anna; Mathew, Christopher G.; Montgomery, Grant W.; Prescott, Natalie J.; Raychaudhuri, Soumya; Rotter, Jerome I.; Schumm, Philip; Sharma, Yashoda; Simms, Lisa A.; Taylor, Kent D.; Whiteman, David; Wijmenga, Cisca; Baldassano, Robert N.; Barclay, Murray; Bayless, Theodore M.; Brand, Stephan; Buening, Carsten; Cohen, Albert; Colombel, Jean-Frederick; Cottone, Mario; Stronati, Laura; Denson, Ted; De Vos, Martine; D'Inca, Renata; Dubinsky, Marla; Edwards, Cathryn; Florin, Tim; Franchimont, Denis; Gearry, Richard; Glas, Juergen; Van Gossum, Andre; Guthery, Stephen L.; Halfvarson, Jonas; Verspaget, Hein W.; Hugot, Jean-Pierre; Karban, Amir; Laukens, Debby; Lawrance, Ian; Lemann, Marc; Levine, Arie; Libioulle, Cecile; Louis, Edouard; Mowat, Craig; Newman, William; Panes, Julian; Phillips, Anne; Proctor, Deborah D.; Regueiro, Miguel; Russell, Richard; Rutgeerts, Paul; Sanderson, Jeremy; Sans, Miquel; Seibold, Frank; Steinhart, A. Hillary; Stokkers, Pieter C. F.; Torkvist, Leif; Kullak-Ublick, Gerd; Wilson, David; Walters, Thomas; Targan, Stephan R.; Brant, Steven R.; Rioux, John D.; D'Amato, Mauro; Weersma, Rinse K.; Kugathasan, Subra; Griffiths, Anne M.; Mansfield, John C.; Vermeire, Severine; Duerr, Richard H.; Silverberg, Mark S.; Satsangi, Jack; Schreiber, Stefan; Cho, Judy H.; Annese, Vito; Hakonarson, Hakon; Daly, Mark J.; Parkes, Miles</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1118-1125</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We undertook a meta-anal. of six Crohn's disease genome-wide assocn. studies (GWAS) comprising 6,333 affected individuals (cases) and 15,056 controls and followed up the top assocn. signals in 15,694 cases, 14,026 controls and 414 parent-offspring trios.  We identified 30 new susceptibility loci meeting genome-wide significance (P < 5 × 10-8).  A series of in silico analyses highlighted particular genes within these loci and, together with manual curation, implicated functionally interesting candidate genes including SMAD3, ERAP2, IL10, IL2RA, TYK2, FUT2, DNMT3A, DENND1B, BACH2 and TAGAP.  Combined with previously confirmed loci, these results identify 71 distinct loci with genome-wide significant evidence for assocn. with Crohn's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1uFTYE1cn1bVg90H21EOLACvtfcHk0liAuHxeYRvY3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGhsrzO&md5=902e2b2f3ffbeef3a3a75f3a757d4350</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fng.717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.717%26sid%3Dliteratum%253Aachs%26aulast%3DFranke%26aufirst%3DA.%26aulast%3DMcGovern%26aufirst%3DD.%2BP.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DRadford-Smith%26aufirst%3DG.%2BL.%26aulast%3DAhmad%26aufirst%3DT.%26aulast%3DLees%26aufirst%3DC.%2BW.%26aulast%3DBalschun%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DR.%26aulast%3DAnderson%26aufirst%3DC.%2BA.%26aulast%3DBis%26aufirst%3DJ.%2BC.%26aulast%3DBumpstead%26aufirst%3DS.%26aulast%3DEllinghaus%26aufirst%3DD.%26aulast%3DFesten%26aufirst%3DE.%2BM.%26aulast%3DGeorges%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DT.%26aulast%3DHaritunians%26aufirst%3DT.%26aulast%3DJostins%26aufirst%3DL.%26aulast%3DLatiano%26aufirst%3DA.%26aulast%3DMathew%26aufirst%3DC.%2BG.%26aulast%3DMontgomery%26aufirst%3DG.%2BW.%26aulast%3DPrescott%26aufirst%3DN.%2BJ.%26aulast%3DRaychaudhuri%26aufirst%3DS.%26aulast%3DRotter%26aufirst%3DJ.%2BI.%26aulast%3DSchumm%26aufirst%3DP.%26aulast%3DSharma%26aufirst%3DY.%26aulast%3DSimms%26aufirst%3DL.%2BA.%26aulast%3DTaylor%26aufirst%3DK.%2BD.%26aulast%3DWhiteman%26aufirst%3DD.%26aulast%3DWijmenga%26aufirst%3DC.%26aulast%3DBaldassano%26aufirst%3DR.%2BN.%26aulast%3DBarclay%26aufirst%3DM.%26aulast%3DBayless%26aufirst%3DT.%2BM.%26aulast%3DBrand%26aufirst%3DS.%26aulast%3DB%25C3%25BCning%26aufirst%3DC.%26aulast%3DCohen%26aufirst%3DA.%26aulast%3DColombel%26aufirst%3DJ.%2BF.%26aulast%3DCottone%26aufirst%3DM.%26aulast%3DStronati%26aufirst%3DL.%26aulast%3DDenson%26aufirst%3DT.%26aulast%3DDe%2BVos%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Inca%26aufirst%3DR.%26aulast%3DDubinsky%26aufirst%3DM.%26aulast%3DEdwards%26aufirst%3DC.%26aulast%3DFlorin%26aufirst%3DT.%26aulast%3DFranchimont%26aufirst%3DD.%26aulast%3DGearry%26aufirst%3DR.%26aulast%3DGlas%26aufirst%3DJ.%26aulast%3DVan%2BGossum%26aufirst%3DA.%26aulast%3DGuthery%26aufirst%3DS.%2BL.%26aulast%3DHalfvarson%26aufirst%3DJ.%26aulast%3DVerspaget%26aufirst%3DH.%2BW.%26aulast%3DHugot%26aufirst%3DJ.%2BP.%26aulast%3DKarban%26aufirst%3DA.%26aulast%3DLaukens%26aufirst%3DD.%26aulast%3DLawrance%26aufirst%3DI.%26aulast%3DLemann%26aufirst%3DM.%26aulast%3DLevine%26aufirst%3DA.%26aulast%3DLibioulle%26aufirst%3DC.%26aulast%3DLouis%26aufirst%3DE.%26aulast%3DMowat%26aufirst%3DC.%26aulast%3DNewman%26aufirst%3DW.%26aulast%3DPan%25C3%25A9s%26aufirst%3DJ.%26aulast%3DPhillips%26aufirst%3DA.%26aulast%3DProctor%26aufirst%3DD.%2BD.%26aulast%3DRegueiro%26aufirst%3DM.%26aulast%3DRussell%26aufirst%3DR.%26aulast%3DRutgeerts%26aufirst%3DP.%26aulast%3DSanderson%26aufirst%3DJ.%26aulast%3DSans%26aufirst%3DM.%26aulast%3DSeibold%26aufirst%3DF.%26aulast%3DSteinhart%26aufirst%3DA.%2BH.%26aulast%3DStokkers%26aufirst%3DP.%2BC.%26aulast%3DTorkvist%26aufirst%3DL.%26aulast%3DKullak-Ublick%26aufirst%3DG.%26aulast%3DWilson%26aufirst%3DD.%26aulast%3DWalters%26aufirst%3DT.%26aulast%3DTargan%26aufirst%3DS.%2BR.%26aulast%3DBrant%26aufirst%3DS.%2BR.%26aulast%3DRioux%26aufirst%3DJ.%2BD.%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DM.%26aulast%3DWeersma%26aufirst%3DR.%2BK.%26aulast%3DKugathasan%26aufirst%3DS.%26aulast%3DGriffiths%26aufirst%3DA.%2BM.%26aulast%3DMansfield%26aufirst%3DJ.%2BC.%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DDuerr%26aufirst%3DR.%2BH.%26aulast%3DSilverberg%26aufirst%3DM.%2BS.%26aulast%3DSatsangi%26aufirst%3DJ.%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DJ.%2BH.%26aulast%3DAnnese%26aufirst%3DV.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DDaly%26aufirst%3DM.%2BJ.%26aulast%3DParkes%26aufirst%3DM.%26atitle%3DGenome-wide%2520meta-analysis%2520increases%2520to%252071%2520the%2520number%2520of%2520confirmed%2520Crohn%25E2%2580%2599s%2520disease%2520susceptibility%2520loci%26jtitle%3DNat.%2520Genet.%26date%3D2010%26volume%3D42%26spage%3D1118%26epage%3D1125%26doi%3D10.1038%2Fng.717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_contrib-group">Bahlo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broadley, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foote, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilpatrick, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lechner-Scott, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moscato, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perreau, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubio, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stankovich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, B. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csurhes, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danoy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drysdale, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Field, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foote, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guru, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMorran, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCallum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merriman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merriman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pryce, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tajouri, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkins, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubio, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahlo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browning, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browning, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubio, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stankovich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broadley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butzkueven, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kermode, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marriott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heard, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pender, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tubridy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lechner-Scott, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, B. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willoughby, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilpatrick, T. J.</span><span> </span><span class="NLM_article-title">Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">824</span><span class="NLM_x">–</span> <span class="NLM_lpage">828</span><span class="refDoi"> DOI: 10.1038/ng.396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1038%2Fng.396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=19525955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnt1ShsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2009&pages=824-828&author=M.+Bahloauthor=D.+R.+Boothauthor=S.+A.+Broadleyauthor=M.+A.+Brownauthor=S.+J.+Footeauthor=L.+R.+Griffithsauthor=T.+J.+Kilpatrickauthor=J.+Lechner-Scottauthor=P.+Moscatoauthor=V.+M.+Perreauauthor=J.+P.+Rubioauthor=R.+J.+Scottauthor=J.+Stankovichauthor=G.+J.+Stewartauthor=B.+V.+Taylorauthor=J.+Wileyauthor=M.+A.+Brownauthor=D.+R.+Boothauthor=G.+Clarkeauthor=M.+B.+Coxauthor=P.+A.+Csurhesauthor=P.+Danoyauthor=K.+Drysdaleauthor=J.+Fieldauthor=S.+J.+Footeauthor=J.+M.+Greerauthor=L.+R.+Griffithsauthor=P.+Guruauthor=J.+Hadlerauthor=B.+J.+McMorranauthor=C.+J.+Jensenauthor=L.+J.+Johnsonauthor=R.+McCallumauthor=M.+Merrimanauthor=T.+Merrimanauthor=K.+Pryceauthor=R.+J.+Scottauthor=G.+J.+Stewartauthor=L.+Tajouriauthor=E.+J.+Wilkinsauthor=J.+P.+Rubioauthor=M.+Bahloauthor=M.+A.+Brownauthor=B.+L.+Browningauthor=S.+R.+Browningauthor=D.+Pereraauthor=J.+P.+Rubioauthor=J.+Stankovichauthor=S.+Broadleyauthor=H.+Butzkuevenauthor=W.+M.+Carrollauthor=C.+Chapmanauthor=A.+G.+Kermodeauthor=M.+Marriottauthor=D.+Masonauthor=R.+N.+Heardauthor=M.+P.+Penderauthor=M.+Sleeauthor=N.+Tubridyauthor=J.+Lechner-Scottauthor=B.+V.+Taylorauthor=E.+Willoughbyauthor=T.+J.+Kilpatrick&title=Genome-wide+association+study+identifies+new+multiple+sclerosis+susceptibility+loci+on+chromosomes+12+and+20&doi=10.1038%2Fng.396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20</span></div><div class="casAuthors">Bahlo, Melanie; Booth, David R.; Broadley, Simon A.; Brown, Matthew A.; Foote, Simon J.; Griffiths, Lyn R.; Kilpatrick, Trevor J.; Lechner-Scott, Jeanette; Moscato, Pablo; Perreau, Victoria M.; Rubio, Justin P.; Scott, Rodney J.; Stankovich, Jim; Stewart, Graeme J.; Taylor, Bruce V.; Wiley, James; Brown, Matthew A.; Booth, David R.; Clarke, Glynnis; Cox, Mathew B.; Csurhes, Peter A.; Danoy, Patrick; Drysdale, Karen; Field, Judith; Foote, Simon J.; Greer, Judith M.; Griffiths, Lyn R.; Guru, Preethi; Hadler, Johanna; McMorran, Brendan J.; Jensen, Cathy J.; Johnson, Laura J.; McCallum, Ruth; Merriman, Marilyn; Merriman, Tony; Pryce, Karen; Scott, Rodney J.; Stewart, Graeme J.; Tajouri, Lotfi; Wilkins, Ella J.; Rubio, Justin P.; Bahlo, Melanie; Brown, Matthew A.; Browning, Brian L.; Browning, Sharon R.; Perera, Devindri; Rubio, Justin P.; Stankovich, Jim; Broadley, Simon; Butzkueven, Helmut; Carroll, William M.; Chapman, Caron; Kermode, Allan G.; Marriott, Mark; Mason, Deborah; Heard, Robert N.; Pender, Michael P.; Slee, Mark; Tubridy, Niall; Lechner-Scott, Jeanette; Taylor, Bruce V.; Willoughby, Ernest; Kilpatrick, Trevor J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">824-828</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To identify multiple sclerosis (MS) susceptibility loci, we conducted a genome-wide assocn. study (GWAS) in 1618 cases and used shared data for 3413 controls.  We performed replication in an independent set of 2256 cases and 2310 controls, for a total of 3874 cases and 5723 controls.  We identified risk-assocd. SNPs on chromosome 12q13-14 (rs703842, P = 5.4 × 10-11; rs10876994, P = 2.7 × 10-10; rs12368653, P = 1.0 × 10-7) and upstream of CD40 on chromosome 20q13 (rs6074022, P = 1.3 × 10-7; rs1569723, P = 2.9 × 10-7).  Both loci are also assocd. with other autoimmune diseases.  We also replicated several known MS assocns. (HLA-DR15, P = 7.0 × 10-184; CD58, P = 9.6 × 10-8; EVI5-RPL5, P = 2.5 × 10-6; IL2RA, P = 7.4 × 10-6; CLEC16A, P = 1.1 × 10-4; IL7R, P = 1.3 × 10-3; TYK2, P = 3.5 × 10-3) and obsd. a statistical interaction between SNPs in EVI5-RPL5 and HLA-DR15 (P = 0.001).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZy7n4G_foY7Vg90H21EOLACvtfcHk0liY0YYpRJvUNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1ShsL8%253D&md5=532ff8b3e608398c2e1be19bcc03577f</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1038%2Fng.396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.396%26sid%3Dliteratum%253Aachs%26aulast%3DBahlo%26aufirst%3DM.%26aulast%3DBooth%26aufirst%3DD.%2BR.%26aulast%3DBroadley%26aufirst%3DS.%2BA.%26aulast%3DBrown%26aufirst%3DM.%2BA.%26aulast%3DFoote%26aufirst%3DS.%2BJ.%26aulast%3DGriffiths%26aufirst%3DL.%2BR.%26aulast%3DKilpatrick%26aufirst%3DT.%2BJ.%26aulast%3DLechner-Scott%26aufirst%3DJ.%26aulast%3DMoscato%26aufirst%3DP.%26aulast%3DPerreau%26aufirst%3DV.%2BM.%26aulast%3DRubio%26aufirst%3DJ.%2BP.%26aulast%3DScott%26aufirst%3DR.%2BJ.%26aulast%3DStankovich%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DG.%2BJ.%26aulast%3DTaylor%26aufirst%3DB.%2BV.%26aulast%3DWiley%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DM.%2BA.%26aulast%3DBooth%26aufirst%3DD.%2BR.%26aulast%3DClarke%26aufirst%3DG.%26aulast%3DCox%26aufirst%3DM.%2BB.%26aulast%3DCsurhes%26aufirst%3DP.%2BA.%26aulast%3DDanoy%26aufirst%3DP.%26aulast%3DDrysdale%26aufirst%3DK.%26aulast%3DField%26aufirst%3DJ.%26aulast%3DFoote%26aufirst%3DS.%2BJ.%26aulast%3DGreer%26aufirst%3DJ.%2BM.%26aulast%3DGriffiths%26aufirst%3DL.%2BR.%26aulast%3DGuru%26aufirst%3DP.%26aulast%3DHadler%26aufirst%3DJ.%26aulast%3DMcMorran%26aufirst%3DB.%2BJ.%26aulast%3DJensen%26aufirst%3DC.%2BJ.%26aulast%3DJohnson%26aufirst%3DL.%2BJ.%26aulast%3DMcCallum%26aufirst%3DR.%26aulast%3DMerriman%26aufirst%3DM.%26aulast%3DMerriman%26aufirst%3DT.%26aulast%3DPryce%26aufirst%3DK.%26aulast%3DScott%26aufirst%3DR.%2BJ.%26aulast%3DStewart%26aufirst%3DG.%2BJ.%26aulast%3DTajouri%26aufirst%3DL.%26aulast%3DWilkins%26aufirst%3DE.%2BJ.%26aulast%3DRubio%26aufirst%3DJ.%2BP.%26aulast%3DBahlo%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%2BA.%26aulast%3DBrowning%26aufirst%3DB.%2BL.%26aulast%3DBrowning%26aufirst%3DS.%2BR.%26aulast%3DPerera%26aufirst%3DD.%26aulast%3DRubio%26aufirst%3DJ.%2BP.%26aulast%3DStankovich%26aufirst%3DJ.%26aulast%3DBroadley%26aufirst%3DS.%26aulast%3DButzkueven%26aufirst%3DH.%26aulast%3DCarroll%26aufirst%3DW.%2BM.%26aulast%3DChapman%26aufirst%3DC.%26aulast%3DKermode%26aufirst%3DA.%2BG.%26aulast%3DMarriott%26aufirst%3DM.%26aulast%3DMason%26aufirst%3DD.%26aulast%3DHeard%26aufirst%3DR.%2BN.%26aulast%3DPender%26aufirst%3DM.%2BP.%26aulast%3DSlee%26aufirst%3DM.%26aulast%3DTubridy%26aufirst%3DN.%26aulast%3DLechner-Scott%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DB.%2BV.%26aulast%3DWilloughby%26aufirst%3DE.%26aulast%3DKilpatrick%26aufirst%3DT.%2BJ.%26atitle%3DGenome-wide%2520association%2520study%2520identifies%2520new%2520multiple%2520sclerosis%2520susceptibility%2520loci%2520on%2520chromosomes%252012%2520and%252020%26jtitle%3DNat.%2520Genet.%26date%3D2009%26volume%3D41%26spage%3D824%26epage%3D828%26doi%3D10.1038%2Fng.396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ban, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorentzen, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihalova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingram, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heard, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogaert, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubois, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbo, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celius, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spurkland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strange, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudbridge, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wason, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Jager, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hafler, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rioux, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivinson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pericak-Vance, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oksenberg, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauser, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawcer, S.</span><span> </span><span class="NLM_article-title">Wellcome Trust Case-Control Consortium (WTCCC).; Compston A. Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor</span> <span class="citation_source-journal">Eur. J. Hum. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1309</span><span class="NLM_x">–</span> <span class="NLM_lpage">1313</span><span class="refDoi"> DOI: 10.1038/ejhg.2009.41</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1038%2Fejhg.2009.41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=19293837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFKnsLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=1309-1313&author=M.+Banauthor=A.+Gorisauthor=A.+R.+Lorentzenauthor=A.+Bakerauthor=T.+Mihalovaauthor=G.+Ingramauthor=D.+R.+Boothauthor=R.+N.+Heardauthor=G.+J.+Stewartauthor=E.+Bogaertauthor=B.+Duboisauthor=H.+F.+Harboauthor=E.+G.+Celiusauthor=A.+Spurklandauthor=R.+Strangeauthor=C.+Hawkinsauthor=N.+P.+Robertsonauthor=F.+Dudbridgeauthor=J.+Wasonauthor=P.+L.+De+Jagerauthor=D.+Haflerauthor=J.+D.+Riouxauthor=A.+J.+Ivinsonauthor=J.+L.+McCauleyauthor=M.+Pericak-Vanceauthor=J.+R.+Oksenbergauthor=S.+L.+Hauserauthor=D.+Sextonauthor=J.+Hainesauthor=S.+Sawcer&title=Wellcome+Trust+Case-Control+Consortium+%28WTCCC%29.%3B+Compston+A.+Replication+analysis+identifies+TYK2+as+a+multiple+sclerosis+susceptibility+factor&doi=10.1038%2Fejhg.2009.41"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor</span></div><div class="casAuthors">Ban, Maria; Goris, An; Lorentzen, Aslaug R.; Baker, Amie; Mihalova, Tania; Ingram, Gillian; Booth, David R.; Heard, Robert N.; Stewart, Graeme J.; Bogaert, Elke; Dubois, Benedicte; Harbo, Hanne F.; Celius, Elisabeth G.; Spurkland, Anne; Strange, Richard; Hawkins, Clive; Robertson, Neil P.; Dudbridge, Frank; Wason, James; De Jager, Philip L.; Hafler, David; Rioux, John D.; Ivinson, Adrian J.; McCauley, Jacob L.; Pericak-Vance, Margaret; Oksenberg, Jorge R.; Hauser, Stephen L.; Sexton, David; Haines, Jonathan; Sawcer, Stephen; Compston, Alastair</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1309-1313</span>CODEN:
                <span class="NLM_cas:coden">EJHGEU</span>;
        ISSN:<span class="NLM_cas:issn">1018-4813</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In a recent genome-wide assocn. study (GWAS) based on 12 374 non-synonymous single nucleotide polymorphisms we identified a no. of candidate multiple sclerosis susceptibility genes.  Here, we describe the extended anal. of 17 of these loci undertaken using an addnl. 4234 patients, 2983 controls and 2053 trio families.  In the final anal. combining all available data, we found that evidence for assocn. was substantially increased for one of the 17 loci, rs34536443 from the tyrosine kinase 2 (TYK2) gene (P = 2.7 × 10-6, odds ratio=1.32 (1.17-1.47)).  This single nucleotide polymorphism results in an amino acid substitution (proline to alanine) in the kinase domain of TYK2, which is predicted to influence the levels of phosphorylation and therefore activity of the protein and so is likely to have a functional role in multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy4Sk3LPBK-LVg90H21EOLACvtfcHk0lhFd1XTdsiu1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFKnsLbP&md5=b4950e39098927ecdb09dee395c7bc52</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1038%2Fejhg.2009.41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fejhg.2009.41%26sid%3Dliteratum%253Aachs%26aulast%3DBan%26aufirst%3DM.%26aulast%3DGoris%26aufirst%3DA.%26aulast%3DLorentzen%26aufirst%3DA.%2BR.%26aulast%3DBaker%26aufirst%3DA.%26aulast%3DMihalova%26aufirst%3DT.%26aulast%3DIngram%26aufirst%3DG.%26aulast%3DBooth%26aufirst%3DD.%2BR.%26aulast%3DHeard%26aufirst%3DR.%2BN.%26aulast%3DStewart%26aufirst%3DG.%2BJ.%26aulast%3DBogaert%26aufirst%3DE.%26aulast%3DDubois%26aufirst%3DB.%26aulast%3DHarbo%26aufirst%3DH.%2BF.%26aulast%3DCelius%26aufirst%3DE.%2BG.%26aulast%3DSpurkland%26aufirst%3DA.%26aulast%3DStrange%26aufirst%3DR.%26aulast%3DHawkins%26aufirst%3DC.%26aulast%3DRobertson%26aufirst%3DN.%2BP.%26aulast%3DDudbridge%26aufirst%3DF.%26aulast%3DWason%26aufirst%3DJ.%26aulast%3DDe%2BJager%26aufirst%3DP.%2BL.%26aulast%3DHafler%26aufirst%3DD.%26aulast%3DRioux%26aufirst%3DJ.%2BD.%26aulast%3DIvinson%26aufirst%3DA.%2BJ.%26aulast%3DMcCauley%26aufirst%3DJ.%2BL.%26aulast%3DPericak-Vance%26aufirst%3DM.%26aulast%3DOksenberg%26aufirst%3DJ.%2BR.%26aulast%3DHauser%26aufirst%3DS.%2BL.%26aulast%3DSexton%26aufirst%3DD.%26aulast%3DHaines%26aufirst%3DJ.%26aulast%3DSawcer%26aufirst%3DS.%26atitle%3DWellcome%2520Trust%2520Case-Control%2520Consortium%2520%2528WTCCC%2529.%253B%2520Compston%2520A.%2520Replication%2520analysis%2520identifies%2520TYK2%2520as%2520a%2520multiple%2520sclerosis%2520susceptibility%2520factor%26jtitle%3DEur.%2520J.%2520Hum.%2520Genet.%26date%3D2009%26volume%3D17%26spage%3D1309%26epage%3D1313%26doi%3D10.1038%2Fejhg.2009.41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Suarez-Gestal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calaza, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endreffy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pullmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ordi-Ros, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebastiani, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruzickova, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jose Santos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papasteriades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skopouli, F. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suarez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanco, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Alfonso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bijl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreira, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliaresi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Reino, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, A.</span><span> </span><span class="NLM_article-title">European Consortium of SLE DNA Collections. Replication of recently identified systemic lupus erythematosus genetic associations: a case-control study</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">R69</span><span class="refDoi"> DOI: 10.1186/ar2698</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1186%2Far2698" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=R69&author=M.+Suarez-Gestalauthor=M.+Calazaauthor=E.+Endreffyauthor=R.+Pullmannauthor=J.+Ordi-Rosauthor=G.+D.+Sebastianiauthor=S.+Ruzickovaauthor=M.+Jose+Santosauthor=C.+Papasteriadesauthor=M.+Marchiniauthor=F.+N.+Skopouliauthor=A.+Suarezauthor=F.+J.+Blancoauthor=S.+D%E2%80%99Alfonsoauthor=M.+Bijlauthor=P.+Carreiraauthor=T.+Witteauthor=S.+Migliaresiauthor=J.+J.+Gomez-Reinoauthor=A.+Gonzalez&title=European+Consortium+of+SLE+DNA+Collections.+Replication+of+recently+identified+systemic+lupus+erythematosus+genetic+associations%3A+a+case-control+study&doi=10.1186%2Far2698"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1186%2Far2698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Far2698%26sid%3Dliteratum%253Aachs%26aulast%3DSuarez-Gestal%26aufirst%3DM.%26aulast%3DCalaza%26aufirst%3DM.%26aulast%3DEndreffy%26aufirst%3DE.%26aulast%3DPullmann%26aufirst%3DR.%26aulast%3DOrdi-Ros%26aufirst%3DJ.%26aulast%3DSebastiani%26aufirst%3DG.%2BD.%26aulast%3DRuzickova%26aufirst%3DS.%26aulast%3DJose%2BSantos%26aufirst%3DM.%26aulast%3DPapasteriades%26aufirst%3DC.%26aulast%3DMarchini%26aufirst%3DM.%26aulast%3DSkopouli%26aufirst%3DF.%2BN.%26aulast%3DSuarez%26aufirst%3DA.%26aulast%3DBlanco%26aufirst%3DF.%2BJ.%26aulast%3DD%25E2%2580%2599Alfonso%26aufirst%3DS.%26aulast%3DBijl%26aufirst%3DM.%26aulast%3DCarreira%26aufirst%3DP.%26aulast%3DWitte%26aufirst%3DT.%26aulast%3DMigliaresi%26aufirst%3DS.%26aulast%3DGomez-Reino%26aufirst%3DJ.%2BJ.%26aulast%3DGonzalez%26aufirst%3DA.%26atitle%3DEuropean%2520Consortium%2520of%2520SLE%2520DNA%2520Collections.%2520Replication%2520of%2520recently%2520identified%2520systemic%2520lupus%2520erythematosus%2520genetic%2520associations%253A%2520a%2520case-control%2520study%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2009%26volume%3D11%26spage%3DR69%26doi%3D10.1186%2Far2698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cunninghame Graham, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhangale, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Criswell, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Syvänen, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rönnblom, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behrens, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyse, T. J.</span><span> </span><span class="NLM_article-title">Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus</span> <span class="citation_source-journal">PLoS Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1002341</span><span class="refDoi"> DOI: 10.1371/journal.pgen.1002341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1371%2Fjournal.pgen.1002341" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=e1002341&author=D.+S.+Cunninghame+Grahamauthor=D.+L.+Morrisauthor=T.+R.+Bhangaleauthor=L.+A.+Criswellauthor=A.+C.+Syv%C3%A4nenauthor=L.+R%C3%B6nnblomauthor=T.+W.+Behrensauthor=R.+R.+Grahamauthor=T.+J.+Vyse&title=Association+of+NCF2%2C+IKZF1%2C+IRF8%2C+IFIH1%2C+and+TYK2+with+systemic+lupus+erythematosus&doi=10.1371%2Fjournal.pgen.1002341"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1002341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1002341%26sid%3Dliteratum%253Aachs%26aulast%3DCunninghame%2BGraham%26aufirst%3DD.%2BS.%26aulast%3DMorris%26aufirst%3DD.%2BL.%26aulast%3DBhangale%26aufirst%3DT.%2BR.%26aulast%3DCriswell%26aufirst%3DL.%2BA.%26aulast%3DSyv%25C3%25A4nen%26aufirst%3DA.%2BC.%26aulast%3DR%25C3%25B6nnblom%26aufirst%3DL.%26aulast%3DBehrens%26aufirst%3DT.%2BW.%26aulast%3DGraham%26aufirst%3DR.%2BR.%26aulast%3DVyse%26aufirst%3DT.%2BJ.%26atitle%3DAssociation%2520of%2520NCF2%252C%2520IKZF1%252C%2520IRF8%252C%2520IFIH1%252C%2520and%2520TYK2%2520with%2520systemic%2520lupus%2520erythematosus%26jtitle%3DPLoS%2520Genet.%26date%3D2011%26volume%3D7%26spage%3De1002341%26doi%3D10.1371%2Fjournal.pgen.1002341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Parganas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stravopodis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marine, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teglund, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanin, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colamonici, O. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">vanDeursen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosveld, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, J. N.</span><span> </span><span class="NLM_article-title">Jak2 is essential for signaling through a variety of cytokine receptors</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">395</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)81167-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2FS0092-8674%2800%2981167-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=385-395&author=E.+Parganasauthor=D.+Wangauthor=D.+Stravopodisauthor=D.+J.+Tophamauthor=J.+C.+Marineauthor=S.+Teglundauthor=E.+F.+Vaninauthor=S.+Bodnerauthor=O.+R.+Colamoniciauthor=J.+M.+vanDeursenauthor=G.+Grosveldauthor=J.+N.+Ihle&title=Jak2+is+essential+for+signaling+through+a+variety+of+cytokine+receptors&doi=10.1016%2FS0092-8674%2800%2981167-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981167-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981167-8%26sid%3Dliteratum%253Aachs%26aulast%3DParganas%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DStravopodis%26aufirst%3DD.%26aulast%3DTopham%26aufirst%3DD.%2BJ.%26aulast%3DMarine%26aufirst%3DJ.%2BC.%26aulast%3DTeglund%26aufirst%3DS.%26aulast%3DVanin%26aufirst%3DE.%2BF.%26aulast%3DBodner%26aufirst%3DS.%26aulast%3DColamonici%26aufirst%3DO.%2BR.%26aulast%3DvanDeursen%26aufirst%3DJ.%2BM.%26aulast%3DGrosveld%26aufirst%3DG.%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26atitle%3DJak2%2520is%2520essential%2520for%2520signaling%2520through%2520a%2520variety%2520of%2520cytokine%2520receptors%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D385%26epage%3D395%26doi%3D10.1016%2FS0092-8674%2800%2981167-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Frenzel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDoom, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capecchi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sayeski, P. P.</span><span> </span><span class="NLM_article-title">A functional Jak2 tyrosine kinase domain is essential for mouse development</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x">, </span> <span class="NLM_fpage">2735</span><span class="NLM_x">–</span> <span class="NLM_lpage">2744</span><span class="refDoi"> DOI: 10.1016/j.yexcr.2006.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2Fj.yexcr.2006.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=16887119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BD28XovVWqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2006&pages=2735-2744&author=K.+Frenzelauthor=T.+A.+Wallaceauthor=I.+McDoomauthor=H.+D.+Xiaoauthor=M.+R.+Capecchiauthor=K.+E.+Bernsteinauthor=P.+P.+Sayeski&title=A+functional+Jak2+tyrosine+kinase+domain+is+essential+for+mouse+development&doi=10.1016%2Fj.yexcr.2006.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">A functional Jak2 tyrosine kinase domain is essential for mouse development</span></div><div class="casAuthors">Frenzel, Kristen; Wallace, Tiffany A.; McDoom, Issam; Xiao, Hong D.; Capecchi, Mario R.; Bernstein, Kenneth E.; Sayeski, Peter P.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2735-2744</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Jak2 is a member of the Janus family of tyrosine kinases and is involved in cytokine signaling.  As a part of a study to det. biol. functions of Jak2, we used mol. modeling to identify W1038 as a residue that is crit. for tyrosine kinase function.  Mutation of W1038, in tandem with E1046, generates a dominant-neg. form of the Jak2 protein.  Mice that were engineered to express two copies of this dominant-neg. Jak2 protein died in utero.  Addnl., heterozygous mice expressing Jak2 with kinase activity that is moderately reduced when compared to wild-type activity appear phenotypically normal.  Collectively, these data suggest that Jak2 kinase activity is essential for normal mammalian development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_eBTfkGGF3rVg90H21EOLACvtfcHk0lgA5TtR59-ylw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovVWqtbg%253D&md5=347e54bb72e8fdb6cce0563020c5656e</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2006.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2006.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DFrenzel%26aufirst%3DK.%26aulast%3DWallace%26aufirst%3DT.%2BA.%26aulast%3DMcDoom%26aufirst%3DI.%26aulast%3DXiao%26aufirst%3DH.%2BD.%26aulast%3DCapecchi%26aufirst%3DM.%2BR.%26aulast%3DBernstein%26aufirst%3DK.%2BE.%26aulast%3DSayeski%26aufirst%3DP.%2BP.%26atitle%3DA%2520functional%2520Jak2%2520tyrosine%2520kinase%2520domain%2520is%2520essential%2520for%2520mouse%2520development%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2006%26volume%3D312%26spage%3D2735%26epage%3D2744%26doi%3D10.1016%2Fj.yexcr.2006.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Neubauer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huffstadt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfeffer, K.</span><span> </span><span class="NLM_article-title">Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">397</span><span class="NLM_x">–</span> <span class="NLM_lpage">409</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)81168-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2FS0092-8674%2800%2981168-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=9590174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADyaK1cXjtFCjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=397-409&author=H.+Neubauerauthor=A.+Cumanoauthor=M.+Mullerauthor=H.+Wuauthor=U.+Huffstadtauthor=K.+Pfeffer&title=Jak2+deficiency+defines+an+essential+developmental+checkpoint+in+definitive+hematopoiesis&doi=10.1016%2FS0092-8674%2800%2981168-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis</span></div><div class="casAuthors">Neubauer, Hans; Cumano, Ana; Muller, Mathias; Wu, Hong; Huffstadt, Ulrike; Pfeffer, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">397-409</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Janus kinases (Jaks) play an important role in signal transduction via cytokine and growth factor receptors.  A targeted inactivation of Jak2 was performed.  Jak2-/- embryos are anemic and die around day 12.5 postcoitum.  Primitive erythrocytes are found, but definitive erythropoiesis is absent.  Compared to erythropoietin receptor-deficient mice, the phenotype of Jak2 deficiency is more severe.  Fetal liver BFU-E and CFU-E colonies are completely absent.  However, multilineage hematopoietic stem cells (CD34low, c-kitpos) can be found, and B lymphopoiesis appears intact.  In contrast to IFNα stimulation, Jak2-/- cells do not respond to IFNγ.  Jak2-/- embryonic stem cells are competent for LIF signaling.  The data provided demonstrate that Jak2 has pivotal functions for signal transduction of a set of cytokine receptors required in definitive erythropoiesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8oeTh0n3FcbVg90H21EOLACvtfcHk0lgA5TtR59-ylw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtFCjtLk%253D&md5=74275b73c807331170c096145e69af94</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981168-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981168-X%26sid%3Dliteratum%253Aachs%26aulast%3DNeubauer%26aufirst%3DH.%26aulast%3DCumano%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DHuffstadt%26aufirst%3DU.%26aulast%3DPfeffer%26aufirst%3DK.%26atitle%3DJak2%2520deficiency%2520defines%2520an%2520essential%2520developmental%2520checkpoint%2520in%2520definitive%2520hematopoiesis%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D397%26epage%3D409%26doi%3D10.1016%2FS0092-8674%2800%2981168-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">Phase 2B doseranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to DMARDs</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">629</span><span class="refDoi"> DOI: 10.1002/art.33383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1002%2Fart.33383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=21952978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVGjurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=617-629&author=R.+Fleischmannauthor=M.+Cutoloauthor=M.+C.+Genoveseauthor=E.+B.+Leeauthor=K.+S.+Kanikauthor=S.+Sadisauthor=C.+A.+Connellauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=G.+Wallensteinauthor=B.+E.+Wilkinsonauthor=S.+H.+Zwillich&title=Phase+2B+doseranging+study+of+the+oral+JAK+inhibitor+tofacitinib+%28CP-690%2C550%29+or+adalimumab+monotherapy+versus+placebo+in+patients+with+active+rheumatoid+arthritis+with+an+inadequate+response+to+DMARDs&doi=10.1002%2Fart.33383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs</span></div><div class="casAuthors">Fleischmann, Roy; Cutolo, Maurizio; Genovese, Mark C.; Lee, Eun Bong; Kanik, Keith S.; Sadis, Seth; Connell, Carol A.; Gruben, David; Krishnaswami, Sriram; Wallenstein, Gene; Wilkinson, Bethanie E.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">617-629</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP-690,550) or adalimumab monotherapy with placebo for the treatment of active rheumatoid arthritis (RA) in patients with an inadequate response to disease-modifying antirheumatic drugs.  Methods : In this 24-wk, double-blind, phase IIb study, patients with RA (n = 384) were randomized to receive placebo, tofacitinib at 1, 3, 5, 10, or 15 mg administered orally twice a day, or adalimumab at 40 mg injected s.c. every 2 wk (total of 6 injections) followed by oral tofacitinib at 5 mg twice a day for 12 wk.  The primary end point was the responder rate according to the American College of Rheumatol. 20% improvement criteria (ACR20) at week 12.  Results : Treatment with tofacitinib at a dose of ≥3 mg twice a day resulted in a rapid response with significant efficacy when compared to placebo, as indicated by the primary end point (ACR20 response at week 12), achieved in 39.2% (3 mg; P ≤ 0.05), 59.2% (5 mg; P < 0.0001), 70.5% (10 mg; P < 0.0001), and 71.9% (15 mg; P < 0.0001) in the tofacitinib group and 35.9% of patients in the adalimumab group (P = 0.105), compared with 22.0% of patients receiving placebo.  Improvements were sustained at week 24, according to the ACR20, ACR50, and ACR70 response rates as well as classifications of remission according to the 3-variable Disease Activity Score in 28 joints (DAS28) using C-reactive protein and the 4-variable DAS28 using the erythrocyte sedimentation rate.  The most common treatment-emergent adverse events (AEs) in patients across all tofacitinib treatment arms (n = 272) were urinary tract infection (7.7%), diarrhea (4.8%), headache (4.8%), and bronchitis (4.8%).  Conclusion : Tofacitinib monotherapy at ≥3 mg twice a day was efficacious in the treatment of patients with active RA over 24 wk and demonstrated a manageable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuu7Uf_SwBXbVg90H21EOLACvtfcHk0lhBFGTR7Zij1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVGjurs%253D&md5=99d7be4fd115ffa87410dcbd6c6ea860</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1002%2Fart.33383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.33383%26sid%3Dliteratum%253Aachs%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DCutolo%26aufirst%3DM.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26aulast%3DSadis%26aufirst%3DS.%26aulast%3DConnell%26aufirst%3DC.%2BA.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DWilkinson%26aufirst%3DB.%2BE.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DPhase%25202B%2520doseranging%2520study%2520of%2520the%2520oral%2520JAK%2520inhibitor%2520tofacitinib%2520%2528CP-690%252C550%2529%2520or%2520adalimumab%2520monotherapy%2520versus%2520placebo%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520with%2520an%2520inadequate%2520response%2520to%2520DMARDs%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3D617%26epage%3D629%26doi%3D10.1002%2Fart.33383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kremer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">French, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Reino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascual-Ramos, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">A phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">970</span><span class="NLM_x">–</span> <span class="NLM_lpage">981</span><span class="refDoi"> DOI: 10.1002/art.33419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1002%2Fart.33419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=22006202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvVygt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=970-981&author=J.+M.+Kremerauthor=S.+Cohenauthor=B.+E.+Wilkinsonauthor=C.+A.+Connellauthor=J.+L.+Frenchauthor=J.+Gomez-Reinoauthor=D.+Grubenauthor=K.+S.+Kanikauthor=S.+Krishnaswamiauthor=V.+Pascual-Ramosauthor=G.+Wallensteinauthor=S.+H.+Zwillich&title=A+phase+2B+dose-ranging+study+of+the+oral+JAK+inhibitor+tofacitinib+%28CP-690%2C550%29+versus+placebo+in+combination+with+background+methotrexate+in+patients+with+active+rheumatoid+arthritis+and+inadequate+response+to+methotrexate+alone&doi=10.1002%2Fart.33419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone</span></div><div class="casAuthors">Kremer, Joel M.; Cohen, Stanley; Wilkinson, Bethanie E.; Connell, Carol A.; French, Jonathan L.; Gomez-Reino, Juan; Gruben, David; Kanik, Keith S.; Krishnaswami, Sriram; Pascual-Ramos, Virginia; Wallenstein, Gene; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">970-981</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective. To compare the efficacy, safety, and tolerability of 6 dosages of oral tofacitinib (CP-690,550) with placebo for the treatment of active rheumatoid arthritis (RA) in patients receiving a stable background regimen of methotrexate (MTX) who have an inadequate response to MTX monotherapy.  Methods. In this 24-wk, double-blind, phase IIb study, patients with active RA (n = 507) were randomized to receive placebo or tofacitinib (20 mg/day, 1 mg twice daily, 3 mg twice daily, 5 mg twice daily, 10 mg twice daily, or 15 mg twice daily).  All patients continued to receive a stable dosage of MTX.  The primary end point was the American College of Rheumatol. 20% improvement criteria (ACR20) response rate at week 12.  Results. At week 12, ACR20 response rates for patients receiving all tofacitinib dosages ≥3 mg twice daily (52.9% for 3 mg twice daily, 50.7% for 5 mg twice daily, 58.1% for 10 mg twice daily, 56.0% for 15 mg twice daily, and 53.8% for 20 mg/day) were significantly (P ≤ 0.05) greater than those for placebo (33.3%).  Improvements were sustained at week 24 for the ACR20, ACR50, and ACR70 responses, scores for the Health Assessment Questionnaire disability index, the 3-variable Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP), and a 3-variable DAS28-CRP of <2.6.  The most common treatment-emergent adverse events occurring in >10% of patients in any tofacitinib group were diarrhea, upper respiratory tract infection, and headache; 21 patients (4.1%) experienced serious adverse events.  Sporadic increases in transaminase levels, increases in cholesterol and serum creatinine levels, and decreases in neutrophil and Hb levels were obsd.  Conclusion. In patients with active RA in whom the response to MTX has been inadequate, the addn. of tofacitinib at a dosage ≥3 mg twice daily showed sustained efficacy and a manageable safety profile over 24 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGQK92I8twr7Vg90H21EOLACvtfcHk0lhBFGTR7Zij1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvVygt78%253D&md5=69d74dbdde12d7d1b45fa3d3a413645a</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1002%2Fart.33419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.33419%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DWilkinson%26aufirst%3DB.%2BE.%26aulast%3DConnell%26aufirst%3DC.%2BA.%26aulast%3DFrench%26aufirst%3DJ.%2BL.%26aulast%3DGomez-Reino%26aufirst%3DJ.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DPascual-Ramos%26aufirst%3DV.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DA%2520phase%25202B%2520dose-ranging%2520study%2520of%2520the%2520oral%2520JAK%2520inhibitor%2520tofacitinib%2520%2528CP-690%252C550%2529%2520versus%2520placebo%2520in%2520combination%2520with%2520background%2520methotrexate%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520and%2520inadequate%2520response%2520to%2520methotrexate%2520alone%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3D970%26epage%3D981%26doi%3D10.1002%2Fart.33419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardanani, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes-Franco, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson-Viitanen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1117</span><span class="NLM_x">–</span> <span class="NLM_lpage">1127</span><span class="refDoi"> DOI: 10.1056/NEJMoa1002028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1056%2FNEJMoa1002028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=20843246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1117-1127&author=S.+Verstovsekauthor=H.+Kantarjianauthor=R.+A.+Mesaauthor=A.+D.+Pardananiauthor=J.+Cortes-Francoauthor=D.+A.+Thomasauthor=Z.+Estrovauthor=J.+S.+Fridmanauthor=E.+C.+Bradleyauthor=S.+Erickson-Viitanenauthor=K.+Vaddiauthor=R.+Levyauthor=A.+Tefferi&title=Safety+and+efficacy+of+INCB018424%2C+a+JAK1+and+JAK2+inhibitor%2C+in+myelofibrosis&doi=10.1056%2FNEJMoa1002028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11c</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span></div><div class="casAuthors">Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cortes-Franco, Jorge; Thomas, Deborah A.; Estrov, Zeev; Fridman, Jordan S.; Bradley, Edward C.; Erickson-Viitanen, Susan; Vaddi, Kris; Levy, Richard; Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1117-1127</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Myelofibrosis is a Philadelphia chromosome-neg. myeloproliferative neoplasm assocd. with cytopenias, splenomegaly, poor quality of life, and shortened survival.  About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiol. of the disease.  INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.  Methods: We conducted a phase 1-2 trial of INCB018424 in patients with JAK2 V617F-pos. or JAK2 V617F-neg. primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis.  Results: A total of 153 patients received INCB018424 for a median duration of more than 14.7 mo.  The initial dose-escalation phase established 25 mg twice daily or 100 mg once daily as max. tolerated doses, on the basis of reversible thrombocytopenia.  A dose-dependent suppression of phosphorylated signal transducer and activator of transcription 3 (STAT3), a marker of JAK signaling, was demonstrated in patients with wild-type JAK2 and in patients with the JAK2 V617F mutation.  We studied addnl. doses and established that a 15-mg twice-daily starting dose, followed by individualized dose titrn., was the most effective and safest dosing regimen.  At this dose, 17 of 33 patients (52%) had a rapid objective response (>50% redn. of splenomegaly) lasting for 12 mo or more, and this therapy was assocd. with grade 3 or grade 4 adverse events (mainly myelosuppression) in less than 10% of patients.  Patients with debilitating symptoms, including wt. loss, fatigue, night sweats, and pruritus, had rapid improvement.  Clin. benefits were assocd. with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myelofibrosis.  Conclusions: INCB018424 was assocd. with marked and durable clin. benefits in patients with myelofibrosis for whom no approved therapies existed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUi05ApP1FLrVg90H21EOLACvtfcHk0ljOWt52XVuzHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ&md5=ba6fe766323a10a1508c686fdb3720b1</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002028%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DPardanani%26aufirst%3DA.%2BD.%26aulast%3DCortes-Franco%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DBradley%26aufirst%3DE.%2BC.%26aulast%3DErickson-Viitanen%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520INCB018424%252C%2520a%2520JAK1%2520and%2520JAK2%2520inhibitor%252C%2520in%2520myelofibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1117%26epage%3D1127%26doi%3D10.1056%2FNEJMoa1002028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Keystone, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drescher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlichting, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beattie, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berclaz, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidelus-Gort, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luchi, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macias, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span> </span><span class="NLM_article-title">Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span><span class="refDoi"> DOI: 10.1136/annrheumdis-2014-206478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1136%2Fannrheumdis-2014-206478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=25431052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVSltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2015&pages=333-40&author=E.+C.+Keystoneauthor=P.+C.+Taylorauthor=E.+Drescherauthor=D.+E.+Schlichtingauthor=S.+D.+Beattieauthor=P.+Y.+Berclazauthor=C.+H.+Leeauthor=R.+K.+Fidelus-Gortauthor=M.+E.+Luchiauthor=T.+P.+Rooneyauthor=W.+L.+Maciasauthor=M.+C.+Genovese&title=Safety+and+efficacy+of+baricitinib+at+24+weeks+in+patients+with+rheumatoid+arthritis+who+have+had+an+inadequate+response+to+methotrexate&doi=10.1136%2Fannrheumdis-2014-206478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11dR"><div class="casContent"><span class="casTitleNuber">11d</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate</span></div><div class="casAuthors">Keystone, Edward C.; Taylor, Peter C.; Drescher, Edit; Schlichting, Douglas E.; Beattie, Scott D.; Berclaz, Pierre-Yves; Lee, Chin H.; Fidelus-Gort, Rosanne K.; Luchi, Monica E.; Rooney, Terence P.; Macias, William L.; Genovese, Mark C.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">333-340</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite treatment with methotrexate.  Methods In this phase IIb study, 301 patients were randomized 2:1:1:1:1 to receive once daily doses of placebo or 1, 2, 4 or 8 mg baricitinib for 12 wk.  Patients assigned to 2, 4 and 8 mg baricitinib continued blinded treatment for an addnl. 12 wk.  Patients assigned to placebo or 1 mg baricitinib were reassigned to 2 mg twice daily or 4 mg once daily baricitinib between weeks 12-24.  The primary endpoint was the proportion of patients in the combined 4 and 8 mg groups achieving an American College of Rheumatol. 20% (ACR20) response vs. placebo at week 12.  Results Significantly more patients in the combined baricitinib 4 and 8 mg groups compared with placebo achieved an ACR20 response at week 12 (76% vs 41%, p<0.001).  At week 12, significant differences vs. placebo were also obsd. in patients achieving ACR50, ACR70 and remission as measured by Disease Activity Score for 28-joint counts, Clin. Disease Activity Index and Simplified Disease Activity Index.  Patients receiving 2, 4, or 8 mg baricitinib maintained or improved in all measures through 24 wk.  Similar proportions of patients experienced at least one adverse event in the placebo and baricitinib groups.  Serious infections developed in three patients receiving baricitinib.  No cases of tuberculosis, herpes zoster, opportunistic infections or deaths were reported.  Dose-dependent decreases in Hb were obsd. with baricitinib.  Conclusions Baricitinib improved the signs and symptoms of RA in methotrexate inadequate responders with active disease.  Baricitinib was well tolerated with no unexpected safety findings through week 24.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz3lYB7HU_KbVg90H21EOLACvtfcHk0ljOWt52XVuzHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVSltbc%253D&md5=2f13c96c1c1dc5f68e69cd3e6da457b7</span></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2014-206478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2014-206478%26sid%3Dliteratum%253Aachs%26aulast%3DKeystone%26aufirst%3DE.%2BC.%26aulast%3DTaylor%26aufirst%3DP.%2BC.%26aulast%3DDrescher%26aufirst%3DE.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DBeattie%26aufirst%3DS.%2BD.%26aulast%3DBerclaz%26aufirst%3DP.%2BY.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DFidelus-Gort%26aufirst%3DR.%2BK.%26aulast%3DLuchi%26aufirst%3DM.%2BE.%26aulast%3DRooney%26aufirst%3DT.%2BP.%26aulast%3DMacias%26aufirst%3DW.%2BL.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520baricitinib%2520at%252024%2520weeks%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%2520who%2520have%2520had%2520an%2520inadequate%2520response%2520to%2520methotrexate%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2015%26volume%3D74%26spage%3D333%26epage%3D40%26doi%3D10.1136%2Fannrheumdis-2014-206478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bachelez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Kerkhof, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strohal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubanov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenzuela, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakusevich, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chimenti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papacharalambous, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proulx, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tawadrous, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, R.</span><span> </span><span class="NLM_article-title">Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">386</span><span class="NLM_x">, </span> <span class="NLM_fpage">552</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1016/S0140-6736(14)62113-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2FS0140-6736%2814%2962113-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=26051365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSgt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=552-61&author=H.+Bachelezauthor=P.+C.+van+de+Kerkhofauthor=R.+Strohalauthor=A.+Kubanovauthor=F.+Valenzuelaauthor=J.+H.+Leeauthor=V.+Yakusevichauthor=S.+Chimentiauthor=J.+Papacharalambousauthor=J.+Proulxauthor=P.+Guptaauthor=H.+Tanauthor=M.+Tawadrousauthor=H.+Valdezauthor=R.+Wolk&title=Tofacitinib+versus+etanercept+or+placebo+in+moderate-to-severe+chronic+plaque+psoriasis%3A+a+phase+3+randomised+non-inferiority+trial&doi=10.1016%2FS0140-6736%2814%2962113-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial</span></div><div class="casAuthors">Bachelez, Herve; van de Kerkhof, Peter C. M.; Strohal, Robert; Kubanov, Alexey; Valenzuela, Fernando; Lee, Joo-Heung; Yakusevich, Vladimir; Chimenti, Sergio; Papacharalambous, Jocelyne; Proulx, James; Gupta, Pankaj; Tan, Huaming; Tawadrous, Margaret; Valdez, Hernan; Wolk, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">386</span>
        (<span class="NLM_cas:issue">9993</span>),
    <span class="NLM_cas:pages">552-561</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">New therapeutic options are needed for patients with psoriasis.  Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe chronic plaque psoriasis.  In this study, we aimed to compare two tofacitinib doses with high-dose etanercept or placebo in this patient population.  In this phase 3, randomised, multicentre, double-dummy, placebo-controlled, 12-wk, non-inferiority trial, adult patients with chronic stable plaque psoriasis (for ≥12 mo) who were candidates for systemic or phototherapy and had a Psoriasis Area and Severity Index (PASI) score of 12 or higher and a Physician's Global Assessment (PGA) of moderate or severe, and had failed to respond to, had a contraindication to, or were intolerant to at least one conventional systemic therapy, were enrolled from 122 investigational dermatol. centers worldwide.  Eligible patients were randomly assigned in a 3:3:3:1 ratio to receive tofacitinib 5 mg or 10 mg twice daily at about 12 h intervals, etanercept 50 mg s.c. twice weekly at about 3-4 day intervals, or placebo.  Randomisation was done by a computer-generated randomisation schedule, and all patients and study personnel were masked to treatment assignment.  The co-primary endpoints were the proportion of patients at week 12 with at least a 75% redn. in the PASI score from baseline (PASI75 response) and the proportion of patients achieving a PGA score of "clear" or "almost clear" (PGA response), analyzed in the full anal. set (all patients who were randomised and received at least one dose of study drug).  This study is registered with ClinicalTrials.gov, no. NCT01241591.  Between Nov 29, 2010, and Sept 13, 2012, we enrolled 1106 eligible adult patients with chronic plaque psoriasis and randomly assigned them to the four treatment groups (330 to tofacitinib 5 mg twice daily, 332 to tofacitinib 10 mg twice daily, 336 to etanercept 50 mg twice weekly, and 108 to placebo).  Of these patients, 1101 actually received their assigned study medication (329 in the tofactinib 5 mg group, 330 in the tofacitinib 10 mg group, 335 in the etanercept group, and 107 in the placebo group).  At week 12, PASI75 responses were recorded in 130 (39·5%) of 329 patients in the tofacitinib 5 mg group, 210 (63·6%) of 330 in the tofacitinib 10 mg group, 197 (58·8%) of 335 in the etanercept group, and six (5·6%) of 107 in the placebo group.  A PGA response was achieved by 155 (47·1%) of 329 patients in the tofacitinib 5 mg group, 225 (68·2%) of 330 in the tofacitinib 10 mg group, 222 (66·3%) of 335 in the etanercept group, and 16 (15·0%) of 107 in the placebo group.  The rate of adverse events was similar across the four groups, with serious adverse events occurring in seven (2%) of 329 patients in the tofacitinib 5 mg group, five (2%) of 330 in the tofacitinib 10 mg group, seven (2%) of 335 in the etanercept group, and two (2%) of 107 in the placebo group.  Three (1%) of 329 patients in the tofacitinib 5 mg group, ten (3%) of 330 in the tofacitinib 10 mg group, 11 (3%) of 335 in the etanercept group, and four (4%) of 107 patients in the placebo group discontinued their assigned treatment because of adverse events.  In patients with moderate-to-severe plaque psoriasis, the 10 mg twice daily dose of tofacitinib was non-inferior to etanercept 50 mg twice weekly and was superior to placebo, but the 5 mg twice daily dose did not show non-inferiority to etanercept 50 mg twice weekly.  The adverse event rates over 12 wk were similar for tofacitinib and etanercept.  This study indicates that in the future tofacitinib could provide a convenient and well-tolerated therapeutic option for patients with moderate-to-severe plaque psoriasis.Pfizer Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKYcpF-XDavrVg90H21EOLACvtfcHk0ljnLVpWISclKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSgt77J&md5=797adf1a67423e82ce47d96aa87daa6b</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2962113-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252962113-9%26sid%3Dliteratum%253Aachs%26aulast%3DBachelez%26aufirst%3DH.%26aulast%3Dvan%2Bde%2BKerkhof%26aufirst%3DP.%2BC.%26aulast%3DStrohal%26aufirst%3DR.%26aulast%3DKubanov%26aufirst%3DA.%26aulast%3DValenzuela%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DYakusevich%26aufirst%3DV.%26aulast%3DChimenti%26aufirst%3DS.%26aulast%3DPapacharalambous%26aufirst%3DJ.%26aulast%3DProulx%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DTawadrous%26aufirst%3DM.%26aulast%3DValdez%26aufirst%3DH.%26aulast%3DWolk%26aufirst%3DR.%26atitle%3DTofacitinib%2520versus%2520etanercept%2520or%2520placebo%2520in%2520moderate-to-severe%2520chronic%2520plaque%2520psoriasis%253A%2520a%2520phase%25203%2520randomised%2520non-inferiority%2520trial%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26spage%3D552%26epage%3D61%26doi%3D10.1016%2FS0140-6736%2814%2962113-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Papp, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menter, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elewski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottlieb, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thaci, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buonanno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proulx, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolk, R.</span><span> </span><span class="NLM_article-title">Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials</span> <span class="citation_source-journal">Br. J. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">173</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1111/bjd.14018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1111%2Fbjd.14018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=26149717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyns73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2015&pages=949-61&author=K.+A.+Pappauthor=M.+A.+Menterauthor=M.+Abeauthor=B.+Elewskiauthor=S.+R.+Feldmanauthor=A.+B.+Gottliebauthor=R.+Langleyauthor=T.+Lugerauthor=D.+Thaciauthor=M.+Buonannoauthor=P.+Guptaauthor=J.+Proulxauthor=S.+Lanauthor=R.+Wolk&title=Tofacitinib%2C+an+oral+Janus+kinase+inhibitor%2C+for+the+treatment+of+chronic+plaque+psoriasis%3A+results+from+two+randomized%2C+placebo-controlled%2C+phase+III+trials&doi=10.1111%2Fbjd.14018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials</span></div><div class="casAuthors">Papp, K. A.; Menter, M. A.; Abe, M.; Elewski, B.; Feldman, S. R.; Gottlieb, A. B.; Langley, R.; Luger, T.; Thaci, D.; Buonanno, M.; Gupta, P.; Proulx, J.; Lan, S.; Wolk, R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">949-961</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis.  Objectives : To det. the 16-wk efficacy and safety of two oral tofacitinib doses vs. placebo in patients with moderate-to-severe chronic plaque psoriasis.  Methods : Patients in two similarly designed phase III studies (OPT Pivotal 1, NCT01276639, n = 901; OPT Pivotal 2, NCT01309737, n = 960) were initially randomized 2 : 2 : 1 to tofacitinib 10 or 5 mg or placebo, twice daily.  Coprimary efficacy end points (week 16) included the proportion of patients achieving Physician's Global Assessment (PGA) of 'clear' or 'almost clear' (PGA response) and the proportion achieving ≥ 75% redn. in Psoriasis Area and Severity Index (PASI 75).  Results : Across OPT Pivotal 1 and OPT Pivotal 2, 745 patients received tofacitinib 5 mg, 741 received tofacitinib 10 mg and 373 received placebo.  At week 16, a greater proportion of patients achieved PGA responses with tofacitinib 5 and 10 mg twice daily vs. placebo (OPT Pivotal 1, 41·9% and 59·2% vs. 9·0%; OPT Pivotal 2, 46·0% and 59·1% vs. 10·9%; all P < 0·001).  Higher PASI 75 rates were obsd. with tofacitinib vs. placebo (OPT Pivotal 1, 39·9%, 59·2% and 6·2%, resp., for tofacitinib 5 and 10 mg twice daily and placebo; OPT Pivotal 2, 46·0%, 59·6% and 11·4%; all P < 0·001 vs. placebo).  Adverse event (AE) rates appeared generally similar across groups; rates of serious AEs, infections, malignancies and discontinuations due to AEs were low.  Twelve patients reported herpes zoster across the tofacitinib treatment groups in both studies vs. none in the resp. placebo groups.  The most common AE across groups was nasopharyngitis.  Conclusions : Oral tofacitinib demonstrated significant efficacy vs. placebo during the initial 16 wk of treatment in patients with moderate-to-severe psoriasis.  Safety findings were consistent with prior studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTWaBXP7bJbLVg90H21EOLACvtfcHk0ljnLVpWISclKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyns73E&md5=2029ed12ccdeaeb36ab87425a8c534c1</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14018%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DMenter%26aufirst%3DM.%2BA.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DElewski%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26aulast%3DGottlieb%26aufirst%3DA.%2BB.%26aulast%3DLangley%26aufirst%3DR.%26aulast%3DLuger%26aufirst%3DT.%26aulast%3DThaci%26aufirst%3DD.%26aulast%3DBuonanno%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DProulx%26aufirst%3DJ.%26aulast%3DLan%26aufirst%3DS.%26aulast%3DWolk%26aufirst%3DR.%26atitle%3DTofacitinib%252C%2520an%2520oral%2520Janus%2520kinase%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520chronic%2520plaque%2520psoriasis%253A%2520results%2520from%2520two%2520randomized%252C%2520placebo-controlled%252C%2520phase%2520III%2520trials%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2015%26volume%3D173%26spage%3D949%26epage%3D61%26doi%3D10.1111%2Fbjd.14018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hsu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, A. W.</span><span> </span><span class="NLM_article-title">JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis</span> <span class="citation_source-journal">J. Immunol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">2014</span><span class="NLM_x">, </span> <span class="NLM_fpage">283617</span><span class="refDoi"> DOI: 10.1155/2014/283617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1155%2F2014%2F283617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=24883332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A280%3ADC%252BC2cfot1ehtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=283617&author=L.+Hsuauthor=A.+W.+Armstrong&title=JAK+inhibitors%3A+treatment+efficacy+and+safety+profile+in+patients+with+psoriasis&doi=10.1155%2F2014%2F283617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis</span></div><div class="casAuthors">Hsu Leeyen; Armstrong April W</div><div class="citationInfo"><span class="NLM_cas:title">Journal of immunology research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2014</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">283617</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Janus kinase (JAK) pathways are key mediators in the immunopathogenesis of psoriasis.  Psoriasis treatment has evolved with the advent of targeted therapies, which inhibit specific components of the psoriasis proinflammatory cascade.  JAK inhibitors have been studied in early phase trials for psoriasis patients, and the data are promising for these agents as potential treatment options.  Tofacitinib, an oral or topically administered JAK1 and JAK3 inhibitor, and ruxolitinib, a topical JAK1 and JAK2 inhibitor, have been most extensively studied in psoriasis, and both improved clinical symptoms of psoriasis.  Additional JAK1 or JAK3 inhibitors are being studied in clinical trials.  In phase III trials for rheumatoid arthritis, tofacitinib was efficacious in patients with inadequate responses to tumor necrosis factor inhibitors, methotrexate monotherapy, or disease-modifying antirheumatic drugs.  The results of phase III trials are pending for these therapies in psoriasis, and these agents may represent important alternatives for patients with inadequate responses to currently available agents.  Further investigations with long-term clinical trials are necessary to verify their utility in psoriasis treatment and assess their safety in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8NFwIZodl1tTiMd2aNQVUfW6udTcc2eZ2utM-uAylEbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfot1ehtw%253D%253D&md5=241b16e23f36ea06d03b49fa4c53104f</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1155%2F2014%2F283617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F283617%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DL.%26aulast%3DArmstrong%26aufirst%3DA.%2BW.%26atitle%3DJAK%2520inhibitors%253A%2520treatment%2520efficacy%2520and%2520safety%2520profile%2520in%2520patients%2520with%2520psoriasis%26jtitle%3DJ.%2520Immunol.%2520Res.%26date%3D2014%26volume%3D2014%26spage%3D283617%26doi%3D10.1155%2F2014%2F283617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Kwatra, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dabade, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustafson, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, S. R.</span><span> </span><span class="NLM_article-title">JAK inhibitors in psoriasis: a promising new treatment modality</span> <span class="citation_source-journal">J. Drugs Dermatol.: JDD</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">913</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=22859235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlOgtb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=913-8&author=S.+G.+Kwatraauthor=T.+S.+Dabadeauthor=C.+J.+Gustafsonauthor=S.+R.+Feldman&title=JAK+inhibitors+in+psoriasis%3A+a+promising+new+treatment+modality"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12dR"><div class="casContent"><span class="casTitleNuber">12d</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibitors in psoriasis: a promising new treatment modality</span></div><div class="casAuthors">Kwatra, Shawn G.; Dabade, Tushar S.; Gustafson, Cheryl J.; Feldman, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drugs in Dermatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">913-918</span>CODEN:
                <span class="NLM_cas:coden">JDDOBA</span>;
        ISSN:<span class="NLM_cas:issn">1545-9616</span>.
    
            (<span class="NLM_cas:orgname">Journal of Drugs in Dermatology</span>)
        </div><div class="casAbstract">A review.  Background: Inflammatory cytokines play a crucial role in the pathophysiol. of psoriasis.  New therapies are targeting Janus kinases (JAKs), enzymes involved with transduction of cytokine receptor signaling.  Objective: Review the utility of JAK inhibitors in the treatment of psoriasis.  Methods: A review was performed using PubMed and Google to identify research relevant to the treatment of psoriasis using JAK inhibitors.  Results: In a CD18 mutant PL/J mouse model with T-cell dependent psoriasiform skin disease, the JAK inhibitor R348 reduced skin inflammation, with redns. in CD4+, CD8+, and CD25+T-cell infiltration and systemic decreases of IL-17, IL-19, IL-22, IL-23 and TNF-α.  Two JAK inhibitors, CP-690,550 (tasocitinib) and INCB018424 (ruxolitinib), were effective in psoriasis clin. trials.  In a phase 1, randomized, double-blind, dose escalation trial for plaque psoriasis, CP-690,050 led to improvements in Psoriatic Lesion Severity Sum score at doses greater than 5 mg.  A phase 2 trial showed CP-690,050 administered at 2, 5, and 15 mg twice daily resulted in a 75% redn. in Psoriasis Area and Severity Index (PASI) in 25%, 40.8%, and 66.7% of patients, resp., for moderate to severe psoriasis.  A phase 3 study of CP-690,550 for plaque psoriasis was begun in Sept. 2010 (NCT01163253).  INCB018424, another JAK inhibitor, was used topically at 3 doses (0.5%, 1%, 1.5%) in a phase 2B, double-blind, placebo-controlled trial, resulting in improved total lesion score, global assessment, and PASI for all doses.  Conclusion: Janus Kinase inhibitors are promising potential therapeutic options for psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsaZPQ6k6CN7Vg90H21EOLACvtfcHk0lgk91HCahwVkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlOgtb%252FK&md5=2640c1c8aca3b20982b06f06e9eeb81f</span></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwatra%26aufirst%3DS.%2BG.%26aulast%3DDabade%26aufirst%3DT.%2BS.%26aulast%3DGustafson%26aufirst%3DC.%2BJ.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26atitle%3DJAK%2520inhibitors%2520in%2520psoriasis%253A%2520a%2520promising%2520new%2520treatment%2520modality%26jtitle%3DJ.%2520Drugs%2520Dermatol.%253A%2520JDD%26date%3D2012%26volume%3D11%26spage%3D913%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Norman, P.</span><span> </span><span class="NLM_article-title">Selective JAK1 inhibitor and selective Tyk2 inhibitor patents</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1233</span><span class="NLM_x">–</span> <span class="NLM_lpage">1249</span><span class="refDoi"> DOI: 10.1517/13543776.2012.723693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1517%2F13543776.2012.723693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=22971156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlynsrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1233-1249&author=P.+Norman&title=Selective+JAK1+inhibitor+and+selective+Tyk2+inhibitor+patents&doi=10.1517%2F13543776.2012.723693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Selective JAK1 inhibitor and selective Tyk2 inhibitor patents</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1233-1249</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The JAK family comprises of the four non-receptor tyrosine kinases JAK1, JAK2, JAK3 and Tyk2, which play key, but differing, roles in cytokine receptor signal transduction.  A non-selective JAK inhibitor, ruxolitinib, has recently been approved to treat myelofibrosis whereas tofacitinib is poised for approval to treat rheumatoid arthritis.  Selective inhibition of JAK3, JAK1 or Tyk2 provides the opportunity to achieve clin. efficacy in the treatment of inflammatory diseases while reducing the risk of dose-limiting effects attributable to JAK2 inhibition.Areas covered: This review considers the small no. of published patent filings that claim either selective JAK1 or selective Tyk2 inhibitors.  These are considered in the context of the considerably larger no. of disclosures and patent filings claiming selective JAK2 or JAK3 inhibitors.Expert opinion: The recent disclosure of the clin. efficacy of a selective JAK1 inhibitor (GLPG-0634) in rheumatoid arthritis and detailed disclosure of the some potent and highly selective JAK1 inhibitors provide a clear stimulus for further activity in this area.  The availability of a selective Tyk2 inhibitor will provide the opportunity for better understanding of the physiol. role of this kinase.  Recent patent applications indicate that Tyk2 selectivity is achievable and Tyk2 inhibitors have potential in the treatment of multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjnYf5xYDtobVg90H21EOLACvtfcHk0lgk91HCahwVkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlynsrvE&md5=288bfaedead4c49351791b517992d8ee</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1517%2F13543776.2012.723693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2012.723693%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DSelective%2520JAK1%2520inhibitor%2520and%2520selective%2520Tyk2%2520inhibitor%2520patents%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2012%26volume%3D22%26spage%3D1233%26epage%3D1249%26doi%3D10.1517%2F13543776.2012.723693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Liang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berezhkovskiy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohli, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantik, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menghrajani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sambrone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S.</span><span> </span><span class="NLM_article-title">Lead identification of novel and selective TYK2 inhibitors</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2013.03.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2Fj.ejmech.2013.03.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=23867602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVejtL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2013&pages=175-87&author=J.+Liangauthor=V.+Tsuiauthor=A.+Van+Abbemaauthor=L.+Baoauthor=K.+Barrettauthor=M.+Beresiniauthor=L.+Berezhkovskiyauthor=W.+S.+Blairauthor=C.+Changauthor=J.+Driscollauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=J.+Halladayauthor=A.+Johnsonauthor=P.+B.+Kohliauthor=Y.+Laiauthor=M.+Liimattaauthor=P.+Mantikauthor=K.+Menghrajaniauthor=J.+Murrayauthor=A.+Sambroneauthor=Y.+Xiaoauthor=S.+Shiaauthor=Y.+Shinauthor=J.+Smithauthor=S.+Sohnauthor=M.+Stanleyauthor=M.+Ultschauthor=B.+Zhangauthor=L.+C.+Wuauthor=S.+Magnuson&title=Lead+identification+of+novel+and+selective+TYK2+inhibitors&doi=10.1016%2Fj.ejmech.2013.03.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Lead identification of novel and selective TYK2 inhibitors</span></div><div class="casAuthors">Liang, Jun; Tsui, Vickie; Van Abbema, Anne; Bao, Liang; Barrett, Kathy; Beresini, Maureen; Berezhkovskiy, Leo; Blair, Wade S.; Chang, Christine; Driscoll, James; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Halladay, Jason; Johnson, Adam; Kohli, Pawan Bir; Lai, Yingjie; Liimatta, Marya; Mantik, Priscilla; Menghrajani, Kapil; Murray, Jeremy; Sambrone, Amy; Xiao, Yisong; Shia, Steven; Shin, Young; Smith, Jan; Sohn, Sue; Stanley, Mark; Ultsch, Mark; Zhang, Birong; Wu, Lawren C.; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">175-187</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as psoriasis and inflammatory bowel diseases (IBD), by selective targeting of TYK2.  Hit triage, following a high-throughput screen for TYK2 inhibitors, revealed pyridine (I) as a promising starting point for lead identification.  Initial expansion of 3 sep. regions of the mol. led to eventual identification of cyclopropyl amide (II), a potent lead analog with good kinase selectivity, physicochem. properties, and pharmacokinetic profile.  Anal. of the binding modes of the series in TYK2 and JAK2 crystal structures revealed key interactions leading to good TYK2 potency and design options for future optimization of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXEWbuB0597rVg90H21EOLACvtfcHk0litoIJilpogwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVejtL%252FL&md5=4271738e73a0b680a4441b9231762ef0</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.03.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.03.070%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DBao%26aufirst%3DL.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBeresini%26aufirst%3DM.%26aulast%3DBerezhkovskiy%26aufirst%3DL.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDriscoll%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DMantik%26aufirst%3DP.%26aulast%3DMenghrajani%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DSambrone%26aufirst%3DA.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DS.%26aulast%3DStanley%26aufirst%3DM.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DLead%2520identification%2520of%2520novel%2520and%2520selective%2520TYK2%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D67%26spage%3D175%26epage%3D87%26doi%3D10.1016%2Fj.ejmech.2013.03.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Liang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berezhkovsky, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delarosa, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVoss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohli, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssikatos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantik, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menghrajani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sambrone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S.</span><span> </span><span class="NLM_article-title">Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4521</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span><span class="refDoi"> DOI: 10.1021/jm400266t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400266t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFakuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4521-36&author=J.+Liangauthor=A.+van+Abbemaauthor=M.+Balazsauthor=K.+Barrettauthor=L.+Berezhkovskyauthor=W.+Blairauthor=C.+Changauthor=D.+Delarosaauthor=J.+DeVossauthor=J.+Driscollauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=J.+Halladayauthor=A.+Johnsonauthor=P.+B.+Kohliauthor=Y.+Laiauthor=Y.+Liuauthor=J.+Lyssikatosauthor=P.+Mantikauthor=K.+Menghrajaniauthor=J.+Murrayauthor=I.+Pengauthor=A.+Sambroneauthor=S.+Shiaauthor=Y.+Shinauthor=J.+Smithauthor=S.+Sohnauthor=V.+Tsuiauthor=M.+Ultschauthor=L.+C.+Wuauthor=Y.+Xiaoauthor=W.+Yangauthor=J.+Youngauthor=B.+Zhangauthor=B.+Y.+Zhuauthor=S.+Magnuson&title=Lead+optimization+of+a+4-aminopyridine+benzamide+scaffold+to+identify+potent%2C+selective%2C+and+orally+bioavailable+TYK2+inhibitors&doi=10.1021%2Fjm400266t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of a 4-Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors</span></div><div class="casAuthors">Liang, Jun; van Abbema, Anne; Balazs, Mercedesz; Barrett, Kathy; Berezhkovsky, Leo; Blair, Wade; Chang, Christine; Delarosa, Donnie; DeVoss, Jason; Driscoll, Jim; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Halladay, Jason; Johnson, Adam; Kohli, Pawan Bir; Lai, Yingjie; Liu, Yanzhou; Lyssikatos, Joseph; Mantik, Priscilla; Menghrajani, Kapil; Murray, Jeremy; Peng, Ivan; Sambrone, Amy; Shia, Steven; Shin, Young; Smith, Jan; Sohn, Sue; Tsui, Vickie; Ultsch, Mark; Wu, Lawren C.; Xiao, Yisong; Yang, Wenqian; Young, Judy; Zhang, Birong; Zhu, Bing-yan; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4521-4536</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the authors report the authors' lead optimization effort to identify potent, selective, and orally bioavailable TYK2 inhibitors, starting with lead mol. 2,6-dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide.  The authors used structure-based design to discover 2,6-dichloro-4-cyanophenyl and (1R,2R)-2-fluorocyclopropylamide modifications, each of which exhibited improved TYK2 potency and JAK1 and JAK2 selectivity relative to 2,6-dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide.  Further optimization eventually led to 2-Chloro-4-cyano-6-fluoro-N-(2-((1R,2R)-2-fluorocyclopropanecarboxamido)pyridin-4-yl)benzamide that showed good TYK2 enzyme and interleukin-12 (IL-12) cell potency, as well as acceptable cellular JAK1 and JAK2 selectivity and excellent oral exposure in mice.  When tested in a mouse IL-12 PK/PD model, 2-Chloro-4-cyano-6-fluoro-N-(2-((1R,2R)-2-ffluorocyclopropanecarboxamido)pyridin-4-yl)benzamide showed statistically significant knockdown of cytokine interferon-γ (IFNγ), suggesting that selective inhibition of TYK2 kinase activity might be sufficient to block the IL-12 pathway in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCinZ75WrtObVg90H21EOLACvtfcHk0ljp4W9e4WW_pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFakuro%253D&md5=290ee5f1e3e093136ac5fbb418323421</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1021%2Fjm400266t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400266t%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBerezhkovsky%26aufirst%3DL.%26aulast%3DBlair%26aufirst%3DW.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDelarosa%26aufirst%3DD.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDriscoll%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLyssikatos%26aufirst%3DJ.%26aulast%3DMantik%26aufirst%3DP.%26aulast%3DMenghrajani%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DI.%26aulast%3DSambrone%26aufirst%3DA.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DB.%2BY.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DLead%2520optimization%2520of%2520a%25204-aminopyridine%2520benzamide%2520scaffold%2520to%2520identify%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520TYK2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4521%26epage%3D36%26doi%3D10.1021%2Fjm400266t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Jang, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Son, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koo, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, N. S.</span><span> </span><span class="NLM_article-title">Discovery of Tyk2 inhibitors via the virtual site-directed fragment-based drug design</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3947</span><span class="NLM_x">–</span> <span class="NLM_lpage">52</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2Fj.bmcl.2015.07.037" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3947-52&author=W.+D.+Jangauthor=J.+T.+Kimauthor=H.+Y.+Sonauthor=S.+Y.+Parkauthor=Y.+S.+Choauthor=T.+S.+Kooauthor=H.+Leeauthor=N.+S.+Kang&title=Discovery+of+Tyk2+inhibitors+via+the+virtual+site-directed+fragment-based+drug+design&doi=10.1016%2Fj.bmcl.2015.07.037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.037%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DW.%2BD.%26aulast%3DKim%26aufirst%3DJ.%2BT.%26aulast%3DSon%26aufirst%3DH.%2BY.%26aulast%3DPark%26aufirst%3DS.%2BY.%26aulast%3DCho%26aufirst%3DY.%2BS.%26aulast%3DKoo%26aufirst%3DT.%2BS.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DKang%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520Tyk2%2520inhibitors%2520via%2520the%2520virtual%2520site-directed%2520fragment-based%2520drug%2520design%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3947%26epage%3D52%26doi%3D10.1016%2Fj.bmcl.2015.07.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Smith, G. F.</span><span> </span><span class="NLM_article-title">Designing drugs to avoid toxicity</span> <span class="citation_source-journal">Prog. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span><span class="refDoi"> DOI: 10.1016/B978-0-12-381290-2.00001-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2FB978-0-12-381290-2.00001-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=21315927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3MXoslekurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=1-47&author=G.+F.+Smith&title=Designing+drugs+to+avoid+toxicity&doi=10.1016%2FB978-0-12-381290-2.00001-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Designing drugs to avoid toxicity</span></div><div class="casAuthors">Smith, Graham F.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-47</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review on designing of drugs to avoid toxicity, including various common safety risks and their structure-toxicity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraIClQQ_p_2rVg90H21EOLACvtfcHk0ljp4W9e4WW_pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXoslekurs%253D&md5=23d0ca0ab1d53a7c90dbed0a89a9eeb2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-381290-2.00001-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-381290-2.00001-X%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DG.%2BF.%26atitle%3DDesigning%2520drugs%2520to%2520avoid%2520toxicity%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D50%26spage%3D1%26epage%3D47%26doi%3D10.1016%2FB978-0-12-381290-2.00001-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Chrencik, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patny, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korniski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmons, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gormley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommers, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenbrink, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomasselli, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, T. E.</span><span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">400</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">433</span><span class="refDoi"> DOI: 10.1016/j.jmb.2010.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+Patnyauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.+C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6&doi=10.1016%2Fj.jmb.2010.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0lh1MDmRQaAikg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.%2BC.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433%26doi%3D10.1016%2Fj.jmb.2010.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">O’Sullivan, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liongue, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephenson, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, A. C.</span><span> </span><span class="NLM_article-title">Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease</span> <span class="citation_source-journal">Mol. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">2497</span><span class="NLM_x">–</span> <span class="NLM_lpage">2506</span><span class="refDoi"> DOI: 10.1016/j.molimm.2006.11.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.1016%2Fj.molimm.2006.11.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=17208301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVSmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2007&pages=2497-2506&author=L.+A.+O%E2%80%99Sullivanauthor=C.+Liongueauthor=R.+S.+Lewisauthor=S.+E.+Stephensonauthor=A.+C.+Ward&title=Cytokine+receptor+signaling+through+the+Jak-Stat-Socs+pathway+in+disease&doi=10.1016%2Fj.molimm.2006.11.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease</span></div><div class="casAuthors">O'Sullivan, Lynda A.; Liongue, Clifford; Lewis, Rowena S.; Stephenson, Sarah E. M.; Ward, Alister C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2497-2506</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The complexity of multicellular organisms is dependent on systems enabling cells to respond to specific stimuli.  Cytokines and their receptors are one such system, whose perturbation can lead to a variety of disease states.  This review represents an overview of our current understanding of the cytokine receptors, Janus kinases (Jaks), Signal transducers and activators of transcription (Stats) and Suppressors of cytokine signaling (Socs), focusing on their contribution to diseases of an immune or hematol. nature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRJCsJ5di3XbVg90H21EOLACvtfcHk0lh1MDmRQaAikg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVSmur8%253D&md5=0011026cc2b9be7e0d7cdb854aab300a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.molimm.2006.11.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molimm.2006.11.025%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DL.%2BA.%26aulast%3DLiongue%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DR.%2BS.%26aulast%3DStephenson%26aufirst%3DS.%2BE.%26aulast%3DWard%26aufirst%3DA.%2BC.%26atitle%3DCytokine%2520receptor%2520signaling%2520through%2520the%2520Jak-Stat-Socs%2520pathway%2520in%2520disease%26jtitle%3DMol.%2520Immunol.%26date%3D2007%26volume%3D44%26spage%3D2497%26epage%3D2506%26doi%3D10.1016%2Fj.molimm.2006.11.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favata, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodgers, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span> </span><span class="NLM_article-title">Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">5298</span><span class="NLM_x">–</span> <span class="NLM_lpage">307</span><span class="refDoi"> DOI: 10.4049/jimmunol.0902819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.4049%2Fjimmunol.0902819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=20363976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=5298-307&author=J.+S.+Fridmanauthor=P.+A.+Scherleauthor=R.+Collinsauthor=T.+C.+Burnauthor=Y.+Liauthor=J.+Liauthor=M.+B.+Covingtonauthor=B.+Thomasauthor=P.+Collierauthor=M.+F.+Favataauthor=X.+Wenauthor=J.+Shiauthor=R.+McGeeauthor=P.+J.+Haleyauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=S.+Yeleswaramauthor=G.+Hollisauthor=R.+C.+Newtonauthor=B.+Metcalfauthor=S.+M.+Friedmanauthor=K.+Vaddi&title=Selective+inhibition+of+JAK1+and+JAK2+is+efficacious+in+rodent+models+of+arthritis%3A+preclinical+characterization+of+INCB028050&doi=10.4049%2Fjimmunol.0902819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050</span></div><div class="casAuthors">Fridman, Jordan S.; Scherle, Peggy A.; Collins, Robert; Burn, Timothy C.; Li, Yanlong; Li, Jun; Covington, Maryanne B.; Thomas, Beth; Collier, Paul; Favata, Margaret F.; Wen, Xiaoming; Shi, Jack; McGee, Ryan; Haley, Patrick J.; Shepard, Stacey; Rodgers, James D.; Yeleswaram, Swamy; Hollis, Greg; Newton, Robert C.; Metcalf, Brian; Friedman, Steven M.; Vaddi, Kris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5298-5307</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases such as rheumatoid arthritis.  Kinase inhibitors have shown promising oral disease-modifying antirheumatic drug potential with efficacy similar to anti-TNF biologics.  Direct and indirect inhibition of the JAKs, with small mol. inhibitors like CP-690,550 and INCB018424 or neutralizing Abs, such as the anti-IL6 receptor Ab tocilizumab, have demonstrated rapid and sustained improvement in clin. measures of disease, consistent with their resp. preclin. expts.  Therefore, it is of interest to identify optimized JAK inhibitors with unique profiles to maximize therapeutic opportunities.  INCB028050 is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).  INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concns. <50 nM.  Significant efficacy, as assessed by improvements in clin., histol. and radiog. signs of disease, was achieved in the rat adjuvant arthritis model with doses of INCB028050 providing partial and/or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3.  Diminution of inflammatory Th1 and Th17 assocd. cytokine mRNA levels was obsd. in the draining lymph nodes of treated rats.  INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematol. effects.  These data suggest that fractional inhibition of JAK1 and JAK2 is sufficient for significant activity in autoimmune disease models.  Clin. evaluation of INCB028050 in RA is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4QiklQbX72bVg90H21EOLACvtfcHk0lgdKPNIWC0J1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D&md5=30b22f275eb2ba2dbca7fb7bec768bb9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902819%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%2BB.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DFavata%26aufirst%3DM.%2BF.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DR.%26aulast%3DHaley%26aufirst%3DP.%2BJ.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DFriedman%26aufirst%3DS.%2BM.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DSelective%2520inhibition%2520of%2520JAK1%2520and%2520JAK2%2520is%2520efficacious%2520in%2520rodent%2520models%2520of%2520arthritis%253A%2520preclinical%2520characterization%2520of%2520INCB028050%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D5298%26epage%3D307%26doi%3D10.4049%2Fjimmunol.0902819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Sohn, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohli, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macleod, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewin-Koh, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dengler, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L. C.</span><span> </span><span class="NLM_article-title">A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">2205</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span><span class="refDoi"> DOI: 10.4049/jimmunol.1202859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=10.4049%2Fjimmunol.1202859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=23894201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=2205-16&author=S.+J.+Sohnauthor=K.+Barrettauthor=A.+Van+Abbemaauthor=C.+Changauthor=P.+B.+Kohliauthor=H.+Kandaauthor=J.+Smithauthor=Y.+Laiauthor=A.+Zhouauthor=B.+Zhangauthor=W.+Yangauthor=K.+Williamsauthor=C.+Macleodauthor=C.+A.+Hurleyauthor=J.+J.+Kulagowskiauthor=N.+Lewin-Kohauthor=H.+S.+Denglerauthor=A.+R.+Johnsonauthor=N.+Ghilardiauthor=M.+Zakauthor=J.+Liangauthor=W.+S.+Blairauthor=S.+Magnusonauthor=L.+C.+Wu&title=A+restricted+role+for+TYK2+catalytic+activity+in+human+cytokine+responses+revealed+by+novel+TYK2-selective+inhibitors&doi=10.4049%2Fjimmunol.1202859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors</span></div><div class="casAuthors">Sohn, Sue J.; Barrett, Kathy; Van Abbema, Anne; Chang, Christine; Kohli, Pawan Bir; Kanda, Hidenobu; Smith, Janice; Lai, Yingjie; Zhou, Aihe; Zhang, Birong; Yang, Wenqian; Williams, Karen; MacLeod, Calum; Hurley, Christopher A.; Kulagowski, Janusz J.; Lewin-Koh, Nicholas; Dengler, Hart S.; Johnson, Adam R.; Ghilardi, Nico; Zak, Mark; Liang, Jun; Blair, Wade S.; Magnuson, Steven; Wu, Lawren C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2205-2216</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">TYK2 is a JAK family protein tyrosine kinase activated in response to multiple cytokines, including type I IFNs, IL-6, IL-10, IL-12, and IL-23.  Extensive studies of mice that lack TYK2 expression indicate that the IFN-α, IL-12, and IL-23 pathways, but not the IL-6 or IL-10 pathways, are compromised.  In contrast, there have been few studies of the role of TYK2 in primary human cells.  A genetic mutation at the tyk2 locus that results in a lack of TYK2 protein in a single human patient has been linked to defects in the IFN-α, IL-6, IL-10, IL-12, and IL-23 pathways, suggesting a broad role for TYK2 protein in human cytokine responses.  In this article, we have used a panel of novel potent TYK2 small-mol. inhibitors with varying degrees of selectivity against other JAK kinases to address the requirement for TYK2 catalytic activity in cytokine pathways in primary human cells.  Our results indicate that the biol. processes that require TYK2 catalytic function in humans are restricted to the IL-12 and IL-23 pathways, and suggest that inhibition of TYK2 catalytic activity may be an efficacious approach for the treatment of select autoimmune diseases without broad immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgACYZYW8b07Vg90H21EOLACvtfcHk0lgdKPNIWC0J1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSgtL%252FP&md5=527289e055e91fe2dfb15d3de7faa894</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1202859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1202859%26sid%3Dliteratum%253Aachs%26aulast%3DSohn%26aufirst%3DS.%2BJ.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DKanda%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DMacleod%26aufirst%3DC.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DLewin-Koh%26aufirst%3DN.%26aulast%3DDengler%26aufirst%3DH.%2BS.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DMagnuson%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DL.%2BC.%26atitle%3DA%2520restricted%2520role%2520for%2520TYK2%2520catalytic%2520activity%2520in%2520human%2520cytokine%2520responses%2520revealed%2520by%2520novel%2520TYK2-selective%2520inhibitors%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D2205%26epage%3D16%26doi%3D10.4049%2Fjimmunol.1202859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, D.</span><span> </span><span class="NLM_article-title">Vilsmeier reaction of enaminones: efficient synthesis of halogenated pyridin-2(1H)-ones</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">9504</span><span class="NLM_x">–</span> <span class="NLM_lpage">9507</span><span class="refDoi"> DOI: 10.1021/jo801959j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo801959j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOrsrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=9504-9507&author=R.+Zhangauthor=D.+Zhangauthor=Y.+Guoauthor=G.+Zhouauthor=Z.+Jiangauthor=D.+Dong&title=Vilsmeier+reaction+of+enaminones%3A+efficient+synthesis+of+halogenated+pyridin-2%281H%29-ones&doi=10.1021%2Fjo801959j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Vilsmeier Reaction of Enaminones: Efficient Synthesis of Halogenated Pyridin-2(1H)-ones</span></div><div class="casAuthors">Zhang, Rui; Zhang, Dingyuan; Guo, Yongli; Zhou, Guangyuan; Jiang, Zijiang; Dong, Dewen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9504-9507</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A facile and efficient one-pot synthesis of halogenated pyridin-2(1H)-ones, e.g., I, from a series of readily available enaminones under Vilsmeier conditions is described, and a mechanism involving sequential halogenation, formylation, and intramol. nucleophilic cyclization is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG9FeHPtloJLVg90H21EOLACvtfcHk0lhWytKIQmUqGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOrsrbM&md5=2e0fcd3b0419c693be4ae511cdc3abd1</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjo801959j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo801959j%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DD.%26atitle%3DVilsmeier%2520reaction%2520of%2520enaminones%253A%2520efficient%2520synthesis%2520of%2520halogenated%2520pyridin-2%25281H%2529-ones%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D9504%26epage%3D9507%26doi%3D10.1021%2Fjo801959j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Baraldi, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baraldi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saponaro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romagnoli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piccagli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recanatini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorman, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaid, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borea, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabrizi, M. A.</span><span> </span><span class="NLM_article-title">Novel 1,3-dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl)xanthines as potent and selective A<sub>2B</sub> adenosine receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">797</span><span class="NLM_x">–</span> <span class="NLM_lpage">811</span><span class="refDoi"> DOI: 10.1021/jm201292w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201292w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=797-811&author=P.+G.+Baraldiauthor=S.+Baraldiauthor=G.+Saponaroauthor=D.+Pretiauthor=R.+Romagnoliauthor=L.+Piccagliauthor=A.+Cavalliauthor=M.+Recanatiniauthor=A.+R.+Moormanauthor=A.+N.+Zaidauthor=K.+Varaniauthor=P.+A.+Boreaauthor=M.+A.+Tabrizi&title=Novel+1%2C3-dipropyl-8-%283-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl%29xanthines+as+potent+and+selective+A2B+adenosine+receptor+antagonists&doi=10.1021%2Fjm201292w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm201292w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201292w%26sid%3Dliteratum%253Aachs%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DBaraldi%26aufirst%3DS.%26aulast%3DSaponaro%26aufirst%3DG.%26aulast%3DPreti%26aufirst%3DD.%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DPiccagli%26aufirst%3DL.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMoorman%26aufirst%3DA.%2BR.%26aulast%3DZaid%26aufirst%3DA.%2BN.%26aulast%3DVarani%26aufirst%3DK.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26aulast%3DTabrizi%26aufirst%3DM.%2BA.%26atitle%3DNovel%25201%252C3-dipropyl-8-%25283-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl%2529xanthines%2520as%2520potent%2520and%2520selective%2520A2B%2520adenosine%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D797%26epage%3D811%26doi%3D10.1021%2Fjm201292w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LXP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LXP','PDB','3LXP'); return false;">PDB: 3LXP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F20" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F20','PDB','5F20'); return false;">PDB: 5F20</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F1Z" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F1Z','PDB','5F1Z'); return false;">PDB: 5F1Z</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i99"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01857">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_65836"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01857">10.1021/acs.jmedchem.5b01857</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental methods for cloning, expression, and purification of TYK2, as well as crystallization, data collection, and structure solution of TYK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01857/suppl_file/jm5b01857_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES and IC<sub>50</sub> data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01857/suppl_file/jm5b01857_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01857/suppl_file/jm5b01857_si_001.pdf">jm5b01857_si_001.pdf (176.14 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01857/suppl_file/jm5b01857_si_002.csv">jm5b01857_si_002.csv (1.16 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F20">5F20</a> for compound <b>8</b> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F1Z">5F1Z</a> for compound <b>20</b>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01857&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-2%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01857%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01857" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6679822fbf79195b","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
